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Abstract 
 
The thesis will highlight both qualitatively and quantitatively that during the twentieth century 
the English population experienced unprecedented improvements in mortality and particularly 
morbidity, which has provided a substantial boost to standards of living and economic 
development. Despite the extensiveness of these health improvements, there have been a very 
limited number of attempts to evaluate and quantify these valuable improvements. None of the 
existing studies that quantitatively assess improved health actually measure health per se, as 
they all utilise mortality as a proxy. Furthermore, there have been no historical studies that aim 
to map the evolution of improving health from the perspective of quality of life for illness 
sufferers. The thesis will fill all of these voids through developing a quantitative health 
(mortality and morbidity) measuring tool that is capable of providing (monetary) estimates 
about the contribution of improved health to standards of living and economic developments 
in twentieth century England. This will be applied to key case study illnesses (blindness, 
breast cancer, stomach cancer and tuberculosis) and then extrapolated forward to include all 
illnesses which will be combined with mortality in order to provide an aggregate health index 
for twentieth century England.  
 
The results of this exercise provide a significant contribution to the twentieth century health 
and economic history of England. The thesis findings that, at a most conservative estimate, the 
value of twentieth century health improvements is in excess of 33 billion (1990 international 
$) substantially adds to a new view of the economics of health and provides very valuable 
historical detail. This new view is that improvements in health have been a major contributor 
to economic welfare in twentieth century England. Put another way: the thesis will highlight 
that during the twentieth century increases in life expectancy and improvements in the quality 
of life associated with morbidity have provided a considerable contribution to standards of 
living and the growth of GDP defined on a utility, ‘Fisherian’ basis, whereby economic 
growth nearly doubles, from 1.4 percent for GDP only versus 2.6 percent when GDP is 
adjusted for improved health. 
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PART I 
1. Introduction 
During the twentieth century there were significant improvements in the life expectancy of 
the English population. Improvements in life expectancy are one important manifestation 
of improvements in human welfare1. Furthermore, improvements in the quality of life 
associated with illness increased, which provided important contributions to the standards 
of living of the twentieth century English population.  
 
Despite the importance of improved health and the numerous implications for standards of 
living and economic prosperity that these changes in health have created, there have been a 
very limited number of attempts to evaluate and quantify these developments in mortality, 
and especially morbidity2. The only studies that have attempted to value health (in an 
extended form of GDP measure, i.e. through ‘Fisherian’ type considerations3) are 
Nordhaus (1999)4 for the USA between 1900 and 1995, Crafts (2001)5 for the UK between 
1870 and 1998 and Hickson (2002)6 for twentieth century Japan. However, none of these 
studies measure health per se, as they all utilise mortality (i.e. increased life expectancy) as 
a proxy for health.   
 
Efforts to measure the health of the population pose a new, difficult and increasingly 
relevant challenge. Unprecedented gains in life expectancy accompanied by concerns 
related to the level of health in these extended life years have exacerbated the need to 
measure health per se and consider twentieth century improvements in the quality of life 
associated with health7. 
 
The main reason for this shortage in health measurements is related to the difficulty in 
trying to gauge actual levels of health. Reported levels of morbidity have increased 
                                                 
1
 Maddison, “The World Economy: A Millennial Perspective”, p. 29 
2
 Nordhaus and Crafts are two of the few authors to make these considerations for mortality (as did Usher, but not to the same extent). Cutler 
& Richardson and Murray & Chen are the only authors to make considerations about morbidity that are directly related to this thesis. 
3
 Fisherian growth is a notion that was coined by Nordhaus (1999) and is defined as the maximum amount that a nation can consume while 
ensuring that members of all future generations can have life time utility that is at least as high as that of current generations. When this 
yardstick is utilised, life expectancy is included in the production function and the value of improvements in mortality can be accounted, in 
terms of consumption. See Appendix 12.16 for methodological algebra. 
4
 Nordhaus, “The Health of Nations: The Contribution of Improved Health to Living Standards” 
5
 Crafts (2005) “The Contribution of Increased Life Expectancy to Growth of Living Standards in the UK, 1870-1998”. Retrieved 17 June 
2005, from: www.york.ac.uk/res/wpeg/documents/crafts.pdf 
6
 Hickson, “The Contribution of Improved Life Expectancy to Standards of Living in Twentieth Century Japan”, MSc Thesis (2002), London 
School of Economics and Political Science 
7
 Cutler & Richardson have considered the improved quality of life associated with illness for the USA, during the last thirty years of the 
twentieth century. These considerations have not been made for England, and consequently this is one of the knowledge gaps that the thesis 
will fill. 
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throughout the twentieth century (in developed economies) for many reasons, some of 
which are not exclusively related to health (which will be explained in detail in Section 
2.2). Moreover, health is an extremely subjective notion. These two factors have meant 
that, to-date the complications associated with measuring health are virtually 
insurmountable. Consequently, existing health measures are very specialised and limited, 
as they only achieve a predetermined narrow objective, usually for clinical outcomes 
research or policy investigations and predictions. 
 
There have been no historical studies that aim to map the evolution of improving health 
from the perspective of quality of life for illness sufferers. To do this would require 
considerations about the shifting burden of disability, disease and death. It would also 
require deliberations about the contribution of improvements in medical technology, which 
have probably adversely affected the prevalence of disease, but have also reduced the 
negativities associated with ill health, and consequently provided an overall contribution to 
health related quality of life.  
 
Furthermore, because of the dogmatic scope of existing health measures, very few have 
adopted a multifaceted stance and included as many variables as is desirable to fully 
consider health, as: “not merely the absence of disease or infirmity, health is a state of 
complete physical, mental and social well-being”8.  
 
This situation has inspired two key questions, which will be answered by the thesis: 
1. What was the extent and value of improvements in health (mortality and morbidity) 
during different periods of the twentieth century in England? 
2. What has been the impact of improved health upon standards of living and the overall 
health related welfare of the population in twentieth century England? 
 
These questions will be answered throughout the remainder of the thesis. Chapter 2 will 
examine the theoretical, practical and historical context of the thesis. This will include a 
detailed investigation into the existing literature and theories related to health and health 
measurement and a detailed evaluation of England’s health in the twentieth century.  
 
                                                 
8
 Preamble to the Constitution of the WHO as adopted as the definition of health since 1948: World Health Organisation (2005): 
“Constitution of the World Health Organisation”. Retrieved 4 October 2005, from: 
http://w3.whosea.org/EN/Section898/Section1441.htm 
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Chapter 3 will explain and justify the processes involved in the thesis for valuing health in 
the thesis. It will highlight how the qualitative illnesses chapters contribute to the 
quantitative results of the thesis. Chapter 3 will also provide a detailed explanation about 
the thesis (extended willingness to pay or Quality Adjusted Life Expectancy [QALE]) 
methodology. This will also entail an outline of how the QALE will be applied and the 
array of sensitivity analyses that will be included in the thesis methodology.  
 
Part II of the thesis will present the qualitative analysis of the twentieth century health and 
welfare situations faced by sufferers of the thesis illnesses, namely, blindness, tuberculosis 
and cancer (breast and stomach). These chapters of the thesis will provide the analysis 
which bolsters the quantitative results, which will be presented in Part III of the thesis.  
 
The final part of the thesis will provide the results which will contain the application of the 
QALE methodology, to the thesis illnesses, in order to derive estimates about the 
(monetary) value of improved health. This contains two broad sections: one which 
provides the summary qualitative results and their subsequent evolution into quantitative 
indices and one which presents the subsequent quantitative results. This part of the thesis 
will also contain a variety of sensitivity analysis approaches and simulation exercises, 
which will be employed to provide a range of QALE gain results for the three illnesses in 
different eras of the twentieth century9. Part III of the thesis is concluded with the 
Extended Results chapter, which develops earlier results in order to generate a lower bound 
estimate about the value of twentieth century health, in its entirety. 
 
Finally, these results will be complemented by the thesis conclusions in Chapter 10, which 
will summarise the key questions of the thesis: What was the extent and value of 
improvements in health (mortality and morbidity) during different periods of the twentieth 
century in England? And, what has been the impact of improved health upon standards of 
living and the overall health related welfare of the population in twentieth century 
England? The thesis will conclude by defining the key contribution to knowledge of this 
analysis.  
                                                 
9
 Although there are actually four illnesses analysed in this thesis (namely: breast cancer, stomach cancer, blindness and tuberculosis) breast and stomach 
cancer will be considered in a combined chapter and therefore, in general, 3 types of illness will be considered. 
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2. Context 
2.1 Theoretical  
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2.1.1 Historical Theories 
The biggest debate that has surrounded considerations about improvements in mortality 
and morbidity in twentieth century England is related to the catalyst for these changes. 
Although much of this debate revolves around the time period that precedes that of the 
thesis and the results of the thesis do not contribute significantly to this debates,  the key 
themes of this debate will be outlined to provide an indication of the state of health in 
England at the beginning of the twentieth century and the grand theories most associated 
with the thesis topic. The debate is also relevant for the thesis because it illustrates the 
influence of factors other than medical technology as important for early twentieth century 
health improvements.  
 
2.1.1.1 Historical Theories / Debate about Health Improvements 
The debate was initiated by McKeown (1976) in the middle of the twentieth century, who 
contemplated whether the reduction in mortality achieved in England and Wales since 
1750 and particularly 1850, was primarily a by-product of improved standards of living, as 
manifested primarily in levels of nutritional intake, or whether it was attributed to technical 
improvements in the means of preventing premature death10.  
 
McKeown established the foundations of his theory through classifying the following 
major causes of disease: 
1. An autonomous change in the character of diseases. I.e. a decline in the virulence of 
the micro-organism itself11. 
                                                 
10
 In its fully developed form, McKeown originally presented a grandiose all-encompassing thesis accounting for Britain’s demographic growth since the 
early eighteenth century, which included claims about the relationship between fertility and mortality as well as claims about the causes of declining 
mortality. The demographic aspects of McKeown’s thesis will not be considered here as they are not important to the thesis. 
11
 McKeown, “The Modern Rise of Population”, p. 89 
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2. An improvement in the overall environment so as to reduce the chances of initial 
exposure to potentially harmful organisms12. This could either be: 
a. Through prevention. I.e. as a result of scientific advances in immunisation 
techniques 
b. Through a reduction in the exposure to diseases. I.e. achieved with public 
health policy (municipal sanitation or hygiene improvements) designed to 
sanitise the urban environment.  
3. An improvement in the human victims’ defensive resources after initial exposure to 
hostile organisms13. This could occur either: 
a. Through treatment. I.e. the development of effective scientific and medical 
methods for treating symptoms 
b. Via an increase in the level and quality of the exposed population’s average 
nutritional intake. I.e. better and more abundant food, thereby improving the 
individual’s own natural defences. 
 
McKeown’s strategy was then to consider the potential influence of each of these 
prospective causes, and systematically explain away factors other than nutrition (3b), as 
key for the mortality decline. Through a simplistic process of deduction (outlined below), 
McKeown arrived at his conclusions about the paramount importance of nutritional factors. 
 
McKeown began by explaining away the potential for a change in the nature of diseases 
(1), through claiming that there was no evidence or consensus to suggest that there had 
been a change in the scientific configuration of disease and the virulence of micro-
organisms. However others have claimed the contrary. For example, Magill has attributed 
the decline in deaths from pneumonia to a change in the nature of the disease14. And more 
generally, Griffith attributed the eighteenth century decline in mortality to medical 
advances, which changed the nature of disease15.  
 
McKeown continued by dismissing the environment and potential exposure (2a and 3a) 
through his claims that: “Certainly…no one…has sufficient therapeutic proof to argue that 
the drugs available at the turn of the century were sufficiently potent to have initiated the 
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 McKeown, “The Modern Rise of Population”, p. 91 
13
 Ibid 
14
 Griffith, “Population Problems of the Age of Malthus” 
15
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precipitous drop in mortality”16. McKeown offers further substance for this claim through 
a consideration about the timing of the introduction of therapy and the decline in major 
diseases: with the exception of smallpox and diphtheria, the dates at which either effective 
immunisation procedures or medical treatment became available were often far too late in 
time to be attributed to anything more than the final, marginal declines of these diseases17.  
 
This process leaves two possible causal factors: public health measures (2b) or nutritional 
factors (3b). McKeown overcomes this hurdle through considering the aetiology of the key 
diseases and grouping them into either ‘water and food borne diseases’ or ‘air borne 
diseases’. The latter were much more significant for the mortality decline (as they were 
more infectious and subsequently rife). According to McKeown, ‘air borne diseases’ could 
only have been reduced as a result of improved resistance in the population, which could 
only have been brought about through improved dietary status (3b).  
 
Therefore, using this a priori argument, McKeown claimed that his data were able to show 
that the air borne category of disease was responsible for the major decline in death rates 
and that this constituted irrefutable evidence that improved nutrition had been the cause of 
the British mortality decline18. Furthermore, McKeown felt it legitimate to extrapolate 
these findings backwards (into the eighteenth century) and forward (into the later part of 
the twentieth century), on the seeming assumption that the mortality decline was a linear 
process across all three centuries19.  
 
Preston (1975) has identified one of the major inaccuracies of McKeown’s assumptions 
through his considerations about the relationship between mortality and per capita income. 
McKeown’s theory of nutritional developments implies a relatively unitary relationship 
between economic developments and improvements in mortality, through his suggestions 
that these improved health dimensions (embodied in improved nutrition) can be conceived 
as direct functions of changes in a country’s per capita real income20. Preston has 
conducted an international cross-country study, which considers the relationship between 
mortality and income, and has concluded, “It is difficult to devise a plausible model in 
which the rate of change of mortality is a direct function of the level of income”21.  
                                                 
16
 McKeown et al, “An Interpretation of the Decline of Mortality in England and Wales during the Twentieth Century”, p. 410 
17
 Ibid 
18
 Szreter, “The Importance of Social Intervention in Britain’s Mortality Decline c. 1850-1914: A Re-interpretation of the Role of Public Health”, p. 10 
19
 Ibid 
20
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21
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Furthermore, in his study, Preston rules out nutrition (and literacy) as fundamental 
mortality change agents in favour of the major contribution of inoculation and 
vaccination22.  
 
Other authors have placed more importance upon literacy, female education and state 
programmes to promote mortality improvements. Caldwell (1979) and others have 
conducted a series of international and historical studies and concluded that personal health 
behaviour has been important in the prevention of infectious diseases, as has the pivotal 
role of government programmes in speeding mortality improvements23.  
 
Many of McKeown’s critics have pointed out that while improved nutrition might be part 
of the story, McKeown’s theory has given too little credit to public health measures and 
medicine24. One of the most famous proponents of this argument is Szreter.  The period 
from the late 1830s to 1875 has come to be seen as encompassing a ‘heroic age’ of 
pioneering advances in public health activism and legislation, and the period thereafter was 
also marked by activity from local governments and municipalities25. This inspired 
numerous developments, for example, improved water systems and sanitation and a great 
reduction in ‘water borne disease’ mortality. Furthermore, the problems of housing quality 
and quantity were gradually being alleviated and there was an expansion of local health 
and maternity services and regulation of milk supply (which was recognised by 
McKeown)26. These developments helped to foster the later decline in infant mortality, 
which occurred during the first three decades of the twentieth century. 
 
Therefore, the McKeown theory, which implies that the invisible hand of living standards 
conceived as an inevitable by-product of economic growth, facilitating an improvement in 
nutritional status, cannot take the leading role as the mechanism for Britain’s mortality 
decline27. Although his thesis is valuable as it emphasises the limited role of medical 
technology before the twentieth century, which is often carelessly overlooked by 
historians, there are many inaccuracies and fundamental components that McKeown has 
disregarded in his dogmatic allegiance to the importance of nutritional factors28. Hence, 
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public works, sanitation, improved housing and material standards of living, improved 
nutrition, medical and scientific developments all contributed to the decline in mortality.  
 
2.1.1.2 Implications of Changes 
The health transition began in Northwest Europe during the eighteenth century and was 
well under way by the middle of the nineteenth century, taking the form of a continuing, 
although not always consistent rise in life expectancy29. These increases continued into the 
twentieth century, which experienced some of the most impressive increases in life 
expectancy: from approximately 50 years at the beginning of the twentieth century to 
nearly 80 years by the close of the century. However, accompanying these improvements 
in mortality has been an increase in the population prevalence of chronic diseases and 
disabilities. This has occurred as a result of the dynamic between mortality and morbidity, 
which has often been referred to as the ‘substitute morbidity and mortality’ effects, defined 
as “that disease and mortality which results from a decrease in another specific 
disease”30. Hence, during the twentieth century, health has been gained on the one hand 
due to the reduction and elimination of one particular disease category (infectious), 
however this gain has been somewhat lost on the other hand because of other diseases 
replacing the original disease category (non-infectious, chronic). 
 
The epidemiological character of twentieth century Britain has come to resemble a 
scenario of disease without death and consequently a seemingly increased burden of 
illness. Over the course of the century, the balance between death and disease has shifted 
towards a longer life but with proportionately more suffering and disabilities. These 
twentieth century changes in the burden of disease and death raise numerous questions 
about the standards of living associated with health.  
 
2.1.2 Epidemiological Transition 
2.1.2.1 What is the Epidemiological Transition? 
In 1971, Abdel Omran detected an ‘epidemiological transition’, consisting of a passage 
from a regime in which there was a conversion of the pattern of mortality from one 
dominated by infectious diseases to one dominated by chronic degenerative diseases, this 
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also entails a decline in the death rates accompanied by a seemingly paradoxical increase 
in morbidity rates31.  
 
2.1.2.2 What Happened to Twentieth Century Mortality and Morbidity? 
A major component of England’s twentieth century epidemiological transition has been the 
decline in the death rate and the increase in life expectancy, which have both meant that 
there has been a radical increase in the number of people surviving to old age32. The 
increasing average age of the population is also reinforced by the change in the 
composition of fatal diseases, as degenerative diseases kill at much older ages than 
infectious disease, and therefore this transition in the causes of death is characterised by a 
general redistribution of deaths from young to older ages33.  
 
The epidemiological transition also describes the shift in the burden of illness, which has 
been experienced in twentieth century England. At the beginning of the twentieth century 
the major killers were infectious epidemics. By the end of the twentieth century the major 
killers were chronic degenerative illnesses. Hence cancer, heart disease and cardiovascular 
disease represented the main killers and the most prevalent illnesses, by a significant 
majority at the close of the twentieth century, which marks a stark contrast with the pattern 
of illness one hundred years earlier when tuberculosis and whooping cough dominated the 
mortality burden.  
 
The link between ill health and death has a further dimension, which the epidemiological 
transition literature addresses. In the vast majority of the literature concerning public health 
and historical changes in the level of health, and even grand theories about the state of 
health, many have inaccurately used mortality as a proxy for morbidity. During certain 
situations this proxy is acceptable, for example, when many illnesses within the disease 
profile of a population cause death in a significant number of the people affected (usually 
at least five percent) and when this level of case fatality rates remains stable. Hence, in 
strict epidemiological terms, this is considering the relationship between mortality and the 
risk of falling sick. During eras before the twentieth century, when the clinical course of 
most sicknesses was brief (eight weeks or less) and most sicknesses were resolved quickly 
(by either recovery or death), this association was acceptable34.   
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Throughout the twentieth century it became increasingly necessary to look further than 
death rates when considering changes in health and the quality of life associated with 
illness. This was a result of the inability of death rates to approximate sickness rates, which 
is most vividly illustrated by the following mechanisms. First, over time the case fatality 
rate may describe a different trend than the death rate35. Second, not all sicknesses pose a 
significant risk to death, which became increasingly true as the twentieth century unfolded. 
As a result of developments in health, the average duration of an illness has increased. For 
example, treatment of most chronic degenerative diseases does not cure these sicknesses 
they only ameliorate the symptoms and prolong the period of illness preceding death. The 
theory of the epidemiological transition implies a shift in the average duration of illness in 
general, rather than merely in diseases causing death, which is an increasingly important 
distinction for the time period being considered in the thesis.  
 
A further advantage of considering the changing burden of illness through the framework 
of the epidemiological transition is for the important distinction it provides between the 
risks of falling sick, which is a measure of incidence and the risk of being sick, which is a 
measure of prevalence. By the onset of the twentieth century, previous developments in 
public health, sanitation, nutrition, and early medical advances had reduced the risk of 
falling sick and in turn increased the risk of being sick. 
  
Hence, by the end of the twentieth century, most of the population survived to the 
boundary of entering old age, but much of the population survived with illness and injuries 
that occupied increasing time. From this perspective the epidemiological transition can be 
defined more broadly as a shift in the leading causes of death from acute to chronic 
diseases and therefore a shift from brief to protracted diseases. A society that has gone 
through such a transition gains additional life years, some in good health and some in poor 
health. This is the central trend that is reflected in the thesis, which will consider the value 
of these additional (disease burdened) life years, in terms of individual quality of life and 
health related welfare of the population as a whole. 
 
2.1.2.3 Implication of the Epidemiological Transition in General 
The situation and events which encompass the epidemiological transition (outlined above) 
combined with the shortage of empirical evidence depicting long term trends in chronic 
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disease has resulted in a wide range of opinions and theories about: the meaning of current 
trends in health, the outlook for future scenarios, and the general nature of the link between 
mortality and morbidity. 
 
One of the most pessimistic theories to evolve from the epidemiological transition is the 
‘failure of success’ hypothesis. Proponents of this theory, most notably, Kramer (1980) and 
Gruenberg (1977), have connected medical improvements (for example, the introduction of 
sulfa, penicillin, Aureomycin, Terramycin, etc) with the postponement of death, rather than 
a universal improvement in health. Consequently, instead of diminishing disease and 
enriching life, the twentieth century products of medical developments have served more 
to prolong disease and increase the proportion of the population suffering from disabling 
and chronic illnesses36. This is vividly highlighted through a consideration of the twentieth 
century changes in the prognosis of Down’s syndrome. As a result of twentieth century 
(1940s) medical developments, the life expectancy of some individuals with Down’s 
syndrome has been extended from early adolescence to seventy years. The net effect has 
been a doubling or quadrupling of the prevalence of Down’s syndrome in the population37. 
These delay of death effects are also significant for numerous other disorders, for example, 
arteriosclerosis, schizophrenia, diabetes, spina-bifida, etc38.  
 
Hence, the key message of the ‘failure of success’ school is the claim that twentieth 
century scientific developments in medical care have only made achievements in life-
saving technologies, rather than health preserving technologies, and that the net effect has 
been to worsen the population’s health and furthermore, without a concentrated effort to 
search for preventable causes of chronic illnesses there will be no further enhancements in 
human health39.  
 
An alternative, optimistic perspective is the theory of ‘dynamic equilibrium’. This 
optimistic view claims that in the long term, chronic illness will be confined to the last few 
years of life so that the proportion of healthy life will increase. Certain policy makers, for 
example, Marshal (1975) in the UK and Robine (1986) in the USA have adhered to this 
utopian opinion40. 
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Along a similar vein is the theory of the ‘compression of morbidity’, coined by Fries 
(1989), which envisages a reduction in illness by postponing the age of onset of chronic 
infirmity relative to the average life duration, such that the period of morbidity is 
compressed between an increasing age of onset and a relatively fixed life expectancy41. 
This model requires the effects of preventative interventions to have a greater effect on 
morbidity than mortality and is also dependent upon the population adhering to favourable 
personal health habits42. 
 
A final theory, which entails the most optimism about future health trends, is the ‘fourth 
stage’ of the epidemiological transition hypothesis. Olshansky (1986) claims that the next 
phase in mortality and morbidity evolution will be marked by a decline in degenerative 
diseases. These predictions are bolstered by the improvements in chronic diseases that 
were achieved in America during the final decades of the twentieth century, for example, 
the decline in heart disease (by more than 20 percent between 1968 and 1978) and 
reductions in the death rates for cancer and strokes since the early 1970s43. 
 
Due to the nature of increased survival and the change in the burden of morbidity and 
causes of mortality, many of these aforementioned trends and theories are not illogical. 
However, to claim that health and standards of living associated with it have worsened, a la 
Gruenberg and Kramer, seems overly pessimistic. This will be justified by the thesis, 
through applying the thesis’ original health evaluation methodology to twentieth century 
health in order to provide estimates about the value (direction and magnitude) of improved 
mortality and morbidity, which will enable the thesis to commentate on the plausibility of 
the above theories.  
 
2.1.2.4 Implication of the Epidemiological Transition for the Thesis 
The theory of the epidemiological transition is useful for highlighting the relationship 
between mortality and morbidity, although it does not extend to quality of life 
considerations. The thesis will consider the nature of the additional life years which have 
been fostered by the substantial and unprecedented twentieth century improvements in 
longevity.  
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First, the increasing average age of the population (which is indicative of improvements in 
life expectancy and the death rate) was a result of the changing nature and declining virility 
of diseases. Infectious epidemics kill (typically children and young adults), whereas this is 
not the case for chronic degenerative diseases (which take their victims in old age). This 
has ramifications for the increase in life expectancy (mentioned above) and also for the 
increased proportion of healthy life years.  
 
Second, the change in the case fatality rate has facilitated a more favourable relationship 
between the chances of contracting an illness and subsequently dying from that particular 
illness. At the onset of the twentieth century the case fatality rate was much higher, which 
essentially means that the chances of illness closely foregoing death were much higher. 
Along a similar vein, it will also be necessary to consider the changing dynamic between 
incidence and prevalence throughout the twentieth century.  
 
Third, the general result of the epidemiological transition, which states that there has been 
a gain in life years enjoyed by the average individual but that not all of these additional life 
years are in good health will be evaluated by the thesis. This trend is undeniable, but the 
prospect of improving comfort in ill health, and consequently more valuable life years, 
even when overshadowed by morbidity, has been completely overlooked in the literature to 
date. The thesis will fill this void through considerations about the changing quality of life 
years associated with different illnesses during the twentieth century.  
 
Lastly, the thesis will highlight the profound distinction between mortality and morbidity 
and through close attention to both and a detailed analysis will polarise the error of using 
death rates as a proxy for health, especially as the twentieth century unfolded.  
 
2.1.3 Choice of Thesis Illnesses 
The epidemiological transition provides the most descriptive and authentic theory about 
the trends in twentieth century mortality and morbidity and consequently provides the best 
framework for the selection of illnesses for consideration in the thesis. It is not possible to 
include all illnesses because of time constraints and also because of the changing 
classification of illnesses and other complications, which would make the task impossible. 
Therefore the thesis will consider illnesses that correlate with the principles of the 
epidemiological transition. I.e. the illnesses evaluated in the thesis will reflect the move 
from infectious epidemics (e.g. tuberculosis) to chronic degenerative diseases (e.g. breast 
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and stomach cancer). These illnesses will be considered qualitatively and quantitatively in 
order to generate numerical counterfactual estimates about the monetary value of 
improvements in health. Blindness will also be considered to provide a proxy for 
disabilities. The reasons for selecting these particular morbidity states will be outlined in 
Chapter 3: Section 3.4. 
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2.2.1 General Problems of Measuring Mortality and Morbidity 
The classic literature (e.g. McKeown and Szreter) and the epidemiological transition theorists 
have highlighted the significant change in the twentieth century English mortality and 
morbidity burden and indicated the subsequent need to try and measure this evolution.  
However, there are numerous problems with the measurement of health, which are outlined 
below.  
  
2.2.2 Epidemiological Transition Forces 
2.2.2.1 Substitution Effect 
The substitution effect is interlinked with the core of the epidemiological transition. The 
changing burden of disease, i.e. the move from infectious to chronic has meant that the 
average time of illness preceding death has increased significantly as degenerative and 
protracted illnesses have replaced acute illnesses. This has been further exacerbated by 
medical developments, which are increasingly able to prolong life in the diseased state but are 
unable to cure the disease. Pessimists identify this as an indication of worsening health, with 
their references to the prolonged average duration of certain diseases and disabilities, rather 
than producing cures44. 
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A more optimistic stance is taken by those who recognise that sicknesses are lasting longer as 
a result of improvements in medical technology, which means that they are resolved in disease 
management rather than death. The positive change in the nature of the key illnesses has 
meant that on the whole, diseases with a long course and low incidence have replaced illnesses 
with a short course and high incidence45. The longer duration of these long course diseases 
exceeds their lower incidence in its effect on sickness time in the population46.  
 
2.2.2.2 Composition Effect 
In each successive period within an era of declining mortality, the population composition 
changes such that people who would have died earlier in the preceding regime are now living 
longer, and these ‘new survivors’ are, on average, more likely to experience health problems47. 
 
Therefore, by virtue of improvements in medical technology, more morbid prone individuals 
are being kept alive. Consequently (despite the improvement in their death rate) they are 
contributing to a ‘failure of success’ type increase in the mortality burden, as there was no 
cure for their morbidity (only for their potential mortality) throughout the twentieth century. 
This phenomenon became increasingly evident during the antibiotic era. 
 
2.2.2.3 Time Effect 
The claim of this theory is that there has been an increase in ill health as a result of 
improvements in survey and diagnostic methods. Hence, because diseases, especially chronic 
ones, are being detected earlier and the life expectancy with these diseases is increasing, the 
prevalence of these diseases has risen, albeit partially artificially. 
 
Increasingly over time medical science has introduced a variety of means of surveillance and 
detection, and these techniques were applied to a rising proportion of the population. This 
meant that individuals were found to be sick sooner than they would have been without these 
screening and diagnostic innovations, and are adding to the prevalence of disease statistics, 
without a worsening per se in the general health level of the population48. This time effect is 
sometimes referred to as the ‘early patients’ phenomenon, as it depicts people being included 
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in morbidity statistics earlier than they had traditionally been as a result of the improved 
ability to detect disease in earlier stages, e.g. hypertension, hypercholesterolemia, etc.  
 
Therefore, although reported levels of illness have increased, this is for reasons not strictly 
related to health. The thesis measurement will be capable of illustrating health improvements 
that will be isolated from these seemingly perverse effects of the epidemiological transition. 
 
2.2.3 Social Forces 
2.2.3.1 Health Expectations 
As economies develop and the population becomes wealthier and enjoys a general increase in 
their standards of living they also become more sensitive to health and adopt more stringent 
expectations about suitable levels of health. For example, at the end of the twentieth century, 
morbidity levels were highest in the wealthiest countries49. This positive correlation between 
national income and reported levels of morbidity provides a likely contribution to part of the 
rise in morbidity in twentieth century England. 
 
2.2.3.2 Stock of Diseases 
The above mentioned personal relaxing of the distinction between wellness and illness is also 
evident from physicians, as they also seem to have lowered the threshold of sickness50. As a 
result, conditions that would not have been regarded as health problems earlier are now 
recognised as such, e.g. depression and glandular fever. Although it is difficult to explicitly 
test and approximate the magnitude of this effect, there is clear historical evidence that shows 
a rising trend in the range of conditions regarded as ailments51. 
 
Additionally, as a result of medical developments, there is an increasingly recognised stock of 
diseases and diagnosable conditions, which creates the potential for physicians and patients to 
diagnose and register their ill health with a disorder. In this sense the incidence rate and 
overall morbidity in a population is a function of the (increasingly) recognised stock of 
diseases52. 
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2.2.4 Economic Incentives 
Some researchers have considered the effects of economic incentives for encouraging people 
to more willingly present themselves as sick. This is a product of the notion that labour force 
participation may become less attractive as a result of the provision of alternative sources of 
more easily obtained income, such as disability payments53.  
 
Wolfe and Haveman (1990) illustrate the correlation between the proportions of registered 
disabled people in America and the level of disability payments over a twenty-year period. In 
1962: 7 percent, in 1973: 11 percent and in 1980: 9.5 percent of working age men were 
classified as disabled54. In combination with this trend, the generosity of disability welfare 
payments also display a ‘hump shaped’ pattern55. These inferences are also consistent with the 
findings of other authors who have suggested that perhaps one third of the rise in disability 
rates has been due to the generosity of disability transfer policy56. 
 
A further type of economic incentive that is potentially increasing registered levels of 
morbidity is the availability and accessibility of health service facilities. The use of healthcare 
services can increase morbidity, as the provision of subsidised healthcare is likely to provide 
an incentive to seek medical help earlier and more frequently. Consequently, ailments are 
diagnosed more frequently, rapidly and in some cases unnecessarily and this creates a pseudo 
worsening in the prevalence of disease57.    
 
Therefore these types of social forces all combine to alter the meaning of illness prevalence 
data. Hence, the same environment of mortality in 1900 would appear much more detrimental 
in 2000, because of the change in social attitudes towards illness and because of the magnitude 
of genuine health improvements. The problem for measuring historical levels of health that 
this poses is the impossibility of separating the influences of these social forces from actual 
changes in health. Consequently, a different angle for considering and measuring health needs 
to be employed in the thesis. This will be achieved through making considerations about the 
quality of life associated with these illnesses. For example, even though the prevalence of 
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arthritis or diabetes has increased between 1900 and 2000, the burden of these illnesses was 
considerably lower by the close of the century, as a result of improvements in medical therapy 
which have increased the quality of life associated with these ailments. The benefit of this 
approach is that the above distortions are overcome. 
 
2.2.5 Recent Studies that Measure Mortality and Morbidity 
During the last quarter of the twentieth century there was mounting attention directed towards 
the concept of measuring health and evaluating the genuine changes in morbidity, as well as 
those for mortality. The majority of studies and measures of health have been conducted by 
two broad groups: social policy experts and health sector professionals. Both of these groups 
are dispersed between the public and private sector. Additionally, there is a peripheral and 
hybrid collection of professionals with an interest in considering the changes in health. Also 
on the margin are those who provide commentary about the authenticity of measurement 
techniques in general. The majority of these critics are economists and philosophers, who have 
an understanding about notions of utility and measurement.  
 
Despite the significant and varied pool of potential health measurers, there is a dearth of 
efforts to consider the changes in health, gauge these in a quantitative manner and also to 
consider broader implications than just health. The table below provides a brief explanation of 
the most prominent approaches to measuring health, which are largely attributable to medical 
professionals and secondly, social policy experts. 
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Table 2.2.1: Summary of most prominent health measurement methodologies58. 
Author Measure Explanation  Type of Index/ Data 
Bebbington (1988)59 
Policy expert 
England and Wales 
Applied study 
Objective measure 
Expectation of Life without 
Disability 
(ELWD) 
ELWD considers the number of individuals who have 
been reported as disabled. This information is then 
developed to provide an estimate of life expectancy 
without disability (in a similar manner to the formula 
which utilises death rates to establish life expectancy). 
 
Statistics on the number 
of registered disabled 
(which are often 
ambiguous). 
Bergner & Bobbitt (1981)60 
Health professional 
USA 
Applied study 
Subjective measure 
Sickness Impact Profile 
(SIP) 
The SIP contains 136 statements about the health 
related dysfunction in 12 areas of activity. The SIP is 
designed to be applicable to individuals and groups of 
diseases and disabilities in order to provide 
information about the sickness related dysfunction. 
  
Questionnaire. 
[Brody] (1985)61 
Health professional 
USA 
Theoretical study 
Subjective measure 
 
Active Life Expectancy Considers disability and the quality of extended life 
expectancy. Active Life Expectancy provides a 
measure that considers the prevalence of good and bad 
health. 
 
Questionnaire. 
Bush et al (1986)62 
Health professional 
USA 
Applied study 
Subjective measure 
 
Quality Well Being  
(QWB) 
Components of QWB: mobility, physical activity, 
social activity and symptom levels are derived through 
questioning patients. 
 
Questionnaire. 
 
 
                                                 
58
 1) The details below each author refer to the following; i) Field: considers the broad industry in which the author works, either health professional, policy expert or economist, ii) Country: considers where the study was 
implemented and / or the type of country specific data the study utilises, iii) Type of study: considers whether the measure is theoretical or whether it was actually applied in a survey, iv) Type of measure considers whether the study 
is ‘objectively’ observed by a professional (conducting the study or utilising data) or subjectively derived through questioning the ill. There is still scope for subjectivity between clinicians, and therefore these terms are relatively 
objective (relative to the subjective measures in the health literature). 
2) When an author’s name is depicted in brackets, for example, [Brody], it indicates that the measure being described was not introduced by this person, but that it has been better described, developed or implemented by the named 
author. 
59
 Bebbington, “The Expectation of Life without Disability in England and Wales” 
60
 Bergner & Bobbitt, “The Sickness Impact Profile: Development and Final Revision of a Health Status Measure” 
61
 Brody, “Prospects for an Ageing Population” 
62
 Balban & Sagi, “Weights for Scoring the Quality of Well Being Instruments among Rheumatoid Arthritics” 
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Cutler & Richardson (1999)63 
Economists 
USA 
Applied study 
Subjective measure 
Quality of life Weights Identifies 10 illnesses that were consistently recorded 
between 1970 and 1990 and applies quality of life 
weights that are derived from responses to the 
National Health Interview Survey (NHIS)64. 
Registratios of disease 
and disability prevalence 
+ NHIS questionnaire. 
Erickson (1998)65 
Health professional 
USA 
Theoretical study 
Subjective measure 
Health and Activity 
Limitation Index 
(HALex) 
Considers perceived health and activity limitation to 
provide a single score about the quality of life related 
to illness. This is achieved through utilising a sample 
of NHIS responses combined with life expectancy 
data. 
 
NHIS questionnaire + 
life tables. 
Ghana Health Project Team (1981)66 
Health professionals 
Ghana 
Applied study 
Objective measure 
 
Healthy days of life lost due 
to disease 
Similar to Sullivan’s methodology  but related to 
specific diseases. They review 48 diseases and 
consider the number of healthy days of life lost due to 
each disease. 
Census information on 
disease. 
[Ho] (1980)67 
Policy expert (WHO) 
Not country specific 
Theoretical study 
Subjective measure 
 
Functional Ability Considers the superiority of measures of functional 
ability instead of symptomatic indicators of morbidity, 
for indicating the burden of different disabilities and 
diseases. 
 
Questionnaire. 
Hyder et al (1998)68 
Health professionals 
USA 
Theoretical study 
Subjective measure 
Healthy Life Years 
(HeaLY) 
The HeaLY measures the amount of healthy life lost 
due to morbidity and mortality, and early mortality 
due to morbidity. This can be calculated at the 
individual or population level. This measure is similar 
to that developed by the Ghana study team, although 
the HeaLY authors claim that their model is superior.  
 
Census information on 
disease. 
                                                 
63
 Cutler & Richardson, “Your Money or Your Life: The Value of Health and what Affects It” 
64
 The National Health Interview Survey (NHIS) is the National Centre for Health Statistics' (NCHS) annual, nationwide survey of about 36,000 households in the U.S. This is a principal source of information on the 
health of the civilian non-institutionalised population. It has been conducted every year since 1957.  As such, it is one of the most significant sources of health data on the US population. The NHIS includes a set of core 
questions which change very infrequently, as well as a series of supplemental special topic questions that are modified from year-to-year in response to current interest and need for data.  The core questions make up 
about 50 percent of the questionnaire and provide estimates of acute conditions, injuries, restriction of activity due to chronic conditions, respondent-assessed health status, and the use of medical services, including 
physician contacts and short-stay hospitalisation. The detail and versatility of this measure have continually improved since its introduction in 1957: National Health Interview Survey (2004). “About the National 
Health Interview Survey”, Retrieved 10 January 2004, from  http://www.chas.uchicago.edu/healthdata/national/nhis/ 
65
 Erickson, “Evaluation of a Population Based Measure of Quality of Life: A Health and Activity Limitation Index” 
66
 Ghana Health Assessment Project Team, “A Quantitative Method of Assessing the Health Impact of Different Diseases in Less Developed Countries” 
67
 Ho, “Measuring Health as a Component of Living Standards” 
68
 Hyder & Rotland & Morrow, “Measuring the Burden of Disease: Healthy Life Years” 
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Mehrez & Gafni (1991)69 
Economists 
Not country specific 
Theoretical study 
Subjective measure 
 
Healthy Years Equivalents 
(HYE) 
They market the HYE as a superior version of the 
QALY70 because the HYE is (apparently) a better 
measure of utility. Many others have highlighted that 
the HYE is simply a TTO71 QALY and therefore not 
superior72. 
Consumer preferences 
elicited through standard 
gamble questionnaire 
techniques. 
Murray & Lopez (1996)73 
Health professionals and policy 
experts 
Global 
Applied study 
Objective measure 
 
 
Disability Adjusted Life Year 
(DALY) 
DALYs are weights for different illnesses. They are 
elicited through a series of revealed preference studies, 
which are conducted on a group of medical experts. 
 
Medical expertise in 
conjunction with weight 
eliciting questionnaires. 
Sullivan (1971)74 
Health professional 
USA 
Theoretical study 
Subjective measure 
 
Disability Free Life 
Expectancy  
(DFLE) 
Considers the number of life years in good health 
through using simple data (life tables and surveys). 
DFLE only provides effective results for long term, 
gradual changes75. 
Life tables + 
questionnaire. 
[Wilson] (1981)76 
Health professional 
USA 
Theoretical study 
Subjective measure 
 
Functional Ability + Life 
Expectancy 
Wilson suggests that functional ability should be used 
in conjunction with life expectancy to provide a 
quality of life indicator. These claims are similar to 
considerations currently being made by the OECD and 
other organisations. 
 
Life tables + 
questionnaire. 
                                                 
69
 Mehrez & Gafni, “The Healthy Years Equivalents: How to Measure them using the Standard Gamble Approach” 
70
 QALY = Quality Adjusted Life Year, which is essentially a life year that has been adjusted for the burden of disease and disability. 
71
 TTO = Time Trade Off, which is a methodology for eliciting revealed preferences about the perceived burden of a disability, which essentially requires the participant to trade off healthy life years for diseased and disabled ones. 
72
 Cuyler & Wagstaff, “QALYs versus HYEs” and Bleichrodt, “QALYs and HYEs: Under what Conditions are they Equivalent?” and numerous others have also made this claim. 
73
 Murray & Lopez, “The Global Burden of Disease Study” 
74
 Bone, “International Efforts to Measure Health Expectancy” 
75
 Mathers & Robine, “How Good is Sullivan’s Method for Monitoring Changes in Population Health Expectancies?” 
76
 Wilson, “Do Health Indicators Indicate Health?” 
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The table above displays the two major approaches towards the measurement of health: 
subjective evidence, which considers how the participants feel and perceive their health 
burden, (functional ability, the SIP, results of the NHIS) and behavioural evidence, which 
considers health through reviewing what has often been referred to as ‘the 5Ds’ (death, 
disease, disability, discomfort, dissatisfaction), which are reflected through rates of 
absenteeism, confinement and seeking medical care (for example, The Ghana study, The 
Global Burden of Disease study and also measures like the ELWD and HeaLY indices) 77. 
 
The most common and increasingly popular method of assessing health is through subjective 
evidence about an individual’s perceived ability to perform tasks of daily living, expressed 
through responses to some form of questionnaire. It is generally agreed that these types of 
consideration about functional ability in conjunction with life expectancy provides the most 
proficient approach for indicating improvements in health78.  
 
Despite the popularity of functional ability, there was still a broad range of health 
measurement methodologies and results. One of the reasons for this is the difficulty involved 
in defining and measuring morbidity. Additionally, there exists inconsistency among theorists 
about what the most important proxy variables are concerning health79. Numerous authors 
have indicated that the variables that are selected, and the manner in which the health 
questions are conveyed, exert a major influence upon the results obtained80. Another problem, 
related to the study design, is the unreliability of data collection as a result of morbidity rates 
being variable in quality.  
 
Further weaknesses of the questionnaire approach are a consequence of the problems with the 
respondents, e.g. symptoms do not always directly reflect the actual disease81, the subjective 
reporting of morbidity is influenced by cultural and individual differences in attitudes towards 
                                                 
77
 Balinsky & Berger, “A Review of Research on General Health Status Indexes”, p. 286 
78
 Numerous authors have stressed the desirability of creating a health measure that combines some proxy for morbidity with life expectancy, for example; 
Balinsky & Berger, Wilson, Bone, Bowling, etc. 
79
 As Table 2 indicates, there are numerous health measures that consider different aspects of disease. This is partly because there is no agreement or proof about 
the most indicative proxies to question and also about the most efficient methodology for framing the questions and therefore this debate still remains unresolved. 
This debate has no crucial relevance for the thesis and therefore it will not be visited in any greater detail than what is provided here. 
80
 Llewellyn-Thomas, “Describing Health States: Methodological Issues in Obtaining Values for Health States”, p. 550 
81
 Ho, “Measuring Health as a Component of Living Standards”, p. 10 
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health, and accounting for handicap at the personal level or the significance of functional 
disability are not catered for in the majority of these questionnaires82.    
 
The diversity between the results that are yielded from observed (e.g. clinical studies) and self 
reported (e.g. functional ability, questionnaire studies) studies implies that self-perceived 
morbidity and observed morbidity may be measuring different aspects of illness83. When 
considering the authenticity of clinical studies of morbidity, it is worrying to note the wide 
variation in the diagnostic skills of clinicians. Elinson and Trussel (1957) compared clinical 
diagnoses by two physicians in the same sample of patients and identified marked differences 
in their diagnoses84.   
 
In addition to these general weaknesses in the above studies there are also numerous specific 
weaknesses for the demands of the thesis. 
 
2.2.6 Recent Studies: Mortality and Morbidity Measurement Weaknesses for the Thesis 
There are two fundamental shortcomings of the aforementioned measures for the requirements 
of the thesis: the lack of historical content and the failure of these measures to explicitly 
connect the burden of morbidity with the quality of life of illness sufferers. 
 
2.2.6.1 Lack of Historical Content 
Virtually all existing approaches to monitoring health are redundant when trying to evaluate 
health from a historical perspective. Self-perceived measurement techniques consist of asking 
or observing present-day sufferers about how they perceive the burden of their diseases and/or 
disabilities. Observed measures of mortality require a physician to monitor and evaluate the 
burden of illnesses upon contemporary sufferers. As a result of the historical nature of the 
thesis it will be impossible to estimate morbidity through interviewing or observing 
contemporary sufferers. And, because efforts to measure health only became commonplace 
towards the end of the twentieth century, there are no existing historical estimates of the 
morbidity burden for any earlier eras. 
 
                                                 
82
 Ibid 
83
 Murray & Chen, “Understanding Morbidity Change”, p. 490 
84
 Elinson & Trussel, “Some Factors Relating to Degree of Correspondence for Diagnostic Information as Obtained by Household Interviews and Clinical 
Examinations” 
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2.2.6.2 Void of Quality of Life Concerns 
The major focus of existing health measures is typically on the effects of different illnesses 
(and the efficacy of therapies for these illnesses) in medical terms or for their implications 
upon the economy in policy terms. These measures are significantly lacking in scope for 
reflecting the implications of the changing burden of morbidity upon quality of life for the 
individual and standards of living of the population in general.  
 
Moreover, there is currently a significant void in the literature that considers the changing 
twentieth century burden of morbidity, and none of these studies have attempted to make 
quantitative estimates about the value of this changing morbidity burden, for the quality of life 
of the English population during the twentieth century. As a result existing measures are 
unsuitable for the demands of the thesis.  
  
2.2.7 Conceptual Requisites of an Ideal Historical, Mortality and Morbidity, Quality of Life 
Measure 
2.2.7.1 Conceptual Requisites of an Ideal Measurement 
The form of measurement that the thesis requires is one that accords with the requisites for a 
representational (as defined by representational theory of measurement) and reliable measure.  
 
2.2.7.2 Representational Measurement 
The core and virtue of this theory is that measurement is a process of assigning numbers to 
objects in such a way that the relevant qualitative empirical relations among the objects are 
reflected in the numbers themselves as well as in important properties of the number system. 
This will be achieved through the measurement instrument of the thesis aspiring to accord 
with the basic criteria of representational measurement85: 
1. The measurement will be ‘accurately indicative’ through precisely representing the 
relative quantities of the variables being measured (e.g. EuroQol component) as well 
as indicating the relations between the variables (e.g. between different EuroQol 
components)86. 
                                                 
85
 Points 1 to 4 have been developed from Boumans, “Representation and Stability in Testing and Measuring Rational Expectations”, p. 383 
86
 EuroQol depicts the foundation matrix of the thesis measure, i.e. it is from the EuroQol matrix that the Quality Adjusted Life Year (QALY) will be derived and 
ultimately the Quality Adjusted Life Expectancy (QALE) will be determined. The EuroQol contains the template and framework of elements that will be 
considered collectively to form the basis of the health related quality of life thesis measure. Please see Chapter 3: Methodology for further explanations about the 
EuroQol matrix. 
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2. The desirability of consistency in the measurement necessitates that the approach to 
measurement is maintained throughout the thesis, for different times and health states. 
For example, whether measuring the health burden of breast cancer in 1900, 
tuberculosis in 1950 or blindness in 2000, the EuroQol matrix will be designed and 
implemented to yield consistent measurements of the QALY, which will ultimately 
provide a consistent estimate about the quality of life related to health across time 
(twentieth century) and space (different diseases and disabilities).  
3. Sensitivity in measurement in order to accurately and entirely gauge changes in the 
objects of measurement. For the demands of the thesis the sensitivity demands are: 
i. To identify marginal and tacit changes in the burden of illness. 
ii. To better achieve the ceteris neglectibus condition (see below for details) 
through minimising the effects of ‘other circumstances’ (OC) not associated 
with health related quality of life87. For example, worsening in the reported 
health of the population as the twentieth century unfolded as a result of 
changes in health expectations, the epidemiological transition and improved 
medical technology will be minimised through adhering to the requisites of 
sensitivity. 
4. In order to achieve the above criteria of representational measurement there is a need 
for a steadfast scale of measurement.  
 
As a result of the need to measure quantity (in this respect the quantity of health and quality of 
life related to health), there is an order relation system which enables the measurer to order 
quantity in a way which has formal similarity to the relations equal, greater and lesser88, which 
provides the basis for developing a scale of measurement89. 
  
Measurement scales can be formed in two ways90: 
1. Direct mapping (from a quality relational system to a numerical relational system). 
2. Indirect mapping (through a relation to the quality to be measured and other qualities, 
for which measurement scales have been defined, because it is impossible to set up a 
satisfactory measurement scale directly). 
                                                 
87
 See Equation 1 below for definition of OC. 
88
 Finkelstein, “Theory and Philosophy of Measurement”, p. 12  
89
 Ibid 
90
 Finkelstein, “Theory and Philosophy of Measurement”, p. 15 
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The thesis utilises the second type of measurement. Quality of life will be measured through 
identifying a QALY as a result of the impossibility of directly gauging health related quality 
of life. The worked examples below provide a further explanation about the mechanics of 
indirect and representational measurement. 
 
In this measurement framework, the representative acts as an instrument for measuring 
attribute X. The table below highlights two examples of the relationship between components 
in an ideal representative measure. 
Table 2.2.2: Comparison of thermometer and thesis QALE components of representational 
measurement91 
Components of Representational 
Measurement 
Example 1: 
Temperature 
Example 2: 
Quality of Life (QoL) 
Instrument: Thermometer EuroQol Index 
Attribute X: Temperature Quality of life (QoL)  
Correlate of attribute X: Height of mercury QALY index (0  1) 
Function: T = f (h) 
T = temperature, h = height 
of mercury 
QoL = f (QALY) 
 
In example 1: the thermometer is the representative of temperature in which the height of the 
mercury column correlates with the temperature. The formal analogy of that correlation is the 
function between height and temperature, T= f (h). 
 
In example 2: the EuroQol index is the representative of quality of life in which the value of 
the QALY index correlates with the overall QoL. The formal analogy of that correlation is the 
function between the QALY and the quality of life, QoL = f (QALY). 
 
                                                 
91
 Referenced and developed from Chang, “Spirit, Air and Quicksilver: The Search for the Real Scale of Temperature” 
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In both of these examples, the only restriction which must be placed upon f is that T and QoL 
must be defined for every value which h and QALY may assume, and the numerical order of 
the temperature and QoL numbers must correspond to the temperature and QoL order.  
 
2.2.7.3 Reliability of an ideal measure 
When trying to develop an indirect measurement tool in the form of representational theory 
there are numerous conditions that need to be achieved. These conditions are further 
complicated when the measurement and the tool developed to gauge it are economical (e.g. 
QALY and QoL) rather than physiological (e.g. thermometer). When conceptualising an ideal 
measurement scale for assessing health related quality of life the initial objective is to achieve 
standardisation and satisfy the condition of minimalist over determination.   
 
Standardisation is achieved through accuracy and stable correlations in order to minimise the 
influence of ‘other circumstances’ (OC) not associated with health related quality of life92. 
This has been adhered to in the development of the thesis methodology through the selection 
of the most precise EuroQol variables.  
 
Chang (2001) has developed a procedure of minimalist over determination, which is designed 
to identify the best measure under conditions of uncertainty, i.e. non ceteris paribus 
environments (which were derived from the history of the development of a standard 
thermometer in the nineteenth century)93. In order to achieve the conditions of minimalist over 
determination Chang outlined the following process:  
Build a series of instruments that are each based on a different but very minimal and 
consistent set of theoretical assumptions, and test these instruments under different 
circumstances. The instrument for which the results are most coherent, under these 
different circumstances is the instrument which can be chosen to be the standard 
measuring device94.   
 
According to Chang, the point of this history of the thermometer is that for endorsing the air 
thermometer as the best standard, Regnault did not need to prove that the expansion of air is 
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 See Equation 1 below for definition of OC 
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 Chang, “Spirit, Air and Quicksilver: The Search for the Real Scale of Temperature” 
94
 Ibid 
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uniform. Through minimalist over determination, the air thermometer was the only thing left 
as all other types of thermometer failed to meet the necessary, minimalist conditions of 
consistency. Hence, the art of practicing this strategy (of minimalist over determination) lies in 
the ability to contrive over determined situations on the basis of as little as possible.    
 
Minimalist over determination has been achieved in the thesis through selecting the most 
indicative variables and versatile methodologies for measuring historical health related quality 
of life. 
 
When applying over determination to history or economics, the process becomes more 
complicated as a result of the inability to create a stable environment under which to compare 
different measuring instruments. Accuracy is achieved through adhering to the ‘ceteris 
neglectibus’ condition95.  
 
The ceteris neglectibus condition for example 2 (QoL) is shown below96: 
 
( ) ( )( ; , ) QALY I QALY IQALY QALY I QoL OC QALE OCQoL OC
∂ ∂
= = +
∂ ∂
V V V V                      (1) 
 
where (I) indicates the components of the QALY. The influence of other circumstances (OC), 
besides quality of life (QoL), on the QALY index QALY (I) is denoted by the partial 
derivative: 
 
( ) 0QALY I
OC
∂
≈
∂
 
 
Equation (1) clarifies the key components that need to be considered when trying to construct 
the ideal measure. The foundations of the health measure that has been developed as part of 
this thesis are more secure as they have been constructed to satisfy the criteria of a good 
measuring tool. Subsequently, the thesis health measure is capable of measuring the 
phenomenon associated with mortality and morbidity most accurately (and minimise the effect 
                                                 
95
 Boumans, “Representation and Stability in Testing and Measuring Rational Expectations”, p. 386 
96
 All formulae is referenced and developed from Boumans, “Representation and Stability in Testing and Measuring Rational Expectations”, p. 386 
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of OC), in order to adhere (as closely as possible) to the criteria of an ideal representational 
measurement (namely: accurately indicative, consistent, sensitive and scaled), through 
achieving standardisation and minimalist over determination and subsequently satisfying the 
ceteris neglectibus condition when measuring health over space (different illnesses) and time 
(different eras of the twentieth century). 
 
2.2.7.4 Ideal Measure in Conjunction with the Demands of the Thesis 
The difficulty in achieving this objective (of an ideal general economic measure) is further 
complicated when combined with the difficulties of defining and measuring health in general 
and specifically in conjunction with the historical measurement of quality of life associated 
with health considerations contained in the thesis.  
 
A major part of the thesis will entail the development of a morbidity (and to a lesser extent, 
mortality) measuring tool that is coherently constructed, statistically reliable, sensitive, 
applicable and valid. Finally, it will be capable of providing estimates about the value and 
contribution of improved health to standards of living in twentieth century England, which is 
to date lacking. The construction of this new measure, namely, the QALE (quality adjusted 
life expectancy) is explained in Chapter 3. 
 
2.2.8 Hickson QALE 
As a result of the aforementioned difficulties and shortcomings associated with existing health 
measurement methodologies, in conjunction with the original, historical and quality of life 
considerations entailed in the thesis, a new health measure will have to be constructed. 
 
This new health measure will be capable of simultaneously considering the value of: 
1. Improvements in the quality of life associated with morbidity (from a health and 
welfare perspective) at different points during the twentieth century, and 
2. Increases in life expectancy at different points during the twentieth century. 
 
This will enable the thesis to identify the improvements in the quality of life associated with 
morbidity and mortality experienced by the English population during the twentieth century. 
Once these developments have been highlighted the thesis will endeavour to quantify the 
extent and impact of these improvements (in qualitative and quantitative terms) upon 
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standards of living and for their contribution towards an extended ‘Fisherian’ notion of 
economic growth. 
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In order to fully establish the historiography underlying this epidemiological transition and the 
general motivation for the thesis this chapter will answer the central underlying question: what 
happened to the health of the English population during the twentieth century? As well as 
considering the change in life expectancy during the twentieth century, it will also be 
necessary to examine the shift in the burden of diseases, particularly as some of the most 
important improvements in health were a product of the changing pattern of morbidity97.  
 
During the twentieth century England experienced unparalleled improvements in health. Life 
expectancy improved from 47 years in 1900 to nearly 80 years by 200098. The burden of 
diseases experienced a remarkable transformation as it shifted from infectious illnesses 
(accounting for 25 percent of deaths in 1911 and 0.5 percent in 199199), such as tuberculosis to 
chronic degenerative disorders (accounting for over 80 percent of deaths by 1991100), such as 
cardiovascular disease and cancer.  
 
Surrounding this change in the health profile are numerous debates and issues. The most 
important for the thesis will be considered. These include the debates about the effect of the 
Great Depression and World Wars on health, which are some of the most frequently visited 
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 The World Health Organisation’s wider definition of health (1979) will be adopted as the definition of health throughout the thesis: health is a 
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arguments when considering English health in the twentieth century. Also, health inequalities 
and the associated shortcomings with the NHS have received consistent attention throughout 
the twentieth century for a variety of reasons, for example, in the 1930s as an adversity of the 
Great Depression and in the 1980s as a concern about the performance of the National Health 
Service, and therefore need to be analysed by the thesis. 
 
2.3.1 Infant Health 
Many of the improvements in standards of nutrition, hygiene and living in general were 
manifest in the death rate of ‘certain diseases of infancy’, which began to decline steadily after 
1901101. By the early twentieth century gastrointestinal infections, such as cholera, enteric 
fever and dysentery had been controlled. This was particularly attributed to the purification of 
water supplies102. The incidence of smallpox dropped to negligible proportion during the first 
decade of the twentieth century103. A similar trend was evident for scarlet fever and whooping 
cough (which declined most impressively between 1870 and 1900)104. These observations are 
confirmed by reviewing the infant mortality rate (IMR) time series.  
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Table 2.3.1: Infant mortality rates (per 1,000) and indexed infant mortality rates (150=100), 
1890s-2000105. 
Period IMR (per 1,000) Indexed IMR (150=100) 
1890s 150 100 
1901-1905 138 92 
1911-1915 110 73 
1916-1920 90 60 
1931-1935 62 41 
1936-1940 55 37 
1941-1945 50 33 
1951-1955 27 18 
1965 19 13 
1980 12 8 
2000 6 4 
 
Table 2.3.1 considers the improvement in the infant mortality rate between 1890 and 2000. 
This is presented in terms of the actual infant mortality rate and also as an index in order to 
more vividly highlight the substantial improvements in infant mortality.  
 
By the last period in the above table the infant mortality rate had declined to about 4 percent of 
the level it was at in the initial period. In addition to improved sanitation and living conditions 
numerous developments in immunisation against many of the most fatal diseases of infancy 
facilitated the decline. The table below provides the chronology of such developments, with 
the most pertinent vaccine introductions highlighted. 
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Table 2.3.2: Chronology of the introduction of major vaccines106 
Disease / Viruses Year  of vaccine introduction Efficacy of vaccine 
Smallpox 1796 Effective for 10-20 years 
Rabies 1885 Effective 
Yellow Fever 1936 Effective 
Influenza 1943 Temporary and partial 
Polio 1954, 1957 Effective 
Measles 1963 Effective 
Mumps 1968 Effective 
Rubella 1969 Effective 
Hepatitis B 1970 - 
Disease / Bacteria Year  of vaccine introduction Efficacy of vaccine 
Cholera 1884 Possible short run immunity 
Tuberculosis 1890 Only effective for diagnosis  
(BCG)107 1906-1921 Often effective for children 
Diphtheria 1890 Unresolved 
Tetanus 1890 Effective 
Plague 1895 Temporary and partial 
Scarlet Fever 1907 Ineffective 
Whooping Cough 1933 Partial effectiveness 
Pneumonia 1945 Effective 
Bacterial Meningitis 1998 Effective (expected) 
 
As a result of developments in sanitation, hygiene, nutrition and to a lesser extent (in many 
cases), scientific developments in the arena of immunisation; diphtheria, tetanus and 
whooping cough had largely been eliminated by the middle of the twentieth century, which 
caused a significant improvement to infant survival probabilities. Polio, measles, mumps and 
rubella were virtually eliminated during the second half of the twentieth century, when the 
necessary vaccines were discovered and generally available. These breakthroughs are 
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highlighted in Table 2.3.2. These improvements resulted in an infant mortality rate that had 
reached a remarkable 6 per 1,000 by the year 2000108. 
 
Despite these staggering declines in infectious diseases, it might be possible to claim that 
developments were postponed because of the discrepancy between the introduction of 
vaccines for some of the major killers and the introduction of ‘publicly notifiable’ legislation 
for the corresponding diseases.  
Table 2.3.3: Chronology of notifiable infectious diseases in England, 1889-1988109 
Year disease 
became notifiable 
Notifiable infectious disease 
1889 Cholera, Smallpox, Typhus, Diphtheria, Scarlet Fever, Typhoid Fever  
1912 Polio, Tuberculosis 
1914 Ophthalmia Neonatorum  
1918 Acute Encephalitis 
1919 Dysentery, Malaria  
1940 Measles, Whooping Cough 
1951 Leprosy 
1960 Anthrax 
1968 Meningitis, Viral Hepatitis, Yellow Fever, Tetanus  
1976 Rabies, Viral Haemorrhagic Fever 
1988 Meningococcal Septicaemia, Mumps, Rubella 
 
If Table 2.3.2 and Table 2.3.3 are jointly considered it becomes clear that there is little 
relationship between notification and immunisation breakthroughs for these illnesses. In the 
majority of cases in the two tables, public notification legislation was introduced a long while 
after the introduction of the vaccine. For example, smallpox inoculation was introduced in 
1796 and not notifiable until 1889, a ninety three year lag.  
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In contrast, polio, measles and scarlet fever became notifiable diseases before the discovery of 
the necessary vaccinations, and therefore adopt a more logical and expected pattern. I.e. one 
would have thought that once a disease is recognised as a public health hazard increased 
efforts are dedicated to the initiatives necessary to combat the disease. When all of the 
twentieth century notifiable diseases are considered in conjunction with their corresponding 
vaccine history, there is very little, if any correlation. It seems reasonable to conclude that 
there is minimal interaction between these two features of public health. Moreover, it is also 
noteworthy that the reduction of many of these diseases was accomplished before the 
discovery of their corresponding immunisation. This highlights the importance of 
improvements in public health for the decline in many of the major diseases, for example, 
smallpox, scarlet fever and whooping cough.  
 
2.3.2 Adult Health 
Between 1900 and 1950 the trend of improved survival prospects through a decline in the 
prevalence of infectious diseases was distributed fairly evenly across all age groups. Since 
1950 ages 0-1 and 15-44 have experienced the sharpest declines while the opposite applies to 
the oldest age groups, although it is noteworthy that, in 1911 the oldest age groups had the 
lowest incidence of infectious disease mortality110. The graphs below provide an illustration of 
the twentieth century health transformation, in support of the epidemiological transition. 
Figure 2.3.1 contains all seventeen international classification of diseases (ICD) categories and 
Figure 2.3.2 details the five most notable disease categories in order to highlight the key trends 
of twentieth century health.  
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Figure 2.3.1: Percentage of deaths in each International Classification of Disease (ICD) 
category 1911-1991111∗. 
Percentage of Deaths in each ICD Category, 1911-1991
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Figure 2.3.2: Percentage of deaths in the five most prevalent International Classification of 
Disease (ICD) categories, 1911-1991112. 
Percentage of Deaths in the Five Most Prevalent ICD Catagories, 
1911-1991
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2.3.2.1 Infectious Disease Decline 
The infectious disease category contains numerous diseases. The six diseases that were 
especially significant for the decline in deaths from infectious diseases are listed below: 
1. Tuberculosis 
2. Diphtheria 
3. Whooping Cough / Pertussis 
4. Measles, Mumps, Rubella 
5. Influenza 
6. Communicable diseases (including STDs) 
 
Although tuberculosis peaked in incidence before the twentieth century, it persisted to be a 
health burden until about 1950. Improved ventilation and host resistance helped to reduce the 
virulence of tuberculosis. In contrast to this ‘McKeown type argument’, others have claimed 
that the reduction in other infectious diseases was more important in abating tuberculosis 
because this reduced the impact of a trigger disease, in this case smallpox113. Although there is 
some accuracy in this claim, as tuberculosis is recognised as a sequel to smallpox, it probably 
only accounts for about 20 to 30 percent of tuberculosis deaths114. The most important factor 
in the reduction of tuberculosis was the introduction of specific chemotherapy in the 1950s115. 
This facilitated a rapid decline and virtual elimination of tuberculosis because the new drugs 
quickly rendered patients non-infectious and thus swiftly controlled a potential source of 
infection for further cases116.  
 
Diphtheria was a major contributor to childhood mortality from the 1890s until the 1940s, 
when successful immunisation was introduced. By the late twentieth century, the disease had 
almost disappeared117. E.g. during the 1980s only 30 cases were reported and many of them 
had been imported118.  
 
Whooping cough has a very long role in the health history of England. Deaths remained at 
about 10,000 per year from the 1840s until 1910. By 1950 improved host resistance facilitated 
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a fall in the mortality rate, to less than 400 per annum119. Widespread immunisation, which 
began in the 1950s, facilitated a continuation and enhancement in this downward trend, 
although public health measures ought to be attributed to the decline in whooping cough as 
this had largely been achieved before the introduction of widespread immunisation. However, 
the decline in whooping cough was interrupted between 1974 and 1994, when there were fears 
that immunisation was linked to encephalopathy and vaccination levels fell to 30 percent120. 
This link was disproved in 1985, and by 1994 vaccination levels had returned to nearly 
complete coverage (93 percent) of the infant population121.   
 
The decline in measles, mumps and rubella is more attributable to medical technology, as the 
prevalence of these diseases declined rapidly when immunisation became widespread in the 
late 1960s122. Notification fell by about two thirds as a result of the introduction of the 
vaccines, to a level of about 90,000 reported cases per year in the 1980s123. When the MMR 
vaccine was introduced in 1988 further declines in mortality from these diseases were 
facilitated such that the 1990s annual notification fell to about 9,000 cases per annum124. 
 
There have been three influenza pandemics during the twentieth century: 1968, 1947, and 
most notably 1918-19, which was of unprecedented scale and particularly detrimental as it 
mainly affected young adults125.  
 
Prior to the establishment of special VD clinics and the introduction of penicillin, STDs were 
responsible for considerable mortality (syphilis) and morbidity (gonorrhoea)126. Despite 
inflation in the number of reported STDs during the 1960s and 1970s, which is likely to be 
caused by changes in population trends of sexual behaviour, by the close of the twentieth 
century most STDs were under control. For example, the number of deaths from syphilis 
declined from 4,375 in 1910 to 18 in 1990127. Much of the concern regarding STDs in the late 
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twentieth century had centred on Chlamydia, Herpes simplex and HIV/AIDS, for which the 
number of reported cases increased every year since the disease was recognised in 1982128. 
 
2.3.2.2 Respiratory Diseases 
The decline in infectious diseases was the most important classification of mortality reduction 
in twentieth century England. Second in importance were respiratory diseases. When 
considering diseases of the respiratory system it is necessary to differentiate between those 
which are infectious and non-infectious, as the reduction in infectious diseases becomes more 
pronounced.  
 
The decline of mortality from infectious respiratory illnesses (e.g. influenza, bronchitis, 
pneumonia, etc) began in the early twentieth century and was not especially aided with the 
advent of antibiotics or the National Health Service although both are thought to be 
conceivable explanations for the continuing downward trend in respiratory related deaths129. 
E.g. the introduction of antimicrobial chemotherapy accelerated the decline of pneumonia in 
the 1930s130.  
 
Decreases in respiratory disease mortality pre 1950 were largely a result of the reduction in 
infectious respiratory diseases. After 1950 two forms of respiratory disease related to smoking 
became the most prevalent: lung cancer and chronic obstructive pulmonary disease 
(COPD)131. By the year 2000 lung cancer was the most important respiratory cause of death.  
 
Because this ICD category contains infectious diseases, e.g. pneumonia, as well as diseases 
that reflect long term damage to the lungs, e.g. asthma, there was a mixture of age related 
trends during the twentieth century132. For ages below 65, mortality has been falling, 
especially for ages 0-14 between the 1940s and 1950s and again from the late 1960s onwards, 
this trend was also evident for ages 15-24, but to a lesser extent133. In ages 25-44 rates fell, 
especially in the post war period, but have been rising since 1980 for men and static for 
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women134. There has been a fall in the oldest ages over the twentieth century as a whole, 
although the pattern is more volatile as these age groups are particularly prone to flu 
epidemics.  
 
2.3.2.3 Degenerative Disease Increase  
The increase in degenerative diseases is related to longer, richer lifestyle characteristics, which 
tend to be correlated with unhealthy lifestyle practices, for example, smoking, high levels of 
alcohol consumption and fat intake, and low levels of exercise.  
 
2.3.2.4 Cardiovascular Diseases 
The most striking trend in Figure 2.3.2 is the major increase in diseases of the circulatory or 
cardiovascular system: from about 16 percent in 1911, to a peak of nearly 52 percent in 1971, 
and in the year 2000 about 45 percent of the population died from circulatory system 
diseases135.  
 
Of cardiovascular disease deaths there are two sub-categories that are particularly noteworthy: 
1. Ischaemic heart disease (IHD) / Coronary heart disease 
2. Stroke / Cerebrovascular disease  
 
By the year 2000, 25 percent of all deaths were caused by IHD and 11 percent related to 
stroke136. Although strokes account for less mortality they have a significantly greater adverse 
impact on morbidity. By the 1990s strokes had become the second most prevalent cause of 
hospital admissions137.  
 
Economic transition, urbanisation and industrialisation have initiated lifestyle changes that 
promote heart diseases. These risk factors include tobacco use, physical inactivity and 
unhealthy diet138. Smokers of all ages have IHD death rates 2-3 times higher than non-smokers 
and physical inactivity doubles the risk of dying from IHD or stroke139. The table below 
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highlights the increase in average intake of fat during the twentieth century, which is another 
significant aggravating factor for cardiovascular diseases. 
Table 2.3.4: Summary of all studies that evaluate mean intake of fat as a percentage of energy, 
1900-1985140 
Time Period No. of Studies No. of Subjects Fat (% energy) 
1900-1909 1 57 24.6 
1910-1919 3 348 24.1 
1920-1929 13 5,220 25.9 
1930-1939 8 916 33.1 
1940-1949 15 2,385 33.2 
1950-1959 13 1,568 38.4 
1950-1969 10 3,873 40.1 
1970-1979 4 2,294 40.3 
1980-1985 20 7,384 38.2 
 
The above table highlights the increase in fat intake, which is one of the many unhealthy 
habits that have become common place as the English economy developed.  
 
Since 1911 there have been very different patterns in the burden of IHD across different age 
groups and genders. In males aged 35+, IHD increased – apart from an apparent temporary fall 
during World War Two – until the 1970s and then declined141. Female IHD rates experienced 
a more gradual rise until the 1970s, thereafter rates began to decline for ages 35-44 but ages 
65-74 did not experience a decline until the 1980s142.  
 
2.3.2.5 Neoplasm 
The proportion of deaths from neoplasms increased from about 7 percent in 1911 to about 26 
percent in 1992, and by 1950 neoplasms represented the second most prevalent mortality 
category143. There are over 200 different forms and locations in which a neoplasm can 
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develop. Therefore, only the major cancer trends will be considered here, namely: lung and 
breast cancer. 
 
Lung cancer was the most common form of cancer for males. Mortality rates decreased during 
the last thirty years of the twentieth century, especially at younger ages144. For women, who 
had significantly lower rates, there was an increase since 1970 especially at older ages145. This 
was so extensive that by the 1990s the female mortality rate from lung cancer was very similar 
to the male rate. These trends in lung cancer generally reflect trends in smoking habits146. 
 
Despite the increases in female lung cancer, the most common fatal cancer in women during 
the twentieth century has persisted to be located in the breast. In 1999 one in four female 
cancers was located in the breast, with around 34,000 new cases diagnosed per annum in 
England147. Since 1970 there has been a decline in breast cancer mortality for ages under 50 
and since the late 1980s for ages over 50148. These improvements are attributable to the 
widespread adoption of new diagnostic, surgical and therapeutic regimes.  
 
Cancer mortality in all aged below 25 years experienced increasing rates between 1900 and 
1950, and declines thereafter149. In ages 25-44 mortality in men shows a similar pattern, 
although the decline began earlier in the 1940s, while rates for women had been falling 
throughout the period150. In men aged 45-64 the rise was reversed during the 1960s. At ages 
65-74 and 75+ male and female mortality rates increased throughout the twentieth century and 
only began to level off at the end of the 1990s151.  
 
2.3.3 Life Expectancy 
By the 1960s deaths from most infectious diseases had declined sharply as a result of 
continuing improvements in hygiene, sanitation, rising standards of living, immunisation and 
after the 1930s, specific therapeutic measures and the 1950s with further developments in 
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pharmaceuticals152. This decline had been substituted with an increase in degenerative 
diseases, such as heart disease and cancer. This shift in the burden of disease created positive 
changes in life expectancy. 
Figure 2.3.3: Gains in life expectancy at age 0, 15, 35, 55, 75, male and female, 1901-1991153 
Gains in Life Expectancy by age for male and female, 1901-1991
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The above figure shows the age and gender distributed increases in life expectancy. The most 
notable trend is the relationship of this increase between different cohorts. The older age 
groups experienced improvements in their life expectancy increasingly later during the 
twentieth century. 
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Figure 2.3.4: Average gains in years of life expectancy by age154 
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This graph provides an average of the gains in life expectancy for both sexes, by age and as an 
addition to 1901 levels of life expectancy at the corresponding ages. The most significant and 
early increase came for life expectancy at birth (LEo), where between 1901 and 1931 LEo 
increased by five years, between 1901 and 1961 by 29 years and from 1901 to 1991 by 34 
years. This graph clearly illustrates that between 1931 and 1961 LEo experienced the most 
significant gains compared to the rest of the century and any other time in history.  Figures 
2.3.4 and 2.3.5 highlight similar trends for life expectancy at other ages (namely: 5, 15, 35, 55, 
75) but none of these ages experienced the magnitude of increase enjoyed by infants.  
 
2.3.4 Mortality Change Implications for Morbidity 
One of the most significant features of twentieth century health was the shift in mortality from 
infectious to degenerative diseases. This has numerous implications for the burden and age 
distribution of morbidity and for mortality/morbidity trade-offs155. 
 
One of the most important contributions to quality adjusted life expectancy (QALE) and the 
trade-off was the improved age-death related profile, such that the burden of mortality shifted 
significantly towards older ages.  
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Figure 2.3.5: Major cause (aggregate) and all cause of death as a percentage of age specific 
population 1901-1997156 
Major Causes and All Causes of Death as a Percentage of Age Specific Population 1901-1997
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Figure 2.3.5 illustrates the increase in the age of death from ‘major causes’ (which comprises 
infectious, respiratory, neoplasm and circulatory mortality, shown by the bars). This trend is 
also evident for ‘all causes’ (shown by the lines). This trend is considered in more, mortality 
cause specific, detail in Figure 2.3.6. 
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Figure 2.3.6: Death rate (per 1000) for major and all causes 1901-1997157 
Death Rate (per 1000) for Major Causes and All Causes 1901-1997
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Figure 2.3.6 illustrates three crucial points. First, the decline in the population death rate, from 
17/1000 in 1901 to 11/1000 in 1997. Second, the increase in circulatory diseases, which has 
substituted for the decline in infectious diseases. Third, respiratory diseases mortality 
remaining relatively constant between 1901 and 1997, which is because this category contains 
causes of death that are infectious and non- infectious and some of the most persistent 
infectious mortality. This is illustrated below. 
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Figure 2.3.7: Distribution of respiratory disease deaths between infectious and non-infectious 
1901 and 1997158 
Percentage of Respiratory Deaths that are Infectious and Non-Infectious by Age 1901 and 1997
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Figure 2.3.7 shows that there have been some expected declines in infectious and 
corresponding increases in non-infectious respiratory diseases. However, the magnitude is not 
large enough to explain the whole story. The second explanation is that infectious respiratory 
diseases represent some of the few remaining infectious diseases, e.g. pneumonia, bronchitis 
and flu. The increasing age profile of the population perpetuates the remaining prevalence of 
these infectious diseases.  
 
2.3.5 Mortality/Morbidity Trade-Offs 
The previous analysis has highlighted that there is a pattern about the implications for 
morbidity from the changes in mortality. First, the notion of a trade-off, between reduced 
mortality at the cost of increased morbidity becomes increasingly pronounced: throughout the 
twentieth century there was a significant decline in mortality which was accompanied by an 
increased proportion of the population living in poor health. This is partially a symptom of 
other factors (exogenous to health per se) and a result of the population living to older ages 
when degenerative diseases become more prevalent (which exacerbates a decline in killers of 
young people), but nevertheless there is still some authenticity to the observation of morbidity 
replacing mortality. This essentially means that ‘quality adjusted life expectancy’ has not 
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improved as much as it would seem when only concentrating on death rates. For example, 
cancer has experienced improvements in mortality but with significant trade-offs for 
morbidity.  
 
However, to claim that health has worsened because of an increase in the reported prevalence 
of disease and/or to claim that every additional year of life expectancy in the population is 
riddled with morbidity is a very simplistic and overly pessimistic conclusion. Even though the 
changed aetiology of diseases has meant that more years are spent in less than perfect health, it 
is clear that the trade-off is in favour of overall health. I.e. the thesis’ analysis will highlight 
that the contributions of the improvements in mortality outweigh the associated deteriorations 
in morbidity and that in many instances the burden of morbidity is less significant than the 
scenario outlined in contemporary literature. Moreover, as a result of improvements in medical 
technology, this trade-off became increasingly less pronounced as the twentieth century 
unfolded. I.e. although medical technology could not cure many ailments it became 
increasingly able to relieve many of the associated adverse symptoms.  
 
2.3.6 Twentieth Century Health Debates 
Despite the seemingly continual improvements in health since the onset of the twentieth 
century, there has been much debate during certain times about the direction and distribution 
of health improvements. Most noteworthy was the debate about what happened to health 
during the inter-war period and issues concerning the persistent health inequalities. These will 
be analysed below. 
 
2.3.6.1 Effects of the World Wars and the Great Depression on English Health 
The pessimistic commentary on the effects of World War One claimed that standards of living 
declined as nutrition and health levels worsened. The foundations of these claims are reports 
of poor nutrition and housing, caused by a lack of income due to unemployment159. Winter 
(1994) indicated the contrary through identifying improvements in nutrition and life 
expectancy160. The evidence provides weight for Winter type claims, as there was no 
interruption in the decline of infectious diseases and mortality (with the exception of life 
expectancy at age 35, - Figure 2.3.3).  
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Along a similar vein, Webster (2001) concedes that the British people did experience some 
overall improvement in living standards during the 1920s and 1930s, but that these 
improvements were slow161. The table below provides weight for this type of argument.  
Table 2.3.5: Consumption per head per week (in lbs) for the United Kingdom, 1909-1913 and 
1924-1928 relative to 1934-1935162 
Product Years (lbs) % + or – of 1934-35 compared to 
 1909-13 1924-28 1934-35 1909-13 1924-28 
Butter 0.30 0.31 0.49 +63 +58 
Cereals 4.45 4.11 4.04 -9 -2 
Cheese 0.14 0.18 0.19 +36 +6 
Eggs, in shell 1.93 2.34 2.90 +50 +24 
Fish 0.79 0.80 0.87 +10 +9 
Fruit 1.19 1.75 2.23 +87 +27 
Margarine 0.11 0.23 0.15 +36 -35 
Meat 2.58 2.56 2.81 +9 +10 
Milk / Cream 3.46 3.35 3.26 -6 -3 
Other Vegetables 1.38 1.81 2.22 +61 +23 
Potatoes 4.68 4.43 4.25 -9 -4 
Sugar 1.52 1.60 1.79 +18 +11 
Tea 0.12 0.17 0.18 +50 +6 
 
The table above highlights an improvement in nutritional standards between 1909 and 1935, 
which provides contrary evidence to many of the pessimistic claims about nutrition during this 
period. The most striking trends in the above table are the improvements in quality and 
quantity of the average British diet163. The increases in pounds worth of produce significantly 
outweigh the declines. Furthermore, the decline in cereals and potatoes is likely to be a direct 
result of the increased availability of meat, other vegetables and fish. The increase in fruit and 
                                                 
161
 Webster, “Caring for Health: History and Diversity”, p. 151 
162
 The National Archives: MH 56(213): Advisory Committee on Nutrition, Ministry of Health Advisory Committee on Nutrition 
163
 In this context diet quality considers the increase in more nutritious and wholesome sources of calorie intake 
Context: Historical 
             - 60 - 
vegetables was substantial and would have provided a valuable contribution to quality of life 
and health standards in general.  
 
It is important to recognise that this table presents aggregate data and therefore may be 
masking poor nutrition for the poorer segments of the population, although there is little 
evidential support for the claims about significant inequality in nutrition. For example, in 
September 1934, a study of 69 working class families (38 of which had an unemployed 
breadwinner) in Newcastle-upon-Tyne (conducted by the Advisory Committee on Nutrition) 
found that the average diet of these families provided 2,960 calories a day per man, which was 
considered to be “just about sufficient”164. 90 percent of all families consumed fresh 
vegetables, 88 percent fresh fruit, 69 percent fresh meat and 71 percent fresh fish165.  
 
In contrast, there were evident inequalities in the death rate and levels of infant mortality. This 
is shown in the table below. 
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Table 2.3.6: Ratio of geographical death rates and infant mortality for all regions of England 
and Wales, 1938166 
Region Deaths at all ages per 1,000 pop Infant mort per 1,000 births 
 Crude Ratio of 
adjusted rate 
I. M. Rate Ratio 
England and Wales 11.6 100 53 100 
South East 10.7 89 47 88 
Greater London 10.2 91 50 94 
Rest of South East 11.4 86 42 80 
North 12.3 115 60 114 
Midlands 11.3 99 52 99 
East 11.8 87 44 84 
South West 12.9 92 47 88 
Wales 12.9 117 57 108 
County Boroughs 12.3 112 60 114 
Other Urban Districts 11.8 101 50 94 
Rural Districts 11.7 90 47 90 
 
Table 2.3.6 highlights geographic inequalities that correspond to areas that experienced a more 
severe Great Depression. Comparing North to the South East indicates significant inequalities 
in the death rate (117:86) and the infant mortality rate (114:88)167. These inequalities are 
exacerbated by the fact that the majority of regions in England and Wales experienced death 
rates that were lower than the average index (100), whereas fewer experienced higher than 
average death rates which by definition of this distribution being highly skewed, indicates that 
these deprived regions were especially depressed. 
 
Moreover, Titmuss used data from the 1930s Registrar General’s reports to calculate the 
‘human wastage’ in the deprived and high unemployment regions of the North and Wales, 
compared to the standards of health achieved in the South of the country, he calculated that 
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50,000 excess deaths were occurring each year because of the presence of intense poverty in 
these areas168.   
 
Despite the adversities associated with England’s World Wars and depression, there were 
some more optimistic developments during these eras. The post World War One era and 1920s 
witnessed the seeds of many developments which facilitated continued improvements in the 
health of the population throughout the twentieth century. Many campaigns of long term 
significance got underway, e.g. birth control, family allowance and local authority housing169, 
when problems of over-crowding and sub-standard homes began to be faced170. Interwar 
developments are even more commendable when scientific achievements are considered. The 
1930s marks the dawn of the modern antibiotic era, when therapies were introduced to treat 
infectious diseases, namely sulphonamides171. These developments were enhanced during the 
following decade (1940s) when the penicillin / tetracycline group of drugs were discovered 
and developed for mainstream use. The General Registrar (1950) claimed “there is no doubt 
that the application of new drugs and remedies to the treatment of bacterial infections since 
1937 has been the main reason for the accelerated decline in all-causes death rates”172.  
 
The culmination of these developments meant that there were considerable health 
improvements in the early 1940s, despite the setbacks outlined above.  
 
2.3.6.2 Health Inequalities 
Analysis of English mortality by social class began in 1921 and was conducted with increasing 
detail throughout the twentieth century173. This analysis has continually generated concerning 
results about the inequality in health, such that poor social classes fair much worse in terms of 
survival and illness probabilities. This has persisted despite the introduction of the NHS 
(whose main objective was to eliminate inequalities through providing equal accessibility). 
This aspect of twentieth century health history is more a prominent theme than an actual 
debate, as all authors agree on the existence and significance of health inequalities, although 
some disagree on the timing and magnitude of this trend.  
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The statistical evidence bolsters the theorists who maintain that social class inequality had not 
been reduced by the end of the twentieth century. The most noteworthy proponent being the 
Black Report (1980), which was initiated by the government in order to identify the source of 
inequalities in health and also problems in the functioning of the NHS174.  
Table 2.3.7: Age standardised mortality ratios to indicate social class mortality differentials, 
males, 1921-1983175 
Year Age (Years) Age Standardised Mortality Ratios by Social Class: Males 
  I II III IV V 
1921-23 20-64 82 94 95 101 125 
1930-32 20-64 90 94 97 102 111 
1949-53 20-64 98 86 101 94 118 
1959-63 15-64 76 81 100 103 143 
1970-72 15-64 77 81 106 114 137 
1979-83 20-64 66 74 103 116 165 
 
Table 2.3.8: Age standardised death rates per 100,000 person years, males, 1986-1999176 
Year Age (Years) Age Standardised Mortality Ratios by Social Class: Males 
  
I and II III  Non-Manual III Manual IV and V 
1986-92 35-64 460 480 617 776 
1993-96 35-64 379 437 538 648 
1997-99 35-64 347 417 512 606 
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Table 2.3.9: Standard mortality ratios for tuberculosis, heart diseases and stomach cancer 
mortality in adult males aged 20-64 by social class, 1930-1972177 
Year Cause of death  Social Class (Standard Mortality Ratios) 
  I II III 
Non Manual / Manual 
IV V 
1930-32 Tuberculosis 61 70 100 104 125 
1950 Tuberculosis 64 62 103 95 149 
1970-72 Tuberculosis 26 41 84 / 89 124 254 
1930-32 Heart Disease 65 92 97 111 112 
1950 Heart Disease 61 87 103 102 114 
1970-72 Heart Disease 77 80 117 / 103 116 124 
1930-32 Stomach Cancer 59 84 98 108 124 
1950 Stomach Cancer 57 67 100 114 132 
1970-72 Stomach Cancer 50 66 79 / 118 125 147 
  
Table 2.3.10: Standard death rate for respiratory disease, heart diseases and stomach cancer 
mortality in adult males aged 35-64 by social class, 1986-1999178 
Year Cause of death  Social Class (Standardised Death Rate) 
  I and II III Non-Manual III Manual IV and V 
1986-92 Respiratory Disease 13 21 37 49 
1993-96 Respiratory Disease 16 28 32 44 
1997-99 Respiratory Disease 11 40 47 61 
1986-92 Heart Disease 160 162 228 270 
1993-96 Heart Disease 97 117 159 215 
1997-99 Heart Disease 90 117 141 167 
1986-92 Stomach Cancer 5 7 15 19 
1993-96 Stomach Cancer 3 7 9 8 
1997-99 Stomach Cancer 6 6 11 7 
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It should be noted, that because these official figures appear to show that differences in 
mortality rates have widened even during periods when the consensus believed that socio-
economic inequalities were diminishing, they have been regarded with considerable 
scepticism179. For example, the table below provides estimates about social class inequality by 
life expectancy and contradicts the specific trends implied by the previous table. 
Table 2.3.11: Life expectancy at age 0 and 65 by social class, male and female average, 1972-
1999180 
Social Class 1972-1976 1982-1986 1992-1996 1997-1999 
At Age 0     
I  75.6 77.8 80.6 80.7 
II 74.4 76.2 78.5 79.5 
III 73.1 74.8 76.9 77.8 
IV  71.7 74.0 75.2 75.6 
V 70.2 71.5 72.6 74.1 
At Age 65     
I  16.8 17.0 18.8 19.2 
II 15.2 16.2 17.5 18.4 
III 14.7 15.4 16.5 17.2 
IV  14.6 15.0 15.5 15.6 
V 14.0 13.9 14.5 14.9 
 
The above table highlights that, during the last three decades of the twentieth century life 
expectancies varied consistently with social class. The table also illustrates that, although each 
social class has increased its life expectancy over this period, some social classes have gained 
more than others. However, the most noteworthy feature is the persistence of social class in 
equality despite twentieth century health developments, especially the National Health 
Service.  
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Despite the slight variation in magnitude and trends between the series of tables above, the 
overall existence of social class inequalities is undeniable. It is most important to recognise 
that there were persistent health inequalities.  
 
Because of the inconsistencies in the numbers some authors have approached the problem 
from a different angle. E.g. Wilkinson (1989) considers relative poverty in twentieth century 
Britain181. His cogent reason for thinking that health is more responsive to changes in income 
at the bottom end of the scale led him to focus more narrowly on trends in relative poverty182. 
As well as providing an insightful analysis, this also provides plausibility to the previous 
mortality inconsistencies. Wilkinson also provides an explanation for why the problem is so 
exaggerated in twentieth century Britain183: 
It might be suggested that the whole population would move down and out along the 
curve so that the death rates of those at the lower end of the income distribution 
would fall faster than others. That this has not happened adds weight to the claims 
that we are dealing with relative rather than absolute poverty. Essentially, Britain 
experienced a situation where as the country got richer, rather than moving along 
the curve relating income to health, the curve itself moves down and to the right. 
 
This is depicted in Figure 2.3.8, where this movement from curve T0 to T1 (rather than along 
curve T0) enables richer people to reduce their death rates further than previously (shown by 
the move from DR0 to DR1), while the poor have to pay more to keep themselves off the 
steeply rising part of the curve (shown by the move from Y0 to Y1)184. 
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Figure 2.3.8: Long run GDP/capita increase and income mortality185 
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These mortality inequalities (in income and relative poverty) are also evident in morbidity, and 
some have claimed to be more pronounced. E.g. by the year 2000 there were no major disease 
conditions that were more prevalent in wealthier social classes186. Even diseases that used to 
be associated with affluence and were more prevalent in wealthier social classes at the 
beginning of the twentieth century became more prevalent in poorer social classes by the end 
of the twentieth century187. E.g. cancer and coronary heart disease were all more prevalent in 
poorer social classes by the close of the twentieth century. This is highlighted in the table 
below, which depicts social class inequality for a selection of mortality causes in 1960, when 
this crossover was largely complete. 
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Table 2.3.12: Cause of death by social class, males,1961188 
Cause of death Standardised mortality ratios: social class 
 I II III IV V 
Tuberculosis 40 54 96 108 185 
Malignant Neoplasm 73 80 104 102 139 
Psychoses 80 77 96 80 179 
Epilepsy 30 39 46 97 251 
Rheumatic Fever 40 67 85 113 207 
Pneumonia 48 54 88 102 196 
Bronchitis 28 50 97 116 194 
Stomach ulcer 46 58 94 106 199 
Accidents in the home 95 78 81 104 226 
Suicide 91 94 87 103 184 
 
A comparative study of mortality rates between 98 area health authorities (AHAs) identified 
considerable variation within their sample of diseases189 (which were chosen for their strong 
association with medical intervention), and this remained even after adjustment for social 
factors190. The table below highlights the extent of the variation in these conditions. 
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Table 2.3.13: Distribution of five-year standardised mortality rates (SMRs) among area health 
authorities of England and Wales, 1974-78191 
Cause of death Age Group SMRs P value 
  Median Minimum Maximum  
Hypertensive Disease 5-64 96 29 213 <0.001 
Cancer of the cervix utteri 5-64 99 43 162 <0.001 
Pneumonia and Bronchitis 5-49 96 39 294 <0.001 
Tuberculosis 5-64 92 19 250 <0.001 
Asthma 5-49 97 31 249 <0.001 
Heart Disease 5-44 105 0 263 <0.001 
Respiratory Disease 5-49 90 0 374 <0.001 
Bacterial Infection 5-64 101 16 257 <0.1 
Hodgkin’s Disease 5-34 98 0 288 <0.1 
Abdominal Hernias 5-64 94 18 279 <0.05 
Cholecystitis 5-64 99 0 323 NS 
Appendicitis 5-64 106 0 228 NS 
Maternal deaths (per 1000 births) 10-44 0.6 0.0 1.8 <0.1 
Deficiency Anemia 5-64 87 0 508 <0.01 
Perinatal (per 1000 births) - 18.0 10.0 24.0 <0.001 
All Causes  101 64 118 <0.001 
All ‘non-preventable’  101 63 119 <0.001 
 
The above table highlights that there was variation in mortality for nearly all of the disease 
groups. This will be elaborated below. 
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Table 2.3.14: Distribution of social indicators by area health authority (AHA), 1977-78192 
Social indicator Distribution 
 Median Minimum Maximum 
Households without cars (%) 41.9 24.5 64.4 
Unskilled workers (%) 6.2 3.2 10.4 
Households renting (%) 41.1 28.0 81.3 
Birth-weights under 2.5kgs 
(1980) (%) 
7.0 4.4 10.3 
 
This table provides an indication about why a substantial variation in survival was still evident 
after controlling for social factors, because a significant part of the above variations in 
mortality is not born from social factors.  
 
Along a similar vein, Tunbridge (1977) conducted a study that considered social class and 
hospital use193. The key finding states that there is “No social class variation in length of stay, 
by specialty or diagnosis” 194. This supports other studies that have failed to show any 
relationship between social class and length of hospital stay or use195.  
 
If the health of lower social classes is generally poorer but their hospital use does not reflect 
this, then there is a clear indication that higher mortality would ensue as a consequence. If this 
tentative argument is accepted as a contender in social class mortality inequality, then the most 
important question would be: what is the cause of the seemingly positive correlation between 
social class/income and hospital use? I.e. is this a story about education and culture or access 
to medical care? 
 
The underpinnings of this question about access to medical care in the first half of the 
twentieth century are related to the markedly varied evaluations of pre-NHS hospitals. For 
example, while some contemporary observers stated that, “it is universally acknowledged that 
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our health services are the best in the world”, others were generally critical196. It is often 
implied that before the advent of the NHS, the poor were denied the healthcare available to 
their wealthy counterpart. A closer analysis of the pre-NHS healthcare system implies that 
might not be strictly true in the pre 1948 era.  
 
Free public and charitable care was available for the working class even in the mid nineteenth 
century and treatment was provided at a small cost through various types of contributory 
scheme197. From 1911, many workers received free general practitioner care under the 
National Health Insurance, and only those above the level of destitution began to be charged 
for their care. Middle class patients were often exempt from such schemes, and by having to 
pay high private fees they subsidised the care of working class patients198. It is possible that in 
terms of GP care, middle class patients received better treatment, but this does not seem to 
have been the case in hospitals, as middle class patients were generally confined to the smaller 
and less well equipped (in both machinery and specialists) private hospitals, as the most 
proficient hospitals were in the voluntary sector and unavailable to the middle classes199. 
Furthermore, there does not seem to be any affluence inequality (by geographic location in 
England and Wales) in hospital distribution. The table below presents geographic variations, 
but without a clear North: South dichotomy, although there does seem to be some evidence of 
variation between hospitals. 
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Table 2.3.15: Hospital beds (per 1,000 population) by region in England and Wales, 1938200 
Region Hospital beds (per 1,000) 
 Acute Chronic Maternity Tuberculosis Infectious 
Diseases 
Total 
North-Western 3.35 1.04 0.33 0.75 0.88 6.34 
North-Eastern 2.43 0.75 0.18 0.84 1.22 5.42 
Yorkshire 2.16 1.16 0.23 0.59 1.18 5.32 
West Midlands 2.57 1.40 0.20 0.59 0.69 5.45 
Sheffield and 
East Midlands 
2.74 1.10 0.27 0.64 0.79 5.55 
Eastern 2.18 2.19 0.13 1.04 0.71 6.26 
South-Western 2.63 1.62 0.22 0.61 0.75 5.83 
Berkshire, Bucks 
and Oxfordshire 
2.20 1.91 0.19 0.35 0.62 5.26 
London and 
South-East 
3.77 1.32 0.31 0.76 1.21 7.38 
England 3.08 1.28 0.27 0.71 1.00 6.35 
 
Possibly more influential was the variation in financial constraints that was faced by interwar 
hospitals. Hospitals in the North-West and South-East were equally constrained201. 
Modernisation and increasing medical staff costs seem to be an important determinant of 
strain and subsequent service of interwar hospitals, which were often unequally distributed 
between hospitals independently of geographical affluence. Without a central system to 
redistribute resources from surplus to deficit hospitals these inequalities were not reduced, 
despite an increase in bed numbers per population in interwar Britain202. It was not until 1948 
that these differences began to be addressed (through an integrated hospital system that was 
more able to allocate resources). 
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Although the NHS reduced some of these problems the NHS has proved to be “remarkably 
ineffective” in reducing class inequalities in health203. What is most persistent and vivid is the 
conclusion that improvements in health (outlined above) were distributed in favour of richer 
social classes.  
 
2.3.6.3 Inefficiency of the NHS 
A consistent theme throughout the findings of the thesis is that the poor performance of the 
NHS detracted from further improvements in quality of life, in general and also as a result of 
the health inequalities it failed to eliminate. 
 
Evidence of the shortcomings of the NHS is highlighted by recent considerations about the 
efficiency of healthcare systems. At the end of the twentieth century evaluations began to be 
made (by scholars and the World Health Organisation) about the overall performance of 
healthcare services in a variety of countries. These measures have considered numerous facets 
that are capable of reflecting efficacy of health care services, for example: the level and 
distribution of health attainment, responsiveness of the health system and the degree of 
fairness in financing relative to the country’s level of economic and educational 
development204. Hence, to establish the contribution of a healthcare system (or ‘mortality 
amenable to healthcare’) it is necessary to determine what the health service achieves in 
excess of what would have been achieved in its absence, in absolute terms and also relative to 
healthcare service investment205. 
 
The results of these studies have highlighted the poor performance of the British NHS. Nolte 
& McKee (2003) have illustrated the fall in Britain’s ranking when ‘mortality amenable to 
healthcare’ is considered206. For example, when considering disability adjusted life expectancy 
the UK achieves a world rank of tenth, but when the healthcare service is considered in 
conjunction with these efficiency proxy outcomes, the UK rank declines to eighteen. Evans et 
al (2001) have painted an even bleaker picture with their considerations about healthcare 
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efficiency, where the UK only achieves a word rank of twenty-fourth, behind much lesser 
developed economies such as Jamaica, Malta and Oman207.     
 
Although it is important to appreciate that these new measures, which consider ‘mortality 
amenable to healthcare’ are in their infancy and that these types of studies have had to contend 
with numerous anomalies and controversies there is still a clear and valid message about the 
paucity of the performance of the NHS, particularly during the last decade of the twentieth 
century (when these studies where conducted). When considering ‘mortality amenable to 
healthcare efficiency’ the UK experiences significant losses in its performance appraisal.  
 
Finally, in conjunction with being inefficient the NHS was also under funded, both of which 
have contributed to comparatively poor healthcare for the English population. For example, it 
was not until the new millennium that the government finally conceded the need to bring its 
health service spending (on cancer) up to the European average. However, there was still no 
guarantee that funds would be available on a sustained basis, necessary to bring the NHS 
standard up to the European average. 
 
The problems of escalating costs, that have plagued the NHS since its introduction, are faced 
by all health services, but during the second half of the twentieth century they have become 
increasingly and particularly acute in the UK because of under spending and neglect, which 
were evident from the birth of the NHS208.  
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The methodology in this thesis will build upon the most commendable existing health 
studies, which only consider the value of improved mortality. These studies will be 
enhanced through the addition of the thesis morbidity considerations, in order to provide an 
accurate and comprehensive health measure, which is currently void in the literature.  
 
This chapter of the thesis will begin with a detailed consideration about the requirements of 
the health measure. It will answer the key question: what is the thesis methodology trying 
to measure? And, why are these features the most important aspects to gauge for 
considering improved health in twentieth century England? 
 
This will be followed by the solutions to the demands above, through providing an outline 
about the existing willingness to pay (WTP) model and how this will be developed into an 
extended willingness to pay or quality adjusted life expectancy (QALE) model which 
forms the thesis’ central methodology.  
 
This chapter will also delineate the sensitivity analysis that will be applied to the results of 
the QALE methodology, in order to provide a broader range of estimates and a more 
comprehensive and justified indication of the possible contribution of improved health.  
 
3.1 Methodology Outline 
A major component of the thesis is the identification and valuation of improvements in 
health related quality of life. Once these developments have been documented, the thesis 
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will endeavour to quantify them so that they can be included in an extended measure of 
national income. This will be achieved through developing the existing willingness to pay 
methodology (WTP) to include morbidity improvements as WTP currently only considers 
mortality improvements. Hence, a significant attribute of the thesis methodology will be 
the creation of an original (extended) WTP model, which considers morbidity in tandem 
with mortality. A simplified version of this process is outlined at the end of this chapter in 
Figure 3.4, which is useful for referencing in order to understand the general features of the 
QALE methodology.  
 
3.2 Willingness to Pay Methodology (WTP)  
The WTP methodology considers what individuals would be willing to forego in income 
for an increased probability of survival with healthy life years. I.e. the amount an 
individual would pay for an increase in their healthy life expectancy in the current period 
(not for a given [future] age of life expectancy or to prevent specific illnesses).  
 
Numerous authors have highlighted the importance of improved mortality to society, to 
such an extent that there is a plausible likelihood of an individual sacrificing any other 
modern standards of living to maintain current mortality rates209. Bradford DeLong (2000) 
has highlighted the contribution of improved health to economic development, which has 
been so extensive during the twentieth century (in developed countries) that there is not 
likely to be any magnitude of income that could compensate a year 2000 family for living 
under 1900 health conditions. Therefore, given the absence of modern vaccines, antibiotics 
and other technologies in 1900, it is hard to argue that anything less than an astronomical 
income in 1900 could compensate for the health of 2000210.  
 
The indifference curve diagram below illustrates these types of claims and subsequently 
illuminates the basic notion of the thesis methodology.  
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Figure 3.1: Indifference curve diagram to illustrate the rationale of the WTP methodology 
 
 
 
 
 
Consider a person observed initially at point 1900 and subsequently at point 2000: between 
1900 and 2000 life expectancy has increased from E1 to E2 and income has increased from 
C1 to C2*, not C2, as traditional measures would indicate. Point C2* is the height of the 
intersection of the indifference curve attained in 2000 with a vertical line at the value of 
life expectancy in 1900, whereby the individual maintains 2000 income with 1900 life 
expectancy. The difference between C2 and C2* indicates the income or consumption 
value of increased life expectancy between 1900 and 2000 and the amount of income that 
an individual would be willing to pay for the improved health conditions of 2000, 
compared to 1900.  
 
The notion of imputing national income measures to account for increases in life 
expectancy was initially proposed by Usher (1980), who recognised the need to consider 
the value of maximising age specific mortality rates and societies’ willingness to pay for 
this improvement211. Usher’s main objective was to find a natural way of combining the 
two social indicators (GNP and mortality rates) into a single comprehensive index, his 
basic contention being that the growth of GNP alone significantly understates the extent to 
which current generations are better off than earlier generations. 
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These considerations have been developed in a limited number of studies, namely: 
Nordhaus (1999)212 for the USA between 1900 and 1995, Crafts (2001)213 for the UK 
between 1870 and 1998 and Hickson (2002)214 for twentieth century Japan. Despite their 
agreement with Usher’s objectives of providing a more indicative national income 
estimate, none of these studies measure health per se, as they all utilise mortality (i.e. 
increased life expectancy) as a proxy for health.  
 
In this willingness to pay approach, gains from improved mortality are treated as an 
imputation for a change in the environment, because increased life expectancy has been 
largely a result of the accumulation of knowledge on how to cure and prevent diseases that 
affect all individuals (rich and poor, educated and uneducated), and subsequently this is the 
reason that these improvements are not included in income measures, and therefore not 
double counted by WTP imputations215.  
 
3.2.1 Extended Willingness to Pay Methodology (WTP) 
The thesis will enhance existing willingness to pay methods in order to consider the value 
of increased life expectancy (as has been accomplished in the Nordhaus, Crafts and 
Hickson studies) and also improved morbidity from a health and welfare perspective. As 
well as considering the reduction in the death rate and the corresponding value of an 
improved mortality profile, the thesis will consider the decline in the burden of morbidity 
and its associated value. Although this more comprehensive health measure can only yield 
estimates it is still superior as these estimates provide a much more accurate indication 
about health than the more precise but less detailed mortality only estimates. Hence, 
through adopting a more comprehensive (utility based) measure of economic growth it is 
possible to indicate how existing (fiscal only) measures are inadequate for providing a 
thorough indication of improvements in welfare. Moreover, through adopting a more 
comprehensive definition of health it is possible to estimate the full gain in utility towards 
an extended national income. This provides results that are greater than those that are 
yielded when extending GDP for mortality only. 
  
Finally, the methodological approach used in the thesis to obtain utility national income 
(which is defined as the maximum amount that a nation can consume while ensuring that 
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members of generations can have expected lifetime utility the same as that of the current 
generation), values improvements in quality adjusted life expectancy by considering the 
change in the population weighted average of age specific mortality rates multiplied by the 
estimated value of death averted in conjunction with the population weighted average of 
the morbidity burden multiplied by the estimated value of unhealthy life years averted. 
This is approximately equal to the increase in quality adjusted life expectancy times the 
value of an additional healthy life year.  
 
The data required to make these willingness to pay methodological adjustments to the 
conventional estimates of national income are population by age, death rates by age and 
the value of death averted (value of a statistical life). The data required to make extended 
willingness to pay estimates are population by age, prevalence of a given disease, the 
burden of the disease (quality adjusted life year, QALY) and the value of ill health averted 
(value of a statistical healthy life year). These two calculations will then be combined to 
estimate the aggregate health improvement, namely, QALE. 
 
3.2.2 Value of a Statistical Life (VSL)  
In order to estimate a society’s willingness to pay for reduced mortality it is necessary to 
establish the amount that a group of people (a society) would be willing to pay for a 
reduction in the current period probability of death. VSL studies estimate the value of fatal 
risk reduction (through evaluating the amount that a society is willing to pay) in the 
expectation of saving one life (of an unidentified person) in the current period216. For 
example, if people are on average willing to pay £10 for a safety improvement that will 
reduce their individual risk of death during the coming year by 1 in 100,000, this risk 
reduction would mean that, on average, in a group of 100,000 people there would be 1 less 
premature death, and these 100,000 people would, between them, be willing to pay £10 x 
100,000 = £1 million for the prevention of 1 statistical fatality217. Hence in this example 
the VSL is £1 million. 
 
There is a growing body of empirical evidence concerning premiums individuals are 
willing to pay to reduce the risk of death by small amounts218. One method for deriving 
such estimates is based on individuals’ observed behaviour in production, e.g. labour 
market risks compensating wage studies. Another approach considers the implications of 
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individuals’ observed behaviour in consumption, e.g. data concerning the time-
inconsistency-safety trade offs involved in car seat belt use, motorway speed decisions, the 
purchase price and the maintenance of smoke detectors and the frequency of car tyre 
replacement219. Both of these approaches are revealed preference studies. The third 
method, contingent valuation (CV), analyses replies to questionnaires that ask individuals 
about their willingness to pay for various hypothetical changes in risk.  
 
The majority of revealed preference studies have focussed on risk compensating wage 
differentials of hedonic price studies, where there is an equilibrium wage risk function such 
that, at any particular point workers are substituting income for risk of death. By estimating 
this equilibrium wage risk function – while controlling for other job characteristics – it is 
possible to identify the compensating wage differential and subsequently estimate the 
value of a statistical life.  
 
Because labour market studies reflect actual behaviour, with decisions that are consistently 
repeated, it is thought that this form of VSL study is most reliable and therefore many 
more studies have been conducted from this perspective, which has generated a much 
richer variety in risk compensating revealed preference studies (from a collection of time 
periods and occupation).  
 
Estimates of the VSL range widely: from less than $100,000 to several million dollars220. 
The table overleaf highlights the extent of this variation among the most credible VSL 
studies conducted over the previous three decades. 
 
 
 
 
 
 
                                                 
219
 Jones-Lee, “The Economics of Safety and Physical Risk”, p. 54 
220
 Dillingham, “The Influence of Risk Variable Definition on Value of Life Estimates”, p. 277 
Methodology 
             - 81 - 
Table 3.1: Estimates of the VSL derived from the most credible studies of the last three 
decades221 
Author / Year Type of VSL study Estimated VSL 
Thaler & Rosen (1973) Compensating wage differential (USA) 1987£420,000 
Smith (1973) Compensating wage differential (USA) 1987£7,950,000 
Melinek (1974) Compensating wage differential (UK) 1987£990,000 
Viscusi (1978) Compensating wage differential (USA) 1987£2,590,000 
Veljanovksi (1978) Compensating wage differential (UK) 1987£4,550,000 
Dillingham (1979) Compensating wage differential (USA) 1987£400,000 
Brown (1980) Compensating wage differential (USA) 1987£1,270,000 
Needham (1980) Compensating wage differential (UK) 1987£130,000 
Olson (1981) Compensating wage differential (USA) 1987£5,260,000 
Arnould & Nichols (1983) Compensating wage differential (USA) 1987£410,000 
Miller (2000) Compensating wage differential (Average of 13 countries) 1995$3,384,000222 
Costa & Kahn (2003) Compensating wage differential (USA  value for 1980) 1990$4,500,000223 
Viscusi & Aldy (2003) Compensating wage differential (USA) 2000$6,600,000224 
Viscusi & Aldy (2003) Compensating wage differential (Average of 10 countries) 2000$5,600,000225 
Viscusi & Kniesner (2005) Compensating wage differential distributed by workers’ relative 
position and life-cycle pattern of consumption (USA) 
2005$4,750,000226 
Melinek (1974) Time-inconvenience-safety trade off: use of pedestrian subways 
(UK) 
1987£400,000 
Jones-Lee (1977) Wealth-safety trade off: frequency of tyre replacement (UK)  1987£1,830,000 
Blomquist (1979) Time-inconvenience-safety trade off: use of car seatbelts (USA) 1987£400,000 
Dardis (1980) Purchase of domestic smoke detectors (USA) 1987£280,000 
Portney (1981) House price-air pollution trade off (USA) 1987£150,000 
Ippolito & Ippolito (1984) Cigarette smokers’ response to health hazard information (USA) 1987£390,000 
Acton (1973) Small non-random sample survey (n=93) of WTP for heart attack 
ambulance (USA) 
1987£50,000 
Melinek et al (1973) Non-random sample survey (n=873) of WTP for domestic fire 
safety (UK) 
1987£250,000 
Melinek et al (1973) Non-random sample survey (n=873) of WTP for hypothetical safe 
cigarette (UK) 
1987£80,000 
Jones-Lee (1976) Small non-random sample survey (n=31) of WTP for airline safety 
(UK) 
1987£8,250,000 
Maclean (1979) Quota sample survey (n=325) of WTP for domestic fire safety (UK) 1987£2,480,000 
Frankel (1979) Small non-random sample survey (n=169) of WTP for elimination 
of small airline risk (USA) 
1987£11,700,000 
Jones-Lee et al (1985) Large random sample survey (n=1,150) of WTP for transport safety 
(UK) 
1987£1,860,000 
  
Table 3.1 highlights a range of some of the most credible VSL studies that have been 
conducted in the UK and the USA between 1973 and 2005. These studies have used a 
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variety of methods, references and samples (across the UK and the USA) to try and derive 
a VSL. Table 3.1 highlights that these studies also report their VSL results in a variety of 
currencies. This is not a problem because the key value of the table is to highlight the range 
of existing VSL estimates, which Table 3.1 highlights is so broad, even without a 
standardised currency. Therefore, Table 3.1 indicates that the collection of even the most 
credible VSL studies lack precision, which has led sceptics to claim that “the variation in 
VSL estimates raises such doubts about their reliability that they are virtually redundant” 
(for example, for a time this sceptical view was adopted by the UK Department of 
Transport)227. A more positive and preferable approach (on philosophical, scientific and 
practical grounds) is to identify the reasons for the large variation in empirical estimates 
and try to define what constitutes a reliable study and subsequent estimate of the VSL228. 
 
Although it is not possible to claim that the VSL selected for use in the thesis is a 
definitively precise estimate, it does supersede many of the shortcomings inherent in 
numerous VSL estimates. The thesis utilises the VSL result from one of the most credible 
and detailed studies available. Miller (2000) provides a summary VSL ‘best estimate’ 
derived from applying a detailed and robust statistical analysis to the most reliable existing 
VSL studies (for the UK)229. The initial stage of Miller’s analysis was the identification of 
reliable VSL studies which are candidates for his aggregate VSL. These are shown in the 
table below.  
Table 3.2: Range and estimate of statistical life values from the most credible studies for 
United Kingdom as selected by Miller (in thousands of 1995 $)230 
Author / Year Type of VSL study Estimated VSL 
Ghosh et al (1975) Consumer Behaviour 1704 
Jones-Lee et al (1983) Contingent Value 3568 
Jones-Lee et al (1995) Contingent Value 2691 
Maclean (1979) Contingent Value 2446 
Marin & Psacharopoulos (1982) Wage-risk 2497 
Melinek (1974) Wage-risk 1457 
Melinek (1974) Consumer Behaviour 1608 
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Hence, the studies in Table 3.2 were used by Miller to estimate the most plausible 
aggregate VSL value. This was achieved through a process of statistical analysis, which 
optimises the credibility of Miller’s VSL results.  
 
At the outset it was necessary for Miller to standardise all of the studies. This was achieved 
through ensuring that they were all measuring the same features (unique to each type of 
VSL derivation study) through regressing any inaccurate or inconsistent variables whilst 
maintaining the necessary features of the study, e.g. through identifying occupation 
specific risk from industry wide risk data. Moreover, all VSLs used in the Miller estimate 
have been standardised for currency, the differing value of currencies over time and tax, 
such that all units of value are in the same convertible format. 
 
After standardising the studies Miller remedied one of the most persistent and obvious 
flaws in numerous VSL studies, which is that they account for actual risk rather than 
perceived risk, and catered for this through including an adjustment for risk 
misconceptions in his regressions. Along a similar vein, numerous labour market studies 
tend to utilise ‘all-cause fatality risk’ rather than ‘work place fatality risk by occupation’ 
and/or use ‘fatality risk by industry’ without including ‘occupational indicator variables’, 
which is often further exacerbated by use of average wage data. Miller’s regression model 
estimates the impact of these problems and subsequently eliminates their influence. This is 
desirable as these flaws tend to artificially influence the value of the VSL: using ‘all-cause 
mortality risk’ tends to underestimate the VSL and failure to use ‘occupational mortality 
risk’ or occupational dummies (in regression analysis) tends to overestimate the VSL.  
 
In addition to compensating for the problems that are evident in labour market revealed 
preference VSL studies, Miller applies similar considerations to revealed preference 
consumption VSL methodologies. The key problem here is that consumer behaviour 
studies tend to underestimate the VSL because these studies are based on (consumer) risk, 
which is typically under-perceived. Hence, labour market and contingent valuation studies 
tend to yield VSL estimates in a similar range, whereas consumer behaviour VSL results 
tend to be lower as a result of misunderstood risk. This is shown in Table 3.2, where, with 
the exception of the Melinek (1974) wage-risk estimate, behaviour studies yield the lowest 
VSL. This artificial influence is amended in the weighting of the estimates in Miller’s 
aggregate best estimate VSL, e.g. Miller’s best estimate VSL (which is a weighted average 
Methodology 
             - 84 - 
of the VSL results in Table 3.2 [see Table 3.3] = 2,750 versus 1,608 and 1,704 which were 
yielded in the consumer behaviour VSL studies [see Table 3.2]). 
  
Lastly, in a best effort to include the broadest range of credible VSL studies whilst yielding 
the most plausible aggregate VSL estimate for the UK, Miller has weighted the VSL 
studies contained within the overall estimate. Hence, the best estimate that is developed 
from the seven studies (outline in Table 3.2) has weighted these studies according to their 
type of VSL study, methodologies within the study and overall results. This optimises the 
plausibility of Miller’s best VSL estimate as it ensures (as far as possible) that any artificial 
influences have been minimised.  
 
The outcome of Miller’s efforts to consider the greatest number of existing VSL studies 
and include them with optimal accuracy in an aggregate or ‘best estimate’ VSL yields 
results that are desirable for the thesis. This is largely because the objective of the thesis is 
to utilise a VSL which is roughly plausible, for twentieth century England. The provision 
of a weighted average of studies is desirable because it provides a broader consideration 
about what the VSL might be. The subsequent application of this broad range of studies to 
detailed statistical analysis is also desirable for the thesis because it helps to eliminate any 
sources of inaccuracy and artificial risk which would in turn yield a distorted VSL value. 
Finally, the inclusion of a representative for all three types of VSL study is also desirable 
as it goes some way in balancing out the advantages and disadvantages inherent in each 
type of study. Moreover, a probable reason for the difference in estimates yielded by the 
three types of VSL study is that they are measuring different risk functions and therefore 
having all of these represented (and weighted accordingly, by Miller) is desirable for the 
accuracy of the thesis’ VSL.  
 
A final appeal of adopting the VSL results of the Miller study is the versatility of the VSL 
results. It is possible to present the VSL as either an aggregate monetary estimate (shown 
in the table below as 2,759,000 [1995 dollars]) or as a VSL multiple (shown in the table 
below as 101, 128 or 154), which is then multiplied by GDP per capita, which yields the 
VSL estimate. The mechanics and appeal of using Miller’s VSL multiple approach are 
outlined below.  
 
Therefore, Miller’s unique and credible efforts of finding an aggregate ‘best estimate’ VSL 
will be utilised in the thesis as a result of the likely accuracy of Miller’s estimates. As a 
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direct result of Miller’s procedure and analysis, the best estimate VSL used in the thesis is 
representative (as it was derived from a broad base of studies) and accurate (as far as 
possible due to detailed statistical analysis) which makes it ideal for the thesis’ 
methodology. The best estimates that this intricate statistical analysis has derived are 
shown in the table below, which presents Miller’s ‘best VSL estimate’ and a range of ‘best 
VSL estimate: GDP multiples’, which will be explained below. 
Table 3.3: Miller’s best VSL estimate (in thousands of 1995 $) and according VSL 
multiple (of GDP per capita) range for United Kingdom231 
 Best VSL estimate Best VSL estimate: VSL multiple 
Range  Low  Mid High 
United Kingdom 2750 101 128 154 
 
Table 3.3 provides the results to Miller’s analysis. There are two ways of thinking about 
the VSL (both of which are considering the same features). First, as an aggregate monetary 
estimate, which is shown in the table above as 2,750,000 (1995 dollars). The second way 
in which the VSL can be considered is as a function of i) a VSL multiple and ii) GDP per 
capita. In this second method, the VSL multiple (shown above as 101, 128 or 154) is 
multiplied by GDP per capita (precisely, GDP for the mid point of the period under 
consideration, is the value prescribed by this methodology to account for the average 
economic wealth during the period under consideration) which yields the VSL estimate. 
For example, for the period 1900 to 2000, 1950 GDP per capita will be multiplied with: 
101 (low VSL), 128 (mid VSL) or 154 (high VSL). Or, for the period 1900 to 1925, the 
thesis will multiply 1913 GDP per capita by 101, 128 or 154. The key point here is that 
both types of VSL are accurate and identical in what they are measuring, although, when 
considering long and/or historical time periods the latter (VSL multiple) approach is 
superior. The reasons for this and the subsequent appeal of using the VSL multiple 
approach (which is the strategy adopted by the thesis’ methodology) will be outlined 
below.  
 
Therefore, in relation to Table 3.3 the VSL(s) that will be used throughout the thesis will 
be those that are derived by using the Miller VSL multiple, either 101 (low estimate), 128 
(mid estimate) or 154 (high estimate), which will be multiplied by the associated GDP per 
capita number (which will be the level of GDP per capita [GDP pc] for the mid point of the 
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era under consideration), in order to identify the VSL for the different eras of the twentieth 
century analysed by the thesis. 
 
When considering the value of the VSL that will be utilised in the thesis, it should be noted 
that the precise value of the VSL is not fundamental in influencing the overall findings of 
the thesis methodology. The thesis will apply a range of VSL estimates (‘low’ 
[101*midpoint GDP pc], ‘mid’ [128*midpoint GDP pc] and ‘high’ [154*midpoint GDP 
pc]) in order to reinforce that even if a low value for the VSL is considered, the twentieth 
century health gains have been extremely valuable and pronounced and contribute to the 
same overall conclusions as the high VSL estimate. Hence, because of the nature of the 
VSL in the thesis methodology combined with the magnitude of improvements in the death 
rate a VSL estimate that is in the correct region will be sufficient to provide an accurate 
approximation about the value of twentieth century mortality improvements in England.  
 
When considering the validity of the thesis’ VSL what is important is that the key issues of 
contention are recognised and that a range of estimates are chosen accordingly. Although it 
is possible to supersede some aspects of inaccuracy in VSL studies (as was achieved by 
adopting Miller’s estimates, as outlined above) there are still inherent problems associated 
with estimating the VSL. The most prominent sources of VSL inaccuracies and contention 
are considered below. 
 
A universal problem with estimating the VSL is the likelihood that individual rates of 
marginal substitution – and hence the VSL – will almost certainly differ from one cause of 
death to another and therefore it may not be appropriate to find one VSL for all 
situations232. For example, the UK Department of Health have estimated that willingness to 
pay for reductions in involuntary and poorly understood risk can exceed that of voluntary, 
familiar risk by a factor of up to two or three233.  
 
A problem associated with evaluating labour market risk is the underlying notion of this 
revealed preference approach: that riskier occupations can be expected to carry clearly 
identifiable wage premiums as compensating for risk. However, this cannot be accepted as 
a universal occurrence. For example, workers in high risk employment may simply be less 
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risk opposed than average, or lack other economic opportunities234. Hence, some of the 
differences in the VSL are surely due, in part to different relative demands for occupational 
safety among the groups studied235.  
 
The extent to which wage premiums are aggregated for labour market conditions often 
reflects non-fatal as well as fatal risks. Lalive (2003) argues that industry aggregation of 
risk is responsible for the wide range in VSL estimates236. This shortcoming is particularly 
problematic from the perspective of the thesis because it creates the potential for double 
counting issues when the VSL (valuation for improvements in fatal risk) is combined with 
the VSHLY (valuation for improvements in non-fatal risk) in the overall QALE 
methodology. However, it should also be noted that this weakness has been amended as far 
as possible by Miller’s statistical analysis which attempts to identify, convert and measure 
accurate risk. 
 
There are also problems concerning model misspecification and risk data sets that are 
inaccurate for estimating the wage differential. For example, the omitted variables problem 
and the over aggregation of data are likely to produce estimates that are not precisely 
accurate. The inability to keep all variables separate (and avoid multicollinearity) is one of 
the greatest problems when trying to estimate the VSL237. Hence, it is necessary, but not 
always possible, to control for other factors in order to isolate the pure wealth risk trade off 
and the subsequent VSL238. Miller has adhered to these problems and overcome them as 
far as possible through his regressions. 
 
A final limitation of the revealed preference approach is that it is inherently incapable of 
generating estimates at an individual level. The questionnaire approach is useful as it is 
able to avoid these major difficulties encountered by revealed preference studies. The 
questionnaire method is also a straightforward procedure for computing the VSL without 
distributional weighting schemes, an exercise that is extremely difficult under the 
compensating wage differential approach. However, contingent valuation (CV) estimates 
are viewed as less indicative than revealed preference, largely because survey respondents 
may have inadequate opportunities or incentive to accurately determine their trade-off 
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between income and mortality risk239. The Miller VSL estimation process used in the thesis 
recognises this short coming of the CV method and weights CV VSL results accordingly.  
It should be noted that, when considering Table 3.2 and 3.3 the best estimate VSL (=2750) 
shown in Table 3.3 seems very close to the results of CV studies shown in Table 3.2 
(=2691, 2446, 3568), which is a coincidence as the final VSL number is a function of a 
very detailed statistical analysis which consolidates a large number of weights and 
estimates. 
 
An additional source of inaccuracy is generated through utilising a constant VSL value 
over time. This problem is exacerbated by the contention that exists in the literature 
regarding the nature of the VSL over time. Costa & Kahn (2003) have highlighted that as 
an economy develops, income, the quantity of safety and the health and well-being of the 
population also increase along with the demand for safety and the subsequent 
compensating wage differential240. For example, they estimate that between 1940 and 1980 
the VSL increased by 300 to 400 percent, rising from roughly 1 million (1990 $) in 1940 to 
5 million (1990 $) in 1980 in the USA, which indicates a VSL income elasticity of 
between 1.5 and 1.7 (estimated here as 1.6, see Table 3.4)241. Conversely, some studies 
have shown that there is an inelastic relationship between income and the VSL. Viscusi & 
Aldy (2003) also consider wage risk studies and conclude that the income elasticity for the 
VSL is less than 1 and they estimates income elasticity as being between 0.5 and 0.7 
(estimated here as 0.6, see Table 3.4)242. There have been no studies, to date, for the 
historical VSL in the UK and it is therefore impossible to provide estimates which indicate 
the income elasticity and subsequent VSL over the twentieth century for England. 
 
However, the thesis makes some progress in addressing this issue through utilising Miller’s 
VSL multiple which is applied to GDP for the mid-point of the era being considered and is 
therefore dynamic to an extent, because changes in the wealth of an economy are 
accounted for with GDP per capita. Moreover, in utilising a constant VSL multiple the 
thesis is estimating income elasticity as unitary, which provides a mid-point between the 
divergences (of 1.6 elasticity and 0.6 inelasticity) in the literature.  
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The implication of these different elasticities is the variance of the VSL relative to GDP. 
Costa & Kahn’s results imply that as an economy develops, increases in longevity or the 
VSL become more valuable (as the VSL rises 60 percent more than GDP or income, 
because the VSL income elasticity they propose is 1.6 percent, on average). This is in 
direct contrast with Viscusi & Aldy’s result, which implies that earlier increases in 
longevity were more valuable (as the VSL rises approximately 60 percent less than GDP or 
income, because they propose that the VSL is inelastic by 0.6 percent). The implication of 
these theories (which are summarised in Table 3.4) is the relative magnitude of the VSL: if 
the VSL is income inelastic (Viscusi & Aldy), the value of the VSL is relatively large in 
earlier time periods, and the opposite is true for an income elastic VSL (Costa & Kahn), 
where the VSL becomes increasingly valuable as the twentieth century unfolds. The 
unitary elasticity (Miller utilised in the thesis) VSL estimates will lie between inelastic and 
elastic, respectively.  
 
The table below provides a summary of the ramifications these different elasticities have 
upon the VSL. In Table 3.4 the VSL is derived from Miller (unitary elasticity), this VSL is 
calculated as the VSL multiple times GDP per capita for 1950 (mid point of 1900 to 2000). 
The alternative VSL values (for elasticity = 1.6 and inelasticity = 0.6) are derived through 
considering the Miller 2000 VSL value and adjusting this accordingly: identifying a VSL 
that has risen by 60 percent and 160 percent relative to income over the twentieth century. 
Table 3.4: VSL value when assuming different levels of VSL income elasticity: Costa 
versus Viscusi, 1900-2000 
Study VSL income elasticity 1900-2000 (= 1950) VSL value (millions) 
Costa & Kahn243 1.6 0.64 
Viscusi & Aldy244 0.6 1.18 
Thesis (Miller)245 1 0.88 
 
In Table 3.4 the thesis VSL assumes a unitary VSL income elasticity. This is calculated 
through multiplying the VSL multiple (128) with GDP per capita for the mid-point of 1900 
to 2000 (1950 GDP per capita = 6907, hence 6907 * 128 = 0.88 million = the VSL for 
1900-2000 using unitary VSL income elasticity), in order to identify the VSL (this is the 
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process of calculating the VSL using a VSL multiple approach, which has been outlined in 
Table 3.3).  
 
The other VSL estimates in Table 3.4 are calculated by considering the Miller VSL for 
2000 and adjusting this accordingly for elasticity of 0.6 and 1.6, in order to identify the 
VSL for these alternative elasticities, in 1950, which will make these results comparable 
with the thesis VSL shown above in Table 3.4. The Costa and Kahn estimates is the 
product of a VSL income elasticity of approximately 1.6 (average of 1.5 and 1.7), which 
indicates that the Miller VSL for the year 2000 estimate needs to be adjusted (in 
accordance with the Costa VSL change) in order to estimate a historical (1950) VSL with 
1.6 VSL income elasticity (i.e. Miller 2000 VSL = 128 [VSL multiple] * 18714 [GDP per 
capita in the year 2000] = 2,395,392; 2.395.392 / 3.735 [percentage change in the Costa 1.6 
income elasticity VSL] = 0.64 million). The same process is necessary in order to adjust 
the Viscusi and Aldy estimate so that the VSL has income inelasticity of about 0.6 
(average of 0.5 and 0.7). Hence, the Miller VSL for 2000 estimate needs to be adjusted in 
accordance with the Viscusi VSL change in order to estimate a historical (1950) VSL with 
0.6 VSL income inelasticity (i.e. Miller 2000 VSL = 128 [VSL multiple] * 18714 [GDP 
per capita in the year 2000] = 2,395,392; 2,395,392 / 2.026 [percentage change in the 
Viscusi 0.6 income inelasticity VSL] = 1.18  million). These results are shown in Table 
3.4. 
 
Another noteworthy point about Table 3.4 is the relationship between the thesis VSL and 
the alternative elasticity VSL results. The relationship between Costa & Kahn, Viscusi & 
Aldy, and the thesis VSL displays the properties that would be expected: income inelastic 
(Viscusi & Aldy) VSL estimates are higher in earlier periods than unitary elastic and 
income elastic (Costa & Kahn), respectively. This is a result of the VSL relationship with 
income, implied by these elasticities, such that for income inelasticity, earlier gains in VSL 
are more valuable and for income elasticity, later gains become more valuable.  
 
Table 3.4 highlights that the VSL is influenced by the elasticity that is adopted and 
therefore the subsequent result (derived in the thesis) about the value of twentieth century 
improvements in mortality will also be a function of the VSL (and its elasticity to twentieth 
century income). However, as has been stated above, this does not cause an overruling 
concern for the thesis because the precise value of the VSL is not fundamental in changing 
the aggregate results, largely as a result of the magnitude of improvements in mortality 
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(and to a lesser extent GDP). I.e. whichever elasticity is adopted the results and 
conclusions of the thesis hold weight. This claim will be justified in Chapter 8.1 sensitivity 
analysis about the VSL (see Table 8.1.11), when the range of elasticity VSL values (shown 
in Table 3.4) are applied to the thesis methodology. Hence, the key value of Table 3.4 is to 
highlight the range of VSL elasticity theories in the literature and indicate how and why 
these will not overly influence the conclusions of the thesis. 
 
An additional source of inaccuracy associated with a constant VSL, which is more 
consistent across all the literature and a problem for the thesis is the change in the age 
profile of the twentieth century English population. Hence, a dynamic VSL multiple is 
desirable to account for changes in the VSL during an individual’s life cycle and the 
overall effect that this phenomenon has upon twentieth century increases in the proportion 
of elderly in the population. VSL studies that are based on hedonic wage model estimates, 
age-specific hedonic wage estimates and a minimum distance indicator estimate, have 
highlighted the effect of age upon the VSL through their findings that workers’ VSL 
exhibits an inverted U-shaped relationship over their life cycle, such that the VSL for a 60 
year old is likely to be less than half the value for 30 to 40 year olds246. The thesis 
overcomes this to an extent through applying Murray’s age-weighting function (to the 
aggregate results) which also operates on an inverted U-shaped function (this will be 
explained later).  
 
The aforementioned problems associated with deriving the VSL are significantly 
heightened when trying to assess the morbidity equivalent, namely the value of a statistical 
health life year (VSHLY).  
 
3.2.3 Value of a Statistical Healthy Life Year (VSHLY) 
The VSHLY follows the same rationale as the VSL, as it tries to establish the amount that 
a group of people (society) would be willing to pay for a reduction in the current period 
probability of ill health (instead of a death that which is estimated by the VSL). The 
VSHLY will estimate the value of illness risk reduction in the expectation of saving one 
healthy life year (of an undefined person) in the current period, and therefore indicate 
society’s willingness to pay for improved morbidity (= VSHLY).  
 
                                                 
246
 Aldy & Viscusi, “Age Variations in Worker’s Value of a Statistical Life”, Abstract 
Methodology 
             - 92 - 
In contrast to the VSL literature, very little has been estimated about the value of a healthy 
life year. Furthermore, the existing initial attempts to consider some form of VSHLY tend 
to be abstract and generalised and do not consider the array of different illnesses.  
 
Cameron and DeShazo (2004) who coined the term ‘Value of Statistical Illness’ (VSI), 
consider this as the rate of substitution between consumption and mortality/morbidity risk 
through evaluating the willingness to pay to avoid five (and only five) generalised 
mortality/morbidity states247. Although this provides an acceptable first effort to provide a 
more accurate VSI, there are noteworthy shortcomings. For example, the very general 
nature of the illness states and the void of considerations about the quality of life mean that 
the VSI is too generalised. Of greater concern is that some of the assumptions in their 
illness model seem incorrect, e.g. the 6 year survival profiles are arbitrary248. Finally, there 
is no indication about the change in the VSI, i.e. the associated trade-off costs as medical 
technology has advanced and the resultant improvement in the health/welfare quality of 
life associated with illness which is likely to have increased the value of the VSI over time.  
 
A more general drawback of the majority of existing VSI methodologies is the 
assumptions that individuals are in one of two mutually exclusive states while alive: 
healthy or ill. The thesis WTP methodology will provide a much more detailed and 
bespoke evaluation about the burden of illness. 
 
The thesis will provide a much more precise VSI estimate through the following process. 
The VSHLY used throughout this thesis will be a function of the VSL adjusted for the 
QALY (for the associated illness and era). The VSL considers a life year with 100 percent 
health and the QALY equals the necessary deduction of a healthy life year and hence the 
VSHLY will deduct the according QALY fraction for the burden of illness (blindness, 
cancer [breast and stomach] or tuberculosis in the context of this thesis). E.g. if the 
morbidity burden of tuberculosis in 1950 was 40 percent, an individual would only have 
gained 60 percent of a healthy life year (1 [full healthy life year] – 0.4 [morbidity burden] 
= 0.6 or 60 percent). The value of this healthy life year has been established above (it is the 
VSL) and this will need to be reduced by 40 percent for the morbidity burden in order to 
provide the VSHLY value. This calculation is summarised below.  
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Equation 3.1: Summary definition of VSL and VSHLY used in the thesis methodology 
 
 
 
 
 
 
 
 
 
The VSHLY will also be considered as a range, containing ‘low’, ‘mid’ and ‘high’ VSL 
and QALY variables. Finally, it is important to reiterate that these indices do not have to be 
estimated with complete precision. The thesis will include a range of VSL and VSHLY 
estimates. All of these estimate values yield similar results that are acceptable for justifying 
the conclusion about the value of improved health in twentieth century England.  
 
3.3 Methodology Application 
As a result of the complexities associated with measuring morbidity and creating a model 
capable of doing this and the level of detail that is necessary to generate meaningful 
results, only a limited number of illnesses can be evaluated. However, these results will 
ultimately be extended in order to provide a lower bound estimate for the value of all 
health improvements in twentieth century England.  
 
3.4 Illnesses Considered for the Morbidity Component 
The morbidity component of the thesis will provide a catalogue of illnesses that have been 
selected within the rationale of the epidemiological transition, in an effort to optimise the 
results of the thesis. To this end, the thesis will provide a detailed (qualitative and 
quantitative) analysis of an infectious disease, tuberculosis and of a debilitating disease, 
cancer (represented by breast and stomach cancer). Blindness will also be considered in 
order to provide an indication about the twentieth century trends in disability.  
 
Tuberculosis was selected because it represents one of the most important infectious 
diseases that declined during the twentieth century in accordance with the epidemiological 
transition. The prominence of tuberculosis in the twentieth century enables more detailed 
*VSLVSL Multiple=  [mid point] pcGDP  
 
*[1 ]VSHLY VSL QALY= −
 
 
Where, VSLMultiple = 101 (low) or 128 (mid) or 154 (high) 
pcGDP  = the level of pcGDP at the mid point of the period under evaluation 
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quantitative considerations due to the availability of better data than alternative infectious 
diseases, for example, whooping cough and especially influenza. 
 
One of the reasons for selecting breast cancer is the same as the appeal mentioned above 
for tuberculosis. Breast cancer was the most funded and researched cancer in twentieth 
century England, which facilitates a deeper insight into the quality of life features of this 
disease. Stomach cancer was utilised as a control for breast cancer and also to represent a 
more generic cancer, as far as possible. Breast and stomach cancer were also selected as 
their burden accords with the epidemiological transition, where debilitating diseases have 
increased to replace (and supersede) the decline in infectious diseases. This cancer trend is 
in contrast to the most prevalent twentieth century debilitating disease, circulatory or 
cardiovascular disease. The reason this has not been used is because of the decline of this 
disease from 50 percent of deaths in 1971 to 45 percent in 2000 (see Table 2.3.2). This 
contradicts the (epidemiological transition) framework of the thesis and would skew the 
results. 
 
Blindness was selected because it represents a significant twentieth century disability. All 
disabilities, including blindness, have inherent measurement problems for the QALE 
(largely because they are not usually resolved in death and therefore prevalence is harder to 
estimate compared to diseases). However, blindness has been well defined and 
documented over the twentieth century which makes it a preferable proxy disability 
compared to alternatives like paraplegia or being deformed. 
 
3.5 QALY Estimating Process 
The QALY needs to be established in order to provide a standardised, numerical indication 
about the burden of morbidity (from the illnesses considered in the thesis) during different 
eras of the twentieth century. Essentially, the QALY is considering the portion of a healthy 
life year lost as a result of illness. The QALY will be presented as a number that is a 
fraction of one: where one represents a full healthy life year and anything between zero 
(which represents no healthy life year, i.e. death) and one is the fraction of a healthy life 
year lost to illness. The QALY number will move closer to one as the burden of disease is 
alleviated. This can occur for numerous reasons, which will be outlined below.  
 
The QALY is fundamental in the methodology of the thesis because it provides the index 
for morbidity. The QALY forms the foundation of the morbidity and value of a statistical 
Methodology 
             - 95 - 
healthy life year (VSHLY) variables, which will amend the mortality and value of a 
statistical life year (VSL) data. Therefore, without the QALY it would be impossible to 
gauge and estimate the numerical/monetary value of improved health and the thesis’ 
aggregate health measure, QALE.  
 
The QALY, in the context of the thesis, considers the quality of life associated with 
blindness, tuberculosis and cancer (breast and stomach) related to health and welfare. In 
order to establish this number it is necessary to provide a detailed and consistent analysis 
of all pertinent literature and data (relevant for the key health and welfare variables in the 
thesis). These considerations will also be made consistently across all the illnesses and eras 
considered in the thesis in order to provide a standardised series of QALYs. This is also 
necessary so that the QALE results for all illnesses can be combined to provide aggregate 
QALE results for twentieth century England. This will be achieved through applying the 
EuroQol standardised spectrum of development, which is explained below. 
  
3.5.1 Key Variables 
The key variables for consideration for each illness in the morbidity chapters of the thesis 
have been selected for their power as the most indicative and relevant aspects of quality of 
life related to health and welfare for sufferers.  
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Table 3.5: Key variables considered for all disease states in the thesis methodology 
Key Variable Description/Significance Example249 
Government initiatives 
and help 
All government legislation, initiatives and 
benefits (financial and non-monetary) directed 
towards sufferers. 
National Health Service Act 
1948 and specific Acts of 
Parliament, e.g. 1922 Cancer 
Bill 
Recognition and 
awareness 
All factors related to public (i.e. non-
governmental) sources of help. This largely 
includes the work of charities raising 
awareness and help for sufferers and also 
preventative campaigns.  
Chest Clinic Samaritan Funds 
for the treatment of tuberculosis 
sufferers in Sanatoria before the 
introduction of government aid. 
Health developments Provides an aggregate score for the 
combination of the three most applicable 
health sub-variables and contains facets such 
as understanding, treatment, cure and 
prevention 
The introduction of 
mammography screening for 
breast cancer and antibiotic 
therapy to treat tuberculosis. 
Pain and discomfort Provides a summary indication of the 
symptoms of a disease in conjunction with the 
associated medical and (to a lesser extent) 
welfare aid available to abate the condition. 
The transformation of twentieth 
century therapy for tuberculosis. 
Ability to lead a normal 
life 
Provides an aggregate score for the 
combination of the three most applicable 
health and welfare sub-variables. These are 
more subtle and peripheral although equally as 
important as the aforementioned categories, 
e.g. depression and anxiety, physical ability, 
financial burden and social difficulties 
experienced by disease sufferers  
The conditions of daily life 
associated with the prognosis 
and treatment of stomach 
cancer. 
 
Each of these variables will be consistently evaluated from the perspective of tuberculosis 
and cancer sufferers in order to provide a detailed and standardised estimate about the 
quality of life burden of these illnesses for all eras of the twentieth century. For all of the 
variables in the above table the consideration point will be matched for tuberculosis, breast 
cancer and stomach cancer, with the exception of the sub-variables contained in ‘health 
developments’ and ‘ability to lead a normal life’. These will be disaggregated for 
tuberculosis and cancer as outlined in the table below. 
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Table 3.6: Sub-variables for ‘health developments’ and ‘ability to lead a normal life’ 
variables in the thesis methodology 
Morbid Condition Key Variable Sub-Variable Sub-Variable Description 
Prevention Medical knowledge about potential 
predisposing factors for cancer, e.g. 
smoking. 
Screening Ability to monitor individuals for 
cancer before they display symptoms, 
e.g. mammography. 
Cancer (Breast and 
Stomach) 
Health 
developments 
Treatment Ability to abate (if not cure) the 
spread of cancer, e.g. chemotherapy. 
Depression The unhappiness associated with 
having such a potentially fatal illness 
and the distraction to normal life this 
can cause. 
Anxiety The worry about the effects of cancer 
and treatment options. 
Cancer (Breast and 
Stomach) 
Ability to lead a 
normal life 
Physical ability The disabling effects of therapy 
(whether successful or not) for the 
treatment of cancer. 
Understanding The biological recognition and 
medical agreement about what the 
tubercle bacillus is, how it is spread 
and ultimately how it can be 
treated/prevented. 
Treatment The discovery of successful therapy 
for relieving, curing and preventing 
tuberculosis and the burden that these 
different twentieth century therapy 
regimes had upon tuberculosis 
sufferers. 
Tuberculosis Health 
developments 
Cure The contribution of having a cure for 
tuberculosis and the associated boost 
to quality of life this yielded. 
Depression/Anxiety The unhappiness associated with 
having such a potentially fatal illness. 
Social difficulties The problems that arose out of 
isolation in the pre tuberculosis 
antibiotic era. 
Tuberculosis  Ability to lead a 
normal life 
Financial burden The problems associated with the 
discontinuation of work that were 
caused by the tuberculosis disease. 
 
It should also be noted that for blindness these variables are slightly different because of 
the different nature of disease versus disability. This is essentially because the emphasis on 
certain quality of life variables is different for a disability than it is for a disease. Although 
it would be possible to consider blindness in the context of the variables above (as it is still 
a form of health burden and therefore compatible), it would not be strictly accurate. The 
key variables for blindness are: government initiatives and help, recognition and 
awareness, health developments (prevention, treatment), status, ability to lead a normal life 
(education, employment, wages). The first two variables are identical to those evaluated 
for diseases (and shown as the first two rows in Table 3.5) and ‘health developments’ is 
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also comparable, just with slightly different sub-variables. The final three are more unique 
to disability and subsequently differ from disease. These are summarised below. 
Table 3.7: Key variables considered for the disability state in the thesis methodology in 
addition to relevant variables in Table 3.5 
Key Variable Description/Significance Example 
Prevention Medical knowledge about potential 
predisposing factors for blindness, e.g. 
the effect of syphilis when giving birth. 
Antibiotic treatment for eye trauma that 
prevent eventual blindness, e.g. cortisone 
Health 
developments 
Treatment Ability to cure causes of blindness, e.g. 
cataract surgery. 
Status Provides a summary indication of the actual 
effectiveness of blind legislation and 
recognition initiatives across all aspects of 
blind health and welfare related quality of life. 
The extent to which anti-discrimination 
legislation was implemented and 
offenders prosecuted 
Education The opportunities for the blind to be 
educated and instilled with an equal 
foundation to the able bodied for later 
employment and wages. 
Employment The extent to which the blind 
experienced equal treatment with the able 
bodied in the labour market. 
Ability to lead a 
normal life 
Wages  The extent to which the blind 
experienced equal wages with the able 
bodied in the labour market. 
 
Therefore, the above table highlights that the general considerations being made by the 
thesis are uniform across all illnesses, but that the most fundamental variables differ 
slightly between disease and disability. 
 
After these key variables have been analysed in qualitative detail they will be transformed 
into a series of index numbers, which are representative of the quality of life associated 
with these conditions during different eras of the twentieth century. The first stage of this 
qualitative to quantitative transformation will be conducted on a standardised spectrum, 
referred to as EuroQol. For the actual transformation of the qualitative analysis, through 
applying EuroQol to the key variables for different illnesses and eras, into a quantitative 
(QALY) index, see Chapter 7. 
 
3.5.2 EuroQol Grid 
EuroQol has been used in numerous studies that try to yield QALY weights for a variety of 
medical conditions250. The appeal of EuroQol is the simple ranking spectrum that it 
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facilitates and the subsequent transparent comparison it provides, through establishing a 
two dimensional information medium. The first set of EuroQol dimensions is the five key 
variables (see Table 3.5). The second set of EuroQol dimensions is the values generated by 
a ranking scale, which, in the context of the thesis, assess the performance of these 
variables from a perspective of quality of life for the sufferer. For all illnesses and eras in 
the thesis there are six possible health and welfare ranks. By applying these rankings to the 
key variables for health and welfare the thesis will provide a standardised comparative 
analysis of all the illnesses and eras compared in the thesis. To summarise, the table below 
provides the (two dimensional) fundamentals of the EuroQol grid. 
Table 3.8: EuroQol standardised spectrum: two dimensional ranking scale of the thesis 
methodology: all possible EuroQol variables, health states and ranks  
 
Therefore, when considering the illnesses in the thesis, there are five key variables (top 
part of Table 3.8) and six possible (whole number) rankings that each of these can achieve 
(bottom part of Table 3.8), i.e. there are 65 or 15,625 different states of health and welfare, 
where the worst situation (of no quality of life for any of the key variables) would be 6, 6, 
6, 6, 6 and conversely the best situation (or complete quality of life for all the five 
variables) would be 1, 1, 1, 1, 1. Once these scores have been established it will be possible 
to convert them into QALY numbers (a fraction between 0 = death and 1 = complete health 
EuroQol Variables (= EuroQol health and welfare variables) 
Government initiatives and help 
Recognition and awareness 
Health developments 
Pain and discomfort 
Ability to lead a normal life 
Status (disability only) 
EuroQol standardised spectrum  
(= EuroQol evaluations of health and welfare variables) 
EuroQol Rank 
Complete quality of life 1 
Good quality of life 2 
Fair quality of life 3 
Some quality of life 4 
Poor quality of life 5 
No quality of life 6 
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or 0.1 percent to 100 percent), which forms a key component of the QALE methodology 
and eventual thesis results.  This is achieved through indexing the EuroQol 1 to 6 range of 
possible values into the equivalent QALY 0 to 1 range (this conversion and the 
corresponding EuroQol and QALY values are presented in Table 7.1). A simplified 
conceptual illustration of these considerations is shown in the figure below. 
Figure 3.2: Simplified QALY ranking grid for tuberculosis 1900 and 2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the above example, which considers the improved quality of life associated with 
tuberculosis at the beginning and end of the twentieth century, the possible burden of 
tuberculosis (and any other illness as the core grid is standard throughout the thesis) can be 
anywhere between about 0.1251 and 100 percent of a healthy life year. In 1900 the burden 
of suffering from tuberculosis was considerable and, in the hypothetical context of the 
diagram, an individual only experienced 25 percent of a healthy life year. By the year 
2000, medical and welfare improvements had been considerable and improved the quality 
of life for tuberculosis sufferers to 75 percent of a healthy life year. These types of 
simplified ranking considerations will be made for all illnesses and all time periods studied 
in the thesis. 
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 The reason that the lowest score is 0.1 and not 0 is a result of the underlying inherent assumption in the thesis that any living state, regardless of how 
severe the burden of morbidity, is better than death. Hence, death is equal to 0 and perfect healthy life is equal to 100, it is theoretically possible to have a 
perfect healthy life but it is not possible to have an illness state that is worse than or equal to death. 
Best Imaginable Health/Welfare State 
Worst Imaginable Health/Welfare State 
100% 
0% 
Tuberculosis 2000 
Tuberculosis 1900 
Best EuroQol situation 
(1, 1, 1, 1, 1) 
Worst EuroQol situation 
(6, 6, 6, 6, 6) 
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3.5.3 Periodisation 
The period that the QALE methodology will be applied to is the twentieth century, because 
during this era there were unprecedented increases in life expectancy and also when the 
epidemiological transition occurred in England. Although this era could be extended back 
in time, e.g. to the late nineteenth century, this would not change the overall findings or 
add any detail that is not captured in the early twentieth century. 
 
In order to estimate how the health and welfare related quality of life evolved over the 
twentieth century it is necessary to analyse the key variables during different periods 
between 1900 and 2000. Because of the pace of health and welfare improvements, charting 
the changes for consecutive years would provide an excessive level of detail. The ideal 
approach is to consider health and welfare related quality of life at reference points 
throughout the twentieth century. To this end the twentieth century has been divided into 
quartiles: 1900, 1925, 1950, 1975 and 2000. The qualitative analysis will chart the 
improvements and breakthroughs that were necessary to change the quality of life at these 
points in time.   
 
The actual process of this appraisal is much more dynamic, as the thesis analysis and 
results will consider the evaluation of health and welfare related quality of life between 
these reference points that contain the eras that are listed below. 
1. 1900 to 1925 
2. 1925 to 1950 
3. 1950 to 1975 
4. 1975 to 2000 
5. 1900 to 2000  
 
3.6 QALY Value Accreditation   
The thesis utilises an unorthodox method for eliciting quality of life values for illnesses 
and it is therefore necessary to identify the conventional methods for deriving QALYs in 
conjunction with the reasons and appeal for the divergence between this and the thesis’ 
approach. It is also desirable to highlight that the thesis QALY results do not bias the 
overall thesis findings, and show that in most instances the thesis QALYs are more 
conservatively estimated than those in mainstream measures.   
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There is no uniformity in how a QALY should be measured and the most common 
methods for evaluating health are: expert ranking and individual self-rating of perceived 
health status, both of which can be aided by the use of tools such as a visual analogue scale 
(VAS), standard gamble (SG) and time trade off (TTO)252.   
 
The most established studies are Cutler and Richardson (1997, 1998, 1999)253, who use a 
combination of expert judgement and individual self-rating to evaluate “health capital” 
and Murray’s (1996)254 global burden of disease study, which derives DALY (disability 
adjusted life years, which are essentially an inverse QALY) through an expert study that 
utilises VAS and TTO. The majority of credible studies which include the value of a 
QALY are based upon these methods and often provide refinements, e.g. age influence.  
 
The most obvious incompatibility with these studies and the thesis is that they all tend to 
be based on modern national health questionnaires, e.g. the National Heath Interview 
Survey (NHIS) in America from 1969 onwards and the British Household Panel Survey in 
Britain from 1996. The QALYs generated through such methods are recent and therefore 
inadequate for considering the changing QALY between 1900 and 2000. This issue 
eliminates all types of QALY measures that rely on any form of self-reporting. 
 
The next obvious alternative is the Murray type approach, of conducting an expert study to 
determine (through a series of revealed preference exercises) the likely QALY burden of 
different illnesses in different eras of the twentieth century. Although this approach has 
numerous attributes, it was felt that for the time and effort required to conduct an unbiased 
expert study was not productive, especially given the unavoidable drawbacks of such an 
approach, e.g. relativity among experts, participant biases which detract from subjectivity, 
and avoidance of issues about adaptation and fist hand understanding of the quality of life 
burden of illnesses. Moreover, although the expert study has ‘consensus’ as the 
compensating feature, it was felt that this did not add enough value for the thesis to 
conduct major research along the lines of an expert study to yield historical QALY values.  
 
Therefore, as a first approximation, the QALY for the thesis illnesses and eras will be as 
well established by the author summarising the consensus of a detailed literature review, 
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 Praag & Ferrer-i-Carbonell, “Age Differentiated QALY Losses”, p. 3 
253
 Cutler & Richardson, “The Value of Health 1970-1990” and “Measuring the Health of the US Population” and “Your Money and Your Life: The Value of 
Health and What Affects It” 
254
 Murray, “Rethinking DALYs”, in Murray & Lopez, “The Global Burden of Disease”, pp. 1-98 
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while appreciating all the potential factors of bias. The major sources of contention of this 
method are: author biases which detract from subjectivity and avoidance of issues such as 
adaptation and first hand understanding of quality of life burden of illnesses. Hence, these 
issues are very similar to those which arise from an expert study.  
 
Because the thesis QALY is derived by the author’s consistent review of all relevant 
sources these estimates escape other problems associated with numerous quality of life 
studies that are based on Cutler and Richardson methods, namely adaptation and relativity. 
Adaptation is defined by Heyink (1993) as “an intra-psychic process in which past, 
present, and future situation and circumstances are given such cognitive and emotional 
meaning that an acceptable level of wellbeing is achieved”255. As the prevalence of disease 
increased during the twentieth century, so did the biasing from ‘adaptation’256.  I.e. 
distortions arise because people’s perception is standardised by their surroundings and 
experiences of themselves and those they know257. This is avoided by the thesis because 
the author is eliciting QALYs from unemotional, unphysical and unconnected experience, 
which eliminates the scope for adaptation and enhances the consistency (and subsequent 
reliability) of the thesis’ QALY estimates.  
 
In an additional effort to consider the validity of the thesis’ unorthodox QALY generating 
process (which can be considered as a definitive survey of all existing relevant sources) it 
is desirable to consider the results that the Cutler and Richardson and Murray studies have 
derived for comparable periods as this will help to indicate the acceptability of the thesis 
results. 
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Table 3.9: Comparison of QALY results from leading studies versus thesis (Hickson) estimates, for all available periods; 1970-2000 
Illness Study Range258 Year 
   1970 1975 1980 1990 1996 2000 
Blindness Cutler & Richardson259  0.73  0.80 0.87   
 Murray260      0.60  
 Mid  0.67    0.67 
 
Hickson 
Low      0.50 
         
Cancer261 Cutler & Richardson  0.70  0.70 0.70   
Breast Cancer Mid  0.67    0.83 
 
Hickson 
Low      0.67 
Stomach Cancer Mid  0.67    0.67 
 
Hickson 
Low      0.50 
         
Heart Disease Cutler & Richardson  0.64   0.70   
‘Heart Disease’262 Hickson Low      0.50 
 
                                                 
258
 For the purposes of the thesis; Mid represents what Hickson deems to be the most likely QALY value and Low represents the most conservative estimate that will be utilised for the extended results lower bound estimate 
259
 Cutler, D. & Richardson, E. (1998) “The Value of Health: 1970-1990” 
260
 Murray, “Rethinking DALYs”, in Murray & Lopez, “The Global Burden of Disease” 
261
 Cutler and Richardson’s cancer estimate is obtained from the ‘National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database’. 
262
 In the Extended Results of the thesis, all non-infectious and classifiable diseases are given the low profile of stomach cancer, and therefore this can be applied to heart disease for exemplary purposes. The rationale of this will be elaborated in 
Chapter 9: Extended Results.  
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The above table highlights the validity of the QALY weights yielded in the thesis, for the 
comparable periods of the twentieth century. The key evidence for this claim is two-fold. Fist, 
the similarity in estimates between the thesis and Murray and Cutler and Richardson, which 
indicates that the thesis QALY is making similar quality of life considerations and 
measurements. Second, the lowest bound QALY estimates yielded by the thesis add weight to 
the eventual conservative estimates of the thesis. However, it should be noted that this 
comparative substantiation is not available for the years prior to 1970, as these types of 
consideration had not been made. In an attempt to eliminate the challenges caused by this void 
in the literature, the thesis QALY has been developed from a detailed and consistent review of 
the literature in order to derive the most universally accurate QALY estimates. Moreover, this 
estimation process was consistent across all illnesses and eras considered in the thesis in order 
to yield the most robust summary of the QALY from all relevant historical sources.  
 
Hence, in every comparable instance the thesis QALY weights are less favourable than 
Murray’s and particularly Cutler and Richardson’s. This is evident for the ‘Mid’ thesis 
estimates, which will be used in the Quantitative Results to provide a range and is deemed to 
be the most likely value by the author. The only exceptions to this are Hickson: breast cancer: 
2000 versus Cutler and Richardson: cancer: 1990 and Hickson: blind: 2000 versus Murray: 
blind 1996. However, these are marginal and also there is the potential for the Cutler and 
Richardson and Murray estimates to have closed this QALY gap by the year 2000. 
 
A final issue which adds extra validity to the thesis QALY estimates is the additional research 
related to QALY measurement a la Cutler and Richardson. These studies have attempted to 
add more precision to existing methods, for example, Praag and Ferrer-i-Carbonell (2001)263 
consider the effects of age upon QALY and Honda and Ohkusa (2001)264 have developed a 
more rigorous model for defining quality of life, which includes economic consideration 
variables. All such studies have found a more optimistic value for the QALY than Cutler and 
Richardson, which implies that when more accuracy is attained the QALY burden declines, 
although estimates of magnitude are still lacking in the literature. 
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Hence, the above analysis highlights that there is no mainstream literature that generates 
results and conclusions that are inconsistent with the thesis. Although the methodology used in 
these studies differs from that in the thesis, this is a result of the unique objectives of the thesis 
and the final QALY results of the thesis are in consensus with those yielded in established 
studies. Although it is not possible to justify in the pre 1970 era, every reasonable process has 
been employed to estimate the most accurate QALY values. Furthermore, compared to the 
estimates yielded by Cutler and Richardson and Murray between 1970 and 2000 the thesis 
results are conservative.  
 
3.7 QALE Methodology  
The measurement of mortality and morbidity will be combined in the quantitative 
methodology in order to provide an aggregate measurement for the value of improved health 
in twentieth century England. This overall (QALE) measure will provide an indication of the 
value of the decline in mortality in conjunction with the improvements in quality of life when 
ill. 
 
Once this has been achieved for the thesis sample of illnesses the findings will be developed in 
order to provide a lower bound estimate about the value of improved morbidity in its entirety, 
which will be combined with all twentieth century mortality improvements to provide an 
aggregate estimate for the value of improved health or QALE for the entire twentieth century 
in England. This is facilitated by the creation of the thesis methodology, which provides the 
thesis’ most significant contribution to knowledge, through facilitating estimates about the 
value and contribution (to a more rounded notion of economic welfare development) of 
improved QALE. This methodology is summarised below. 
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Equation 3.2: Summary of the thesis methodology: quality adjusted life expectancy 
(QALE)265. 
Willingness to Pay Morbidity (MB): 
MBWTP  Considers increased quality of life with an illness or disability   
MBWTP = VSHLY * population weighted fall in the burden of disease / disability 
For MBWTP this would have to be calculated for each type of illness and disability and their 
associated QALY ( λ ) 
 
This will then be combined with the equivalent information for mortality improvements 
 
Willingness to Pay Mortality (MT): 
MTWTP  Considers increased life expectancy   
MTWTP  = VSL * population weighted fall in the death rate 
 
Quality Adjusted Life Expectancy (QALE): 
Such that 
MBWTP  +  MTWTP  = QALE improvement: 
 
* ( *)
[ ] ( [ ])
dc u c
d µ λ ρ µ λ
−
=
+ + +                                                                                    
 
( *)u c = the goods value of life,  
*c = consumption or income,  
ρ = the pure rate of individual time preference,  
µ = set of mortality rates,  
( Pr[λ = ∑ Condition D at t + k] * [QALY for D at t + k])  
 
Hence, the willingness to pay mortality represents the monetary value estimate for 
improvements in mortality and will be estimated through combining the decline in the death 
                                                 
265
 For detailed methodological algebra see Appendix 12.16. 
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rate with a value of this decline, which is represented here as the value of a statistical life 
(VSL). The willingness to pay morbidity represents the monetary value estimate for 
improvements in morbidity (through an improvement in quality of life associated with illness) 
and will be estimated through combining the decline in the burden of illness with a value of 
this decline, which is represented here as the value of a statistical healthy life year (VSHLY). 
These two measures will be combined to provide an overall indication about the (extended) 
willingness to pay for improved health which is depicted here as the quality adjusted life 
expectancy (QALE). 
 
3.8 Methodology Sensitivity Analyses 
Because of the numerous assumptions and estimates that were necessary to produce the 
overall results of the thesis it is desirable to try and accommodate for this through providing a 
range of possible results. The thesis will apply two broad categories of sensitivity analysis: the 
provision of a range of estimates, which will then be applied to an age-weighting function. 
These processes will provide an additional, more sophisticated set of QALE estimates.  
 
3.8.1 Sensitivity Analysis: Range of QALE Gain Results 
This sensitivity analysis will provide a range of aggregate estimates in order to overcome 
some of the uncertainty associated with estimating the QALY, VSL and VSHLY (which is a 
function of the VSL and QALY values) and subsequently add authenticity to the results.  
 
The QALY will be considered with a degree of error of one EuroQol category in either 
direction. This will help to highlight the robustness of the overall conclusions. For example, 
the overall rank for tuberculosis in 2000 was 2 (‘good’ quality of life) on the scale of 1 to 6266. 
In the final results, the values 1 and 3 will also be considered. This range of (low [3], mid [2] 
and high [1]) QALY estimates will highlight that even if the QALY is not precisely 2, the 
results and overall implications of the results still hold weight. The VSL and VSHLY will also 
be subject to a similar range of estimates. Because the VSHLY is a combination of the QALY 
and VSL this will be subject to both of the aforementioned sensitivity analyses. Hence, the 
thesis will provide a range of VSHLY estimates which reflect low, mid, high VSL and QALY 
estimates.  
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The above analysis has provided a detailed explanation about why there is such wide variance 
between VSL estimates and has identified a subsequent best estimate for the VSL. Although 
the value that has been selected avoids many of the associated problems, additional sensitivity 
analysis (the provision of a low and high as well as a mid VSL value) will be applied in an 
effort to further overcome inaccuracies. As well as providing a range of results, this analysis 
also recognises the likelihood that there is no definitively correct VSL estimate, and highlights 
that, regardless of the value utilised, the findings remain the generally unchanged.  
 
The results of this sensitivity analyses process will be an extremely broad range of estimates, 
for example, instead of providing twenty QALE results (one QALE gain estimate for five eras 
and four illnesses) the thesis’ sensitivity analyses will extend this series of QALE results to 
more than one thousand. The QALY, VSL and VSHLY sensitivity analysis will yield 27 
estimates for each of the 4 illnesses and 5 eras (= [27*4]*5 = 540) the age-weighting will 
double the number of estimates for the three illnesses (= {[27*4]*5}*2 = 1080) and therefore 
there will be an aggregate number of 1080 estimates about the aggregate QALE gain in 
twentieth century England, all of which contribute to the same conclusion.  
 
3.8.2 Sensitivity Analysis: Results Application: Age-Weighting 
There is evidence that the VSL is not constant across all age groups and therefore a more 
valuable approach for estimating society’s willingness to pay would be a methodology that 
considers the potential for different ages to have varying values. Barnum (1987) has indicated 
that relying on calculations of health effects that are un-weighted for different ages is not 
wholly satisfactory267.   
 
There are numerous perspectives associated with these calls for age-weighting. Some have 
highlighted that age-weighting can be conducted from an equity standpoint, where age-
weights reflect the feeling that everyone is entitled to some normal span of life268. Anyone 
failing to achieve this has been cheated, while anyone getting more than this is ‘living on 
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borrowed time’269. In this type of ‘fair innings’ argument, the younger population receive a 
higher age weight as they have completed a smaller portion of their normal life span270.  
 
At the opposite end of the spectrum, certain authors have identified the need to consider more 
indicators of economic contribution than just age. Cooper and Rice (1976) adopt a human 
capital approach to include income differentials of workers, where higher income groups who 
contribute more to total economic product are given a greater weighting, i.e. income weighted 
years of life271. Others have studied the extra contribution of more educated workers, and 
emphasised the importance of including differentiations between high school and college 
graduates272.  
 
The preferable – and more commonly utilised – method of age-weighting considers the 
relationship between age and efficiency, by reflecting an individual’s social role, where people 
in general are supported by others during infancy and old age but support others during 
adulthood273. This form of age-weighting is provided by Murray (1996) in his Global Burden 
of Disease Study for the World Health Organisation (WHO) where he considers the age 
weight function of Disability Adjusted Life Years (DALYs). Murray provides values with 
which to calculate an age weighted value of death averted, supported by the notion that greater 
importance needs to be attached to years of productive adult life274. The continuous age weight 
function outlined by Murray is presented in the graph below. 
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Figure 3.3: Murray’s age weight function of DALYs: relative value of a year of life lived at 
different ages275 
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The appeal of this particular study is its versatility in conjunction with its power to highlight 
that improvements in health at different ages have different values to society. Furthermore, 
Murray’s model is detailed and accurate enough to provide the necessary indication for the 
purposes of the thesis.  
 
Despite the appeal of Murray’s methodology there are some areas of unavoidable conflict 
which need to be recognised. In the context of the thesis there are evident problems with the 
static nature of Murray’s age-weighting model. The economic contribution from different ages 
and genders is likely to have altered considerably over the twentieth century. Therefore, it 
would be ideal to have a different set of age weights for different eras of the twentieth century. 
As this option is not feasible, the Murray age-weighting will be utilised in order to provide a 
more accurate indication, rather than a definitive estimate, about the value of improved health, 
particularly compared to not making any age-weighting considerations.  
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The age-weighting represents the final aspect of the thesis’ QALE methodology. This process 
is summarised in the flow chart overleaf. The commentary below also provides a summary to 
the QALE methodology, outlined in detail above. 
 
In the context of the methodological series in the flow chart below: defining a measurement 
scale was achieved through constructing the QALE and (its measuring tool) the two 
dimensional ranking scale, EuroQol. The illnesses that were applied to this measure were 
chosen within the rational framework of the epidemiological transition (the appeal of which 
has been outlined in Part I of the thesis). The detailed qualitative review will be conducted in 
Part II of the thesis in order to provide a transparent analysis (about the key EuroQol 
variables) for the reader. This analysis will also provide the justification for the EuroQol rank 
which will subsequently be transformed into an aggregate QALY for each illness and 
corresponding era (in Chapter 7).  
 
Concurrently, the thesis has also identified the most credible VSL estimate. This process has 
been outlined previously in this chapter. This VSL can be combined with the change in the 
death rate in order to establish the WTP or value of improved mortality. Along a similar vein, 
the VSL can be combined with the previously identified QALY in order to provide the 
VSHLY. This can then be combined with data about the burden of illness (which is 
established through considering the prevalence of an illness in conjunction with the QALY for 
the corresponding illness and era) in order to identify the WTP morbidity, or value of 
improved health. The WTP mortality can then be summed with the WTP morbidity in order to 
identify the QALE gain. 
 
For completeness and in an effort to provide the most robust results, this QALE gain will then 
be subject to a series of sensitivity analyses. The first will recalculate the QALE gain for lower 
(‘low’) and higher (‘high’) QALY, VSL and VSHLY values. This will provide a wide range 
of results which will then be applied to Murray’s age-weighting function (see Figure 3.3). 
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Figure 3.4: Flow chart summary of the thesis’ methodological process  
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Therefore, once this new health measure has been applied to the data it will enable a 
simultaneous evaluation about the value of improvements in the quality of life associated with 
morbidity (from a health and welfare perspective) and mortality. These considerations will be 
made for different points of the twentieth century in order to identify the extent and value of 
improvements in health and welfare related quality of life.  
 
3.9 Extended Results 
Once the methodology has been applied to the thesis illnesses (Chapter 8) the analysis will be 
extended in order to optimise the results of the thesis. The findings for individual (proxy) 
illnesses will be developed to provide an aggregate lower bound estimate about the value of 
improvements for the entire twentieth century morbidity (and mortality) burden (Chapter 9). 
This will provide the fullest evidence for the importance and meaningfulness of the claims of 
the thesis. 
 
3.10 Methodology Location 
A fundamental component of the quantitative thesis results is the qualitative evaluation of 
different illness states and the subsequent estimation of the quality of life burden (QALY) of the 
illness for different eras of the twentieth century. This will be achieved in detail in Part II of the 
thesis, after which it will be possible to summarise the key qualitative results and subsequently 
utilise this in the quantitative chapters, which form the results of the thesis.  
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PART II 
4. Blindness 
4.1 Government Initiatives towards Blindness       117    
4.2 Socio-Economic Initiatives towards Blindness       126 
4.2.1 Employment         126 
4.2.2 Education           131 
4.2.3 Status          133 
4.3 Blind Discontent          134 
4.4 Medical Developments          136 
4.5 Summary           146 
 
          
“Blindness is a disability that has far-reaching social, economic and developmental 
implications. When visual disability occurs at birth or in childhood it provides a challenge to 
development and learning. When it is apparent in working age individuals it lowers 
productivity and capability. Across the lifespan it increases the scope for inequality, poverty, 
discrimination, poor status and ultimately devaluation in the quality of life”276. Consequently 
the recognition and help provided by the government and society have very important 
implications for the overall quality of life of the blind, as do improvements in medical 
technology. 
 
The number of blind people has been counted in Britain since 1851, starting with a simple 
declaration of blindness on census returns. This was discontinued after 1911, but after the 
1920 Blind Persons Act, with its statutory benefits to the blind, a register of blind persons was 
established. This was refined during the 1930s with the introduction of the BD8 forms, which 
were accepted only if they had been signed by a recognised ophthalmologist. The legal 
definition of blindness, which has been used throughout the twentieth century, was “so blind 
as to be unable to perform any work for which eye sight is essential”277. This is usually 
considered as 3/60 vision or worse in better eye or 6/60 or worse in better eye with markedly 
restricted fields278.  
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The number of registered blind people in England continually increased during the twentieth 
century, from approximately 23,907 in 1901279* to 75,420 in 1950280 and peaking at 157,820 
by 2000281.  For the first half of the twentieth century this increase was a likely result of 
improved registration and not a genuine increase (at least not entirely). For the second half of 
the century the increase in the number was strongly affected by the growth of the elderly 
population (70 years and over).  
Figure 4.1: Prevalence of blindness in twentieth century England, 1901-2000282 
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There was also a change in the age distribution of the blind population. The most common age 
of blindness increased so that by 1975 and especially 2000 this disability was mainly prevalent 
in old ages. This is an improvement over the first 50 years of the twentieth century when 
blindness was most common in working aged individuals and therefore hindered quality of life 
for a greater number of years. These types of consideration will be made at the end of this 
chapter (Table 4.9) and in the blind results chapter (Chapter 8.2). Before this is achieved, this 
chapter of the thesis will consider the key quality of life variables for blindness (see Tables 3.5 
and 3.7) throughout the twentieth century.  
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Hence, this chapter will highlight the welfare conditions faced by the blind during the 
twentieth century and identify the improvements in blind quality of life by examining three 
fundamental areas: legal, socio-economic and health.  
 
The legal history encompasses government acts and monetary aid to assist the blind and also 
various other state initiatives to help compensate the blind for their handicap. These questions 
are important because legislation had the potential to help the blind obtain equal quality of life 
in most socio-economic domains of life and facilitate an improvement in their quality of life, 
despite their disability.  
 
The socio-economic history will be evaluated in order to highlight the actual conditions faced 
by the blind in the major domains of their lives. This will include the following: employment 
and wages, education, and the status of the blind and the major issues of blind discontent 
during the twentieth century.  
 
Medical developments will be considered in order to determine how effective and valuable 
preventative and curative technological breakthroughs have been for blind quality of life. 
 
4.1 Government Initiatives towards Blindness 
Table 4.1 provides a summary of the legal legislation that was provided to help the blind 
during the twentieth century. Table 4.2 provides a summary of the average income received by 
the blind (independently and due to government welfare). Many of these policies were 
insufficient for improving the blind quality of life. However, others were more far reaching 
and these will be discussed in more detail after the tables. 
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Table 4.1: Government legislation for the blind 1906-1999283 
Year Title of government legislation Provisions of government legislation 
1906 Blind Aid Act Established technical schools, workshops and home-workers schemes. 
Also provided limited financial maintenance for the unemployable 
blind. 
1920 Blind Persons Act The blind were recognised and helped more explicitly, welfare 
payments increased, pensions were introduced and numerous charities 
established. 
1929 Local Government Act Forced Local Authorities to donate funds to voluntary associations 
providing services for the welfare of the blind and to provide funds for 
other blind services – workshops, home teachers, hostels, libraries, etc. 
Local Authorities were also expected to augment central spending on 
the blind. 
1934 Old Age Pensions A reinforcement of pension policies under the 1920 BPA. 
1938 Blind Persons Act Forced Local Authorities to promote blind welfare. Improvements in 
aid for the blind. Pension age for the blind was lowered: from 50 to 40 
years of age. The pension levels were the same as under the 1920 BPA. 
1942 Scheme to employ suitable blind 
persons 
Forced Local Authorities to encourage and facilitate the employment 
of blind persons in normal industry. 
1948 National Assistance Act Removed the blind from the Poor Law. Further provision for the 
disabled, in the form of increased welfare payments. 
1966 Travel Concessions Act Provided monetary concessions for the blind when using public 
transport. 
1970 Chronically Sick and Disabled 
Persons Act 
Extended the powers of Local Authorities to help disabled people and 
forced Local Authorities to publicise services to help the disabled. 
1981 Education Act Required the provision of special education for blind children to be 
conducted in normal schools (as far as possible). 
1986 Disabled Persons Act Promoted the inclusion of disabled people on committees and bodies, 
especially for issues concerning the interests of disabled people. 
1992 Disability Living Allowance Provided financial payments to the blind (£15 to £30 per week in 1992 
and this increased since its introduction). 
1992 Disability Working Allowance Provided a ‘top-up’ for low earning disabled people who worked 16+ 
hours per week. 
1995 Disability Discrimination Act Made it illegal to discriminate against disabled people and introduced a 
quota system which forced large companies to employ a certain 
number of disabled workers. 
1999 Disability Rights Commission Act Established the disability rights commission, which helped to promote 
equal opportunities for the disabled. 
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In addition to the provisions outlined in Table 4.1, there were also financial measures within 
some of the Acts. These are summarised below in Table 4.2, which highlights the average 
income of the blind from different sources during different eras in twentieth century England.  
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Table 4.2: Comparison of blind and able bodied sources of weekly income (per person), all values in new money, 1900-2000284 
 
  1920-1921 1924 1933 1944 1948 1988 1992-1993 2000 
 Blind285  5p-50p       £40.40286 
Blind Soldiers287  94p-£6.00       £116288 
Pension 
Able Bodied289   25p      £67.50290 
Blind  (>£1.38)291   £1.05-£1.75292 £1.25-£2.75293  £15-£30294 £35.80295 Benefits 
Able Bodied        £44.65296  
Blind 
(mainstream) 
 50p-60p297   £3.49298    
Industry  13p-£1.20 31p-£1.37 £3.27301    Blind  
(blind industry)300 Home  65p 71p   
£134 (all 
disabled)299 
  
Semi-skilled302  £2.25 £2.35   £240303 £385 
Wages 
Able Bodied 
Un-skilled304 £2.11305 £1.99 £2.09  £5.44306 
£159 (all 
employed) 
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1920 Blind Persons Act 
With the introduction of the 1920 Blind Persons Act, aid for the blind became, for the first 
time, widespread and specific. The provision of assistance under this Act was designed to 
ensure that no blind person was deprived as a result of their disability. The conditions of this 
groundbreaking Act were generally regarded – among the blind population – to be 
“exceedingly wide and comprehensive”307.  
 
Under Section 1 of this Act pensions were provided for blind men and women aged between 
50 and 70 years of age. The rate of the pension ranged from 5 to 50 pence per week, 
dependent upon existing income. Additionally, the vast majority of Local Authorities provided 
another 50 pence, which provided an extra boost for blind pensioners’ quality of life308. 
 
Although the National Institute of the Blind (NIB) did not regard the maximum under the Act 
as “nearly adequate for the proper maintenance of those who were completely dependent 
upon the pension”, they still recognised that it was a useful beginning309. The Advisory 
Committee on the Welfare of the Blind (hereafter the advisory committee) adopted a more 
positive view with their claims that the provision of pensions “has provided a great boon to 
the unemployable blind, and has secured for them a greater degree of comfort than 
previously…and has done much to alleviate stress among unemployed blind people”310. 
 
A further credit for Section 1 of the Act was the wide coverage from the onset of this 
legislation. In 1922 it is estimated that 93 percent of the blind aged between 50 and 70 were 
receiving the full pension311. Furthermore, for the first four years of the 1920 Blind Act 
pension, the blind were especially privileged compared to the rest of the population as there 
was no state pension before the Royal Assent in 1924.  
 
Under Section 2 of the 1920 Blind Persons Act the scale of blind assistance “was to be 
provided by Local Authorities; as it was thought to be a matter which should be determined by 
the local councils as representatives of the ratepayer who will meet the costs, and the Minister 
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of Health would probably only criticise the scale if it was excessively low or high”312. The 
1920 level of weekly income that the low amount had to exceed was £1.38313. The actual level 
of weekly payouts for the blind, around the midpoint of the twentieth century (1944), was 
between £1.05 and £1.75, with a median of roughly £1.35314. These payments also took into 
account the existing means (wages, pensions, charitable grants, investments, etc) of blind 
individuals who were applying for benefits. This represents an average blind welfare payout 
which was about 26 percent315 to 40 percent316 of semiskilled and unskilled wages, 
respectively, in 1944. In addition to these blind welfare payments, some Local Authorities also 
provided allowances for winter, rents, fuel, and other paraphernalia317. The government also 
provided a grant for the maintenance of blind services. 
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Table 4.3: Grants from the Ministry of Health in respect of services provided for the welfare 
of the blind 1921 to 1930 (£s)318 
Services 1921 – 2 1922 – 3 1923-4 1926-7 1927-8 1929-30 
Counties 
Associations 
6844 7002 7169 8428 
Workshops 31476 33356 35809 42212 
Home workers 6117 9212 10838 20007 
Homes 6673 6705 7409 7628 
Hostels 739 786 842 1001 
Home Teaching 12978 14753 16667 23209 
Tools and 
equipment 
147 187 213 418 
Books and 
production 
4912 3414 4440 6552 
Capital 
expenditure 
- 30 63 3035 
Miscellaneous - - 20 20 
 
TOTAL 69,886 75,445 83,470 112,510 120,550 131,368 
 
The advisory committee have highlighted that the total amount paid under the 1920 Blind 
Persons Act was: “satisfactory, in as much as it represents the considerable addition in the 
number of services for the blind and also indicates that additional blind persons were 
constantly being brought within the scope of the services”319. Table 4.3 highlights that nearly 
all the services show progressive increase during the twentieth century and the value of grants 
had nearly doubled between 1921 and 1930320. Another achievement of this Act was “the 
efforts made by the workshops to keep blind workers fully employed during the times of 
economic depression”321. 
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This Act also catalysed the formation of numerous regional and national blind charities. 
Although the National Institute of the Blind (known as the Royal National Institute for the 
Blind since 1953) was established in 1899 (and since has represented the main vehicle for 
blind promotion and help) many more specialist and regional charities evolved out of the 1920 
Act. These charities and voluntary agencies were generous with the support they donated to 
the blind population, and consequently they played a key role in enhancing the quality of life 
of the blind population during the twentieth century. 
 
1942 Scheme to Employ Suitable Blind Persons 
In 1942 the government introduced a scheme to employ suitable blind persons This 
government initiative forced Local Authorities to facilitate the blind joining normal 
employment. Within four years (by January 1946) “this policy had been so well received by 
blind persons that there was a need to employ additional staff for the placement of blind 
workers in normal industry”322. 
 
This enabled blind employment in normal industry, which represents one of the most 
important contributions towards blind equality with the able bodied population. “There can be 
no doubt about the benefit to the individual blind person who has been found a place in 
industry. Many were now able to work for the first time since being diagnosed as blind, while 
others were being given the opportunity of doing work previously regarded as beyond their 
capacity”323.  
 
1948 National Assistance Act 
The blind population was not removed from the Poor Law until 1948 when the National 
Assistance Act was introduced. This Act made further provisions for the disabled, sick and 
aged. The scales of assistance of this Act ranged from £1.25 to £2.75 per blind person, 
dependent upon age. In addition to these basic rates, blind individuals also received financial 
help for their rents and mortgages. 
 
 
 
                                                 
322
 The National Archives: MH 55 (1089): 1943-1946 Employment of the Blind, Placement in Industry 
323
 Ibid 
Illnesses: Blindness 
                                                                                                                                                                                                                          - 125 - 
1981 Education Act 
The 1981 Education Act required that “the provision of special education of the blind be 
conducted in mainstream schools as far as possible”, but did not abolish schools for the 
blind324. This indicates a step towards equality and integration of the blind. Although the 
effectiveness of normal schools compared to special schools for the education of the blind is 
contentious, the blind were still provided with the opportunity for equality, which facilitated 
an improvement in their quality of life. 
 
1992 Disability Living and Working Allowances  
The introduction of the Disability Living Allowance was an important development in welfare 
payments for the unemployable blind and in legal recognition and help for the blind in general. 
The Disability Living Allowance replaced the Attendance Allowance and Mobility 
Allowance, which were introduced in the 1970s but did not cater for the blind. This allowance 
paid blind individuals a weekly sum of between £15 and £30 (which increased later in the 
1990s), regardless of any other income. This highlights increased recognition of the blind and 
improved financial aid for the needs of their disability, which would have enhanced their 
quality of life325. 
 
Also in 1992 the government introduced the Disability Working Allowance (DWA), which 
was designed to ‘top-up’ low earnings of disabled people who worked at least 16 hours per 
week. This indicates a further effort to recognise and cater for the needs of the blind in the 
labour market. Unfortunately “when this policy was first introduced, the number of disabled 
people who received DWA was far lower than the official projections”326.  
 
1995 Disability Discrimination Act & 1999 Disability Rights Commission Act 
“The blind community experienced another milestone on the path to full equality and civil 
rights with the introduction of the 1995 Disability Discrimination Act”327. This legislation 
made it illegal to discriminate against blind people. It also forced companies who employed 
more than 20 workers to hire a certain number of disabled (including blind) individuals. 
Although this Act provided important rights for the blind, some areas were not covered and 
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other aspects of the Act were poorly designed, which often left the blind without 
comprehensive and enforceable rights. For example, the Act did not apply to manufacturers or 
cover transport vehicles. The provisions of this Act were formalised through the creation of 
the Disability Rights Commission Act in 1999. Both forms of legislation provided an 
improvement in quality of life. 
 
4.2 Socio-Economic Initiatives towards Blindness 
The analysis below draws heavily on the reporting in the Beacon magazine, as a source of 
evidence about the standards of living experienced by the (overall) blind population. The 
Beacon was published monthly by the RNIB and was aimed at people with sight problems and 
also those who were involved with the blind. The typical content of a Beacon magazine would 
be a collection of topics that were relevant to contemporary blind issues. The tone of the 
beacon was upbeat, which is a likely result of the underlying objective of the Beacon, which 
was to empower, inspire and inform the blind. The Beacon should be considered as a reliable 
source, although some of the claims need to be interpreted with cautions of journalism and 
bias. Journalism in the language and possible over enthusiasm and bias concerning features 
related to the contribution of the RNIB and conversely, the government. 
 
4.2.1 Employment 
1900  1925 
Blind employment initiatives were developed many centuries before the twentieth, however 
during this century the blind experienced the most significant developments towards equality 
with their able bodied counterparts. Home working began in the 1850s, as welfare schemes 
with aid from charitable funds. “In the industrial circumstances of the time, very few blind 
people were ever able to become self supporting and so the pattern of supported employment 
was established. This pattern was redrawn on employment lines in the early twentieth century 
as a result of war time needs, which saw the development of workshops and the government 
established its factories for disabled ex-servicemen. Such arrangements continued to be 
envisaged as welfare or therapy rather than commercial employment and genuine 
rehabilitation”328. 
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This attitude changed in around 1920 when: “the great aim of those who had the welfare of 
the blind as their objective campaigned to get them into normal life, so that they could work 
shoulder to shoulder with their sighted colleagues”329. The leader of the NIB had pointed out 
in 1918 that “workshops throughout England and Wales employed less than 3,000 blind out of 
a possible 34,000”330.  
 
Furthermore, the wages that blind individuals were earning at this time were insufficient. For 
example, there were 700 blind workers existing in London on less than 50 pence per week331. 
This is compared to the recommendation of the advisory committee that blind workers should 
be earning about one pound per week332.  
 
During the 1920s conditions improved somewhat for the blind who were seeking employment. 
There was an increase in the number of blind employed, for example by 1923 there were 8,246 
blind people in employment (compared to 6,391 in 1918)333. Blind employment opportunities 
were further helped by the 1922 Ministry of Health grant of £20 per head for each home 
worker, to assist with: provision of material, sale of produce, and also to enhance the scheme 
so that home working could become a good career option for the blind. Although the average 
wages for home workers did not reach the recommended level they still provided the blind 
with employment and some form of economic compensation334. The extent to which this 
applies varied widely between occupations: in 1924 the highest weekly earning were £1.20 
(piano tuners) versus the lowest weekly earnings, 13p (boot repairers). This gap was evident, 
although reduced, in 1933 when the highest weekly earnings were £1.37 (piano tuners) versus 
31p (hand knitters). Full details of the range of weekly wages are shown in Appendix 12.13.3.  
 
1925  1950 
There was a slight increase in the wages of home workers during this time, however relative to 
the wages of comparable mainstream industries the blind were still not close to equality. This 
is highlighted by comparing the average wage of blind workers in home industries with the 
average wage for semi-skilled and unskilled mainstream industry, shown in Table 4.2, which 
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highlights that the blind only earned as much as 34 percent of their sighted counterparties 
between 1924 and 1935. This unequal situation motivated criticism from blind supporters, e.g. 
“I have examined in the closest detail most of the systems of remuneration obtaining in the 
institutions for the blind in Great Britain, and, in my judgement, none of them can be regarded 
as entirely satisfactory”335. However the home worker scheme is still thought to have been a 
success in other ways. “Because of the increase in the number it employed and the extension 
of this service, many blind were capable of working and obtained training”336.  
 
The advisory committee had stated that by the 1930s many blind people had been employed in 
ordinary factories and workshops. Furthermore, “between 1910 and 1935 nearly every 
workshop for the blind had been enlarged or rebuilt and many more have been introduced”337. 
As well as developing existing blind industries this helped foster new blind industries. For 
example, in 1900 flat machine knitting was a practically unknown industry for the blind and 
by 1932 it was one of the main industries for the employment of blind females. These 
developments contributed to the valuable 49 percent increase in the number of blind in 
employment between 1919 and 1930338. Wages also improved during this period where the 
average weekly wage paid to blind men in workshops increased from 60p in 1910 to £1.24 by 
1935339.  
 
However, even though many blind persons had been employed in workshops, there were 
evident problems in finding employment for the younger working age blind. Furthermore, 
“many of these workshops were too small to be efficient and about 60 percent of the blind 
workers would not have been employed if strict standards of productivity were enforced”340. 
Furthermore, blind employment levels were geographically very uneven, for example the 
proportion of employed blind persons in 1931 varied from about 14 to 21 percent between 
different regions341. Also, out of the blind who were employed during the 1930s (and this is 
generally true for all times during the twentieth century), less than half were in workshops or 
under home workers schemes, which suggests that many of the blind were only casually or 
                                                 
335
 Purse,“The Blind in Industry”, p. 76 
336
 Beacon 1924: Home Industries for the Blind 
337
 Beacon 1935: 1910-1935 
338
 Beacon 1930: A Record of Useful Work 
339
 Ibid 
340
 Beacon 1924: The Employment of the Blind; A Survey of the General Problem 
341
 Beacon 1931: Report of the Advisory Committee on the Welfare of the Blind 
Illnesses: Blindness 
                                                                                                                                                                                                                          - 129 - 
partially employed. Another area of inequality was evident between male and female 
employment of the blind, whereby women experienced discrimination.  
 
Despite the problems with employment opportunities for the blind, the situation with wages 
continually improved during this era. Between 1938 and 1955 there was a substantial increase 
in normal industry wages and blind wages appear to have also experienced this increase, 
which marks a valuable achievement for the blind. This comparison is shown in Table 4.2. 
 
1950  1975 
In 1963 a new comprehensive service for placing blind people in industrial employment was 
introduced by the Ministry of Labour. During the first year of this scheme 921 blind people 
were placed in industry, of which 761 were placed in open employment, which the RNIB 
considered a “good start”342.  
Table 4.4: Employment of the blind: number and percentage of working age blind in 
employment and areas of employment, 1968-1975343 
 1968 % blind age 
working 
population 
employed 
1969 % blind age 
working 
population 
employed 
1970 % blind age 
working 
population 
employed 
1975∗ % blind age 
working 
population 
employed 
Total 
Employed 
9143 24 8969 24 8683 24 7837 31 
In open 
employment 
6269 17 6241 17 6123 17 5687 23 
 
Table 4.8 considers the total number of blind in employment and the percentage of the blind 
working age population that this represents. This table highlights that despite the efforts of the 
Ministry of Labour, the blind employment rate failed to improve before 1975. This is best 
highlighted by there never being more than 24 percent of the blind working age population in 
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employment. However, the percentage of blind employed in general and in open industry by 
1975 was a considerable increase from the previous levels.  
 
1975  2000 
“Between 1991 and 2000 there is not thought to have been very much improvement in the 
percentage of the blind population who [were] employed”, and between 1975 and 1991 the 
data show a considerable decrease in blind employment344. The RNIB suggest that “the 
problem is one of discrimination and inadequate government help to train the blind and place 
them in open employment”345. This was exacerbated by the decline in blind workshops (from 
4,000 in 1949 to 1,500 in 1975). 
 
Between 1985 and 1991 the RNIB conducted a major survey of blind and partially sighted 
adults in Britain, which identified that only 17 percent of the working age blind were in 
employment346. This is considerably worse than what the blind employment rates had been for 
the rest of the century.  
 
Therefore, the above data indicates that there was still deep seated discrimination against the 
blind in employment. This is partly because “there [were] still many situations where disabled 
people [could] be discriminated against legally”, despite government legislation347. Most 
noteworthy is that only direct discrimination was prohibited which enabled the more subtle 
forms of oppression that were sustained by in-built or institutions patterns of inequality348. An 
additional source of inequality was between the blind and the able bodied population was that 
“visually impaired people are less likely to be in professional jobs than non-disabled and 
disabled people in general”349. This is summarised in Table 4.5. 
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Table 4.5: Occupational status of visually impaired people, disabled people and non-disabled 
people as a percentage of the workforce, 1990-2000350 
 Professional Semi-skilled and Unskilled 
Visually impaired people 14% 36% 
Disabled people 25% 31% 
Non-disabled people 34% 23% 
 
These problems in employment are exacerbated by labour market changes which should have 
boosted the ability of the blind to obtain employment. Throughout the twentieth century there 
was a shift in Britain’s employment structure away from industry and towards manufacturing 
and the service sector, where the blind would have been more able to engage in employment. 
The increase in the size of the labour market between 1979 and 1999 from 24.5 million to 27 
million should have helped provide employment for a higher proportion of the blind 
population351. During this time there was an increase in part-time temporary jobs, which suited 
the employment needs of the blind more favourably, and should have boosted blind 
employment. Finally, developments in workplace technology should have facilitated 
additional employment. 
 
Despite the efforts of the government and charities the blind did not experience any significant 
reductions in the adverse effects of blindness in employment. “In 1990, 53 percent of the 
visually impaired were living on less than half the national average income”352. This is a 
strong indication of the poor quality of life that the majority of the blind consistently faced in 
twentieth century England. 
 
4.2.2 Education 
1900  1950 
The provision of education was the most developed socio-economic aspect of blind welfare at 
the start of the twentieth century.  
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The education of the blind has traditionally been conducted in special blind schools, which 
were funded by the government. In 1918 the government grant (which was increased during 
the twentieth century) was £10 per unit of average attendance in a certified day school for the 
blind and £16.50 in a boarding school, both per annum353.  
 
At this time it was generally considered that the special blind schools were the best place to 
educate the blind and that these schools were satisfactory at this task. Some even highlighted 
how “blind schools were superior to a blind child attending a normal school”354. There had 
been a continual improvement in the standards of these schools and by 1930 there was “ample 
provision for the education of blind children and the facilities to educate them to the same 
extent as seeing children”355.  
 
An alternative method for educating the blind was through home teachers. During the 1920s 
the number of home teachers began to expand rapidly: in 1924 there were 270 home teachers 
and by 1928 there were 390356. Despite the merits of home teaching, as technology advanced 
and special schools for the blind improved there was an increase in the number of blind 
children who attended school and a decline in the number who were taught at home.  
 
There was also a decrease in the number of blind children who did not receive any kind of 
tuition. In 1921, 15.7 percent of normal blind children were not attending school. By 1930 
only 10 percent of blind children were not attending school. 
 
1950  2000 
These improvements in education for the blind continued and are likely to have inspired the 
Warnock Report and the 1981 Education Act, which encouraged greater integration for 
children with disabilities into mainstream schools357. However, the blind were slow to enter 
mainstream schools and instead remained at special schools for the blind. “In the year 2000 in 
England, Wales and Scotland, 59 percent of primary aged children and 46 percent of 
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secondary aged children with visual impairments attended mainstream schools”358. The 
majority of blind children who were attending mainstream schools were at infant schools and 
it is likely that they would have graduated to blind schools for their further education. The 
other type of blind pupil at mainstream schools was one-off placements.   
 
Despite these developments in equality for educating blind children, the number of blind 
university graduates provides a depressing contrast as there was never more than 3 percent of 
the blind population (1969-1985) and usually only about 0.5 percent (1901-1985, mode 
average) attending university359.  
 
4.2.3 Status 
1900  1950 
The first improvement in the status of the blind was delivered under the 1920 Blind Persons 
Act. This was the first time that the blind had been exclusively recognised and helped for their 
disability. However, it was not until the Second World War (and after) that the blind 
experienced their most significant improvement in status. This boost in blind persons’ 
standing was a result of their inclusion in the war effort, which continued throughout the rest 
of the twentieth century with an increased proportion of the blind workforce (albeit small) 
working in open industry. However, the blind standing, particularly in employment, was still 
not overly impressive (see Table 4.4). 
 
1950  2000 
As a result of continued problems in gaining employment and the failure of legal legislation to 
completely cater for the needs of the blind, their status did not reach optimum levels during 
the second half of the twentieth century. In the areas of recognition and help the status of the 
blind had improved considerably. These developments indicate that some of the burden of 
blindness had been alleviated. However, much of the help and treatment of the blind still 
seemed to be aimed more at welfare rather than rehabilitation, which was undesirable for the 
status related quality of life of the blind. 
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 Mason, H. & McCall, S. (1997) Visual Impairment, Access to Education for Children and Young People, p. 16 
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 Calculated from: Butler, “Visually Handicapped Studies: A Survey”  
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An improvement in status was experienced by blind children with the introduction of the 1981 
Education Act.  
 
The 1986 Disabled Persons Act promoted the inclusion of disabled persons on committees, 
especially for issues concerning the interests of disabled people. This highlights another small 
improvement in the standing of the blind population. The 1995 Disability Discrimination Act 
provided equality between the blind and the able bodied populations. However, in actuality 
this did not provide equality, to the detriment of the status of the blind. 
 
Therefore, as a result of better education, employment opportunities and various social 
improvements “the status of the blind has improved such that the word blind no longer has 
unpleasant connotations, in the way it might have done at the start of the century”360. 
However the blind population had not reached a point where their opportunities and treatment 
were equal to able bodied individuals. One of the key frustrations for this achievement was the 
experiences of the blind with regard to policy. As well as the government introducing more far 
reaching measures (which had been stated) it could also be argued that the blind charities 
could have taken a more involved and influential role in order to reiterate the precise 
legislative needs of the blind to policy makers.  
 
4.3 Blind Discontent 
Regional Inequalities 
The organisation of blind welfare differed between Local Authorities. For example in 1944 
there was nearly a 100 percent difference between the highest and the lowest levels of welfare 
payments to the blind361. The provision of other services for the blind were also unevenly 
distributed: in some areas there were many more provisions for home working, workshops and 
schools. The densely populated urban areas tended to lead with the provision of blind aid and 
the sparse rural areas were able to provide comparatively very little to their blind residents.  
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Preferential Treatment of Blinded War Veterans 
Another area of discontent was the treatment of blinded ex-service men, who received 
substantial state pensions (shown in Table 4.2) and comprehensive retraining at St. Dunstans, 
which was the rehabilitation and training centre for blinded ex-servicemen.  
 
There were approximately 2,000 of these war veterans who received this special treatment that 
was generally considered to be excellent362. Their benefits were considerably more extensive 
than the welfare benefits received by the rest of the blind population, for example, the 
maximum veteran pension was £6, which was twelve times greater than the 50p maximum for 
the normal blind, who interpreted this as a very unfair situation, and demanded “an equal 
standard of living for all blind persons, the standard of living that is presently enjoyed by 
soldiers and sailors blinded in the Great War”363.  
 
Perceived Inadequacy of State Help 
Perceived inadequacy of state treatment of the blind is best measured by the demonstrations 
and marches of the blind. During the twentieth century these started in around 1915 as a result 
of demands for aid, which culminated in the 1919 NIB demonstration, which was supported 
by numerous trade unions, cooperatives and labour bodies. Their demands were to secure 
decent conditions of life and labour for every sightless person in Britain364. This process was 
re-enacted in 1920 when there was a march of about 200 blind people who were campaigning 
“to highlight and improve the unsatisfactory social and industrial conditions faced by the 
blind and to demand that the government shall, without delay redeem its promises by 
providing the necessary financial arrangement”. In 1936 there was another march of the 
blind, which was very similar in nature to the 1919 campaign. Finally, in 1990 there was a 
major demonstration by over 250 disabled groups and charities: of this group the RNIB were 
present on behalf of the blind. They were campaigning for a new system of benefits for 
disabled people, in order to bridge the gap between the living standards of the able bodied and 
disabled.  
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Also insightful is the stigma that was associated with blind welfare payments, which was 
evident throughout the twentieth century. Hence, as well as welfare payment levels being low 
there was a stigma in take-up, which meant that the welfare state failed to guarantee the blind 
against poverty and financial exclusion365. 
 
4.4 Medical Developments 
1900  1925 
During the first quarter of the twentieth century there was no knowledge about the causes and 
treatment of blindness, although it was known that much of childhood blindness was caused 
by venereal disease. The known causes of blindness and associated childhood prevalence of 
these causes are shown in the table below. 
Table 4.6: Major causes of blindness in blind children as a percentage of the blind children 
population, 1913 -1991 (%)366 
Cause 1913 1920 1950 1991 
Ophthalmia Neonatorum 24 18 16 - 
Syphilitic inflammation 30 31 - - 
Optic Atrophy - - 8 16 
 
The table above highlights the proportion of children suffering from blindness caused by 
known congenital defects during the twentieth century.  
 
Table 4.6 highlights that ophthalmia and syphilitic inflammation were both major causes of 
blindness at the beginning of the twentieth century and that by 2000 (and even the 1950s) 
these causes had been completely eliminated, which was achieved through the treatment of 
venereal disease. This was helped by the Local Government Board in 1914, when they made 
ophthalmia neonatorum a notifiable disease. The discovery of safe and effective antibacterial 
treatment in the 1930s eliminated venereal diseases. This decline was partially substituted with 
an increase in congenital optic atrophy.  
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1925  1950 
By 1950 the key causes of blindness had started to change, from infectious diseases (e.g. 
syphilitic keratitis) to old age degenerative health problems (e.g. macular degeneration).  
Table 4.7: Major causes of blindness in all ages of blind as a percentage of the blind 
population, 1922-1991 (%)367 
Cause 1922 1950 1991 
Cataract 16 25 3 
Congenital defects 6 10 - 
Glaucoma 9 13 12 
Macular degeneration - 6 49 
 
The above table considers the proportion of blindness distributed among major causes. The 
most noteworthy is the decline in congenial defects. There was a significant increase in 
blindness due to macular degeneration, which is not surprising if it is seen within the context 
of the epidemiological transition. Also noteworthy in the context of the epidemiological 
transition is the trend in blindness experienced by cataracts and glaucoma: both of these are 
related to the change in mortality and the burden of disease. These both worsened around the 
middle of the century and improved by the end, which is a direct result of medical 
technological improvements that arrived by 2000 but not 1950, when these types of blindness 
associated with a degenerative disease environments became more prevalent.  
 
1950  2000 
Increasingly from the late 1950s the introduction of cortisone diminished the risk of blindness 
from numerous causes, from chemical accidents in industry to Iritis and Iridocyclitis 
(inflammation of the iris).  
 
Also at this time, surgical treatment for cataracts was introduced and continued to develop 
throughout the second half of the twentieth century so that by the year 2000 curing cataracts 
was a very simple procedure, especially as by 1960 it had become possible to remove a 
cataract before it was fully mature (and causing complete vision loss).  This development 
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explains the – inverted ‘U’ shaped – trend of the prevalence of cataracts during the twentieth 
century. In 1922 16 percent of the population (25 percent of the blind old aged population) 
suffered from cataracts. At this time there was no medical procedure that could alleviate the 
problem and eventual blindness was inevitable. The prevalence of cataracts peaked in 1950, at 
25.4 percent (43 percent for old ages), caused by the ageing of the population without the 
medical developments to eliminate cataracts. By 1991, only 3.5 percent of the blind old aged 
population suffered from cataracts. This is a direct result of modern cataract surgery, and 
indicates the significant contribution of medical technology to blind quality of life.  
Table 4.8: Blindness (caused by cataracts, glaucoma and diabetic retinopathy) in old aged 
blind as a percentage of the old age blind population, 1922-1991 (%)368 
Cause 1922 1950 1991 
Cataract 25.4 43.0 3.5 
Diabetic Retinopathy - - 2.2 
Glaucoma 29.8 18.0 12.9 
 
Developments similar to those for cataracts have been made in the treatment of glaucoma, 
which also tends to be an old age disease. Blindness caused by glaucoma is a result of 
increased intraocular tension on the eyeball, which causes changes in the optic disk and affects 
vision. The solution to this disease is early diagnosis and adoption of appropriate treatment: 
eye drops and/or laser surgery. This can be achieved with regular screening, which was 
provided by the National Health Service (NHS) during the last quarter of the twentieth century 
for relatives of glaucoma sufferers who were are aged 40 years or older.  
 
Finally, increased awareness about diabetic retinopathy (when the blood vessels in the retina 
enlarge and leak fluid which eventually causes blindness), evident during the last decade of 
the twentieth century, also provided a contribution towards the reduction of blindness. In the 
same way as glaucoma, retinopathy can be managed through regular screening, which is free 
on the NHS for diabetics (because of the close correlation of diabetes and vision disorders). 
However, there was still no curative treatment for glaucoma or diabetic retinopathy at the 
close of the twentieth century.  
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These developments created an increase in the average age of onset of blindness and a 
subsequent reduction in the average number of life years spent in blindness. This represents a 
significant improvement in the quality of life associated with blindness that is especially 
important to measure because it is a more subtle development.  
 
However, estimating the average number of years in blindness is very difficult, due to a void 
of detailed blind data. There is no information about the age of onset of blindness and the only 
remaining alternative data about the prevalence of blindness only exists in 10 (sometimes 5) 
year blocks, which makes it impossible to determine the precise age of onset of blindness 
(particularly as prevalence is not equal to the contraction of blindness and the lower the 
frequency of data points for prevalence, the more pronounced this difference becomes 
between prevalence and contraction). Moreover, unlike the other illnesses considered in the 
thesis, blindness is not considered with survival rates and it is therefore impossible to 
determine the average number of years spent with blindness (per case of blindness). The 
combination of these problems means that the thesis is only able to provide a rough 
impression about the average number of blind years at different times during the twentieth 
century. Hence, the results yielded in Table 4.9 should only be considered only as a general 
indication about the likely number of years in blindness.  
 
These estimates are derived through the following methodological process, which entails 
numerous assumptions that are also outlined below. The most common age of onset of 
blindness was identified for 1900, 1925, 1950, 1975 and 2000. This was achieved through 
reviewing the percentage of the population that were blind at different ages (the illustration of 
this is shown below in Figure 4.2.i and 4.2.ii). This often contained two (and three in 1950) 
reference points in an attempt to be more representative about the most common ages of onset 
of blindness. The fundamental assumption here is that a peak of blindness represents an 
increase in blindness and another subsequent peak will imply an additional increase in the 
number of blind. These assumptions are coupled with another, even more tenuous assumption, 
which is the estimate about the average duration of blindness from these peaks, in order to 
identify the average number of blind years in different eras. Because blindness was (generally) 
resolved in death, the age of onset of blindness in these peaks is considered relative to life 
expectancy at that age. 
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Figure 4.2.i: Prevalence of blindness by age, 1900, 1925, 1950, 1975 and 2000369 
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Figure 4.2.ii presents the same data but on a preferable scale. 
Figure 4.2.ii: Prevalence of blindness by age, 1900, 1925 and 1950370 
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Hence, once these most common ages of onset of blindness had been identified this 
information was considered in conjunction with life expectancy by age. This was necessary in 
order to estimate the end point of blindness (through death) and subsequently identify the 
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 For a more detailed graphical analysis see Appendix 12.13.1 
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average number of blind years. This methodological process identified the most common ages 
of onset of blindness, which is combined with life expectancy at the age of onset of blindness 
in order to provide an estimate for the average number of years in blindness. These results are 
shown in Table 4.9. 
 
For completeness it is also desirable to consider the results in Table 4.9 in their wider context. 
This will be achieved in Table 4.10, which considers the proportion of the blind population 
that is represented in the most common age of onset of blindness. Table 4.10 will also develop 
this information one stage further through identifying the number of blind years that Table 4.9 
implies. This will provide an indication about the average number of blind years during 
different eras of the twentieth century.  
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Table 4.9: Average number of years spent in blindness during the twentieth century371 
Year Average most 
common age of onset 
of blindness 1 
(Age) 
Average most 
common age of onset 
of blindness 2 
(Age) 
Average most 
common age of onset 
of blindness 3 
(Age) 
LEx372 
Life Expectancy at age of onset of 
blindness  
(Years) 
Average number 
of years of 
blindness 1 
(Years) 
Average number 
of years of 
blindness 2 
(Years) 
Average number 
of years of 
blindness 3 
(Years) 
1900 35-55  45 65-77  71  LE45 = 
23 
LE71 = 
8 
23 8  
1925 55  55 70+  70  LE55 = 
19 
LE70 = 
9 
19 9  
1950 0  0 40-60  50 70+  70 LE0 = 
68 
LE50 = 
24 
LE70 = 
10 
68 24 10 
1975 50  50 75+  75  LE50 = 
26 
LE75 = 
9 
26 9  
2000 75+  75   LE75 = 
11 
11   
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Table 4.10: Proportion (%) and number of the blind population represented in Table 4.9 and subsequent number of blind years from most 
common ages of onset of blindness 
Year Blind at common age of 
blindness onset 1 
Blind at common age of 
blindness onset 2 
Blind at common age of 
blindness onset 3 
Total number of blind years (from life expectancy at most 
common ages of onset) 
 Percent Number Percent Number Percent Number  
1900 39 10069 33 8520   (10069*23=231587) + (8520*8=68160) = 
299,747  
1925 26 10956 43 18120   (10956*19=208164) + (18120*9=163080) =  
371,244 
1950 13 10572 24 19517 22 17890 (10572*68=718896) + (19517*24=468408) + 
(17890*10=178900) = 
1,366,204 
1975 25 24900 54 53783   (24900*26=647400) + (53783*9=484047) =  
1,131,447 
2000 69 108896     (108896*11) = 
1,197,856 
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Therefore the above tables have considered the prevalence of blindness by age for 1900, 1925, 
1950 and 2000 and have reported on the peak episodes in column two, three and four, i.e. the 
‘common age of onset of blindness’ in both tables. These have then been compared with life 
expectancy in order to produce the results in columns seven, eight and nine, ‘average number 
of years of blindness’ in Table 4.9. This last part of the calculation is derived through 
considering the average age of onset of blindness with the average length of life (life 
expectancy at age of onset of blindness - average age of onset of blindness = average number 
of years of blindness) in order to determine how many years are spent in blindness. These 
considerations in Table 4.9 enable Table 4.10 to generate more aggregate indications about the 
‘total number of blind years (from most common ages of onset)’. This table also indicates the 
depth of these calculations through identifying the percentage of the blind population that are 
included in the most common ages of onset.  
 
Once this has been achieved, it is possible to illustrate that, although the trend has not been 
uniform, and although the trends are based on very ambiguous data and assumptions, there is 
an indication that the burden of blindness, in terms of the average number of blind years 
endured by the average blind person, improved between 1900 (about 16 years on average), the 
peak in 1950 (about 34 years on average) and 2000 (11 years on average). Conversely, Table 
4.10 highlights a substantial increase in the number of people afflicted with blindness. 
Although this is a set back for improvements in blindness (related to prevalence), it does not 
detract from: i) improvements in the average durations of blindness and ii) other 
(aforementioned) quality of life gains for the blind in twentieth century England. 
 
A final caveat for these findings requires a consideration to be made about cohort effects. This 
is necessary to add validity to the above claims about the increasing most common age of 
onset of blindness, as part of this increased average age of blindness is likely to be due to a 
cohort effect, as some of the 69 percent of the blind population who were aged over 75 in 
2000 were also blind at ages 50+ in 1975. In order to provide the most accurate indication of 
the changes in the dynamics of the burden of blindness it is necessary to identify the 
extensiveness of these cohort effects. Table 4.11 considers the magnitude of this influence. 
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Table 4.11: Cohort effects of increased average age of onset of blindness373 
Year (T) Most 
common 
age group 
Period T-1 Age in 
period T-1 
Number of 
blind in age 
group in T 
Number of 
blind in age 
group in T-1 
Cohort effect (%) 
% in T that are 
from T-1 
1900 - - - - - - 
1925 16-64 1900 1-39 24723 8676 35 
1950 16-64 1925 1-39 39472 12027 30 
1975 75+ 1950 50-60 54638 11394 21 
2000 75+ 1975(6) 50-65 108360 11179∗ 10 
 
In Table 4.11 the most common ages of blindness are identified (and presented as a broader 
age group than in Tables 4.9 and 4.10) and are then considered for their relationship with the 
number of blind in the previous era, T-1. For example, in 1925 the most common age of onset 
of blindness was between ages 16 and 64 (this has been conservatively estimated as 55 in the 
tables above). However, this could be a result of earlier generations’ blindness, e.g. if 
blindness was contracted between ages 1 and 39 in 1900. Therefore, to decipher the extent of 
this effect, the thesis considers the number of blind in aged 16-64 in 1925 (T), relative to the 
number of blind aged 1-39 in 1900 (T-1), in order to identify the percentage of blind who 
could be part of the cohort effect. 
 
These considerations about the extent of spill-over (from period T-1 to T), which are made by 
the thesis in order to assess the accuracy of the average number of blind years as considered in 
Table 4.9 and 4.10 show that in most eras there was an evident cohort effect but that this was 
not far-reaching enough to over turn the trend in the reduction of average blind years. The 
most substantial cohort effects were in 1925, where 35 percent of the blind were also blind in 
1900, versus 2000, which had the lowest cohort effects, where only 10 percent of the blind in 
2000 had also been blind in 1975.  The results of this analysis indicate that although there 
were evident spill-over or cohort effects, these were not large enough to drastically change the 
overall findings about the increasing age of onset of blindness, and the contribution that this 
had towards improving the quality of life of the blind, especially by the year 2000, when these 
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∗
 For 1975 there is no data of enough detail. This estimate was derived from estimating the proportion of the blind population aged 50 to 65 out of the 16-65 age 
groups. In 1950 and 2000 (for which detailed data exists) the 50 to 65 age group = 45 percent of the entire 16 to 65 age group. Applying this to 1976  16 to 64 
age group = 24843*0.45 = 11179 
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cohort effects were least significant. The consistently declining magnitude of the cohort effect 
also adds weight to earlier indications about a decline in the average number of years of 
blindness. Finally, the key value of Table 4.11 is that it substantiate earlier judgements related 
to the quality of life associated with (the average number of years of) blindness in twentieth 
century England, which marks an important improvement and a valuable development, which 
will be analysed further in Chapter 8.2, blind quantitative results. 
 
4.5 Summary 
By the end of the twentieth century socio-economic standards of living for the blind had 
improved to levels which were regarded as good by some and adequate by most, and 
consequently the burden, discomfort and unpleasantness of blindness had been somewhat 
alleviated. The result of this was an improvement in the quality of life for the blind during the 
twentieth century. The developments in government legislation, blind peoples’ recognition and 
status and a move towards equal rights and opportunities in employment and education have 
generated improvements in blind welfare, such that by the close of the twentieth century the 
blind had a satisfactory quality of life. However, there still remained considerable scope for 
improvement in the health and particularly welfare related quality of life associated with 
blindness. The extensiveness and value of these twentieth century changes in blind quality of 
life will be summarised in Chapter 7.1 and quantified in Chapter 8.2.  
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During the twentieth century, Britain experienced a significant decline in the burden of 
tuberculosis. In 1901 tuberculosis was responsible for 11 percent of deaths and by 2000, 
only 0.07 percent374. This is illustrated below in Figure 5.1, which considers the decline in 
tuberculosis (blue bars and left-hand side Y axis) and this tuberculosis decline relative to 
all deaths (pink line and right-hand side Y axis). 
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 Calculations from: Office of National Statistics, “Twentieth Century Mortality: 100 Years of Mortality Data in England and Wales by Age, Sex, Year and 
Underlying Cause” 
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Figure 5.1: Tuberculosis deaths: total and as a percentage of all deaths, 1901-2000375 
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The reduced tuberculosis mortality (shown in Figure 5.1) has been accompanied by a 
decline in morbidity, as measured by the tuberculosis notification rate. Table 5.1 highlights 
the course of the 90 percent decline in the prevalence of tuberculosis between 1915 and 
2000376.  
Table 5.1: Total number of notifications for respiratory tuberculosis, 1915-2000377 
Year Notifications Year Notifications 
1915 70,000 1955 33,000 
1920 58,000 1960 21,000 
1925 60,500 1965 12,000 
1930 54,000 1970 9,000 
1935 45,000 1975 7,000 
1940 35,000 1980 6,000 
1945 41,000 2000 6,087 
1950 42,000   
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376
 The Standing Medical Advisory Committee for the Central Health Services Council, “Tuberculosis: Epidemiology and Control”, p. 3 
377
 1915-1980: Citron et al, “Tuberculosis Today”, p. 6. 1990: Watson et al, “Notifications of Tuberculosis in England and Wales, 1982-1989”, p. R13. 2000: 
Joint Tuberculosis Committee of the British Thoracic Society, “Control and Prevention of Tuberculosis in the UK: Code of Practice 2000”, p. 887 
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Although there is widespread agreement about the significance of this decline, there have 
been numerous debates about the key features for the virtual elimination of tuberculosis by 
the close of the twentieth century.  
 
This chapter will highlight the health and welfare conditions faced by tuberculosis 
sufferers during the twentieth century and identify the changes in these conditions and 
ultimately the improvements in quality of life associated with this disease. This will be 
achieved through a detailed consideration of the key features associated with the health and 
welfare experiences of tuberculosis sufferers.  
 
The chapter will begin by providing a background on this disease, in order to highlight 
vividly how improvements in the prognosis of tuberculosis affected quality of life. The 
thesis will provide a detailed explanation of the changing aetiology, pathogenesis and 
prognosis and the changes in related courses of therapy associated with tuberculosis in 
twentieth century England. This will be followed by an outline of the statistical detail 
related to the mortality and morbidity burden of tuberculosis during different eras of the 
twentieth century.  
 
After this has been achieved this chapter will provide the twentieth century chronology that 
details the efforts made by government, charities and medical technology in the fight to 
treat, aid and cure tuberculosis. This section will concentrate on evaluating the outcome of 
these efforts for their contribution towards improving the quality of life for tuberculosis 
sufferers.  
 
After the improvements have been analysed it will be desirable to identify the areas where 
there has been a comparative lack of progress in improving quality of life for tuberculosis 
sufferers in twentieth century England. This will provide the final necessary details to 
enable comprehensive conclusions.  
 
5.1 Aetiology and Prognosis 
5.1.1 Definition 
Tuberculosis is an infection with the bacterium Mycobacterium tuberculosis (hereafter 
M.tuberculosis), which most commonly affects the lungs (in at least 75 percent of cases), 
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where it is called pulmonary tuberculosis378. Extrapulmonary sites include the pleura, 
central nervous system, lymphatic system, genitourinary system, and bones and joints. An 
especially serious form is disseminated or miliary tuberculosis, which is more common in 
immunosuppressed persons and in young children. Pulmonary tuberculosis can co-exist 
with extrapulmonary tuberculosis. Additional terminology for tuberculosis are shown in 
the table below∗. 
Table 5.2: Common synonyms for tuberculosis379 
Synonym Rational for synonym  
Consumption 
 
Wasting 
Because tuberculosis seemed to consume people from within 
with its symptoms of bloody cough, fever, pallor, and long 
relentless wasting. 
White Plague  Tuberculosis sufferers tended to appear  markedly pale. 
Phthisis Greek for consumption. 
Phthisis Pulmonalis  
Scrofula Swollen neck glands. 
Pott’s Disease Of the spine. 
Miliary Tuberculosis X-ray lesions look like millet seeds. 
Tabes Mesenterica Tuberculosis of the abdomen. 
Lupus Vulgaris 
The Common Wolf 
Tuberculosis of the skin. 
 
5.1.2 Epidemiology 
The epidemiology of tuberculosis is influenced by two important factors: exposure and 
susceptibility. Exposure is a result of M. tuberculosis being transmitted between an 
infectious patient and susceptible contacts via droplet nuclei that are expelled by coughing, 
sneezing and other forceful respiratory activities380. In order to develop the disease a victim 
must have contact with a source case. 
 
The probability of transmitting tuberculosis depends upon: the infectiousness of the carrier 
(quantity expelled), environment of exposure, duration of exposure, virulence of the 
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 Hereafter, respiratory and pulmonary tuberculosis will be used interchangeable, and when tuberculosis morbidity, incidence and notification are mentioned 
tuberculosis is referrs to respiratory/pulmonary tuberculosis only. 
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organism, and susceptability of the contact. The chain of transmission can be stopped by 
isolating patients with the active disease (pre 1950 this was the common solution)  and 
starting effective anti-tuberculous therapy (which became increasingly effective and 
commonplace from the 1950s). 
 
The outcome of exposure is dependent upon individual susceptibility to disease. A number 
of conditions are associated with altered host immunity and increase the risk of developing 
tuberculosis, e.g. HIV infection, extremes of age, immunosuppressive therapy, cancer, end 
stage renal disease, diabetes, severe malnutrition and some upper gastrointestinal 
surgeries381. In addition, injection drug use is associated with an increased risk of 
developing tuberculosis (for reasons that are not well described). Close contacts (i.e. 
persons with prolonged, frequent or intense contact) are at highest risk of becoming 
infected.  
 
During the twenteith century this infection rate (i.e. the chance of an individual being 
infected after close contact with a contagious tuberculosis agent) fell to about 22 percent 
from a level much closer to 100, largely as a result of improvements in standards of 
living382.  
 
5.1.3 Pathogenesis  
The pathogenesis of tuberculosis is relatively complex as a result of the variety of possible 
temporary and permanent states associated with an initial exposure to the tubercle bacillus 
bacteria. Most noteworthy is the distinction between tuberculosis infection and disease. A 
diagnostic staging system for tuberculosis is shown below.  
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Table 5.3: Classification of tuberculosis383 
Classification Description 
TB0 No exposure 
No infection 
TB1 Exposed to tuberculosis 
Infection status unknown 
TB2 Latent infection 
No disease (positive PPD) 
TB3 Active tuberculosis 
TB4 Inactive tuberculosis 
Healed / Adequately treated 
TB5 Possible tuberculosis 
Status unknown (“rule out” tuberculosis) 
 
In those people in whom the tuberculosis bacillus overcomes the immune system defenses 
and begins to multiply, there is progression from tuberculosis infection to tuberculosis 
disease (i.e. a move from TB1 to TB3). This can occur soon after infection, primary 
tuberculosis or post primary, secondary, reactivation tuberculosis disease of dormant 
bacilli384. About five percent of infected persons will develop the tuberculosis disease in 
the first two years, and another five percent will develop the disease later in life385. In 
aggregate, about 10 percent of infected persons with normal immune systems will develop 
the tuberculosis disease in their lifetime386. However, while only 10 percent of tuberculosis 
infections progresses to tuberculosis disease, when untreated (in earlier parts of the 
twentieth century) the death rate was more in the region of 50 percent. 
 
Symptoms of developed tuberculosis include a prolonged cough, chest pain, and 
hemoptysis. Systemic symptoms include fever, chills, night sweats, appetite loss, weight 
loss and easy fatigability387.  
 
Some medical conditions increase the risk of progression from tuberculosis infection (or 
latent tuberculosis) to disease. In HIV infected persons with a tuberculosis infection, the 
                                                 
383
 Johns Hopkins Centre for Tuberculosis Research (2005). Retrieved 24 February 2005, from:  
http://www.hopkins-id.edu/diseases/tb/tb_class.html 
384
 Ibid 
385
 Ibid 
386
 Ibid 
387
 Wikipedia (2005), “Tuberculosis”. Retrieved 24 February 2005, from: http://en.wikipedia.org/wiki/Tuberculosis 
Illnesses: Tuberculosis 
                                                                                                                                                                                                                          - 153 - 
risk increases to 10 percent each year instead of 10 percent over a lifetime. Other such 
conditions include drug injection, substance abuse, recent tuberculosis infection (within 
two years) or a history of inadequately treated tuberculosis, a chest X-ray suggestive of 
previous tuberculosis (fibrotic lesions and nodules), diabetes mellitus, silicosis and 
prolonged corticosteroid therapy388. 
 
In an attempt to summarise the process and potential outcomes of tuberculosis, which will 
be considered throughout the remainder of the chapter the diagram below provides an 
illustration of the basic pathogenesis associated with tuberculosis. This figure also includes 
the above stages from Table 5.3 (blue rectangles) and highlights the series of tuberculosis 
risk factors (red circles).  
Figure 5.2: Epidemiological process of the tuberculosis infection389 
 
 
Exposure is defined as occurring in a person who breathes in an environment that contains 
tubercle bacilli390. Infection is defined as a person harbouring viable bacilli but without 
having any clinical, bacterial or radiographic signs or symptoms of the disease. Infectious 
tuberculosis is the form of disease that facilitates symptoms and the potential transmission 
of tubercle bacilli, while the non-infectious form does not. Death or survival from 
tuberculosis are the final stages in the pathogenesis of tuberculosis. The probabilistic 
relationship between these final outcomes changed considerably during the twentieth 
century as did the risk factors for exposure and infection.  
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5.2 Tuberculosis Data 
Concerns about tuberculosis were rife at the beginning of the twentieth century, and 
consequently, there are numerous data, from varied sources which provides detailed 
information about tuberculosis morbidity and particularly mortality.  
 
Since 1927 tuberculosis deaths have been registered in compliance with WHO regulations, 
which provides a consistent and reliable mortality index for tuberculosis, although this 
does not escape the general problems of death registration and also displays some 
classification inconsistencies.  
 
Tuberculosis morbidity data is more problematic. Although some very vague estimates for 
the beginning of the twentieth century exist, it was not until the 1950s that this data 
became more common place and reliable. This is despite continual government efforts to 
create an accurate index of the prevalence of tuberculosis morbidity. For example, the 
Public Health Act 1896 legislated the “provision for the notification (to the medical officer 
of health of sanitary authorities) of cases of pulmonary tuberculosis occurring amongst the 
inmates of Poor Law institutions, or amongst persons under the care of the district medical 
officers…”391. Despite these efforts, under notification was a consistent problem 
throughout the twentieth century: even after the introduction of the NHS the Ministry of 
Health recognised that “notification remained incomplete and delayed”392. 
  
These morbidity data shortcomings before 1950 are not overly problematic because it is 
not until about 1950 that mortality declined significantly, such that notification rates 
(which are a proxy for morbidity) became the premier index of the burden of tuberculosis.  
 
5.2.1 Mortality Data 
Figure 5.3 highlights the significant twentieth century decline in tuberculosis mortality. 
This decline began in the late nineteenth century, for example in 1881 the death rate from 
pulmonary tuberculosis per 10,000 was 18.25, in 1891 it was 15.99 and in 1901 it was 
12.64. This trend gathered pace throughout the twentieth century, such that, by 1980 
tuberculosis had virtually been eliminated.  
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Figure 5.3: Tuberculosis deaths, 1901-2000393 
Tuberculosis Deaths 1901-2000
0
10000
20000
30000
40000
50000
60000
70000
1901 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000
Year
TB
 
D
ea
th
s
 
 
The trend in Figure 5.3 is verified when the decline in tuberculosis mortality is considered 
in conjunction with all mortality. Figure 5.4 highlights that the substantial decline in the 
level of tuberculosis mortality is genuine, as this trend is maintained when considering the 
tuberculosis morbidity rate.  
Figure 5.4: Tuberculosis mortality rate: tuberculosis deaths as a percentage of all deaths, 
1901-2000394 
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In Figure 5.3 and 5.4 there is a significant decline between 1901 and 1960, after which the 
pace slows. These figures also show that by the last quarter of the twentieth century, 
tuberculosis was virtually eliminated. 
 
These improvements are accentuated when the age distribution of tuberculosis mortality 
are considered. This is shown in the graph below. 
Figure 5.5: Tuberculosis deaths by age, 1901-2000395 
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During the twentieth century the age profile of tuberculosis mortality changed 
considerably. In 1901 the majority (nearly 50 percent) of tuberculosis deaths occurred in 
ages 25-54, and ages 0-4 accounted for nearly 20 percent of tuberculosis mortality. The age 
distribution continually improved such that, by 2000 nearly 75 percent of deaths occurred 
at ages 65+. The only exception to this trend was in 1920, possibly due to reporting issues 
associated with World War One.  
 
These improvements can be further elaborated by considering age specific tuberculosis 
mortality in relation to all deaths in the population, i.e. the death rate by age. 
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Figure 5.6: Tuberculosis deaths as a rate of all deaths by age 1901-2000396 
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Figure 5.6 shows a consistent improvement in the burden of tuberculosis, which was 
generally evident throughout the twentieth century (with the exception of the 1920 
anomaly). 
 
An additional detail that deserves mention is the distribution of tuberculosis by gender.  
Figure 5.7: Tuberculosis deaths by gender, 1900-2000 
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Figure 5.7 highlights that for the entire twentieth century tuberculosis mortality was greater 
in males than in females for the corresponding decade. The extent to which this was 
evident ranged from female mortality only being 37 percent of male in 1960 to 93 percent 
in 1920. 
Table 5.4: Tuberculosis deaths: female as a percentage of male, 1901-2000 
Year 1901 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 
F as a 
% of M 
74 80 93 81 74 60 37 45 49 45 78 
 
One possible explanation for this is the higher male labour force participation rates, which 
would have meant that male exposure to the tuberculosis disease was greater than female. 
This potential explanation is supported by Figure 5.8, which illustrates the age distribution 
of deaths by gender.  
Figure 5.8: Tuberculosis deaths by age and gender, 1901-2000 
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The most noteworthy feature in Figure 5.8 is the higher male mortality in the oldest ages, 
which differs from the majority of causes of death. Also evident is the higher prevalence of 
male mortality in the youngest and working age groups, although decreasingly pronounced 
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as the twentieth century unfolded. The only other persistent trend is the consistently higher 
female mortality in ages of about 15 and 20s.   
 
5.2.2 Morbidity Data  
A factor that needs to be noted when comparing mortality and morbidity statistics for 
twentieth century tuberculosis in England is that the mortality data includes all forms of 
tuberculosis, whereas the morbidity data only considers pulmonary tuberculosis. This is 
because pulmonary tuberculosis is the only form of tubercle bacillus that is highly 
contagious and therefore a public health threat that warranted notification. Table 5.5 
indicates the extent to which the above aggregate tuberculosis mortality data reflects 
pulmonary tuberculosis. 
Table 5.5: Pulmonary tuberculosis deaths as a percentage of total tuberculosis deaths, 
1901-2000397 
Year Total TB deaths Pulmonary TB deaths Pulmonary TB deaths 
as a % of total TB 
deaths (%) 
1901 60,556 50,459 83 
1910 51,320 40,046 78 
1920 40,634 33,853 83 
1930 35,748 29,414 82 
1940 27,865 23,462 85 
1950 15,897 14,076 88 
1960 3,427 3,101 91 
1970 1,506 1,345 89 
1980 587 529 90 
1990 378 340 90 
2000 366 310 85 
 
During each time period of the twentieth century pulmonary tuberculosis was the major 
component of aggregate tuberculosis, although the extent to which this was the case varied 
slightly.  
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Since the introduction of chemotherapy (in the 1950s) it has become necessary to consider 
tuberculosis morbidity in order to obtain the most accurate picture of the health related 
welfare burden of tuberculosis.  
 
The most viable way to assess tuberculosis morbidity is through the notifications made to 
the medical officer. This data needs to be analysed with much caution due to the strong 
prospect of under and uneven reporting. Although this distortion is more pronounced in the 
earlier years it should be regarded as applicable to the entire twentieth century, despite 
numerous efforts to improve reporting, e.g. through the 1948 National Health Service Act, 
numerous [Infectious Disease] reporting regulations, and compulsory notification of all 
smear positive patients in 1973, there were still likely to be many undetected and 
unreported cases.  Although problematic, under reporting notifications is not thought to be 
significant enough to affect the overall trends in the number of notifications in twentieth 
century England and Wales, as shown in Figure 5.9.  
Figure 5.9: Number of tuberculosis notifications, 1915-2000398 
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Figure 5.9 illustrates the decline in the incidence of tuberculosis during the twentieth 
century, which was particularly pronounced between 1915 and 1955 when the prevalence 
of tuberculosis was halved, largely due to an improvement in environmental factors. The 
decline between 1955 and 2000 is nearly entirely attributable to medical developments, 
which will be explained in detail later in this chapter. This fall in prevalence was not 
                                                 
398
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consistent because of the increase in 1945/1950, which is thought to be a result of the 
Second World War399 and 1990-2000, which is likely to have been caused by increased 
deprivation particularly among ethnic minorities. E.g. in 1998 the crude incidence rate of 
tuberculosis per 100,000 populations in indigenous white residents in England and Wales 
was 4.4 compared with 121 in Indian sub-continent groups and 210 per 100,000 in black 
African ethnic groups400.  
 
As with tuberculosis mortality, it is possible to gain a more detailed understanding about 
the burden of tuberculosis morbidity by considering the age and gender distribution. 
Figure 5.10 and 5.11: Tuberculosis notification rate: male and female, 1940-2000401 
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Tuberculosis Notification Rate: Female 1940-2000
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Figures 5.10 and 5.11 highlight trends which are similar to those identified for tuberculosis 
mortality. In all years except 1940 male notifications were higher than female, except for 
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ages 15-24. This heightened level of female tuberculosis morbidity in 1940 could have 
been a result of increased female participation in factories as part of the war effort402. 
 
Also noteworthy is the increase in male notifications between 1940 and 1950 versus the 
significant decline in female notifications during this period. This could be related to 
reporting inaccuracies associated with World War Two, especially as by 1960, male 
notification rates had declined to something similar to the female notification levels.  
 
An additional factor which needs to be considered when analysing the incidence of 
tuberculosis in the population is the size of the population, i.e. the notification rate.  
Figure 5.12: Tuberculosis notifications: number and rate, 1920-2000403 
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Figure 5.12 highlights that there was a decline in the number of notifications between 1920 
and 1980, and that between 1980 and 2000 this trend was reversed when notifications 
increased from 6000 to 6087 (shown by the blue bars and the left-hand side Y axis).  
 
The trend for the notification rate (shown by the turquoise line and the right-hand side Y 
axis) is slightly more optimistic. When considering the number of notifications in 
conjunction with the population (shown by the pink bars and the left-hand side Y axis), 
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there is a decline. This is better illustrated by Figure 5.13, which makes the same 
considerations as Figure 5.12 for 1980 and 2000, but on a magnified scale. 
Figure 5.13: Tuberculosis notifications: number and rate, 1980-2000404 
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Figure 5.13 highlights that, when the increase in the number of tuberculosis notifications is 
standardised against the increase in the population there is actually a decline in the 
tuberculosis notification rate. Although this is not the most positive story about the 
incidence of tuberculosis (a universal decline in the prevalence would be ideal), it still 
detracts from the pessimism that was associated with tuberculosis and its re-emergence at 
the end of the twentieth century.  
 
As a result of this decline in tuberculosis mortality and morbidity, the implications of 
having tuberculosis improved, such that by the end of the twentieth century tuberculosis 
was not associated with mortality in the way it was at the beginning. This transformation is 
further highlighted in Table 5.6.  
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Table 5.6: Tuberculosis deaths in relation to tuberculosis notifications, 1920-2000405 
Year Notifications Deaths Deaths: Notifications (%) 
1920 60,500 36,504 60 
1930 54,000 35,814 66 
1940 35,000 27,751 79 
1950 42,000 15,953 38 
1960 21,000 3,420 16 
1970 9,000 1,506 17 
1980 6,000 587 10 
1990 5,432 378 7 
2000 6,087 366 6 
 
Table 5.6 highlights that the severity and fatality of tuberculosis declined considerably 
during the twentieth century. In 1900 sixty percent of tuberculosis morbidity was resolved 
in death, versus only six percent in the year 2000. As a result of the improved tuberculosis 
survival rates the probability of becoming infected with tuberculosis declined significantly. 
This development has provided contributions to quality of life that are equally as 
significant as the decline in the prevalence of the disease and therefore ought to be noted, 
particularly because of their tacit nature. I.e. the counterfactual of ‘had the prognosis of 
tuberculosis not improved, then the prevalence of cases would have remained higher and 
increased the virus in the environment which would have heightened the risk of 
tuberculosis infection in the population’ is not quantified in the thesis methodology and it 
is therefore necessary to highlight this here qualitatively. 
 
5.3 Government and Non-Government Initiatives towards Tuberculosis 
“As a fundamental destructive social force tuberculosis was rivalled among illnesses only 
by venereal disease and insanity at the dawn of the twentieth century”, and therefore, state 
intervention had the potential to play a vital role in the control of the spread of 
tuberculosis406. Because of the infectious nature of tuberculosis and the social problems 
that it threatened, the government faced a greater incentive to intervene in trying to reduce 
the number of tuberculosis sufferers.  
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As with any illness, for example, cancer and blindness (analysed within this thesis) the 
government and charities had the potential to improve the quality of life for sufferers, 
either through economic support, pressure for positive legislation and the provision of 
research initiatives and motivation for recognition and help for tuberculosis sufferers.  
 
5.3.1 Government: Overview of Twentieth Century Legislation  
The seeds of government legislation for tuberculosis were planted in the nineteenth century 
(under the Public Health Act 1896). The culminations of these early movements towards 
tuberculosis legislation are shown in the Table 5.7, which provides a brief summary of the 
twentieth century legislation concerning tuberculosis. The most far reaching legislation in 
Table 5.7 will be analysed in further detail below.  
Table 5.7: Government legislation for the control of tuberculosis 
Year Government legislation Provisions of government legislation 
1907 School Medical Service The Board of Education established the School Medical Service, which led to 
the surveillance and detection of tuberculosis in children and promoted the 
removal of causes of its occurrence407.  
1908 Public Health (Tuberculosis) 
Act 
Regulation for the notification to the medical officer of health of sanitary 
authorities (within 48 hours) of cases of pulmonary tuberculosis occurring 
amongst the inmates of Poor Law institutions, or amongst persons under the care 
of the district medical officers408. 
1909 Housing and Town Planning 
Act 
The building of back-to-back houses was forbidden for the first time409.  
1911 Finance Act £1,500,000 was made available for the construction of sanatoria410. Additional 
funds were made available for tuberculosis related research411. 
1912 Notification of Infectious 
Diseases Act (1889) 
All forms of tuberculosis were added to this Act, which created the compulsory 
duty of notification of infectious disease upon the head of the family or the 
medical practitioner, with a penalty of forty shillings for default412. 
1912 Health Insurance Act 1912 This Act provided insurance against ill health and unemployment and applied to 
the majority of employed persons who received less than a stated remuneration. 
The Act provided funds for the treatment of tuberculosis and thus stimulated the 
building of sanatoria413. 
1916 Tuberculosis (Domiciliary 
Treatment in England) Order  
Provided for treatment in the patient’s own home and was designed as a remedy 
to the shortage of sanatorium beds414. 
 
 
                                                 
407
 Coltart et al, “Social Work in Tuberculosis”, p. 120 
408
 The National Archives: MH55(521): Compulsory Notification of Pulmonary and Non-Pulmonary Tuberculosis: Public Health (Tuberculosis) Act 1912 
409
 Coltart et al, “Social Work in Tuberculosis”, p. 121 
410
 Coltart et al, “Social Work in Tuberculosis”, p. 124 
411
 The National Archives: MH 81(44): Tuberculosis Treatment and Applications by Various Bodies for Funds 193-1914  
412
 Coltart et al, “Social Work in Tuberculosis”, p. 119 
413
 Coltart et al, “Social Work in Tuberculosis”, p. 123 
414
 Coltart et al, “Social Work in Tuberculosis”, p. 127 
Illnesses: Tuberculosis 
                                                                                                                                                                                                                          - 166 - 
1921 Public Health (Tuberculosis) 
Act 
Gave the minister of health power to make arrangements himself in areas where 
the county council or county borough council had failed to set up a satisfactory 
scheme of treatment. This Act also authorised councils to arrange after-care for 
tuberculosis sufferers415. 
1925 Public Health Act Made additional provisions with regard to tuberculosis, e.g. this Act provided 
for compulsory segregation of infectious patients, where risk was being caused 
to others416. 
1929 Local Government Act Transferred the function of the Poor Law authority to the county council and 
county borough council. It became the duty of the Local Authority to finance the 
costs of tuberculosis treatment and recover the expense of treatment if the 
patient could not reasonably pay. This demand for payment (from tuberculosis 
patients) was often not made as many local authorities thought it to be in the 
interest of the community to provide treatment without fee417. 
1929 Public Health (Tuberculosis)  
Regulations 
Consolidated previous tuberculosis regulations of 1912, 1921 and 1925. 
1936 
(1961) 
Public Health Act Legalised the right to force upon someone treatment / hospitalisation if they 
appear to have tuberculosis418. This Act was re-issued in 1961 for notifiable 
disease (which includes tuberculosis). 
1943 266/T A scheme of special financial help for tuberculosis. This provided for early 
diagnosis and financial allowances for sufferers (and their dependents) who had 
to give up work in order to take treatment419. Also introduced x-rays, and 
implemented mass miniature radiography, for detecting tuberculosis. 
1948 National Assistance Act This replaced 266/T (which was a war time measure) and removed tuberculosis 
sufferers from the Poor Law. Different provisions were applied to tuberculosis, 
such that patients who had to suffer loss of income received additional 
compensation. 
1948 National Health Service Act Responsibility for the entire health service was placed on the Minister of Health. 
Various additional services were provided for tuberculosis, under Section 28 
(which served to make arrangements for the purpose of prevention of illness, the 
care of persons suffering from illness to after-care)420. 
1969 Public Health (Infectious 
Diseases) Regulations 
Reiterating earlier policy which states that a person should be notified as 
suffering from tuberculosis and provides the definition of such a person. 
1984 Public Health (Control of 
Disease) Act 
Reiterating earlier legislation which states that all forms of tuberculosis are 
compulsorily notifiable. And compulsory admission to hospitals is only possible 
where the person has tuberculosis of the respiratory tract. It also re-emphasises 
that all local authorities should have a written, agreed and integrated policy 
outlining their policy for tuberculosis control and prevention421.  
 
Another area of government policy, which was important although not as mainstream as 
the above listed, legislation was policies concerning milk. The link between cows and 
tabes mesenterica and other tuberculosis affections in children had long been assumed and 
increasing awareness that raw milk was a vehicle of human infection inspired legislation.  
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Table 5.8: Government legislation for the control of bovine tuberculosis422 
Year Government legislation Provisions of government legislation 
1913 and 
1938 
The Tuberculosis Orders Provided for the slaughter of cows suffering from tuberculosis 
and paid compensation. 
(1924) The Milk and Dairies Act 1914 Regulated the production, sale and distribution of milk and 
prohibited the sale of tuberculosis milk423. 
(1924) The Milk and Dairies 
(Consolidation) Act 1915 
Provided for the regulation and supervision of dairymen and 
their premises and for their supervision424. 
1922 Milk and Dairies (Amendment) 
Act  
Permitted local authorities to refuse registration to purveyors of 
milk. Authorised the official grading of milk. 
1923 The Milk (Special Designations) 
Order 
Provided for the establishment of tuberculin tested herds.  
1925 The Tuberculosis Order Made further provisions with regard to tuberculosis in cattle, 
their inspection and slaughter. 
1925 Public Health (Prevention of 
Tuberculosis) Regulations 
Prohibited the employment of persons suffering from 
tuberculosis of the respiratory tract in various branches of the 
milk trade.  
1926 Milk and Dairies Order  Consolidated the entire provision of previous Orders under the 
Milk and Dairies Act.  
1936 The Milk (Special Designations) 
Order  
For the first time included a pasteurised tuberculin-tested grade 
in the list of designated milk. 
 
The culmination of these policies enabled Britain’s dairy herds to be declared free from the 
tuberculosis infection by 1960, despite many of the above policies being ineffective due to 
problems of enforcement and the dominant representation of rural interests425.  
 
The biggest contribution is likely to have been generated from the pasteurisation of milk. 
This can be illustrated through a comparison of (abdominal) tuberculosis death rates 
between different milk consumption environments. No milk was pasteurised until 1924 and 
less than 15 percent in 1930426 and nationwide pasteurisation was not evident until 1950427. 
However, in larger cities, such as London, a (unknown) quantity of milk was flash heated 
to prevent souring (which can be considered as a similar, although less effective, form of 
pasteurisation). In 1938 as much as 98 percent of the milk consumed in London was 
effectively (flash heated) pasteurised. Table 5.9 considers the difference in (abdominal) 
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tuberculosis death rates between London and all other regions of England in order to 
indicate the importance of pasteurised milk in the elimination of non-respiratory 
tuberculosis, particularly abdominal.  
Table 5.9: Crude death rate from abdominal tuberculosis (per million living), 1921-1950428 
 1921-1930 1938 1950 
London 20 7 4 
Rest of England & Wales 44 15 4 
 
It is impossible to conclusively state the precise influence of pasteurisation (in whatever 
form) without milk consumption rates. However, if it is accepted that the greater 
proportion of abdominal tuberculosis is due to bovine type infection, then the above table 
goes some way in attesting to the benefits of pasteurisation.  
 
1900  1925 
By 1900 the controversy associated with Koch’s announcement in April 1882, that 
tuberculosis was a communicable disease, had mostly subsided and the mainstream 
opinion had come into alignment with Koch. This was reflected in the government’s 
approach to combating tuberculosis429. (Prior to this discovery it was generally thought that 
tuberculosis was a hereditary disease)430. During the early years of the twentieth century 
government policy was built upon regulations regarding notification.  
 
Under the 1908 Public Health Act, it was the duty of the medical officer of a Poor Law 
Institution: “to within 48 hours of his first recognition of the symptoms of pulmonary 
tuberculosis in the case of a poor person who is an inmate of the institution, report to the 
medical officer of health of the sanitary district”431. This approach was enhanced as the 
twentieth century unfolded. The special methods that the government felt necessary 
culminated in the 1912 Notification of Infectious Diseases Act, when further regulations 
were made extending the compulsory reporting system to cases occurring among the in-
patients or out-patients of hospitals or other similar institutions for the treatment of the 
sick. Notwithstanding the strength of the desires of the government to control tuberculosis 
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and the feeling that compulsory notification was an “indispensable preliminary to its 
[tuberculosis] effective administration”, these policies were not overly successful432. 
 
The success of this legislation was mixed. In certain towns compulsory notification had 
been well established and in others the approach was haphazard and incomplete. For 
example, between 1915 and 1918 in England and Wales, 19 percent of deaths certified as 
resulting from tuberculosis had not been notified and 27 percent of tuberculosis deaths had 
occurred within three months of notification433. Even after the Ministry of Health tightened 
its rules in 1921, 87 percent of tuberculosis deaths in Barnsley were cases previously un-
notified or notified only within six months of death434. The average duration of life after 
the commencement of the disease in an individual was about five years435. 
 
Even more damaging to the success of this legislation was the disregard many practitioners 
had towards it. Resistance of British physicians to Koch’s theory, largely because his 
findings devalued current therapeutic practices, led them to settle for passive resistance: 
some notified without telling the patient and others only notified if the consumption 
seemed active436.  
 
A more optimistic claim regarding government legislation towards tuberculosis during the 
first quarter of the twentieth century would be that it provided a foundation for later, more 
successful legislation.  
 
The 1911 Finance Act initiated provisions for the treatment and cure of tuberculosis. Under 
Section 16 (2), various organisations were able to apply for research grants, which were 
underway by 1914437.  
 
A more far-reaching aspect of the 1911 Finance Act was the funds provided for the 
extension of tuberculosis treatment (£1,500,000 for the UK and approximately £1,116,000 
went to England), which were directed towards providing organised expert treatment of 
tuberculosis in the form of sanatoria, hospital accommodation and dispensaries438.   
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The 1912 Health Insurance Act has been coined by certain historians as: “one of the 
greatest social measures of the century”439. The crux of its contribution to welfare was the 
provision of insurance for practically all regularly employed men (and their dependents) 
receiving less than a stated remuneration, at the discretion of the insurance companies440. 
The original weekly contribution (paid half by the employer and half by the employee) was 
four pence and a government subsidy increased this to nine pence441. Under this Act, the 
state overtook the responsibilities previously carried out (generally sporadically) by 
charities and organisations, of providing funds for the treatment of tuberculosis, 
particularly contributions towards sanatorium expenses. This promoted the treatment of 
tuberculosis and would have helped to reduce the infectiousness, which provided a positive 
contribution towards standards of living, for the sufferer and population in general. 
Furthermore, the insurance committee was able to extend sanatoria benefit to dependents 
of any insured person. 
 
This Act also provided additional powers to the Minister of Health to ensure that local 
authorities had satisfactory tuberculosis treatment and after-care schemes. Hence, for the 
first time, after-care was included in the treatment of tuberculosis442. However, this 
legislation only partially met the demands for aftercare, which were persistent until the 
virtual elimination of tuberculosis in the 1960s.  
 
1925  1950 
It was not until 1929 that state policies advanced from merely notification to more welfare 
orientated initiatives although, even by 1950, tuberculosis legislation was by no means 
comprehensive. 
 
The 1929 Local Government Act provided the first decisive step towards the unification of 
tuberculosis treatment centres and an improvement in tuberculosis treatment, particularly 
for sufferers who were uninsured. The Act moved the treatment of tuberculosis from the 
jurisdiction of the Poor Law authorities to the local authorities and subsequently enabled 
Poor Law infirmaries to be developed into hospitals, which became better staffed and 
equipped for the treatment of tuberculosis.  
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This unification in tuberculosis treatment arrived in 1948 under the National Health 
Service Act, when responsibility for the entire health service was placed upon the Minister 
of Health and treatment was administered without insurance. Under Section 28 
arrangements were legislated for the comprehensive care of tuberculosis sufferers: from 
prevention to medical care for sufferers, including after-care. The fundamental benefits for 
tuberculosis sufferers were the improvements in access to treatment for their condition 
without the financial burden.  
 
The policy that emerged out of the government’s concern about an increase in tuberculosis 
due to war time conditions (associated with World War Two) provided a significant 
contribution to the welfare of tuberculosis sufferers, with specific legislation to manage 
tuberculosis patients, and the recognition that their illness was a social disease that 
warranted the provision of funds and compensation for ceasing work in order to receive 
treatment. This was provided under the 226/T Act during war time and was succeeded by 
the National Assistance Act in 1948, which eliminated the Poor Law and provided sickness 
benefit for those who contributed to the insurance scheme, which was the majority of the 
population. The rates which were applicable to pulmonary tuberculosis sufferers (as in the 
case of the 266/T this was the only form of tuberculosis covered) are shown in Table 5.10. 
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Table 5.10: National Assistance rate, weekly allowances, 1948443 
Special scale for “persons who have suffered a loss of income in order to undergo treatment 
for respiratory tuberculosis”444. 
Recipient Weekly allowance 
  s. d. 
(a) For a husband and wife:   
 Of whom one is such a person 96 0 
 Of whom both are such persons 110 0 
(b) For any other such person, being:   
 Aged 21 years or over 65 0 
 Aged 18 years or over but less than 21 years 48 6 
 Aged 16 years or over but less than 18 years 40 0 
 Aged 11 years or over but less than 16 years 20 0 
 Aged 5 years or over but less than 11 years 17 0 
 Aged under 5 years 14 6 
 
Although these rates provided a significant improvement in provisions for tuberculosis 
sufferers (they were more than double the rates provided under 266/T), many felt that these 
rates only facilitated a minimum standard of subsistence, which did not finance the special 
needs of tuberculosis sufferers, particularly during after-care or for those who received 
treatment at home445. In the pre antibiotic era the only way to combat tuberculosis was 
through a strong immune system (and this was the rationale underlying sanatoria 
treatment), which required a nourishing diet, warm clothing and good living conditions 
(including adequate fuel supply), and it was felt that these elements were not afforded by 
the National Assistance allowance. E.g. when the tuberculosis sufferer was the 
breadwinner, it was thought that his family could get by on only National Assistance 
payouts for about a year446. 
 
Therefore government policy during this era was still very much initiated out of desires to 
prevent the spread of tuberculosis and compared to many other illnesses at the time 
including the other conditions in the thesis, namely the rights experienced by sufferers of 
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blindness and cancer, tuberculosis sufferers experienced poor levels of recognition and 
rights.  
 
1950  2000 
During the second half of the twentieth century the only tuberculosis legislation that was 
passed was regarding the management of the contagiousness of this disease, through 
strengthening existing notification and segregation policies, under the 1969 Public Health 
(Infectious Diseases) Regulations and the 1984 Public Health (Control of Disease) Act. 
And, between 1950 and 1960 there were considerations about strengthening regulations on 
immigration policy, although there was never any legislation passed on this issue447. Table 
5.11 indicates that, although many immigrants were tested, very few of these were refused 
entry into England. 
Table 5.11: London airport tuberculosis in immigrants: number medically examined, x-
rayed and refused entry into England and percentage that were refused entry as a 
percentage of the number medically examined, 1965448 
Date Number medically 
examined 
Number 
x-rayed 
Number refused 
entry into England 
Percent refused 
entry into England 
12.2.65 – 31.3.65 2,494 165 3 1 % 
1.4.65 – 16.5.65 2,547 253 1 0 % 
17.5.65 – 11.6.65 1,465 164 5 3 % 
 
Therefore, during the second half of the twentieth century and especially the final quarter 
there was very little activity by the government to improve the standards of living of 
tuberculosis sufferers and despite the continued efforts to enforce notification during this 
period it was still noted “how much tuberculosis existed in a community at any one time 
has never been known since many cases do not come to the notice of a doctor or having 
done so fail to be notified”449.  
 
Finally, despite the lack of commitment shown by the government towards improving the 
standards of living of tuberculosis sufferers, there were other areas that made considerable 
efforts towards a significant boost to the welfare related quality of life of tuberculosis 
patients, namely, charities, committees, organisations and the medical profession.  
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5.3.2 Non-Government 
The consideration of the roles of charities, committees, societies, medical organisations, 
etc, is important because they provided an important contribution to the quality of life of 
tuberculosis sufferers and also because they provide an indication about the shortcomings 
of the government.  
 
5.3.2.1 Charities 
The main role of charities was to provide financial aid to help support tuberculosis 
sufferers and their families, especially during the early years of the twentieth century, 
when less government help was available. The growth of sanatoria before 1911 was mainly 
a result of voluntary efforts450. These charities, for example, the British Red Cross Society 
and the Chest Clinic Samaritan Funds, provided assistance for tuberculosis sufferers’ 
treatment and household income451. This assistance was evident even after the introduction 
of the National Assistance Act in 1948: during this time the focal point of charity 
initiatives became the augmentation of funds available under this Act.  
 
The type of aid provided by charities was not in the form of a regular allowance provided 
for the duration of a sufferer’s tuberculosis infection, as this was beyond the financial 
capacity of the charities that helped tuberculosis sufferers. Instead, help was usually 
applied for special, non-recurring needs. Although, there were some forms of charity 
which were consistent and ongoing, for example, The Women’s Voluntary Services 
(WVS) which, like the Red Cross, covered the whole country and provided a ‘meals on 
wheels’ service at a small charge. The WVS also ran depots for second hand clothing, 
bedding and furniture452.  
 
Charity services had practical importance for the sufferer because they provided nursing 
equipment, food and better living conditions, which were all essential to the restoration of 
a patient’s physical health. Additionally, numerous charities existed to try and help the 
patient with mental and social problems. E.g. voluntary organisations provided psychiatric 
help on matrimonial problems and emotional problems brought about by the onset of 
tuberculosis453. 
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Despite the contribution of charities there were some shortcomings, which were largely 
related to resource allocation. Gerard (1983) among others suggests that resources were not 
evenly distributed among those who needed them most, whereby the rich and less needy 
tend to receive more than their fair share454. Additional resource allocation problems may 
have been generated by the number of small tuberculosis charities, whereby greater 
cooperation and coordination could have generated economies of scale benefits and 
possibly more impact when campaigning for improved government commitment to helping 
tuberculosis sufferers. 
 
5.3.2.2 Committees and Associations 
Committees (both governmental and charitable) played an important (largely indirect) role 
in boosting the welfare of tuberculosis sufferers.  
 
The Joint Tuberculosis Council and medical associations (especially the British Medical 
Association) served to campaign for improved welfare treatment of tuberculosis sufferers. 
For example, the Tuberculosis Council took issue with the level of funds payable to 
patients for undergoing treatment and pushed for increases.  
 
The British Medical Association consistently drew attention towards the flaws in the 
government’s approach to tuberculosis treatment. Even in 1950, the BMA’s National 
Health Service Report stated that “the inadequacy of present provision for the diagnosis, 
treatment and after-care of tuberculosis in this country is a national scandal which can no 
longer be viewed with complacency”455. During the 1960s the BMA (along with numerous 
other regional health boards and charitable tuberculosis committees) was also very active 
in pushing for medical examinations for immigrants upon entering England, in order to 
help prevent a worsening in the epidemiological situation associated with this 
tuberculosis456.  
 
In alignment with these observations, which highlight the shortcomings of government 
legislations, the Medical Research Council Committee on Tuberculosis in War-time 
(World War Two) pointed out that “in view of the disturbing increase in tuberculosis and 
in order to effect its control, it is an urgent necessity to provide more efficient detection of 
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cases in order to secure early treatment at an early stage and to reduce the prevalent 
source of infection”457. These types of claims were also voiced by the National Association 
for the Prevention of Tuberculosis. This organisation was founded in 1891 and throughout 
the twentieth century, consistently propagated the most prominent issues facing 
tuberculosis sufferers.  
 
There were also organisations that consistently monitored the progress of contemporary 
tuberculosis issues. Most noteworthy was the Tuberculosis Advisory Committee, who 
focused much attention towards the re-housing of tuberculosis sufferers, and more 
precisely, the consistent shortages (during the late 1950s)458. Additionally, the Joint 
Tuberculosis Council also considered tangential concerns, e.g. the nutrition and treatment 
of tuberculosis sufferers459.  
 
A further contribution to quality of life of tuberculosis sufferers that these committees and 
organisations provided was through increasing community awareness about tuberculosis, 
which may have in turn perpetuated charitable work.  
 
Hence, non-government organisations were important in helping to improve the standards 
of living of tuberculosis sufferers and had it not been for the lack of government pursuance 
in implementing their suggestions, their contribution could have been much more far-
reaching. However, improvements in the quality of life associated with tuberculosis did not 
really originate with the work and policies of charities and government legislation, instead 
these improvements were primarily yielded from medical developments. Moreover, it 
could be argued that tuberculosis charity had a new demand at the end of the twentieth 
century (manifest in the unconventional tuberculosis charity needs of infected AIDS 
sufferers, poor immigrants and homeless who were largely responsible for the resurgence 
of tuberculosis in England), and that charities were slow to adapt to this challenge.  
 
5.4 Medical Developments 
The twentieth century technological developments that were important for tuberculosis 
sufferers were those that were experienced in antibiotics, vaccination, radiography and 
environmental factors. The degree to which the last two facets contributed has been 
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debated throughout the twentieth century and the most profound elements of this debate 
will be considered here.  
 
5.4.1 Antibiotics 
Certainly one of the most important achievements of modern medicine has been the 
development of therapy for tuberculosis460.  
 
On 20 November 1944 an event of tremendous significance took place in the treatment of 
tuberculosis, when streptomycin was first successful in curing a patient (who had advanced 
pulmonary tuberculosis) at the Mayo Clinic in the USA461. The streptomycin strain of 
streptomyces griseus was isolated in September 1943 and the first public announcement of 
the antibiotic was made in January 1944462. By 1947 streptomycin was being distributed in 
small quantities in the UK463.  
 
This discovery marked the beginning of a new era in the combat of tuberculosis as it 
drastically reduced the epidemiological consequences of tubercle bacillus. Moreover, 
within a few years of the streptomycin revolution, the impetus for further developments in 
the treatment of tuberculosis had yielded positive results. Part of this impetus was a result 
of the shortcomings of streptomycin. Despite the fact that it had provided the biggest single 
improvement in the prospect and subsequent quality of life associated with tuberculosis, it 
was not potent enough to combat the entire tuberculosis problem, as the tuberculosis 
organism showed signs of resistance to the streptomycin drug as early as the 1950s. 
Furthermore, high doses of streptomycin, necessary for the treatment of tuberculosis, 
produced toxic effects. E.g. streptomycin was known to have adverse effects on the hearing 
and balance nerves. Additionally, although of less significance, but still potentially 
minimally damaging for quality of life, was the way in which streptomycin was 
administered (because of poor absorption when given by mouth), which was through a 
daily intramuscular injection, which caused significant pain and scarring (bruising) on the 
area of injection (usually the top legs/bottom)464.   
 
Fortunately, from the perspective of sufferers’ quality of life, two additional medications 
were discovered shortly after streptomycin. Para-amino-salicylic acid (in 1948) and 
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isoniazed (in 1952) provided the necessary partners to streptomycin, such that when 
patients were treated with therapy combining all three antibiotics, not only were they cured 
of the disease but there was no (initial) emergence of resistance465.    
 
Despite the significant attributes of these discoveries, when this therapy was first devised, 
in the early 1950s, its implementation was problematic, due to the uncertainty with the 
ideal course of therapy: courses were short (four to six weeks), dosages were small (partly 
because supplies were short) and some initial results were ambiguous and some physicians 
only viewed this chemotherapy as ‘supplemental’466. A further drawback of this therapy 
regime is the continued side effects. Most noteworthy is the potential for hepatitis from the 
isoniazed component467.   
 
With the introduction and mainstream utilisation of tuberculosis combined therapy, the 
development of drug resistance and failure of cure became very rare468. This achievement 
was enhanced by the relatively cheap, coordinated and rapid mainstream utilisation of this 
therapy. As a result of the National Health Service access to the cure for tuberculosis was 
facilitated to all tuberculosis sufferers. Furthermore, because of the cheap and largely 
straightforward nature of tuberculosis therapy the scope for problems was reduced and 
subsequently tuberculosis treatment was largely successful. This was achieved very soon 
after the initial introduction of a tuberculosis therapy regime, by the late 1950s there was 
very little evidence of drug cost, administration or availability issues469. This success can 
be measured in the surplus of hospital beds that was evident by 1955 and the closure of 
many former tuberculosis treatment centres470. Although drug treatment still required 
hospitalisation the treatment time had been significantly reduced471.   
 
The only exception to the above success story was salvage therapy which was considerably 
more expensive than standard therapy. Salvage therapy was necessary for the exceptional 
cases of standard drug resistance and was over 10 times more expensive than the standard, 
albeit available if needed472.  
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One of the most far-reaching benefits of these antibiotic inventions is the reduction in the 
contagiousness of tuberculosis that they created. This meant that the prevalence of 
tuberculosis declined markedly during the second half of the twentieth century. On an 
aggregate level this has meant that the threat of tuberculosis was no longer something that 
triggers anxiety and pandemonium, as it had at the beginning of the twentieth century. In 
the pre-antibiotic era the contraction of the tuberculosis disease almost certainly meant 
hardship, suffrage (physically, mentally and often economically) and often death. After the 
mainstream implementation of chemotherapy tuberculosis no longer had such severe 
implications. Instead of years of isolation in a treatment centre (usually a chest clinic or 
sanatoria) and potentially radical resolution, for example, surgery which was rarely 
successful, a sufferer would now undergo a course of therapy which had a much shorter 
duration (average treatment time was reduced from 24 to 6 months473) and was almost 
certain to have a successful resolution. Hence, “before the introduction of chemotherapy in 
the treatment of tuberculosis, treatment spread over long periods, patients were kept in 
sanatoria beds, allowed to do very little for themselves and ceased to be productive 
members of the community, sometimes for years; furthermore, although they were able to 
return to work and a full life few of them could be said to have been cured from the disease 
which was to dominate the rest of their lives”474.  
 
Hence, these antibiotic developments provided a substantial contribution to the improved 
quality of life associated with tuberculosis, largely because they substantially reduced the 
contagiousness and virtually eliminated tuberculosis mortality. An indication of this feat is 
shown in the table below. 
Table 5.12: Percentage reductions in tuberculosis mortality and morbidity, 1950-1970 and 
1950-2000475 
Mortality (Tuberculosis Deaths) Morbidity (Tuberculosis Notifications) 
1950 – 1970 1950 - 2000 1950 – 1970 1950 - 2000 
90 98 79 86 
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The above table illustrates the significant declines in morbidity and particularly mortality 
associated with tuberculosis, such that during the second half of the twentieth century 
mortality had been reduced by 98 percent and morbidity by 86 percent.  
 
5.4.2 Vaccination 
The benefit of the BCG (Bacille Calmette et Guerin [named after its discoverers]) vaccine 
was in the preventative effects it had upon tuberculosis, which ultimately contributed to 
reducing the infectiousness of this disease and therefore provided an (indirect) positive 
contribution to aggregate (population) health related quality of life476.  
 
BCG was not administered widely in England until the 1950s, after which the incidence of 
tuberculosis had fallen sharply with the advent of streptomycin. Despite the vaccination 
being discovered thirty years earlier plus the necessary proof of its efficacy, the scepticism 
among British medical practitioners retarded introduction of the BCG. The BCG was first 
tested on humans in 1921 and had been demonstrated to protect about 80 percent of the 
population at risk (under early clinical trial conditions), but British doctors dismissed the 
information and blocked lay attempts to act on it477. The mainstream utilisation of the BCG 
vaccine was also frustrated by problems in testing of the vaccine and errors in accurate 
dosages. For example, during early testing of the vaccine in 1930 in Lubeck the vaccine 
was administered to 200 children of which 54 died and many survivors developed 
tuberculosis478. Although it was later proved that this was an error with vaccine 
administration rather than the vaccine per se, this incident was a great setback in the use of 
BCG479.  
 
The culmination of these issues meant that agreement on the use of the BCG vaccine was 
not achieved in Britain until 1949 in Britain480. And initially, the vaccine was only 
administered to those at especial risk of developing tuberculosis (i.e. through known 
contact with a case). It was not until 1953 that BCG was recommended for all school 
children by the Ministry of Health481.  
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Despite the above problems regarding the introduction of the BCG, by the 1970s it had 
provided a great boost in the prevention of tuberculosis in England. Evidence suggested 
that by the 1970s the BCG was providing a protection level of about 75 percent482.  
 
Moreover, the vaccine was thought to be so effective as to have eliminated tuberculosis (in 
conjunction with the above developments), that there were some who thought the school 
BCG programme should be stopped as a result of a falling incidence of tuberculosis in the 
UK, during the 1970s483. This marks a stark contrast with the situation twenty years earlier 
when it was claimed, by the government, that “there is no scientific evidence of its [BCG 
vaccination] true value”484.  
 
5.4.3 Radiography  
A final area of improved medical technology, which was able to provide a positive 
contribution to the quality of life associated with tuberculosis, was radiography. Although 
this invention provided a significantly lower contribution than the other components of this 
chapter, the aid radiography provided in the detection of tuberculosis ought to be noted.  
 
Mass Miniature Radiography was introduced in 1943, under the recommendations of the 
Medical Research Council established by the Minister of Health485. Since its introduction 
mass miniature radiography made great strides in the examination of large groups of 
apparently healthy individuals486. As a result, mass miniature radiography, was able to 
detect cases of tuberculosis by chance, i.e. those cases which had revealed no obvious 
symptoms. By the mass radiography schemes introduced in the 1940s an active case rate of 
1 per 1,000 was discovered among those previously unsuspected of having tuberculosis487. 
It should be noted that the key contribution here would be related to the prevention of 
further cases being created. 
 
Owing to war time limitations on the production of the requisite apparatus and to the 
availability of manpower, it was only possible to provide these mass radiography units 
gradually in selected areas in the country. However, by the end of 1953 there were about 
70 units in operation, more than double the number when the NHS was introduced, and 
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examined about two million people a year, particularly those in industrial employment488. 
Since the 1950s the use of radiography has been used as a means of effectively diagnosing 
tuberculosis.  
 
5.4.4 Environmental Factors 
There is evidence that environmental factors played some role in the decline in 
tuberculosis, which began in the mid nineteenth century before the provision of any kind of 
medical advances and in conjunction with significant improvements in public health 
reforms which provided cleaner water, more effective waste disposal, safer food handling 
and improved housing conditions489. Hence, there does seem to be strong evidence for 
environmental factors playing a role in the early declines in the tuberculosis death rate, 
which fell from about 22.3 per 1,000 in 1840 to 10.6 per 1,000 in 1960, before the 
mainstream utilisation of antibiotics490. 
 
When considering environmental factors and their relation to tuberculosis it is possible to 
dichotomise these features into two broad categories: environmental developments that 
reduce exposure to tuberculosis and those which increase resistance to tuberculosis. It 
should be noted that there is strong evidence of interaction between these two broad 
explanations. 
 
The most popular environmental explanation relates a story about the decline in 
tuberculosis being related to a reduction in the effective contact between individuals, 
which is related to many factors associated with improved standards of housing. The most 
obvious feature here is the reduction in domestic crowding, as the average household size 
decreased, from at least five individuals per household in 1901 to 2.5 by 1991491. I.e. as the 
population moved away from excessive overcrowding the mortality from tuberculosis 
diminished492. Overcrowding in housing as well as within houses was also important: in 
districts where all the houses were built in a back-to-back formation the death rate from 
pulmonary tuberculosis was 5.2 per 1,000 versus 2.8 per 1,000 in districts void of back-to-
back housing493.  
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Following on from this, the importance of general living conditions in determining the 
transmission of tuberculosis has also been studied, where the following relationship was 
identified: the prevalence of tuberculin sensitivity among contacts was inversely 
proportional to the standards of housing494. Improved ventilation in housing and work 
environments is also thought to have helped reduce the risk of the aerosol transfer of 
tuberculosis495.   
 
In all aspects of tuberculosis it is thought that the wealthier faired better, both before and 
after the introduction of chemotherapy in the 1950s. This provides one of the strongest 
indications that better nutrition, superior housing with less crowding and better ventilation, 
the ability to afford warm clothing and the necessary fuel were important in the reduction 
of tuberculosis.  
 
A final environmental facet which played a role in the early declines in tuberculosis, 
although to a lesser extent than the features analysed above, is the awareness of 
tuberculosis and understanding about how to abate tuberculosis. For example “a potent 
reason for why so many cases of consumption escape detection at the early stage among 
working class is the fact that working classes have not yet been educated to the point of 
grasping the importance of an early diagnosis”496. 
 
The table below considers the effectiveness of environmental factors versus medical 
intervention in the elimination of tuberculosis in the twentieth century. This simple 
comparison considers the decline in tuberculosis in the pre and post antibiotic era. I.e. any 
decline in tuberculosis pre 1950 can be generally regarded as a result of environmental 
factors. Conversely, any reduction in tuberculosis morbidity and mortality post 1950 can 
be considered as a primary result of medical intervention. 
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Table 5.13: Percentage reductions in tuberculosis mortality and morbidity attributable to 
environmental and medical developments, 1900-2000497 
‘Environmental’ ‘Medical intervention’ 
Mortality Morbidity Mortality Morbidity 
1900 - 1950 1900 - 1950 1950 - 2000 1950 - 2000 
74 40 98 86 
 
Table 5.13 highlights the significant contribution of improved environmental factors to the 
decline in tuberculosis and the improvement in the quality of life associated with this 
disease. The decline in mortality and morbidity in the pre 1950 eras can be considered as a 
result of environmental factors as this was the only ‘therapy’ available. Therefore, the table 
highlights that both environmental and health developments provided valuable 
contributions to the combat of tuberculosis, even though much of the decline in 
tuberculosis was well under way before the introduction of medical developments, 
although tuberculosis would not have been virtually eliminated without medical 
developments.  
 
5.5 Lack of Progress Considerations 
The far-reaching progress in eliminating tuberculosis during the twentieth century began to 
halt in the 1980s498. During the last two decades of the twentieth century tuberculosis 
recaptured the concerns of public health as a result of increases in the prevalence of this 
disease. Although it should be noted that this is not strong enough to have caused an 
increase in the prevalence rate (see Figure 5.13), this reversal still needs to be 
contemplated.  
 
The most popular reason for the re-emergence of tuberculosis in England is as a 
consequence of the HIV epidemic. The presence of HIV creates a substantially increased 
scope for the perpetuation of tuberculosis: an AIDS carrier’s immune system is weakened 
and this helps the tubercle bacilli to survive and spread499. This spread is further 
perpetuated by the living conditions associated with many AIDS victims, i.e. deprived 
housing, poor nutritional conditions and adverse social circumstances. Additionally, 
resistance to tuberculosis therapy is a more pertinent issue for AIDS sufferers.  
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Increased migration and globalisation has also contributed to the re-emergence of 
tuberculosis in populations that have comparatively low levels of tuberculosis. Hence, in 
developing countries tuberculosis presents a similar scenario to what was evident in Britain 
at the beginning of the twentieth century. With increased travel and migration the tubercle 
bacilli are being increasingly introduced back into populations that have achieved a very 
low prevalence level. In England, at the end of the twentieth century this transmission was 
most evident within populations from the Indian sub-continent and black Africa. For 
example, the tuberculosis prevalence rates in these populations, as compared with the 
indigenous English population were, respectively, 121 and 210 times higher500. Along a 
similar vein to the AIDS carriers, these immigrants tend to live in deprived and 
overcrowded conditions, which perpetuate the spread of tuberculosis.   
 
The increase in the number of homeless people has also contributed to the re-emergence of 
tuberculosis. Accurate estimates about the occurrences of tuberculosis in the homeless, and 
even the number of homeless people, are difficult to obtain because of definition and 
measurement problems and the mobility of this population501. However, all available 
studies point to tuberculosis being a particular problem in this group502.  
 
The association between tuberculosis and deprivation is also evident in the unequal social 
class distribution of tuberculosis. During the first half of the twentieth century, there was a 
strong relationship between deprivation (social class being the proxy) and tuberculosis 
mortality, where the poorest social classes experienced higher tuberculosis mortality. This 
is shown in Table 5.14. 
Table 5.14: Standardised mortality ratios for tuberculosis by social class: indexed (all 
males = 100), males aged 20-64503 
Period Social Class (All males = 100) 
 I II III IV V 
1921-23 49 81 95 97 137 
1930-32 61 70 100 104 125 
1950 64 62 103 95 149 
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For all the periods in the above table there is a consistent trend between deprivation and 
mortality, such that the poorer social class experienced greater tuberculosis mortality.  
 
Although this provides further evidence in favour of the intuitive relationship between 
deprivation and tuberculosis mortality, it does not provide a causal explanation as it is not 
capable of indicating which deprivation variables are fundamental. I.e. is it a story about 
unfavourable environmental conditions (e.g. poor nutrition) or is it a story about 
environmental risks (e.g. crowded housing/working conditions)?  
 
Throughout the twentieth century and especially in the pre-antibiotic era there were 
persistent debates about the most fundamental environmental facets associated with 
tuberculosis mortality. The two contrasting opinions were those which prioritised nutrition 
versus those that emphasised overcrowding in the home and increasingly industrial 
workplace. Cobbett (1930) claimed that diet was: “of the utmost importance”504, versus 
Collins (1925) who identified high mortality from respiratory tuberculosis in printers and 
shoe makers despite low general mortality, both of these industries require men to work 
under circumstances of poor ventilation and crowding505.  
 
It is clear that both categories of environmental conditions risks had a strong (positive) 
association with the tuberculosis infection, and it would seem virtually impossible to 
disaggregate them further and conclude upon the single most important environmental 
factor associated with tuberculosis506.  
 
All of these problems of the re-emergence of tuberculosis have been exacerbated by 
inadequate medical management and ineffective public health surveillance programmes. In 
conjunction with adverse patient meddling with dosages by patients, physicians must also 
accept some of the blame for the re-emergence of tuberculosis through an increase in 
tubercle bacillus drug resistance507. Because of the virtual elimination of tuberculosis in the 
years preceding the re-emergence many physicians have become less knowledgeable about 
treatment and consequently prescribe therapy inappropriately508. These problems are 
enhanced by inadequate monitoring of tuberculosis. Despite the introduction of the 1984 
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Public Health (Control of Diseases) Act, which reiterated the compulsory notification of 
tuberculosis, there are still shortcomings in the monitoring of tuberculosis509. This in turn 
affects control of the disease and compounds the above problems as it provides scope for 
the continual re-emergence of tuberculosis.  
 
5.6 Summary 
The above analysis has highlighted that the standards of living associated with tuberculosis 
experienced significant improvements during the twentieth century, particularly between 
1950 and 1975. Mortality associated with tuberculosis declined almost consistently 
throughout the twentieth century, with the exception of war time increases and a marginal 
re-emergence in the last part of the twentieth century. Although this re-emergence in 
prevalence detracts from the widespread improvements it was still a very minimal setback, 
especially compared with the twentieth century in its entirety.  
 
The culmination of the developments documented in this chapter, especially those in 
medicine, meant that the quality of life associated with tuberculosis had improved 
considerably during the twentieth century as it advanced from ‘poor’ levels in 1900, which 
were associated with significant distress, hardship and usually death to ‘good’ levels by 
2000, when tuberculosis was no longer a significant threat to the population, despite the 
marginal re-emergence in the 1990s. 
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“By the end of the twentieth century cancer had developed into a major public health 
problem, with over 250,000 people developing cancer each year and over 150,000 dying of 
the disease”510. This scenario had dramatic implications for the health and welfare related 
quality of life of the population, which became increasingly evident as the twentieth 
century unfolded. 
 
Cancer is an extremely complex disease, which even by 2000 was only partially 
understood. This problem is exacerbated by the fact that there is no such thing as cancer 
per se. I.e. there is no single homogeneous disease and therefore no singular cure or 
preventative measure to remedy the health burden of cancer. Instead, each cancer (of 
which there are more than 200 different types) should be considered as a different disease 
with a different aetiology, pathogenesis and prognosis511. Two of these cancers will be 
considered here: breast cancer and stomach cancer, both featured in the top ten most 
common cancers during the twentieth century. Breast cancer was one of the most heavily 
researched cancers during the twentieth century and will therefore be more thoroughly 
detailed than stomach cancer in many parts of this chapter. 
 
Throughout the twentieth century breast cancer was one of the most common cancers for 
women. At the end of the twentieth century (1999) one in four female cancers was located 
in the breast, with around 34,000 new cases diagnosed per annum in England512. This 
cancer develops in the milk-producing glands in the breast, or in the passages or ducts that 
deliver milk to the nipples. Breast cancer can also occur in men, but this is extremely rare.  
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Stomach cancer is another common form of the disease, which is especially prevalent in 
males (who are two times more likely to develop stomach cancer than their female 
counterparts)513. Stomach cancer (also known as gastric cancer) is caused when cells on the 
inner lining of the stomach become abnormal and start to divide uncontrollably, which 
ultimately causes a tumour.  
 
As well as the merits of considering these two diseases independently, they also provide 
valuable complements in comparison. During the twentieth century there were continual 
innovations in the identification, treatment and prognosis related to breast cancer, which 
was not evident for stomach cancer. This scenario provides a contrast about the extent and 
value of technological developments that have impacted positively upon the health related 
quality of life of the population with breast cancer, versus those individuals suffering from 
stomach cancer, who did not enjoy the same improvements. 
 
This chapter will begin with an analysis of the existing data for breast and stomach cancer. 
This will comprise an investigation into the prevalence and survival rates during different 
eras of the twentieth century.  
 
The following section will improve the readers understanding of breast and stomach cancer 
with an outline of the aetiology and pathogenesis of breast and stomach cancer and the 
fundamental differences between these cancers will also be explained.  
 
After this has been achieved the thesis will provide the twentieth century chronology that 
details the efforts made by government, charities and other bodies, in the fight to prevent, 
diagnose and treat cancer and evaluate how these efforts impacted upon quality of life for 
cancer sufferers. Following on from this, the health history will be considered in order to 
evaluate the impact of medical improvements upon quality of life for breast and stomach 
cancer sufferers.  
 
Finally, the thesis will consider why the previously identified improvements have not been 
more marked. This will be achieved through identifying reasons for the lack of progress in 
increasing the quality of life for breast and stomach cancer sufferers.  
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6.1 Cancer Data 
Efforts to measure cancer exist in a variety of forms and completeness throughout the 
twentieth century. Cancer registration began under the aegis of the Radium Commission in 
the 1920s514.  Subsequent considerations about cancer and the effect that it was having 
upon the population appeared in the 1939 Cancer Act. Although a reporting system was 
not actually called for under this Act, the Ministry of Health specified that “clinical 
records relating to each patient should be kept so as to show clearly and accurately the 
history of the case”515. By 1946 a national system of records for all cancer patients was 
instituted516. The collection and processing of these cancer statistics became the 
responsibility of the General Register Office (and its successor, the Office of Population 
Censuses and Surveys) when the National Health Service was introduced in 1948. 
 
During the majority of the twentieth century the most common method for evaluating the 
incidence of cancer was by referencing mortality statistics. This tendency in conjunction 
with the voluntary nature of reporting (evident before 1971) contributed to the erroneously 
low level of cases registered in comparison with the estimated total experiences517. For 
example, in 1946 5,311 individuals were registered with breast cancer and approximately 
7,891 died from breast cancer and 1,684 individuals were registered with stomach cancer 
compared to approximately 14,171 who died from this disease518. 
 
Progress towards a full national registration of cancer scheme was slow. This is highlighted 
by the formation of the Cancer Registration Working Party in 1963 (with a membership of 
officials from the Ministry of Health and General Register Office together with regional 
representation) to consider the organisation techniques of regional cancer registries and to 
make recommendation for their improvement519.  
 
By the end of 1970 the Advisory Committee on Cancer Registration had devised a 
simplified scheme for the collection of cancer data, with an aim of 100 percent registration 
of all the patients seen at or admitted to hospital with a diagnosis of cancer, and also to 
define, as far as possible cases of cancer never apparently seen in hospital, i.e. cases treated 
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by general practitioners, which came to light through death notification schemes520. This 
initiative was introduced in 1971 and coined the National Cancer Registration Scheme, 
which provided annual information about the incidence and survival of each cancer and 
other cancer related statistics. The survival rate is facilitated by the one, five and ten year 
follow up of patients, which is conducted by the Regional Cancer Registries to provide 
notification either of either death or survival521.   
 
The registration of cancer deaths also suffers from various shortcomings, despite 
complying with the WHO format regulations since 1927522. Death data suffer more from 
bias and therefore criticism as death is not always correctly certified or the underlying 
cause correctly coded523. Many studies have shown wide variability in certification and 
coding. However the largest problem is not of major consequence here, as the effects are 
probably only a few percent or less524. For example, the percentage of mortality coded to 
ill defined conditions decreased from 2 percent in 1950 to 0.4 in 1980, but then increased 
to 0.9 in 1990525. Despite the undesirability of these inaccuracies associated with cancer 
mortality data, they are not of a great enough magnitude to bias the findings of the chapter, 
which marks a contrast with the morbidity (or incidence) data for the early decades of the 
twentieth century, which significantly underestimates the number of cancer sufferers. 
 
Neither mortality nor (and especially) incidence rates are ideal measures. Both will be used 
here as there is no better alternative and these indices are still very indicative, particularly 
when used in tandem. The advantages and drawbacks of this data are summarised in Table 
6.1. 
 
 
 
 
 
 
                                                 
520
 The National Archives: MH 160 (644):  “Cancer Registration: Advisory Committee Reports”  
521
 Ibid 
522
 Rooney & Devis, “Mortality Trends by Cause of Death in England and Wales 1980-94: The Impact of Introducing Automated Cause Coding and Related 
Changes in 1993”, p. 29 
523
 Coleman, “Trends in Breast Cancer Incidence, Survival and Mortality in England and Wales”, p. 590 
524
 Swerdlow, “Cancer Registration in England and Wales: Some Aspects Relevant to the Interpretation of the Data”, p. 159 
525
 Ibid 
Illnesses: Cancer 
                                                                                                                                                                                                                          - 192 - 
Table 6.1: Advantages and disadvantages of incidence and mortality data for considering 
cancer 
Incidence Mortality 
Advantages: Advantages: 
• High quality coding • Virtually 100% complete 
• Cancer site and histology  • Timely  
• Low proportion of site unspecified • Very long time series 
• Incidence date known  
Disadvantages: Disadvantages: 
• May not be complete • Diagnostic accuracy less certain than 
for incidence 
• May not be sufficiently timely • Site only, no histology 
• Evidence of under-ascertainment into 
the early 1970s 
• Around 10% unspecified 
 • Deaths in any one year result from 
cases diagnosed over a long previous 
period 
 
As a result of these aforementioned weaknesses, the twentieth century analysis of cancer 
data has to be considered in conjunction with the following caveats.  
1. Death rates will be considered in conjunction with incidence rates (although not 
interchangeably). This is necessary because of the varying formats of cancer data over 
the twentieth century, whereby the first fifty years consider death rates and the last 
thirty years of the twentieth century consider the number of registered cancer sufferers. 
Therefore the terms ‘incidence’ and ‘prevalence’ will be used loosely, so as to describe 
both forms of measurement. 
2. Trends will be considered in favour of explicit numbers, due to the unreliability of 
twentieth century (especially pre 1970) cancer data. 
3. When considering the survival rate it is necessary to be aware of inaccuracies related to 
‘loss of follow up’ problems, which arise when cancer registries are unable to trace an 
individual who will then not be recorded as dead from cancer, when in fact they might 
be. Although this problem largely subsided by the end of the twentieth century (due to 
improved registration), it is still necessary to be aware of this distorting factor when 
considering survival rates. 
 
During the first fifty years of the twentieth century there were significant increases in the 
number of breast and stomach cancer deaths. During the second half of the century 
mortality rates for stomach cancer experienced substantial declines. The increase in deaths 
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from breast cancer was generally constant between 1900 and 2000, with the exception of a 
decline in the increase around the time of World War Two (which might be more a product 
of registration problems than a genuine improvement) and a genuine decline in breast 
cancer mortality during the last decade of the twentieth century.  
Figure 6.1: Breast and stomach cancer mortality rate, 1911-1997526 
Breast and Stomach Cancer Mortality Rate 1911-1997
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Figure 6.1 shows that, in 1911 the burden of breast and stomach cancer was relatively 
equal. The increase in male stomach cancer deaths between 1911 and 1955 was more 
pronounced than for breast cancer and female stomach cancer, respectively. The aggregate 
number of stomach cancer deaths was greater than breast cancer deaths. This trend was not 
maintained during the second half of the twentieth century, when mortality from breast and 
stomach cancer diverged, with an increase in breast cancer mortality, such that by the close 
of the twentieth century the burden of breast cancer mortality was more prominent than 
(aggregate) stomach cancer.  
 
These mortality trends are similar to the incidence rates for breast and stomach cancer 
during the final quarter of the twentieth century. This is shown in the graph below. 
Between 1972 and 2000 there was a decline in the burden of stomach cancer accompanied 
by a significant increase in the incidence of breast cancer. Between 1984 and 1992 this 
increase in breast cancer prevalence was likely to be a result of improved screening, which 
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became increasingly evident from 1988 onwards, and also more comprehensive 
registration, which was increasingly achieved throughout the period in the graph below.  
Figure 6.2: Rates of newly registered cases of breast and stomach cancer (per 100,000), 
1972-2000527 
Rates of Newly Registered Cases of Breast and Stomach Cancer 
1972-2000 (per 100,000)
0
20
40
60
80
100
120
140
160
1972 1974 1976 1978 1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000
Year
N
ew
ly
 
R
eg
is
te
re
d 
Ca
se
s 
(p
er
 
10
0,
00
0)
Breast Cancer (F) Stomach Cancer (M) Stomach Cancer (F)
 
Figure 6.1 and 6.2 show that the incidence and mortality rate of stomach cancer 
experienced much greater improvements than breast cancer, especially if the relationship is 
considered for the twentieth century as a whole, when stomach cancer was more prevalent 
than breast cancer for the first half but as a result of increases in the incidence and 
mortality rate of breast cancer and a decline in stomach cancer, the opposite was true by 
2000. 
 
In order to comprehensively determine the trends in the burden of these two diseases it is 
necessary to consider two additional factors: the age distribution and the survival rate.  
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Figure 6.3: Number of breast cancer deaths by age 1911-1955528 
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Figure 6.4: Number of newly registered cases of breast cancer by age, 1971-1998529 
Number of Newly Registered Cases of Breast Cancer by Age 1971-1998
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Figures 6.3 and 6.4 highlight that, in conjunction with an increase in the incidence of breast 
cancer there has also been an increase in the average age of incidence of this disease. The 
peak age of incidence of breast cancer deaths increased from 55-60 years of age in 1911 to 
65-70 in 1955. However, this trend was reversed, so that the age declined between 1992 
and 1998, which is likely to be most indicative of more comprehensive screening, such that 
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women of younger ages were being tested for breast cancer, and identified as positive for 
this disease at an earlier stage than would have been the case in earlier time periods. Breast 
cancer deaths and registrations have experienced an increase in the number of individuals 
at the oldest ages (85+). This is not the only age group for which there has been an increase 
but it highlights the only consistent trends over the twentieth century.  
 
The incidence of stomach cancer over the twentieth century shows many similar trends and 
also a more complementary picture with regards to the burden of this disease upon quality 
of life.  
Figure 6.5: Number of stomach cancer deaths by age, 1911-1955530 
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Figure 6.5 highlights the increase in the burden of stomach cancer at the oldest ages in 
conjunction with a decline at younger and middle ages. If the increase in the incidence of 
stomach cancer at the oldest ages is seen in relative terms then it becomes particularly 
pronounced compared to the increase for other ages. For example, between 1911 and 1955 
there was more than a twenty fold increase in the number of stomach cancer deaths at ages 
85+, compared to the next largest increase, which was about three fold for age 70. This 
change represents an improvement in the quality of life burden of stomach cancer as there 
were fewer healthy life years lost to this disease, which was also evident for breast cancer, 
although to a lesser extent. 
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Figure 6.6 shows that between 1996 and 1999 there was an important decline in the 
number of registered cases of stomach cancer for all ages, including (although to a lesser 
extent) the oldest ages. In conjunction with the fall in the burden of stomach cancer there 
was also a continual increase in the peak age of incidence.  
Figure 6.6: Number of newly registered cases of stomach cancer by age, 1971-1998531 
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When considering the age distribution of the burden of breast and stomach cancer, the 
situation is better than in absolute terms. This is especially true for stomach cancer.  
 
One of the most indicative measures of the burden of these diseases is the survival rate, 
which identifies the proportion of individuals surviving cancer within a particular time 
span, usually one, five or ten years. The proportion of cancer patients who survive five 
years has become the most widely reported figure for cancer survival. Therefore, this 
provides the best insight into the effects of cancer upon quality of life and life expectancy 
for sufferers of this disease, when considered in conjunction with incidence and mortality 
measures532. The graphs below provide information about the changes in the one and five 
year survival rate (1Y SR and 5Y SR) for breast and stomach cancer (BC and SC) during 
the second half of the twentieth century, the only times at which this data exists. 
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Figure 6.7: One and five year survival rate from breast cancer, 1945-2001533 
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Figure 6.8: One and five year survival rate from stomach cancer, 1945-2001534 
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Figures 6.7 and 6.8 illustrate that the prognosis for breast and stomach cancer improved 
between 1945 and 1990, particularly during the final years of this period. This is especially 
pronounced for the five year survival rate for stomach cancer. Between 1945/6 and 1986-
1990 there was a 100 percent improvement in the percentage of stomach cancer sufferers 
surviving longer than five years, albeit at very low levels (from 5 to 10 percent of the total 
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number diagnosed with stomach cancer). Breast cancer survival prospects also experienced 
improvements but of a lesser magnitude. 
 
These survival rates highlight the different burden of these two diseases. For those who 
were diagnosed in 1998-2001 with stomach cancer there was less than a 15 percent chance 
of survival beyond five years compared to the more favourable 80 percent chance of 
survival from breast cancer. The contrast in the breast and stomach cancer one year 
survival rates is even more pronounced. 
 
The relationship between the one and five year survival rate also has important 
implications for quality of life. There is a very small margin between the one and five year 
survival rates for stomach cancer, which implies that many of those who are diagnosed 
with this disease do not survive beyond one year. This margin is much larger for breast 
cancer, which provides an additional advantage in the prognosis of this disease. I.e. many 
people with breast cancer will survive for longer than a year, which is not the case for 
stomach cancer. 
 
The above analysis has highlighted that the prevalence of breast cancer has increased 
considerably over the twentieth century, while it has declined for stomach cancer. The age 
distribution of these diseases shows a general trend of increasing average age and an 
increase in the burden of these diseases at older ages, which in many cases can be regarded 
as an improvement in the burden of these diseases with respect to quality of life. Survival 
probabilities from these two cancers had improved over the second half of the twentieth 
century, although still remained bleak, particularly for stomach cancer. 
 
6.2 Definition of Breast Cancer and Stomach Cancer 
The human body is made up of individual units called cells. Cells make up the tissues and 
organs, such as the heart or lungs. All cells divide to produce more cells when the body 
needs them, for example, when an individual is growing. However, sometimes cells can 
divide when they are not supposed to, as a result of the cells receiving the wrong signals or 
if there is a mistake in the DNA535. If cells engage in this division and the growth of cells 
gets out of control then they will form a mass of cells, which is a tumour. There are two 
types of tumours: those that are harmless (benign) and those that are cancerous. Malignant 
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tumours can also spread and damage other tissue, this is known as an infiltrating or 
invasive carcinoma or metastasis536. 
 
Since the 1920s, when the staging system was introduced537, malignant tumours are 
classified according to the tumour size and extent of metastasis in order to determine the 
extent of the cancer538. Most frequently, cancers are grouped into four stages539. Stage I 
cancers are small, localised cancers that are usually curable, while stage IV usually 
represents inoperable or metastatic cancer. Stages II and III cancers are usually locally 
advanced. The precise definition of these stages is different for each cancer. In addition, it 
is important to realise that the prognosis for a given stage also depends on the type of 
cancer, such that a stage II stomach cancer has a different prognosis from a stage II breast 
cancer540. For example, if breast cancer is detected when still confined to the breast (stage 
II) the cure rate is over 95 percent541. This is a far better prognosis than stage II stomach 
cancer. The tables below provide a brief definition of the stages prescribed for breast and 
stomach cancer. 
Table 6.2: Breast cancer diagnostic stages542 
Stage Description 
I Early stage: tumour is less than 2cm wide and has not spread outside the 
breast. 
II Tumour is small (2-5cm wide) or has spread to axillary (armpit) lymph nodes, 
or both.  
III Tumour is larger than 5cm wide and has usually spread to axillary lymph 
nodes and may have spread to the chest or overlying skin. 
IV Tumour of any size, usually affecting lymph nodes, has spread to other parts 
of the body such as bones, lungs, or liver (secondary/ metastasic tumours). 
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Table 6.3: Stomach cancer diagnostic stages543 
Stage Description 
I Tumour has grown no further than the inner layer of the stomach. 
II Tumour has grown into the muscle layer of the stomach wall. 
III Tumour has broken through the membrane covering the outside of the 
stomach. 
IV Tumour has grown into other organs or body structures nearby such as the 
liver or abdominal wall. 
 
6.3 Risk Factors for Breast and Stomach Cancer 
Although the precise causes of breast and stomach cancer have not been identified, several 
potential factors have led to increased numbers of individuals developing the disease and 
therefore significant risk has been associated.  
 
Gender: Both breast and stomach cancers are associated with this factor. Approximately 
half of all women who develop breast cancer have no identifiable risk factor other than 
being female (and ageing)544. Although men can also get breast cancer, the incidence is 
extremely low545. Stomach cancer is twice as prevalent in men as it is in women546. 
 
Age: Besides being female, the greatest aetiological factor for breast cancer is age. Older 
women are much more likely to develop breast cancer. Figure 6.4 highlights the increase in 
prevalence (and therefore risk) of breast cancer between the ages of 50 and 70, throughout 
the twentieth century. The prevalence of stomach cancer is also a direct function of age. 
During the twentieth century the age incidence of stomach cancer increased, so that during 
the first half the major risk ages were those between 50 and 70 years old, during the second 
half of the twentieth century this increased to the region of 60 to 80 years of age, which is 
shown in Figures 6.5 and 6.6.  
 
Diet: The potential of dietary factors being related to the development of cancer gained 
much interest towards the end of the twentieth century. Many epidemiological studies have 
indicated that dietary practices are the most promising area of cancer reduction to 
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explore547. The most notorious study was conducted by Sir Richard Doll (1980), in which 
he suggested that seventy percent of cancers (other than those caused by tobacco) were 
related to diet548. Breast cancer risk is believed to be increased among women with an 
unbalanced and unhealthy diet and particularly one high in animal fat and alcohol549. For 
example, women who drink a great deal are more likely to develop invasive breast cancer 
than women who do not drink550.  
 
The most popular explanatory variable for stomach cancer is related to diet. An extensive 
number of studies in many countries were conducted towards the end of the twentieth 
century, all of which provided a link between dietary factors (which extend to 
environmental factors) and stomach cancer551. The most popular aetiological link is 
between food preservation (and the availability of fresh fruits and vegetables) and stomach 
cancer552. Coggon et al (1989) have highlighted the link between a low intake of salad 
vegetables and fruit and a high intake of salt being clearly associated with stomach cancer 
development553. Other studies have highlighted the potential harm of non-refrigeration 
techniques of food preservation, for example, salting, pickling and smoked foods554.  
 
Environment: The likelihood of a link between stomach cancer and dietary intake has led 
many to identify the link between improvements in refrigeration (which occurred during 
the twentieth century) and the decline in stomach cancer555. This ultimately identifies 
environmental factors as critically important (as this sort of technological development is 
defined as an ‘environmental factor’ in the scientific literature). In addition to this type of 
environmental factor, exposure to radiation, living in close proximity to industrial areas 
and adverse lifestyle practices in general (i.e. smoking, lack of exercise and an unhealthy 
diet) are thought to increase the risk of stomach and breast cancer556. 
 
The importance of environmental factors in the development of cancer is confirmed by 
cross-country comparisons about the prevalence of cancer557. This has been highlighted 
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through migrant studies (where individuals develop the cancer patterns of their host 
country, e.g. Japanese people who have migrated to Hawaii and experienced a decline in 
stomach cancer rates, which correlates with those in Hawaii)558. The importance of 
environmental factors has also been confirmed by observations that adopted children 
whose adoptive parents have died of cancer have a five fold increased risk of getting the 
disease559. 
 
Genetic and hormonal factors are thought to play a role in the development of breast 
cancer. Much research has been conducted on the DNA relationships with breast cancer. 
This has yielded some crucial results, for example, the discovery of two breast cancer 
genes, namely, BRCA1 (in 1994) and BRCA2 (in 1996)560. Approximately five to ten 
percent of breast cancers occur as a result of highly penetrant germline mutations in cancer 
predisposing genes and half of these are due to mutations in BRCA1 or BRCA2561.  
 
Breast cancer is also related to the sex hormones562. Oestrogen imbalances can cause cells 
to grow and divide rapidly. These imbalances can occur for numerous reasons, e.g. 
prolonged periods of oestrogen production (due to the early age of menarche and late 
menopause), the long term use of oral contraceptives and late age of the first child birth or 
not having children563. Alternatively, women who have their first baby before the age of 30 
and who breast feed are less at risk from breast cancer564. 
 
Previous exposure: several studies have identified a bacterium (Helicobacter pylori) that 
may cause stomach ulcers and chronic infections in the stomach may lead to stomach 
cancer565. Furthermore, individuals who have suffered from ulcers and other forms of 
stomach disorder could potentially be at an elevated risk of developing stomach cancer566. 
 
6.4 Government and Charity Initiatives towards Cancer 
Shimkin (1977) noted that man recognised cancer and named it over two thousand years 
ago, but for all except the last 100 years he could do little against it567. Despite the long 
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history of cancer, it only became a relatively (and increasingly) important public health 
problem only during the twentieth century.  
 
6.4.1 Government  
The first significant action towards the English cancer problem was provided by the 1939 
Cancer Act. The main purpose of this bill was to establish a cancer service under which, in 
every part of the country, modern facilities for diagnosis and treatment of cancer would be 
available568. This was to be achieved through improvements in facilities, better liaison 
between local authorities, the Radium Commission, and local medical professionals and an 
increase in funding from the Exchequer to facilitate the desired improvements in cancer 
services569. However, this Act was never actually implemented because of the war570. 
 
In 1948 this Cancer Act was repealed when the National Health Service Act came into 
force. From this time the provision of cancer service was to be achieved under the National 
Health Service, which would provide more accessible service for the population571. Prior to 
the introduction of the NHS, healthcare was provided under a two-tiered (voluntary [only 
in name, by the beginning of the twentieth century] and municipal) system, which was 
facing increasing financial difficulties, which were largely unaided by the government572. 
For example, immediately prior to the introduction of the NHS, the government (local and 
central) had provided less than one-tenth of hospital funding573.  
 
For cancer sufferers, the principal innovation of the NHS was twofold. The first change 
was improved access to existing cancer services for large groups of the population who had 
previously been excluded574. The second change arose from the introduction of state-
owned and funded hospitals and the government plans to modernise and equalise hospital 
services in England during the 1960s575. Before these initiatives, cancer services had been 
very unequally distributed geographically. Therefore, the NHS provided more accessible 
(and affordable) treatment for cancer sufferers. Although, even at the end of the twentieth 
century, services were by no means universally accessible or ideal. 
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As well as data collection policies, a major part of the government’s contribution towards 
increased awareness, understanding and help for improving the quality of life of cancer 
patients was born from the numerous working committees that the government established. 
The Radium Commission were initially in charge of cancer data collection and processing, 
and also provided valuable advice for the government in the form of policy suggestions 
and approaches to improve cancer facilities and practices576. The Working Party on Cancer 
Registration (1962) and the Advisory Committee on Cancer Registration were also 
prominent as they were responsible for the introduction of the first comprehensive (nearly 
100 percent coverage) cancer registration system in 1971577. The Joint Working Party on 
Computers in Radiotherapy (1967) provided initial initiatives for the electrical processing 
of cancer data. This working party also provided the stimulus necessary to achieve a more 
comprehensive understanding of cancer (and the many years of historical statistics about 
the diagnosis, treatment and survival of cancer patients) through electronic data processing 
with the use of digital computers.  
 
The Standing Advisory Committee on Cancer and Radiotherapy (1949) and the Central 
Health Services Council Standing Medical Committee on Cancer Care Organisation (1969) 
provided valuable considerations and findings about the most productive organisation of 
cancer services. The former stimulated advances in radiotherapy practices and 
improvements in the provision of radiology services. The latter considered the organisation 
of cancer care under the NHS and provided numerous recommendations for improvements, 
many of which were still being contemplated by equivalent committees at the end of the 
twentieth century.  
 
The government also supported working groups that could consider the nature and 
aetiology of cancers and subsequently recommend the optimal methods for combating 
these diseases. The Standing Sub-Committee on Cancer (1967), which contained members 
as distinguished as Sir Richard Doll, was sponsored by the state to make considerations 
about the effects of early diagnosis of cancer, the value of public awareness and various 
other issues related to the identification, diagnosis and eventual treatment of cancer578.  
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Despite the continual efforts of the government to improve registration and understanding 
about cancer through various initiatives and working parties, the ‘Smithers Report’ (1971) 
highlighted that there were numerous shortcomings in the government’s efforts to combat 
cancer579. The ‘Smithers Report’ painted a depressing picture of the limitations in data 
gathering, the lack of coordination, and the absence of standardisation in procedures in the 
cancer services, all of which jeopardised the early detection and effective treatment580. A 
later indictment on the NHS was their failure to adhere to any of the suggestions made in 
the ‘Smithers Report’. By the time of the NHS reorganisation in 1974, only four regions 
had produced provisional regional cancer schemes. Continued reflection of slow progress 
of the organisation of cancer services came in 1995, when the government conceded that 
the quality of cancer care was patchy and variable in the skills and technology available in 
different hospitals and also in clinical outcomes.  
 
During the last decade of the twentieth century the government embarked on a wide 
ranging initiative to improve the health of the nation, which was incorporated in the 1992 
‘Health of the Nation’ strategy, which was designed to identify the key areas for health 
improvements, set targets for such improvements and also improve knowledge and 
understanding of these illnesses581. Within this Act, the government identified cancer as 
one of the major burdens to the nation’s health582. However, only certain cancers were 
included in the legislation: cancers of the lung, breast, cervix and skin were singled out for 
special attention and numerical targets were set for the reduction in the incidence or 
mortality within a period of 10-15 years. The target for breast cancer was to reduce the 
death rate by at least 25 percent by the year 2000 (i.e. from 95.1 per 100,000 in 1990 to no 
more than 71.3 per 100,000)583. This was to be achieved through “everyone with suspected 
breast cancer [being] able to see a specialist within two weeks of their general practitioner 
deciding they need to be seen urgently and requesting an appointment”584.  
 
In 1995 the Calmann-Hine Report was published. This report recommended major 
organisational changes at the local level and an improvement in specialisation in cancer 
care, which, in 1997, became policy objectives. Hence, it was not until the 
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recommendations of the Calman-Hine Report were implemented in 1997 that cancer 
became a top priority and additional resources were committed to its treatment and care585. 
 
During the last year of the twentieth century the Health Secretary announced a £96 million 
plan for reducing the number of deaths from five major causes, one of which was cancer. 
Furthermore, this white paper, entitled ‘Saving Lives’, also considered the health divide 
and the social inequality gradient in cancer prognosis, and aimed to improve the quality of 
life of the population as a whole, and not just those in the highest social classes586. 
 
Finally, in the year 2000 the government introduced ‘The NHS Cancer Plan’. This 
established the first comprehensive national cancer programme for England. This plan had 
four aims: saving more lives, ensuring that patients get the right professional support and 
best treatments, tackling inequalities in health (that mean unskilled workers are twice as 
likely to die from cancer as professionals) and investment in the cancer workforce and 
treatment infrastructure. These objectives are valuable in their own right and are also 
useful for indicating where the NHS was continuing to fail cancer sufferers most.  
 
The effects of the persistent failure of the NHS are vividly illustrated through international 
comparisons of the age standardised death rate during the second half of the twentieth 
century, which is shown in the following tables and figures587. 
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Table 6.4: Stomach cancer age standardised death rate (world) for males and females, 
1950-2000 (19 country comparison)588 
Stomach Cancer – Male Stomach Cancer - Female 
Rank 1950 Rank 1970 Rank 2000 Rank 1950 Rank 1970 Rank 2000 
USA  
(17.7) 
USA 
(8.4) 
USA 
(3.9) 
USA 
(9.3) 
USA 
(4) 
USA 
(1.9) 
Australia 
(25.4) 
Australia 
(14.7) 
Australia 
(5.6) 
Canada 
(13.3) 
Australia 
(7.1) 
Australia 
(2.4) 
Canada 
(25.9) 
Canada 
(15.2) 
Canada 
(5.7) 
Australia 
(13.9) 
NewZealand 
(7.3) 
Canada 
(2.5) 
Spain 
(26.1) 
NewZealand 
(16.5) 
Sweden 
(6.3) 
NewZealand 
(15) 
Canada 
(7.5) 
France 
(2.5) 
NewZealand 
(28) 
Sweden 
(17.6) 
Switzerland 
(6.6) 
Spain 
(15.6) 
France 
(8.2) 
Denmark 
(3) 
Ireland 
(28.5) 
France 
(17.6) 
France 
(6.8) 
France 
(15.6) 
Sweden 
(9.6) 
Switzerland 
(3.1) 
France 
(29.1) 
Denmark 
(17.7) 
Denmark 
(6.9) 
England 
(17) 
Denmark 
(10) 
England 
(3.2) 
Portugal 
(29.1) 
Scotland 
(20.2) 
NewZealand 
(7.1) 
Portugal 
(17.7) 
England 
(10.3) 
Sweden 
(3.4) 
England 
(29.8) 
Switzerland 
(21.1) 
England 
(8) 
Japan 
(20.4) 
Switzerland 
(12) 
Belgium 
(3.5) 
Scotland 
(30.8) 
England 
(21.7) 
Belgium 
(8.1) 
Sweden 
(20.7) 
Scotland 
(12.1) 
NewZealand 
(3.5) 
Sweden 
(32.6) 
Ireland  
(21.7) 
Finland 
(8.2) 
Ireland 
(21.6) 
Belgium 
(12.2) 
Netherlands 
(3.6) 
Belgium 
(33.6) 
Norway 
(22.5) 
Netherlands 
(8.5) 
Italy 
(21.7) 
Netherlands 
(12.2) 
Norway 
(3.7) 
Italy 
(36.9) 
Belgium 
(23.0) 
Scotland 
(8.6) 
Scotland 
(22.3) 
Norway 
(12.6) 
Finland 
(4.1) 
Netherlands 
(41) 
Netherlands 
(23.9) 
Norway 
(8.8) 
Netherlands 
(26.3) 
Ireland 
(14.2) 
Scotland 
(4.1) 
Norway 
(43.4) 
Spain 
(27.2) 
Ireland 
(9.7) 
Switzerland 
(29.2) 
Spain 
(14.5) 
Ireland 
(4.5) 
Switzerland 
(43.5) 
Finland 
(30.6) 
Spain 
(11.2) 
Norway 
(29.2) 
Italy 
(15.2) 
Spain 
(4.7) 
Denmark 
(46) 
Italy 
(30.9) 
Italy 
(12.5) 
Denmark 
(32.9) 
Finland 
(16) 
Italy 
(6.1) 
Japan 
(66.3) 
Portugal 
(34.3) 
Portugal 
(20.2) 
Japan 
(35.8) 
Portugal  
(18.9) 
Portugal 
(9.4) 
Finland 
(69.1) 
Japan 
(62.9) 
Japan 
(29.2) 
Finland 
(40.2) 
Japan 
(33) 
Japan 
(11.7) 
 
Rank 8 / 19 9 / 19 9 / 19 6 / 19 8 / 19 6 / 19 
Vs Leader + 41 % + 61 % + 51 % + 45 % + 61 % + 41 % 
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 The number in brackets after each country name is the (world) standardised death rate. The last two (detached) rows represent: 1) England’s rank relative 
to the 19 countries considered in the table. 2) The extend to which the standardised death rate is lower in the leading country compared to England, 
represented in percentage terms. I.e. in 1950 male stomach cancer mortality was 41% lower in the USA (lowest death rates related to stomach cancer) than in 
England.  
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Table 6.4 shows that during the second half of the twentieth century English stomach 
cancer mortality maintained a relatively stable relationship with the 19 countries 
considered in the above table, with the exception of a worsening (compared to the [USA] 
leader country) during the 1970s, which was evident and equally extreme for both males 
and females. By 2000 the situation had improved such that females regained their 1950 
rank and reduced their percentile difference with the leader. Males had moved closer 
towards their comparatively more favourable 1950 rank and had also partially abridged 
their percentile lag behind the leader country.  
 
The international relationship for female breast cancer highlights a slightly more 
favourable trend. However, this could potentially be related to the very poor starting point. 
In 1950 breast cancer was 83 percent lower in the leading country (Japan) than in Britain. 
Out of the 19 country comparison, England only achieved seventeenth place. By 2000 the 
situation had improved as England moved into twelfth place and reduced their relative 
excess breast cancer mortality (in relation to the leader, which was still Japan) by 19 
percent (from 83 to 64 percent).  
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Table 6.5: Breast cancer age standardised death rate (world) for females, 1950-2000 (19 
country comparison)589 
Breast Cancer – Female 
Rank 1950 Rank 1970 Rank 2000 
Japan (3.9) Japan (4.4) Japan (7.9) 
Spain (5.4) Spain (11.2) Spain (15.6) 
Portugal (10.4) Portugal (12.6) Finland (16.1) 
Finland (10.7) Finland (14.1) Portugal (16.2) 
Italy (12.6) Norway (17) Sweden (16.4) 
France (12.8) France (17) Norway (17.5) 
Sweden (15.5) Italy (17.6) Australia (17.5) 
Ireland (17.7) Sweden (18.5) USA (18.4) 
Norway (19.2) Australia (19.9) Italy (18.8) 
Australia (19.3) Ireland (22) France (19.2) 
Belgium (20.1) USA (22.5) Canada (20) 
USA (21.2) Belgium (23.1) Switzerland (20.1) 
Scotland (21.8) Switzerland (23.2) England (22) 
Switzerland (22) England (23.8) Scotland (22.2) 
Canada (22.4) New Zealand (25.6) New Zealand (22.5) 
New Zealand (23.1) Canada (26.4) Ireland (24.8) 
England (23.5) Scotland (26.4) Netherlands (25.3) 
Netherlands (24.2) Netherlands (26.5) Belgium (26.3) 
Denmark (29) Denmark (26.6) Denmark (27.2) 
 
Rank 17 / 19 13 / 19 12 / 19 
Vs Leader + 83 % + 82 % + 64 % 
 
Tables 6.4 and 6.5 highlight that, despite the operation of the NHS and the aforementioned 
efforts of charities and medical technology, England was still faring relatively badly in the 
war against cancer when compared to similar economies. These ominous findings are 
generally maintained when England is considered in a smaller, more homogenous country 
comparison, which is illustrated in the figures below. 
                                                 
589
 The number in brackets after each country name is the (world) standardised death rate. The last two (detached) rows represent: 1) 
England’s rank relative to the 19 countries considered in the table. 2) The extend to which the standardised death rate is lower in the 
leading country compared to England, represented in percentage terms. I.e. in 1950 female breast cancer mortality was 83% lower in 
Japan (lowest death rates related to breast cancer) than in England. World Health Organisation (2002), “WHO Mortality Data Base”. 
Retrieved 1 October 2002, from: http://www.who.org 
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Figure 6.9: Stomach cancer age standardised death rate (ASDR) for world, males, 1950-
1999 (5 country comparison)590 
Comparison of Stomach Cancer Male ASDR 1950-1999
0
10
20
30
40
50
A
SD
R
Netherlands 43.0 31.2 23.9 17.4 12.0 8.5
France 29.2 25.2 17.6 12.4 8.7 6.8
Denmark 46 28.1 17.7 12.2 7.7 6.9
USA 18.6 12.7 8.4 6.1 5.2 3.9
UK 29.1 26 21.7 16.9 12.2 8.0
1950 1960 1970 1980 1990 1999
 
Figure 6.10: Stomach cancer age standardised death rate (ASDR) for world, females, 1950-
1999 (5 country comparison)591 
Comparison of Stomach Cancer Female ASDR 1950-1999 
0
5
10
15
20
25
30
35
A
SD
R
Netherlands 28.1 17.0 12.2 7.1 4.8 3.6
UK 17.2 13.6 10.3 7.4 4.9 3.2
USA 10.0 6.4 4.0 2.8 2.4 1.9
Denmark 32.9 16.4 10.0 6.3 3.9 3.0
France 15.8 12.7 8.2 5.4 3.5 2.5
1950 1960 1970 1980 1990 1999
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 World Health Organisation (2002), “WHO Mortality Data Base”. Retrieved 1 October 2002, from: http://www.who.org 
591
 World Health Organisation (2002), “WHO Mortality Data Base”. Retrieved 1 October 2002, from: http://www.who.org 
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The death rates in comparable economies (namely, the Netherlands, Denmark, France and 
America) show greater improvements than in the UK. As a result of Britain’s smaller 
relative decline in the stomach cancer death rate, her comparative position has worsened. 
This scenario is also evident for British females, although there has been greater 
convergence between the five countries and therefore less of a difference in the stomach 
cancer death rate by the end of the twentieth century. 
 
England’s international performance for breast cancer has been more favourable. During 
the 1990s the UK experienced important declines in the death rate, which enabled Britain 
to improve their rank among the five countries.  
Figure 6.11: Breast cancer age standardised death rate (ASDR) for world, females, 1950-
1999592 
Comparison of Breast Cancer Female ASDR 1950-1999
0
5
10
15
20
25
30
35
A
SD
R
Netherlands 23.2 24.5 26.5 25.6 26.7 25.3
UK 23.6 23.8 26.4 28.2 28.4 22.0
USA 21.6 21.7 22.5 22.0 22.5 18.4
Denmark 29.0 23.9 26.6 26.7 26.9 27.2
France 12.9 16.0 17.0 18.3 19.6 19.2
1950 1960 1970 1980 1990 1999
 
Figures 6.9, 6.10 and 6.11 highlight that, despite the introduction of the NHS, Britain has 
not experienced any relative improvements for stomach cancer. And although the 
performance is more favourable for breast cancer sufferers, this was not achieved until the 
very end of the twentieth century and had still not reached levels associated with the claims 
(about a leading healthcare economy) of the British government about the superiority of 
the NHS.   
 
                                                 
592
 World Health Organisation (2002), “WHO Mortality Data Base”. Retrieved 1 October 2002, from: http://www.who.org 
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There is speculation about the precise causes of these lags. The most common propositions 
all indicate shortcomings in the operations of the NHS: problems such as a variation in the 
provision of services across the country, under investment in specialists and equipment and 
a failure to modernise are blamed for Britain’s relatively poor prognosis593. Hence, there is 
considerable evidence, summarised most recently in the UK Treasury’s ‘Walness Report’, 
that health outcomes in the UK lag behind those in other advanced industrialised 
countries594, and this evidence had facilitated the Treasury’s decision to increase NHS 
expenditure595.   
 
Concurrently, the NHS could be complimented for its policies on mammography. The 
English screening framework falls within the consensus of efficient screening practices: 
the age range (50 to 69 years of age), the frequency of screening (every three years), and 
mammography methods are considered acceptable to women596. However it is important to 
recognise the debate about the efficacy of breast cancer screening. Some have claimed that, 
“the effect of the screening programme is small, if any, and the balance between beneficial 
(saved lives) and harmful (over diagnosis and false positive diagnosis due to carcinoma in 
situ) effects is delicate”597. Others have highlighted that, given the uncertainty about the 
effects of screening funds may be better investing in developing Calman-Hine proposals 
for specialist cancer care598. Both of these findings are especially applicable to pre-
menopausal women, but towards the end of the twentieth century some started to consider 
whether these accusations are applicable to all women. The bottom line for the thesis is 
that it is not possible to conclude on the precise value of breast cancer screening here, but 
government provision of mammography provided women with an option for screening. 
 
The government’s biggest contribution to the alleviation of the standard of living burden of 
cancer came through their commitment to a better understanding of the disease (both 
through their sponsorship of a wide variety of working parties and also through their public 
awareness and target initiatives). The provisions provided by the National Health Service 
Act 1948, facilitated increasingly improved cancer treatment for the population. Finally, 
the strategic approach provided in the ‘Health of the Nation’ 1992 legislation indicates that 
the government had recognised that, although life expectancy had improved, individuals 
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 Government Papers, “The NHS Cancer Plan, A Plan for Investment, A Plan for Reform” 
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were still dying prematurely and having their quality of life impaired by potentially 
avoidable ill-health599. ‘The NHS Cancer Plan 2000’ marked an increase in the 
government’s commitment to cancer care, which had previously been lacking. However, 
the policies and initiatives introduced by the government in the last years of the twentieth 
century indicate that the government was still failing to reach its potential, especially given 
the various retardations in the introduction of genuinely effective and helpful legislation 
for cancer sufferers. 
 
6.4.2 Charities 
Another important medium for generating improvements in the population’s quality of life 
related to cancer was provided by the initiatives of cancer charities, which were especially 
pertinent as a result of the NHS shortcomings. Increasingly throughout the twentieth 
century there has been a growth in the number and diversity of such support mechanisms.  
 
The largest in England (and Europe) was the Imperial Cancer Research Fund, which was 
established in 1902 and, throughout the twentieth century was prominent and active in a 
variety of arenas, all aimed at improving the quality of life for cancer sufferers600. The 
objectives of the Imperial Cancer Research Fund, which have been maintained throughout 
the twentieth century, highlight this601: 
1. To provide, extend and equip and maintain laboratories to be devoted to 
cancer research. 
2. To encourage research on the subject of cancer in the UK or in the British 
Dominions beyond the seas. 
3. To assist in the development of cancer research in various hospitals and 
institutions approved by the executive committee. 
4. And, generally to provide means for systematic investigations into the 
causes, prevention, and treatment of cancer. 
 
Therefore, the key contributions of the Cancer Research Fund and numerous other cancer 
charities have been the following.  
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 Department of Health, “The Health of Nations” 
600
 This was then renamed the Imperial Cancer Research Fund in 1904. This organisation split into the British Empire Cancer Campaign for Research (BECC) 
and The Imperial Cancer Research Fund in 1923. In 1970 the BECC was renamed The Cancer Research Campaign. During the next 30 years these two 
fundamental charities worked in close collaboration and their cooperation culminated in 2002 when they merged and became Cancer Research UK. Cancer 
Research UK (2003) “History of Cancer Research”. Retrieved 21 November 2003, from: www.cancerresearchuk.org 
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To conduct research into the biology and causes of cancer: it is through efforts of this 
nature that many important breakthroughs have occurred. For example, the discovery of 
the BRCA1 gene was partially dependent upon charity funding from the UK’s ‘Cancer 
Research Campaign’602.  
 
To provide authoritative information about findings from their research: many cancer 
charities provide the public, government, commercial organisations and those responsible 
for cancer care with their research results. This is best highlighted by campaigns aimed at 
eliminating smoking in an effort to reduce lung cancer. These findings are also valuable for 
their potential to improve treatment and prevention strategies which can be implemented 
by governments and physicians.  
 
Although, it could be argued that cancer charities were too conformist with the government 
rather than campaigning more heavily for early cancer legislation and perhaps a stronger 
emphasis on preventative initiatives. Hence, another criticism of cancer charities is that 
they should have concentrated more on preventative initiatives.  
 
Through developing effective treatments that can improve the quality of life for cancer 
patients: research that is conducted by cancer charities is aimed at improving cancer cure 
rates and ultimately translating knowledge about this disease into effective treatments. 
Research is also directed towards improving the identification and diagnosis of cancer. 
This is best illustrated through the continual discoveries and implementation of screening 
for breast cancer. Hence, the demonstration in the 1980s of the efficacy of mammography 
in reducing mortality from breast cancer by twenty five to thirty percent led to the adoption 
of guidelines in a number of countries, including England, to introduce routine screening 
on a population basis603. Furthermore, many charities – initiated by the introduction of the 
UK National Society for Cancer Relief in 1911 – provide research into life prolonging 
medication and emotional support in an effort to ensure that for those patients whose 
disease cannot be cured, their quality of life is somewhat improved604.  
 
Cancer charities have continually developed throughout the twentieth century to remain on 
the leading edge of cancer research and provide a key support mechanism for the 
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government, doctors and patients. This dynamism has meant that charities are often the 
change agents and improvement implementers, which provides an example for the 
government and the most valuable support for cancer sufferers. However, it would seem 
that the approach of cancer charities was generally complimentary to government policy 
rather than substitutive and therefore it can be argued that cancer charities did not manage 
to initiate change or policy responses. 
 
Cancer charities have played a crucial role in helping to improve the quality of life of the 
English population during the twentieth century, through providing diagnosis and 
treatment innovations, identifying lifestyle risks, providing guidelines and encouraging the 
government and doctors about the ideal codes of conduct. Additionally, the provision of 
information and condolence for individuals and families that have been affected by cancer 
has also contributed to improving the quality of life of cancer sufferers. However, a 
drawback is likely to have been that there were inequalities in these provisions. Gerard 
among others claims that for all charities, the rich receive as much as the poor and perhaps 
more convincingly, that the educated population enjoyed considerably higher levels of 
charity help605. This implies that to some extent there were inequalities in charity which 
indicates a setback in charity provision. An example of how this is manifest would be in 
the understanding and embracing of cancer prevention campaigns, e.g. anti smoking 
campaigns, which seem to have been more effective on richer social classes.  
 
6.5 Medical Developments 
The twentieth century provided some of the most far reaching developments in medical 
technology, many of which provided a substantial improvement in the understanding and 
treatment of cancer. When analysing medical developments and the impact they had upon 
the quality of life of breast and stomach cancer sufferers there are four key areas to 
consider: screening and scanning, radiotherapy, surgery, chemotherapy and hormone 
treatment. It will also be necessary to consider environmental factors606 as changes in this 
broad category have provided many boosts to the welfare of cancer patients, both 
independently and synergistically with medical developments.  
 
                                                 
605
 Gerard, “Charities in Britain: Conservatism or Change?”, p. 21 
606
‘Environmental’ is used here in the widest sense, encompassing all those external influences impinging on an individual organism. 
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6.5.1 Screening and Scanning 
“The surgical revolution that occurred during the twentieth century, which has enabled 
this 100 years of medical innovation to be coined ‘The Golden Age of Surgery’, would 
have been impossible without all manner of technological innovations that aid surgery”607. 
The breakthrough of greatest significance for the treatment of cancer (beyond surgical 
removal of tumours) was the discovery of X-rays608. Even in their most primitive form X-
rays provided an indication of the presence of cancer, which enabled surgical removal of 
the cancer.  
 
A further contribution of x-rays was the foundation they provided for more sophisticated 
visual diagnostics. In 1972 Hounsfield pioneered a system whereby x-ray beams could be 
resolved with computer assistance to produce a cross-sectional picture of the human body. 
The result – computer-assisted axial tomography (CAT) was a major breakthrough in the 
non-invasive diagnosis of disease, which provided an important contribution to the 
diagnosis and prognosis of cancer609. The development of magnetic resonance imagery 
(MRI), which is specifically useful for the detection of abnormalities in the soft tissue of 
the body, has also provided a boon to the identification, treatment and outcome of many 
cancers610. As a result of increasingly precise mechanisms for identifying tumours, the 
potential of successfully removing cancerous tumours before they became large and 
metastasised was improved with modern x-ray techniques, facilitated by the development 
and introduction of the CAT and MRI scans.  
 
Modern x-ray techniques have also helped improve cancer prognosis through improved 
and frequent screening. In 1967 mammography for detecting breast cancer was introduced, 
and provided a much more efficient approach to the identification of cancerous tumours611. 
By the end of the twentieth century nearly all females between the ages of 50 and 69 were 
being screened for breast cancer on a triennial basis. For example, between March 1991 
and April 1992, 71.3 percent of women aged 50 to 64 accepted screening612. This exceeds 
the target of a seventy percent acceptance rate and is considered to be extremely 
satisfactory613.  
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A final contribution of the introduction of X-rays was the discovery of the effects of 
radioactivity upon cell destruction and ultimately radiotherapy.  
 
6.5.2 Radiotherapy 
By 1900, through the work of radium institutes (the London Radium Institute was founded 
in 1911, and numerous regional branches were developed soon after614), radiology journals 
and societies, there were more than a hundred diseases for which the new miracle cures 
had been used, although it was for cancer that the new therapies seemed to promise the 
most615. By the 1920s many surgeons were adopting radium therapy as a substitute or an 
adjunct to surgery616. In 1929 radium therapy was officially introduced in the UK as a 
cancer therapy and the National Radium Trust and Radium Commission were 
established617. By 1937 the Ministry of Health had drafted implementation policies for 
radiotherapeutic departments in general hospitals nationwide618. These developments were 
further fostered by the 1948 NHS Act, as this provided the initiatives and funds necessary 
to install hospitals with the necessary equipment and increase the number of centres 
providing treatment619.  
 
Despite the improvements in quality of life that these preliminary developments in radium 
therapy were yielding, the initial enthusiasm for radium therapy was largely uncritical and 
exposed patients, doctors and technicians to heavy doses of radiation, with results that 
were disastrous to many, most notoriously, Marie Curie620. This situation detracted from 
the overall contribution to improved standards of living provided by the introduction of 
radium therapy, as did the shortcomings in the NHS radiology provision objectives, which 
meant that, at no point in the twentieth century was radiotherapy care universally and 
equally accessible to the English population. 
 
A more comprehensive improvement in quality of life was facilitated by radiation in the 
post World War Two era. Technological advances (driven by a better understanding about 
the process and dangers of radiation) during this time resulted in the replacement of radium 
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therapy by more precise and effective radiation therapy621. Since this time there have been 
continual innovations in the methods of utilising radiation for the treatment of cancer, such 
that by the close of the twentieth century this provided an important complement to 
surgery. 
 
The ability to use a combination of complementary approaches improved the survival 
prospect of many breast cancer patients. The benefits of radiotherapy are more pronounced 
in many stomach cancer cases. Because of the nature of stomach cancer, the mild 
symptoms and long gestation period until the disease has progressed into an advanced 
stage means that many are faced with harrowing surgery needs, for example, a total 
gastrectomy or worse still, the inability of their cancer to be cured by surgery. Radiation 
therapy has provided a viable option for those sufferers who, during the twentieth century 
were faced with the aforementioned predicaments. Hence, in many instances of stomach 
cancer radiation therapy has prolonged the life of sufferers. Although this therapy does not 
provide a cure for stomach cancer it does provide a slight retardation to the cancer process, 
which albeit small is an improvement in the quality of life for sufferers of this disease. 
 
6.5.3 Surgery 
Cancer surgery was introduced in the 1880s. By the turn of the century there had been 
many extensions and improvements in technique, but it rarely yielded a cure for cancer622. 
This is because by the time the tumour had become identifiable (through primitive forms of 
diagnosis) the cancer had already advanced (metastasised)623.  
 
For the first half of the twentieth century breast cancer surgery was drastically destructive. 
Radical mastectomies were commonplace treatment for breast cancer from the 1890s until 
they began to be questioned in the 1960s. This procedure involved the surgical removal of 
the breast, all the lymph glands in the nearest armpit and the chest wall muscles, and 
ultimately the complete disfiguration of female breast cancer sufferers624. A further blow to 
quality of life was the non existence of any type of counselling for this disfiguration and 
the lack of life saving success yielded by this technique.       
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In 1964 these draconian methods started to be questioned. The first scientific study of 
breast-sparing surgery was begun at Guy’s Hospital in London. This study compared 
tumour excision plus low dose radiotherapy with radical mastectomy625. This particular 
study did not achieve sufficiently powerful results to overturn the then current medical 
practices and mainstream beliefs about the superiority of radical mastectomies. However, 
the dispute continued and escalated, such that by the 1970s the treatment of breast cancer 
was one of the most argued subjects in medicine626. For example, a 1972 editorial in the 
British Medical Journal stated that “there is more controversy about the management of 
breast cancer than almost any other topic in tumour therapy, and more so now than ever 
before”627. 
 
By the 1980s it had been affirmed that breast conserving surgery worked and that it was 
just as effective as radical surgery in the treatment of breast cancer628. By the 1990s only 
39 percent (approximately) of consultant surgeons would perform a radical mastectomy629. 
This development provided the largest single improvement in quality of life for twentieth 
century breast cancer sufferers. Additionally the increased utilisation of adjuvant therapy 
(i.e. conservative breast surgery complemented by chemotherapy, hormone therapy or 
radiotherapy) and the improvement in survival it facilitated consolidated this leap forward 
in standards of living. 
 
The twentieth century history of stomach cancer provides a comparatively mundane and 
unsuccessful contrast. By the beginning of the century operations for the removal of 
stomach tumours had been introduced. These surgical interventions became increasingly 
sophisticated by the continual developments in the field of medicine630. For example, the 
ability to be more precise reduced the amount of stomach that had to be removed due to 
cancer. Furthermore, developments in radiotherapy and chemotherapy meant that it was 
sometimes possible to reduce the size of a tumour before surgery and consequently 
diminish the loss631. These advances in medical techniques would have provided small 
improvements in the quality of life of stomach cancer sufferers throughout the twentieth 
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century, although the magnitude of improvement was still rather minimal by the close of 
the twentieth century. 
 
6.5.4 Chemotherapy and Hormone Treatment 
In the explosion of biochemical and pharmaceutical research which followed the Second 
World War, drugs were discovered that relieved a multitude of ailments632. The biggest 
contribution to cancer chemotherapy was the discovery that substances called nitrogen 
mustards selectively kill a particular type of cancerous cell633. This provided the 
foundation for a continued improvement in the sophistication of cancer chemotherapy, 
although cancer chemotherapy drugs were largely palliative and consequently, the 
contribution of chemotherapy to improved quality of life has experienced diminishing 
marginal improvements since the initial revolutionary introduction of this therapy in 
1960634. 
 
Around the middle of the twentieth century the potential for hormone therapy to treat 
cancer was discovered635. Hormone therapies became increasingly used as adjuvant 
therapies for early stage breast cancer and provided a valuable alternative to chemotherapy 
(in older women [usually aged 50+] who have the type of breast cancer that is responsive 
to oestrogen blocking drugs – oestrogen receptor positive tumours)636.  
 
The scope of hormone therapy was consolidated with improvements in hormone drugs, 
particularly the breakthrough provided by Tamoxifen. This drug was introduced in the 
early 1970s and over the proceeding thirty years increasingly became the endocrine 
treatment of choice in breast cancer (especially during the 1990s when the risk-reducing 
benefits of Tamoxifen were unequivocally demonstrated)637. Tamoxifen has undoubtedly 
been one of the greatest success stories in the pharmacological management of breast 
cancer and has consequently provided many valuable improvements in quality of life for 
post menopausal, early stage, oestrogen receptor positive breast cancer638.  
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Furthermore, during the last years of the twentieth century initial discoveries were being 
made, such as Goserelin, which signified the birth of a new generation of hormone drugs 
that will eventually add new vitality and diversity to the search for an improved endocrine 
therapy for early breast cancer639.  
 
The reduction in breast cancer mortality, which has been evident during the last fifteen 
years of the twentieth century in England, is partly attributable to the widespread adoption 
of adjuvant, systematic treatment, which includes hormone therapies, such as 
Tamoxifen640. Certain studies have attributed these treatments to a reduction in mortality of 
between 12.2 and 14.9 percent by the end of the twentieth century641. Hence, hormone 
therapies have provided a significant improvement towards quality of life for late twentieth 
century breast cancer patients, both through saving life years and through improving the 
general health of many females who have been living with breast cancer. 
 
6.5.5 Environmental Factors 
By the year 2000 it was thought that up to a third of all cancer deaths were related to 
dietary factors642. Knowledge about the potential influence of environmental factors 
became increasingly prominent as the century unfolded and the cure for cancer persisted to 
elude modern medicine. Environmental factors resemble potential preventions for cancer, 
which, at the close of the twentieth century, remained the most promising mechanism for 
superseding cancer.  
 
Many authors have emphasised the importance of dietary factors in the prevention of 
cancer, especially stomach cancer. For example, dietary factors which are related to 
improvements in food storage and handling are thought to be the leading catalysts for the 
worldwide reductions in stomach cancer mortality643. Conversely, the increase in breast 
cancer has often been partially attributed to increased fat consumption644. The culmination 
of these discoveries meant that, by the end of the twentieth century, environmental factors 
featured as one of the key strategies in the British government’s battle against cancer. For 
example, ‘The NHS Cancer Plan 2000’ five-a-day programme and continued initiatives to 
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reduce smoking645. As a result of twentieth century economic and technological advances, 
this type of diet (high in fruit, vegetables and fibre, and low in fat, sugar and salt) has 
become increasingly achievable. 
 
An additional environmental harm that has received increased awareness during the 
twentieth century is industrial/ work related carcinogens. Some of these cancers are now so 
well established that they are designated as ‘prescribed diseases’ entitling the victim to 
possible compensation646, e.g. skin cancer from employment in soot, tar and mineral oil 
industries647.  
 
Despite the developments in recognising these potentially harmful environmental factors, 
progress to reduce these adverse factors had been slow in twentieth century England. There 
were very few organisations that represented the broader public interest and lobbied the 
government accordingly. This marks a contrast with other developed countries, for 
example, America, where environmental and consumer lobbies are larger, more broadly 
based and have formed better alliances with trade unions, which have been able to use their 
power to achieve more protection from these environmental externalities648.  
 
Finally, during the twentieth century it has become increasingly recognised that the general 
environment is a potential source of carcinogens. I.e. that people are not only potentially at 
risk from their occupations and the commodities they consume but also from the air they 
breathe and the water they drink. This is best illustrated by the marked difference between 
higher urban and lower rural rates of cancer in England during the twentieth century649.  
 
Improvement in environmental factors provided an ebb in cancer, but not a cure. Because 
of the perceived trade-offs (in the short term in order to reduce long term risk) and the 
inability of many to change their circumstances (largely the most deprived who are faced 
with an excess cancer risk as a result of the aforementioned environmental factors) a better 
understanding of environmental factors was not able to provide any kind of cure for the 
twentieth century English population.  
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6.6 Lack of Progress Considerations 
Despite the research and funding that has been dedicated to cancer (cures, screening, 
diagnosis, treatment) the returns have been scanty. For example, the prognosis and quality 
of life faced by stomach cancer sufferers was still poor at the end of the twentieth century. 
The outlook was more favourable for breast cancer sufferers. However, breast cancer is the 
most heavily funded and researched cancer and therefore, in this respect the outcome is 
still relatively meagre compared to the investments towards curing this disease. 
Nevertheless, the quality of life for breast cancer sufferers has improved favourably during 
the twentieth century and the breakthroughs in ‘prevention’ and treatment for breast cancer 
are commendable. This marks a stark contrast with stomach cancer. The key frustration for 
stomach cancer improvements is that there is no mechanism for early identification of the 
disease. Furthermore, because stomach cancers engulf a major bodily organ there are few 
options for remedy at a late stage. These are the reasons why quality of life improvements 
have not been more pronounced for stomach cancer during the twentieth century. 
 
Health providers, charities and governments ought to be commended for their efforts 
towards trying to improve the standards of living of cancer sufferers. Their efforts during 
the twentieth century, increasingly as the century unfolded provided many valuable 
improvements in the quality of life associated with stomach and particularly breast cancer. 
The main drawback was that despite substantial investments, the benefits that they yielded 
were very low. This was largely a result of the complicated and poorly understood nature 
of cancer throughout the twentieth century and numerous weaknesses in the functioning of 
the NHS, which have been detailed above. A final factor that could have been improved, 
and would subsequently have improved the overall prognosis from breast and stomach 
cancer, were the socioeconomic inequalities in health that persisted and increased during 
the twentieth century.  
 
Sigerist (1956) stated that “in any given society the incidence of illness is largely 
determined by economic factors” and that “the problem of public health is ultimately 
political”650. Despite the introduction of the NHS in 1948, socioeconomic mortality [and 
morbidity] differences have persisted and often increased. E.g. for the ten most common 
cancers (including breast and stomach), Schrijvers (1995) identified much better five-year 
survival rates for affluent patients651. Tomatis (1995) went as far as claiming that “the total 
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incidence of cancer at all sites is greater in lower socioeconomic groups”652. Kogevinas et 
al (1991) found that both male and female council tenants had significantly worse survival 
than owner-occupiers653. Moreover, other studies have found that this inequality is 
exacerbated for cancers with poor prognosis (e.g. stomach cancer), as these are more 
prevalent in the lower socioeconomic groups654.  
 
These social class inequalities are not an English phenomenon and are evident in other, 
comparable countries. However the extent of the social class inequality seems to be more 
severe in the UK655. The twentieth century evolution in social class inequality adds a 
further blow to NHS progress.  
 
The breast cancer social class gradient was consistently in favour of the professional 
classes, whereby their five years survival rate was higher than their social class V 
counterparts. Stomach cancer illustrates a different trend: the survival rate was equal across 
all social classes, but was marginally more favourable for lower classes, i.e. social class V, 
in the 1970s and probably earlier. This margin was eliminated by the later years of the 
twentieth century (the 1980s), when the higher social classes, e.g. social class I, were 
enjoying equal or marginally greater years of survival. A noteworthy point to recognise for 
stomach cancer, when evaluating the social class mortality gradient, is the prevalence of 
stomach cancer in social class V, which was significantly higher than for social class I. The 
social class survival rates for breast and stomach cancer are shown in the table below. 
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Table 6.6: Five year survival rate for breast and stomach cancer by social class (I to V), 
1971-1990 (%)656 
 1971-1975 1976-1980 1981-1985 1986-1990 
Social Class I II III IV V I II III IV V I II III IV V I II III IV V 
Breast 
Cancer 
52 49 47 45 42 57 54 51 50 47 60 56 54 52 49 63 60 59 56 53 
Stomach 
Cancer 
4 4 4 4 5 5 5 5 5 5 8 7 6 6 7 8 8 7 7 8 
 
Table 6.6 highlights a clear social class gradient for survival from breast cancer, which was 
consistently about 10 percent more favourable for the top social class versus the lowest. 
This relationship was not evident for stomach cancer, where there are marginal differences 
between the survival rates across the social classes. Table 6.6 also highlights that very few 
sufferers survive stomach cancer. This point is particularly important when the prevalence 
of stomach cancer by social class is considered, whereby stomach cancer is more prevalent 
in the lower social classes. Therefore, there is some form of a social class gradient for 
stomach cancer, which is not highlighted above but will be illustrated in the Figures below, 
which represent the standardised mortality rate for stomach cancer (and indicates the 
greater prevalence of this disease in lower social classes). The standardised mortality rate 
considers the level of mortality relative to the population. For males and females there was 
generally more stomach cancer deaths in social class V than I and hence there is a vivid 
social class gradient for stomach cancer mortality.  
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Figure 6.12: Stomach cancer standardised mortality rate (SMR) by social class, males, 
1911-1971657. 
Male Stomach Cancer Social Class SMR 1911-1971
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With the exception of 1911 (where stomach cancer mortality was higher in social classes II 
and III than IV), there is an ordinal and increasingly substantial social class gradient 
associated with stomach cancer in English males. The social class gradient increased 
throughout the period largely as a result of the decline in stomach cancer between 1931 
and 1971 in social classes I and II in conjunction with the increase in social classes III to 
V.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
657
 Logan, “Cancer Mortality by Occupation and Social Class 1851-1971”, p. 30 
Illnesses: Cancer 
                                                                                                                                                                                                                          - 228 - 
Figure 6.13: Stomach cancer standardised mortality rate (SMR) by social class, females, 
1931-1971658 
Female Stomach Cancer Social Class SMR 1931-1971
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The relationship for female stomach cancer mortality is not as clear as that for males. This 
is largely due to the anomaly of 1951 mortality in social class I (for which there is no 
obvious explanation) and also because mortality was greater in social classes I than II in 
1971.  The data used for the above table is somewhat hybrid (1931 considers only married 
women, 1951 considers only single women and 1971 contains an average of both) and this 
may be the cause of the anomalies. However there is still an evident general trend of an 
increasing social class female stomach cancer mortality gradient.  
 
The causes of this socioeconomic cancer gradient are not as pronounced as the social 
inequalities themselves. This is because of the difficulty in measuring different social 
classes and also because of the incomplete knowledge of cancer causes, which was still 
limited at the end of the twentieth century. However, there is a general consensus in the 
literature about the most likely causes of the gradient, which are summarised in Table 6.7. 
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Table 6.7: Summary of major studies and their findings about the cause of social 
inequalities in cancer survival659 
Study Key findings 
Gillis & Hole 
(1996) 
• There is a substantial survival benefit for patients cared for by a 
specialist. 
• Specialist care is more commonly received by higher social classes. 
 
Kogevinas 
(1991) 
• Differences in treatment. 
• Time of diagnosis. 
• Stage at presentation: delay in seeking treatment in lower social 
classes is a major contributing cause of the gradient. 
• Poor host resistance among the deprived. 
 
Linden 
(1996) 
• Stage at diagnosis. 
 
Richards et al 
(1997) 
• Variations in the management of breast cancer in clinics and hospitals 
and in surgical standards, whereby the affluent receive better quality 
treatment. 
 
Schrijvers et al 
(1995) 
• Poor host resistance among the deprived (co-morbidity, adverse 
nutritional status, poor social support, likelihood of anxiety and 
depression due to cancer, are all more severe in deprived classes). 
 
Wells & Horm 
(1992) 
• Stage at diagnosis strongly influences cancer survival. Women of 
lower socioeconomic status are more likely to be diagnosed with 
breast cancer at a later stage. 
 
Later stage at diagnosis, poorer host resistance (related to nutritional and health status) and 
a variation in cancer treatment were largely responsible for the socioeconomic cancer 
gradient at the end of the twentieth century, when social inequalities in cancer became a 
major public health issue. The variation in quality and provision of cancer care (as a result 
of NHS weaknesses) is a key factor when considering England’s lag behind other 
comparable, developed countries660.  
 
It should be noted that the lack of improvement in the quality of life associated with cancer 
during the twentieth century could partially be a result of non-health and welfare related 
factors. Firstly, the ageing of the population as a result of the nature of degenerative 
diseases, which has meant that people are living longer and are therefore, increasing the 
scope for developing cancer, as a result of the nature of degenerative diseases. Or, as Davis 
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et al (1990) have claimed “because the elderly have had more opportunity for exposure to 
carcinogens in their lifetime”661.  
 
Therefore, although the problems associated with cancer could have been more 
comprehensively remedied by the government, there are aspects of this disease that 
continue to frustrate all of those involved in the fight against it. The key problem is the 
failure in finding a cure and understanding this disease more comprehensively. And the 
nature of the ageing of the population has also exacerbated the twentieth century burden of 
cancer. 
 
6.7 Summary 
The above analysis has highlighted that the standards of living associated with breast and 
stomach cancer improved over the twentieth century, although to a lesser extent for 
stomach cancer. These advances are important as quality of life improved from a ‘poor’ 
level in 1900 to a ‘good’ level for breast cancer and a ‘fair’ level for stomach cancer by the 
year 2000.  
 
The prevalence of breast cancer increased considerably during the twentieth century, while 
it declined for stomach cancer. This worsening situation was aided by the improvement in 
the age distribution and also survival prospects of these diseases (although less so for 
stomach cancer). Furthermore, enhancements in the quality of life experienced by sufferers 
of stomach and breast cancer have also helped to relieve the aggregate burden of these 
diseases upon overall standards of living. 
 
Medical developments, increased medical practitioner skills, improvements in the 
interaction and understanding of environmental factors, government initiatives and the 
work of charities all played key roles in initiating these quality of life improvements.  
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PART III 
This part of the thesis reports the results, which are derived from the previous analysis. 
Chapter 7 will also provide the conversion of the previous qualitative analysis to quantitative 
summary results.  
 
The first stage of these results will concentrate on the construction of a ‘quality adjusted life 
year’ (QALY) measure from the previous qualitative analysis. The QALY that is derived 
below is the result of an original process, which was necessary because of the central 
questions of the thesis (i.e. the historical health and welfare quality of life of sufferers had to 
be approximated). The best solution was to consider the historical health and welfare quality 
of life in detail, for a sample of illnesses. The next stage was to apply a mechanism that 
transformed this detailed qualitative analysis into a series of quantitative indices. This was 
achieved through applying the EuroQol standardised spectrum of development to all the key 
quality of life features (see Chapter 3: Tables 3.5, 3.6 and 3.7 for an outline of the key 
EuroQol variables) in the qualitative analysis. This yielded a series of results (or EuroQol 
ranks which can be converted into QALY indices) about the quality of life for different 
illnesses, eras and aspects of health and welfare standards of living, which are comparable 
across all illnesses and eras. The justification for utilising this approach and a more detailed 
explanation about the construction of this methodology (i.e. the conversion of the qualitative 
analysis into a quantitative QALY index through applying EuroQol) is provided in Chapter 3: 
3.5 QALY Estimating Process and 3.6 QALY Value Accreditation. 
 
Hence, the QALY in this thesis (which represents the quantitative index) will be based upon 
the previous qualitative analysis. This information will be transformed from qualitative into 
quantitative through the thesis consistently (for all illnesses and eras in the thesis) gauging the 
qualitative results on the EuroQol spectrum. The EuroQol results (or ranks) will then be 
evolved into QALY weights. The range of EuroQol ranks (and how they translate into 
associated QALY weights) is shown below.  
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Table 7.1: EuroQol standardised spectrum and ranks and corresponding QALY values 
EuroQol standardised spectrum EuroQol Rank Corresponding QALY value 
Complete quality of life 1 1 
Good quality of life 2 0.8333 
Fair quality of life 3 0.6667 
Some quality of life 4 0.5000 
Poor quality of life 5 0.3333 
No quality of life 6 0.1667 
 
The QALY results in Table 7.1 are achieved through converting EuroQol ranks into QALY 
ranks. On EuroQol there are 6 possible values between 1 and 6: 1, 2, 3, 4, 5, or 6. For the 
QALY there are 6 possible values between 0 and 1: 1, 0.8333, 0.6667, 0.5, 0.3333, 0.1667. 
These QALY rank are equivalent to their respective EuroQol rank, but expressed on a 
different scale. 
 
This exercise provides one of the thesis’ key contributions to knowledge. Hence, the QALY is 
crucial for making quantitative considerations about health improvements which is facilitated 
by applying the EuroQol standardised spectrum of development to the qualitative analysis of 
all illnesses in all eras in the thesis.  
  
Hence, the key value of developing and utilising a standardised spectrum, namely EuroQol, is 
so that the twentieth century developments in quality of life (documented in Part II of the 
thesis) can be converted into QALYs, so that morbidity can be included in an extended 
(quantitative) willingness to pay (or QALE) model, which includes mortality as well as 
morbidity (which is comparable across all illnesses and era). This process will be utilised (in 
Chapter 7 and 8) in order provide quantitative answers to the major questions of the thesis: to 
what extent have improvements in mortality and morbidity improved quality of life and 
contributed to better standards of living and economic growth in twentieth century England? 
And, how valuable (in monetary terms) are the improvements in quality adjusted life 
expectancy (QALE gains)?  
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The development and implementation of this new approach to measuring health (mortality and 
morbidity), both the qualitative and quantitative aspects of historical health and welfare related 
quality of life, will enable the thesis to provide robust estimates about the contribution of 
improved health to standards of living, which will provide an original contribution to the 
existing literature. Furthermore, these considerations and the results that the QALE 
methodology will yield represent a more precise health measurement methodology in 
adherence to the criteria mentioned in earlier sections of the thesis (see ‘Representational 
Measurement’ in Chapter 2.2.7) and a more comprehensive ‘Fisherian’ measure of twentieth 
century English economic development (explained under the rationale of ‘Willingness to Pay’ 
in Chapter 3). 
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7. Qualitative Findings: EuroQol Summary and Quantitative (QALY) Transition 
The following chapter will consolidate the findings of Part II through providing the EuroQol 
summary of these results, which can then provide overall health and welfare associated quality 
of life (QALY) approximations. This chapter will summarise the evolution of the quality of 
life associated with blindness, tuberculosis and cancer during the twentieth century, both 
qualitatively and quantitatively by presenting the range of EuroQol scores and the associated 
QALY. This will provide a verbal and numerical answer to the key underlying question of the 
chapter: what was the overall quality of life for sufferers (in the years 1900, 1925, 1950, 1975 
and 2000)?  
 
This will provide the EuroQol standardised comparative analysis – between the government, 
charity, medical developments, pain and discomfort, and ability to lead a normal life variables 
– of the developments that were made for blindness, tuberculosis and cancer quality of life, 
which are used to construct a corresponding QALY index.  
 
The EuroQol and subsequent QALY values that are presented here represent what the author 
deems to be the most appropriate value, from a conservative standpoint (this is best 
highlighted by the QALY result comparison in Chapter 3: Table 3.9). The QALY values 
outlined here pertain to the ‘Mid’ values utilised in later stages of the quantitative analysis. 
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7.1 Blindness 
7.1.1 Twentieth Century Qualitative Results        235 
 
7.1.1 Twentieth Century Qualitative Results 
The table below provides a summary of the EuroQol rank results for the quality of life variables 
(see Chapter 3: Table 3.5 and 3.7 for a detailed explanation of these variables), for blindness in the 
key eras of the twentieth century considered in the thesis.  
Table 7.1.1: EuroQol results for blindness and EuroQol aggregate average conversion into QALY 
Blind: EuroQol Variable Blind: EuroQol Score and Equivalent QALY 
 1900 1925 1950 1975 2000 
Government initiatives and help 6 3 3 3 3 
Recognition/ awareness 5 3 3 3 2 
Health developments 6 5 3 2 2 
Status 5 4 3 3 3 
Ability to lead a normal life 5 4 3 3 3 
Aggregate Average EuroQol Score 
Equivalent QALY 
5  
0.3333 
4  
0.5000 
3  
0.6667 
3  
0.6667 
3  
0.6667 
Note: In Table 7.1.1 the aggregate average is calculated as the average score (to the nearest whole number) of the key 
variables: government initiatives and help, recognition/ awareness, health developments, status, ability to lead a 
normal life. Ability to lead a normal life variable score is calculated as the average of the sub-variables in this 
category, which are presented below in Table 7.1.2. For the definitional interpretation of the EuroQol ranks shown in 
Table 7.1.1 see Table 7.1, above. 
 
Table 7.1.1 illustrates that, in 1900 there was ‘no’ quality of life (EuroQol rank = 6) facilitated for 
the blind by ‘government initiatives and help’. When the Blind Persons Act was introduced in 
1920 government aid improved considerably and the blind population experienced ‘fair’ quality of 
life (EuroQol rank = 3) related to government help. However this state of legal recognition and 
help did not improve enough between 1925 and 2000 to move the blind to a higher indifference 
curve (i.e. an extra mark on the spectrum). There were numerous Acts designed to help the blind, 
which were seemingly very comprehensive, but none of these were effective enough to become 
more far reaching than the 1920 Blind Persons Act. This meant that the standards of living for the 
blind were only partially improved by government legislation: from ‘no’ to ‘fair’ quality of life 
during the twentieth century. 
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After the introduction of the 1920 Blind Persons Act the blind experienced a considerable 
improvement in their levels of ‘recognition’ (from ‘poor’ quality of life to ‘fair’ quality of life). 
During the last decade of the twentieth century a stream of legislation pertaining to equal rights 
helped change the perception of the disabled and improved recognition of the blind, such that by 
the year 2000 the blind were experiencing ‘good’ quality of life regarding their levels of 
recognition (shown in Table 7.1.1 as a EuroQol rank of 2 in 2000, for ‘recognition /awareness’).  
 
The introduction of the 1920 Blind Persons Act meant that by 1925 the blind were experiencing 
‘some’ quality of life in their ‘status’ compared to ‘poor’ quality of life which was previously the 
case. By 1950 the blind had achieved ‘fair’ quality of life regarding their standing, largely as a 
result of the improvement in employment opportunities (discussed below). Finally, although there 
were numerous government Acts which extended the achievements of the 1920 Blind Persons Act 
(especially during the 1990s) these attempts at improving the status of the blind population were 
largely unsuccessful, as the blind status did not improve beyond the 1950 level of ‘fair’ quality of 
life for 1950-2000.  
 
The state of ‘health developments’ at the start of the twentieth century contained no prevention or 
provisions for treatment of blindness (‘no’ quality of life). Increased awareness about infectious 
diseases causing blindness, the introduction of safe and effective treatment, and improvements in 
the prevention of blindness facilitated ‘fair’ quality of life for blind health by 1950. These 
breakthroughs and developments were enhanced during the last quarter of the twentieth century 
through further technological developments, e.g. cataract surgery, so that by 2000 the blind were 
enjoying ‘good’ quality of life levels of prevention and treatment of blindness (shown in Table 
7.1.1 as a EuroQol rank of 2 in 2000, for ‘health developments’).  
 
The value of the improvements in these (prevention and treatment of blindness) ‘health 
developments’ are best illustrated by (approximations about) the increasing average age of onset of 
blindness: in 1900 16 percent of the blind were over 70, in 1950, 24 percent and by 2000, 69 
percent of the blind population were over the age of 75. Consequently there would seem to be 
much fewer years spent in blindness: in 1900 the average number of years of blindness was about 
16 years versus 11 years in 2000 (this is especially impressive as life expectancy increased by 27 
years between 1900 and 2000). Even though these numbers are approximate, due to the 
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assumptions that had to be made in order to consider the prevalence by age of blindness (see 
Chapter 4), this trends is very important for the welfare of the blind. 
 
The ‘ability to lead a normal life’ also improved for the blind population. This variable comprises: 
employment, wages and education. This breakdown and the associated EuroQol scores are shown 
in the table below. 
Table 7.1.2: EuroQol results for sub-variables in ‘Ability to lead a normal life’ for disability 
Blind: EuroQol Sub-Variables Blind: EuroQol Score 
 1900 1925 1950 1975 2000 
Ability to lead a normal life 5 4 3 3 3 
Employment 6 5 4 4 4 
Wages 5 5 3 3 3 
Education 4 3 3 3 2 
 
The development of help and equality for the blind in the labour market was one of the slowest 
aspects of socio-economic quality of life to improve. Table 7.1.2 highlights that the blind 
experienced ‘no’ quality of life in employment in 1900, and this did not improve to ‘some’ quality 
of life levels until 1950. The developments that occurred between 1950 and 2000 were not far 
reaching enough to improve the blind’s quality of life associated with employment, beyond the 
1950 level of ‘some’ quality of life.  
 
The increase in the blind’s wages provided an important development in equality, such that by 
1950 the blind were experiencing ‘fair’ quality of life in wages. During the last quarter of the 
twentieth century there were no far reaching improvements in equality of wages upon the 1950 
level of ‘fair’ quality of life and this remained the scenario for blind wages for the second half of 
the twentieth century.  
 
Education was one of the most developed and equal areas for blind welfare during the twentieth 
century. Table 7.1.2 highlights that as early as 1900 the blind were enjoying ‘some’ quality of life 
in education. Between 1925 and 1975 blind children in education experienced continual 
improvements, so that during this time they enjoyed ‘fair’ quality of life in the provision and 
standards of blind education. The 1981 Education Act illustrates an initiative to provide improved 
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equality, opportunity and standards for educating the blind, and although this was not overly 
successful, this was still a development that marked an improvement in blind quality of life, which 
meant that by the end of the twentieth century the blind were enjoying ‘good’ quality of life in 
education, even if the result of those in higher education were unsatisfactory.  
 
Therefore, the culmination of these developments (or lack thereof) meant that the ‘aggregate 
average quality of life’ faced by the blind evolved from; ‘poor’ in 1900 to ‘some’ by 1925 and 
peaked at ‘fair’ in 1950 to 2000 (shown in Table 7.1.1).  
 
This final aggregate EuroQol rank for the quality of life associated with blindness can now be 
converted into a QALY value. Table 7.1 provides the translation from EuroQol rank to QALY 
value. For a detailed explanation about the nature and appeal of this process, see Chapter 3: 3.5 
QALY Estimating Process and 3.6 QALY Value Accreditation. 
 
Therefore, Table 7.1.1 highlights that the blind QALY improved from 0.3333 of a healthy life year 
(which is represented as 1) to 0.6667 of a healthy life year. Hence, in 1900 the collection of health 
and welfare standards of living meant that the blind only enjoyed about one third of a healthy life 
year. By the year 2000, improvements in health and welfare enabled the standards of living for the 
blind to improve to about two thirds of a healthy life year. This numerical index will be utilised 
below, in the wider QALE methodology in order to estimate the value of the above improvements 
in the quality of life associated with blindness (shown here, as the improvements in the QALY 
from 0.3333 in 1900 to 0.6667 in 2000). 
 
Finally, although the developments made in the quality of life for the disabled are not as far 
reaching as those experienced by disease sufferers, these improvements are still commendable. 
This will be highlighted in the following chapters of the thesis. 
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The table below provides a summary of the EuroQol rank results for the quality of life 
variables (see Chapter 3: Table 3.5 and 3.7 for a detailed explanation of these variables), for 
tuberculosis for the key eras of the twentieth century considered in the thesis.  
Table 7.2.1: EuroQol results for tuberculosis and EuroQol aggregate average conversion into QALY 
Tuberculosis: EuroQol Variable Tuberculosis: EuroQol Score and Equivalent QALY 
 1900 1925 1950 1975 2000 
Government initiatives and help 5 4 3 3 3 
Recognition/ awareness 4 3 2 3 3 
Health developments 5 5 4 2 2 
Understanding 5 3 2 2 2 
Treatment 5 5 5 2 2 
Cure 6 6 4 1 1 
Pain and discomfort 5 4 3 2 2 
Ability to lead a normal life 5 5 4 1 1 
Financial burden 5 4 3 1 1 
Social difficulties 5 5 4 1 1 
Anxiety/ depression 5 5 4 2 2 
Aggregate Average EuroQol Score 
Equivalent QALY 
5  
0.3333 
4  
0.5000 
3  
0.6667 
2  
0.8333 
2  
0.8333 
Note: In Table 7.2.1 the aggregate average is calculated as the average score (to the nearest whole number) of the 
key variables: government initiatives and help, recognition/ awareness, health developments, pain and 
discomfort, ability to lead a normal life. Health developments and ability to lead a normal life variable scores are 
calculated as the average of the sub-variables in each category. For the definitional interpretation of the EuroQol 
ranks shown in Table 7.1.1 see Table 7.1, above. 
 
Table 7.1.2 highlights that during the twentieth century the implications of having tuberculosis 
improved substantially: in 1900 tuberculosis sufferers experienced ‘poor’ quality of life versus 
2000 when the quality of life associated with tuberculosis was ‘good’. The variable EuroQol 
rank results in Table 7.2.1 are indicative of tuberculosis being a rampant, incurable, poorly 
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understood and life threatening illness, which inspired widespread fear and anxiety and a 
significant threat to the public health of the nation at the beginning of the twentieth century. 
And, by the year 2000 tuberculosis was an innocuous disease, which, in most cases was 
relatively easily cured and short-lived.  
 
Unlike the other illnesses considered in the thesis, tuberculosis had standard of living 
ramifications beyond the individual sufferer, because in addition to debilitating the health of 
the sufferer, tuberculosis was a destructive social force. Therefore, there are numerous 
developments which are far reaching but do not appear in Table 7.2.1 (and in the quantitative 
results below), for example, the contribution to the aggregate population of the reduced 
infectiousness of tuberculosis. These are not direct features of the thesis and cannot be 
included in the methodology, however it should be noted that there were additional values to 
the documented tuberculosis reduction. This also represents another instance where the thesis 
Extended Results are lowest bound estimates.  
 
7.2.1 Nineteen Hundred 
Table 7.2.1 highlights that in 1900 the quality of life burden generated by tuberculosis was 
substantial. There was relatively little ‘government help’ or understanding about the specific 
problems and distinctive needs of tuberculosis sufferers (embodied by ‘poor’ quality of life 
associated with ‘government recognition and help’ in Table 7.2.1: EuroQol rank = 5). 
Although tuberculosis had been prevalent for nearly a century, and charities and committees 
were already active by 1900 (embodied by ‘some’ quality of life associated with ‘recognition/ 
awareness’ in Table 7.2.1: EuroQol rank = 4), understanding of the aetiology of tuberculosis 
was still very limited (embodied by ‘poor’ quality of life associated with ‘health 
developments’ in Table 7.2.1: EuroQol rank = 5).  
 
The ‘pain and discomfort’ associated with this tuberculosis was significant and in 1900 there 
was relatively little that could be done to abate the symptoms. Because of the method of 
treatment this physical pain was also likely to have been matched by emotional and mental 
distress as a result of the segregation that many experienced as a course of their treatment, and 
the financial burden that was placed upon a family, particularly if the sufferer was the 
breadwinner, and the ‘anxiety’ associated with the contraction of a disease that was so strongly 
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associated with no cure. This burden is represented by the ‘poor’ quality of life associated with 
tuberculosis sufferers’ ‘ability to lead a normal life’, shown as EuroQol = 5 in Table 7.2.1.  
 
This meant that the overall quality of life experienced by tuberculosis sufferers was ‘poor’ in 
1900. Standards of living had been slightly improved by the work of charities, which helped 
promote recognition and aid for the condition, although this could have been more effective 
and far reaching in some instances. Most detrimental to tuberculosis sufferers’ quality of life 
was the complete lack of any kind of cure, which exacerbated all of the other quality of life 
variables.  
 
7.2.2 Nineteen Twenty-Five 
The most important quality of life variable, the cure for tuberculosis, continued to elude the 
population, but there were evident developments made in its pursuit. By 1925 understanding 
of tuberculosis had fundamentally advanced, although this had not managed to yield any 
positive results for the treatment of tuberculosis at this time. Therefore, by 1925 quality of life 
associated with ‘health developments’ had still not managed to improve from ‘poor’ levels, 
although the foundations for a later improvement were evident.  
 
This phenomenon was also evident with tuberculosis sufferers’ quality of life associated with 
their ‘ability to lead a normal life’. The key reason for this is that the social difficulties, 
anxiety and depression invoked by tuberculosis had not declined and therefore, quality of life 
related to the ability to lead a normal life remained ‘poor’ in 1925. 
 
By 1925 ‘government initiatives and help’ had begun to develop as legislation began to 
display that the state had adopted a more comprehensive stance towards tuberculosis. E.g. the 
1921 Public Health (Tuberculosis) Act included after-care legislation for tuberculosis 
sufferers. The increase in government involvement in welfare issues associated with 
tuberculosis welfare provided an improvement in quality of life for tuberculosis sufferers, 
from ‘poor’ in 1900 to ‘some’ by 1925 (shown in Table 7.2.1 as an improvements in the 
EuroQol rank from 5 to 4).  
 
The state also ought to be partially credited with the improvement in ‘pain and discomfort’ 
associated with tuberculosis (which, like government help above, improved from ‘poor’ to 
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‘some’ quality of life between 1900 and 1925). The most important mechanism for this 
improvement is related to the expansion and improvement in treatment facilities for 
tuberculosis, generated by the state subsidising the provision of treatment for tuberculosis. E.g. 
under the 1911 Finance Act £1,500,000 was provided for the building of sanatoria and, under 
the 1912 National Health Insurance Act funds were provided for the treatment of tuberculosis 
and, the 1916 Tuberculosis (Domiciliary Treatment in England) Order enabled treatment in 
the home in an attempt to alleviate the shortages in sanatoriums.  
 
During this period the efforts and campaigns of charities continued to provide a contribution to 
the plight of tuberculosis sufferers and as a result continued to yield a ‘fair’ quality of life for 
tuberculosis patients, regarding ‘recognition and awareness’ (this is shown as EuroQol = 3 for 
recognition/ awareness in 1925 in Table 7.2.1). 
 
The culmination of these developments and persistent frustrations was an improvement in the 
‘aggregate average quality of life’ associated with tuberculosis: from ‘poor’ in 1900 to ‘some’ 
in 1925 (this is shown in the final row of Table 7.2.1, where the EuroQol rank improves from 
5 to 4).  
 
7.2.3 Nineteen Fifty 
By the middle of the twentieth century improvement in the health and welfare related quality 
of life for tuberculosis sufferers had made significant progress: Table 7.2.1 highlights that 
nearly every variable enjoyed an improved EuroQol rank between 1925 and 1950. 
 
The most impressive improvements were related to ‘medical developments’. By 1950 
streptomycin had been established and was widely available. However, this antibiotic did not 
provide a universal cure for tuberculosis (due to resistance problems), and it was not until 
1975 that this aggregate ‘health developments’ variable achieved ‘complete’ quality of life for 
tuberculosis sufferers. Nonetheless, by 1950 this ‘cure’ sub-variable of ‘health developments’ 
had improved from a level of ‘no’ quality of life to a level of ‘some’ and was rapidly on the 
way to ‘complete’ quality of life. This development drove the improvement in overall ‘health 
developments’ from ‘poor’ in 1900 and 1925 to ‘some’ by 1950.  
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As a result of the improved medical profile associated with tuberculosis, the pain, discomfort, 
anxiety, depression and adverse social circumstances triggered by tuberculosis had all 
improved by 1950 (shown in Table 7.2.1 as the improving EuroQol rank for the ‘ability to 
lead’ a normal life variable and associated sub-variables). However, because streptomycin did 
not actually provide a universal cure and as a result of the newness of this treatment, the 
general stress and burden associated with tuberculosis welfare was still only at a level of 
‘some’ quality for the ‘ability to lead a normal life’. The ‘pain and discomfort’ associated with 
tuberculosis had improved to a level of ‘fair’ quality of life for tuberculosis sufferers (shown 
in Table 7.2.1 as EuroQol rank = 3).  
 
By 1958 the work of charities and committees and various organisations had helped to 
highlight the conditions and additional needs associated with tuberculosis and to an extent 
provide these accordingly, and therefore by 1950 charities were providing ‘good’ quality of 
life. The government also improved their contributions to tuberculosis welfare during this 
period. The main contributions from the state were an improvement in medical access for 
tuberculosis sufferers and an improvement in welfare payments, which also improved the 
standards of living associated with tuberculosis. However, there still were numerous flaws in 
legislation and the state’s approach to the problems of tuberculosis sufferers, such that 
‘government initiatives and help’ had only reached ‘fair’ levels of quality of life for 
tuberculosis sufferers.  
 
As a direct result of government and charity aid and also a reduced severity of tuberculosis (as 
a result of medical advances), the ‘financial burden’ of tuberculosis had declined and this 
variable was now associated with ‘fair’ levels of quality of life.  
 
Therefore, by 1950 the most widespread range of twentieth century improvements had 
occurred for the health and welfare quality of life for tuberculosis sufferers. This can be 
largely attributed to the early developments in antibiotics that had begun to provide a cure and 
valuable improvements in the profile of tuberculosis. As a result of these far-reaching 
developments the overall or ‘aggregate average quality of life’ associated with tuberculosis 
had reached ‘fair’ levels by 1950 (shown in the final row of Table 7.2.1 as EuroQol rank = 3).  
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7.2.4 Nineteen Seventy-Five 
The most remarkable and important improvement in the tuberculosis story had been achieved 
by 1975. In the 1960s tuberculosis therapy became common place and changed the entire 
aetiology and pathogenesis of tuberculosis, such that this disease was no longer associated 
with death. Hence, by 1975 the ‘cure’ for tuberculosis had achieved ‘complete’ quality of life 
levels.  
 
This was not the case for the ‘understanding’ of the disease and ‘treatment’, largely because 
there was still evidence of problems of notification and therapy and although the new 
antibiotics were able to prevent mortality they still had adverse side effects which detract from 
overall quality of life. However, these variables had improved in general and particularly in 
comparison to the levels they were at during earlier eras of the twentieth century. By 1975 
‘understanding’ and ‘treatment’ of tuberculosis had reached ‘good’ levels. Therefore, by 1975 
overall levels of ‘health development’ had reached ‘good’ levels of quality of life for 
tuberculosis sufferers. 
 
These improvements in ‘medical developments’ had a positive impact on the ‘pain’ and 
‘anxiety’ associated with tuberculosis, which both had also improved to ‘good’ levels by 1975. 
Further improvements were evident in the ‘financial burden’ and ‘social difficulties’ related to 
tuberculosis, which had improved to ‘complete’ levels of quality of life. This meant that the 
overall ‘ability to lead a normal life’, despite having the tuberculosis disease had improved to 
‘complete’ levels. 
 
By 1975 there had been no genuine advances in ‘government initiatives’ beyond 1950s levels. 
The state was providing the curative medical therapy which provided a significant contribution 
to improved quality of life, but this was evident in 1950 under the 1948 National Health 
Service Act. Therefore, the level of government initiatives remained at ‘fair’ quality of life for 
tuberculosis sufferers. 
 
Finally, the work of charities and committees in raising ‘recognition and awareness’, which 
had been so fundamental in early quality of life improvements for tuberculosis sufferers, 
declined significantly in importance during this new era, when tuberculosis was curable. 
Charities and committees were still evident but their importance and popularity had declined 
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substantially and they were therefore unable to play as much of a role as they had in previous 
times. Consequently, the contribution for ‘recognition and awareness’ worsened from ‘good’ 
levels in 1950 to ‘fair’ levels in 1975. However, it should be noted that the major reason for 
this is positive. I.e. recognition and awareness diminished because tuberculosis was no longer 
a subject of concern to the population. Although it could be argued that this decline was too 
exaggerated when considering the re-emergence of tuberculosis in the later years of the 
twentieth century.  
 
Therefore, the combination of these developments meant that the ‘aggregate average quality 
of life’ facing 1975 tuberculosis sufferers had reached ‘good’ levels.  
 
7.2.5 Two Thousand 
By the close of the twentieth century there had been no further improvements (upon the 1975 
level) in health and welfare related quality of life for tuberculosis sufferers. This is not to say 
that the conditions did not improve slightly, as they did, but it was more a micro consolidation 
of earlier developments rather than any macro achievements.  
 
Despite the void of any further EuroQol rank improvements in the last era of the twentieth 
century, those which had been evident by 1975 ought to receive credit for their substantial 
contribution to the quality of life associated with tuberculosis, this is most true for ‘medical 
developments’ and least for ‘government initiatives’. The culmination of this progress meant 
that during the twentieth century the ‘aggregate average quality of life’ associated with 
tuberculosis improved from ‘poor’ to ‘good’ levels and in doing so provided one of the most 
significant contributions to standards of living for the twentieth century English population. 
 
These improvements in the aggregate average EuroQol have facilitated equally far reaching 
improvements in the QALY. Table 7.2.1 highlights that, the tuberculosis QALY improved 
from 0.3333 of a healthy life year (which is represented as 1) to 0.8333 of a healthy life year. 
Hence, in 1900 the collection of health and welfare standards of living meant that tuberculosis 
sufferers only enjoyed about 30 percent of a healthy life year. By the year 2000, improvements 
largely in health but also welfare enabled the standards of living associated with tuberculosis 
to improve to a level that represents about 80 percent of a full healthy life year. The numerical 
indices will be utilised below in the wider QALE methodology in order to estimate the value 
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of the above improvements in the quality of life associated with tuberculosis, which was 
extensive. 
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At the beginning of the century cancer was an incurable, largely unidentifiable, poorly treated, 
crippling and completely life threatening illness. By the year 2000 cancer was more feared (as 
it was seen as the fundamental killer, for example, several population surveys have shown that 
cancer is perceived with more alarm and considered more seriously than any other disease) but 
was less disabling, unmanageable, painful and fatal662. This outcome, which is very valuable 
for the population was created by the developments in medical technology, government 
initiatives and the work and campaigning of charities. The twentieth century transition of these 
developments, documented by the EuroQol standardised spectrum, are shown in the table 
below. 
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 Fallowfield, “Breast Cancer”, p. 4 
Results: Qualitative: Cancer 
                                                                                                                                                                                                                          - 248 - 
Table 7.3.1: EuroQol results for breast and stomach cancer and EuroQol aggregate average 
conversion into QALY 
Breast Cancer: EuroQol Variable Breast Cancer: EuroQol Score and Equivalent QALY 
 1900 1925 1950 1975 2000 
Government initiatives and help 6 6 4 3 3 
Recognition/ awareness 6 4 4 3 2 
Health developments 5 5 4 3 2 
Pain and discomfort 5 5 4 3 2 
Ability to lead a normal life 5 4 4 4 3 
Aggregate Average EuroQol Score 
Equivalent QALY 
5  
0.3333 
5  
0.3333 
4  
0.5000 
3  
0.6667 
2  
0.8333 
Stomach Cancer: EuroQol Variable Stomach Cancer: EuroQol Score and Equivalent QALY 
 1900 1925 1950 1975 2000 
Government initiatives and help 6 6 4 3 3 
Recognition/ awareness 6 4 4 3 2 
Health developments 5 5 4 3 3 
Pain and discomfort 5 5 4 3 3 
Ability to lead a normal life 5 4 4 4 3 
Aggregate Average EuroQol Score 
Equivalent QALY 
5  
0.3333 
5  
0.3333 
4  
0.5000 
3  
0.6667 
3  
0.6667 
Note: In Table 7.3.1 the aggregate average is calculated as the average score (to the nearest whole number) of the 
key variables: government initiatives and help, recognition/ awareness, health developments, pain and 
discomfort, ability to lead a normal life. Health developments and ability to lead a normal life variable scores are 
calculated as the average of the sub-variables in each category. The sub-variables for cancer are the same as those 
presented in Table 7.2.1 for tuberculosis, but are not presented here and the following text provides no crucial 
reference to these sub-variables. 
 
7.3.1 Nineteen Hundred  
In 1900 cancer sufferers were not a recognised or prominent group. There were no 
‘government initiatives’ to help prevent, treat or cure cancer (embodied by ‘no’ quality of life 
associated with ‘government initiatives and help’ in Table 7.3.1: EuroQol rank = 6) and cancer 
charities had not been established (embodied by ‘no’ quality of life associated with 
‘recognition/ awareness’ in Table 7.3.1: EuroQol rank = 6). The state of medical technology 
was largely primitive as concepts of prevention, screening, comprehensive treatment (e.g. 
adjuvant therapy) and pain relief had not yet been coined in relation to cancer (embodied by 
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‘poor’ quality of life associated with ‘health developments’ and ‘pain and discomfort’ in Table 
7.3.1: EuroQol rank = 5).  
 
This meant that the ‘aggregate average quality of life’ experienced by cancer sufferers in1900 
was ‘poor’ (embodied by EuroQol = 5 for the ‘aggregate average quality of life’ in the last 
row of Table 7.3.1). Standards of living had been slightly improved by limited ‘health 
developments’ namely, surgery and x-rays. And, comparatively speaking (to the end of the 
century) notions of healthy life years and the hysteria associated with cancer had not become 
commonplace, which alleviated some of the perceived adversities of cancer. During the early 
1900s, the English population was only just departing from an age of epidemics which 
entailed widespread mortality at relatively young ages and therefore the depression and 
anxiety which had been so closely linked to cancer by the 1970s was not yet evident.  
 
7.3.2 Nineteen Twenty-Five  
This overall quality of life situation for cancer sufferers had not really improved by 1925. 
Early developments were being made by cancer charities: the Cancer Research Fund had been 
established and was operational and the British Empire Cancer Campaign for Research 
(BECC) began to invest in detailed research to try and identify the causes of cancer663. Early 
developments were also being made in the treatment of cancer: the introduction of radium was 
laying the initial foundations for radiotherapy. These two developments provided small 
improvements in the quality of life associated with ‘recognition/ awareness’ and the ‘ability to 
lead a normal life’. However the overall or ‘aggregate average quality of life’ associated with 
cancer was still ‘poor’ in 1975. 
 
7.3.3 Nineteen Twenty-Five to Nineteen Fifty 
By the middle of the twentieth century there had been many valuable developments in the 
treatment of cancer and also provisions by the government to aid the battle against this 
disease. Many of these developments were the fruition of earlier inventions and also the initial 
benefit of new post war inventions and interventions. The 1939 Cancer Act provided an 
increase in ‘government initiatives and help’ through its aim to ensure that every cancer 
patient received the medical attention they required, even though the provision of this Act was 
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not implemented until the introduction of the NHS in 1948. The policies of the NHS provided 
an important boost to the quality of life faced by cancer sufferers as it meant that treatment for 
their illness became more accessible, which in turn improved their prognosis and the negative 
effects that cancer would have had upon quality of life. However, services and provisions were 
by no means ideal and treatment options were severely limited. Therefore government 
changed their position from ‘no’ help towards improving the cancer related quality of life to 
‘some’ help (shown in Table 7.3.1 as an improved EuroQol rank, from 6 to 4).  
 
The most important development for cancer in 1950 were the initial breakthroughs associated 
with medical technology, which improved the ‘health developments’ and ‘pain and 
discomfort’ related standards of living for cancer from ‘poor’ to ‘some’ quality of life.  
 
Improvements in ‘government initiatives and help’, ‘pain and discomfort’ and ‘medical 
developments’ (and the stability of all the other variables in Table 7.3.1) fostered an improved 
‘aggregate average quality of life’ score for stomach and breast cancer: the quality of life 
improved from ‘poor’ to ‘some’ between 1925 and 1950. 
 
7.3.4 Nineteen Fifty to Nineteen Seventy-Five 
The period between 1950 and 1975 included some of the most important inventions and 
innovations of the twentieth century, from the perspective of care for cancer that could 
improve the quality of life of sufferers. During this time the ‘government initiatives’ provided 
an important contribution to knowledge through their sponsorship of numerous working 
parties that catered for many aspects of cancer, from the causes to diagnosis, statistical 
recording and analysis of cancer prevalence to the potential benefits of screening. This 
awareness, about the potential benefits of screening was shared by cancer charities. The fusion 
meant that by 1963 a screening programme had been introduced for breast cancer, which was 
especially beneficial for quality of life, as it meant that mammography could identify cancer 
much earlier and consequently reduce many of the potential adversities of later stage cancer.  
 
The invention of the CAT scan in 1972 provided one of the most valuable weapons in the 
therapeutic armamentarium against cancer. This equipment allowed a substantially heightened 
precision in scanning for cancer, thus improving the prognosis and conditions faced by cancer 
sufferers and ultimately the quality of life associated with cancer. However the availability of 
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CAT scans was severely limited, largely due to costs “which were beyond the capacities of 
many district health funds and hospitals”664. Nonetheless, this benefit facilitated developments 
in screening and improved this aspect of quality of life.  
 
During this time some of the largest gains were experienced in adjuvant therapies. 
Chemotherapy experienced many improvements that were largely facilitated by the post 
World War Two pharmaceutical revolution. Radium therapy became much better understood 
and as a result much safer and more effective. It was during this time that hormone therapy 
was introduced and significantly enhanced the management of breast cancer. This meant that 
by 1975 adjuvant therapy for breast cancer had become increasingly systematic and was 
contributing to a reduction in recurrence rates and mortality from breast cancer665. This created 
a ‘good’ quality of life for ‘medical developments’ in breast cancer treatment and ‘fair’ quality 
of life for stomach cancer. 
 
The combination of these factors meant that by 1975 the overall or ‘aggregate average quality 
of life’ associated with cancer had reached levels that were considered ‘fair’. 
 
7.3.5 Nineteen Seventy-Five to Two Thousand 
During the final quarter of the twentieth century the foundations of the aforementioned 
developments were built upon. Surgical techniques became more advanced, which yielded 
more precision, accuracy and less disruption to an individual’s ‘ability to lead a normal life’. 
Another development in surgery was provided by reconstructive surgery. This provided the 
biggest boost to breast cancer sufferers, who underwent mastectomies. Hence, it was possible 
to remove the cancer, even a large stage II type tumour, and not loose a breast as it was 
possible to recreate one artificially. Chemo, hormone and radio therapies also became more 
sophisticated and effective. The combination of these developments and screening meant that 
many cases of breast cancer were survivable by the end of the century. This was not the case 
for stomach cancer, which, despite these improvements, was still associated with a harrowing 
prognosis, even by the year 2000. 
 
                                                 
664
 Webster, “The National Health Service: A Political History”, p. 114 
665
 Richards et al, “Variations in the Management and Survival of Women Under Fifty Years with Breast Cancer in the South East Thames Region” 
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Another development which provided a glimmer of hope for eventual reduction in cancer rates 
and in an overly idealistic form, a potential cure was the increasing understanding of 
environmental factors and their ability to prevent the onset of cancer.  
 
The combination of these developments in prevention, screening and treatment created an 
improvement in ‘medical developments’ and ‘pain and discomfort’ which had reached ‘good’ 
(breast cancer) and ‘fair’ (stomach cancer) quality of life levels by the year 2000. Table 7.3.1 
highlights how this marks an improvement over the 1975 health related quality of life for 
breast cancer and that stomach cancer did not improve beyond its 1975 level. This emphasises 
the value of improvements in surgery and therapy for breast cancer. 
 
During the last decade of the twentieth century the government provided valuable initiatives, 
which were aimed at reducing the number of cancer deaths through: improved screening 
(ensuring that all women between the ages of 50 and 64 received mammograms every three 
years, which continually achieved its targets since its introduction in 1988-1991666), trying to 
educate the public about the risks of cancer, and their efforts to eliminate social inequalities in 
cancer incidence. The government should be complimented with at least part of the 
improvements in the quality of life associated with cancer mortality and morbidity.  
 
However, the improvements in government efforts and NHS cancer treatment during the last 
quarter of the twentieth century were not far reaching enough to improve ‘government 
initiatives and help’ related quality of life above levels that were ‘fair’ for cancer sufferers. 
Hence, by the close of the twentieth century the government had failed to achieve ideal or 
even ‘good’ levels of quality of life for cancer patients. This is largely a result of decades of 
under-investment in the people and equipment involved in the fight against cancer. The NHS 
has too few cancer specialists of every type for example, at the close of the twentieth century, 
England had approximately eight oncologists per million population, which is less than half 
the number in other comparable European countries667. All of these factors had contributed to 
England lagging behind comparable economies (namely, America and European Union 
members) in cancer survival rates at the end of the twentieth century and, consequently, not 
                                                 
666
 The NHS breast cancer screening programme has continued to meet its target rates for uptake, recall, biopsy, benign biopsy, and detection of cancer. Quinn et 
al, “Changes in the Incidence of and Mortality from Breast Cancer in England and Wales since Introduction of Screening”, p. 1394 
667
 Government Papers, “The NHS Cancer Plan, A Plan for Investment, A Plan for Reform”, p. 19 
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achieving any fundamental or genuine improvements in government related quality of life 
during the last quarter of the twentieth century. 
 
During this time cancer charities enhanced their efforts and there was increased collaboration 
between the two largest cancer charities: the Imperial Cancer Research Fund and the Cancer 
Research Campaign, which helped the plight of cancer sufferers. This meant that charity 
support had achieved ‘good’ quality of life levels by the year 2000 for ‘recognition and 
awareness’ associated with stomach and breast cancer. 
 
7.3.6 Two Thousand  
By the close of the twentieth century the ‘aggregate average quality of life’ associated with 
breast cancer had improved further to reach a level that could be considered to be ‘good’, and 
stomach cancer had improved to a lesser extent, to quality of life levels that were ‘fair’. This 
should be considered as an important development from the 1900 level of ‘poor’, although less 
so for stomach cancer. The final row for the breast and stomach cancer sections in Table 7.3.1 
shows the QALY equivalent of the aggregate EuroQol score, which evolved from 0.3333 in 
1900 to 0.6777 in 2000 for stomach cancer and 0.8333 for breast cancer. Both of these QALY 
transitions, although especially breast cancer, represent important developments in the quality 
of life for cancer sufferers. The precise value of this gain will be estimated below. 
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8. Quantitative Findings 
This Chapter will contain the quantitative analysis that is evolved from the previous 
qualitative results. The twentieth century improvements that have been identified for 
morbidity (defined by the QALY weights which were transformed from EuroQol, above) 
and the improvements in life expectancy (defined by the death rate) will be considered 
here, in conjunction with other crucial facets of the thesis’ quantitative, extended 
willingness to pay or QALE methodology. The theoretical details of the thesis’ QALE 
methodology are provided in Chapter 3. Before this methodology is applied it is desirable 
to reiterate the key features and mechanics of this methodology, which will be achieved 
here, with the aid of the flow chart summary of the thesis’ methodological process. This 
will also identify the location of all the components of the QALE methodology (in earlier 
chapters of the thesis) and highlight the interaction of these features in this quantitative 
section. 
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Figure 8.1: Flow chart summary of the thesis’ methodological process 
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Figure 8.1 represents the summary of the thesis methodological processes that were 
necessary to facilitate the quantitative results contained below. These processes are 
summarised here (in accordance with the numbering in Figure 8.1). 
 
1) Define measurement scale and select illnesses: A detailed outline and justification of the 
thesis methodology and illnesses applied to this QALE calculation is provided in Chapter 
3. To summarise: the methodology used here is an original adaptation of willingness to 
pay, where quality of life improvements in mortality and morbidity are valued, which 
forms an extended willingness to pay or quality adjusted life expectancy, QALE. The 
morbid states that are utilised in this QALE methodology are: blindness, tuberculosis, and 
breast and stomach cancer. A key contribution of this measurement is the evaluation (and 
later quantification) of the quality of life associated with morbidity over the twentieth 
century.  
 
2) Detailed qualitative review of C20th history of illness: This provides an introduction to 
the thesis (and is subsequently presented in Part I of the thesis). This provides a valuable 
foundation for the more detailed and specific considerations and claims of the thesis. This 
exercise is also valuable because it provides a practical justification for the selection of the 
thesis illnesses. 
 
3) Detailed qualitative analysis: The literature is currently void of any historical (pre 1970) 
QALY estimates for illnesses and therefore the thesis had to make an informed best 
estimate from reviewing major literature sources for the thesis morbid states (namely, 
breast and stomach cancer, tuberculosis and blindness). This warranted a comprehensive 
account of the conditions associated with the thesis morbid states for different eras of the 
twentieth century, from a health and welfare perspective for quality of life. This was 
formulated around the thesis’ spectrum of key standardised variables: government help, 
recognition and awareness, health developments, pain and discomfort, ability to lead a 
normal life (for an elaboration see Chapter 3: Table 3.5 to 3.7). These considerations 
represent the main body of the thesis and are presented in Part II.  
 
4) Summary EuroQol rank: In addition to a detailed and standardised qualitative analysis 
about the health and welfare related quality of life of the thesis’ morbid states, the thesis 
has also gauged these on a standardised spectrum of development, namely EuroQol. This 
was necessary so that the qualitative analysis (summarised by EuroQol) could be evolved 
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into quantitative indices (summarised by the QALY). EuroQol is explained in more detail 
in Chapter 3 and applied in Chapter 7. 
 
5) EuroQol rank (1-6)  QALY (0-1 or 0%-100%): This stage is crucial for the 
quantitative thesis methodology because it provides the conversion from qualitative to 
quantitative. In doing this, it also provides one of the thesis’ key contributions to 
knowledge. Hence, the QALY is crucial for making quantitative considerations about 
health improvements. The QALY is derived by applying the EuroQol standardised 
spectrum of development to all illnesses in all eras considered in the thesis. This has 
facilitated a quantitative index (QALY) from the detailed qualitative analysis in the thesis 
(summarised by EuroQol). The summary EuroQol and subsequent QALY results are 
presented in Chapter 7: Table 7.1.1, 7.2.1, 7.3.1 and the QALY results are summarised in 
the table below. 
Table 8.1: QALY estimates (derived from EuroQol analysis) for thesis illnesses and eras668 
Year QALY (as a proportion of one healthy life year) 
 Blind Breast cancer Stomach cancer Tuberculosis 
1900 0.3333 0.3333 0.3333 0.3333 
1925 0.5000 0.3333 0.3333 0.5000 
1950 0.6667 0.5000 0.5000 0.6667 
1975 0.6667 0.6667 0.6667 0.8333 
2000 0.6667 0.8333 0.6667 0.8333 
1900-1925 0.4167 0.3333 0.3333 0.4167 
1925-1950 0.5834 0.4167 0.4167 0.5834 
1950-1975 0.6667 0.5834 0.5834 0.7485 
1975-2000 0.6667 0.7485 0.6667 0.8333 
1900-2000 0.5000 0.5833 0.5000 0.5833 
 
6) Select VSL: The VSL represents the valuation for the decline in mortality. It was 
therefore necessary to identify the most plausible VSL so that the twentieth century 
declined in mortality could be most accurately valued. This was achieved through adopting 
the VSL multiples that were presented by Miller’s study. The table below provides the 
VSL values utilised in the thesis, which uses the VSL multiple approach (VSL multiple * 
                                                 
668
 See Appendix 12.6.1 and 12.6.2 for alternative QALY values and calculations. 
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GDP per capita at mid point) in order to yield the VSL. The rationale and selection of 
Miller’s best VSL estimate are outline in Chapter 3. 
Table 8.2: Calculation and results of VSL values utilised in the thesis, derived from 
Miller’s VSL multiple estimates (1990 international $)669 
Period   VSL Multiple GDP per capita (GDP pc) 
at period mid-point 
VSL (Millions) 
  Mid-point GDP pc  
1900-1925 128 1913 5032 0.64 
1925-1950 128 1938 5983 0.77 
1950-1975 128 1963 9070 1.16 
1975-2000 128 1988 15988 2.05 
1900-2000 128 1950 6907 0.88 
 
7) Calculate VSHLY (QALY * VSL = VSHLY): The VSL was also necessary in the thesis 
methodology as it forms part of the VSHLY measure. Hence, the VSHLY represents the 
valuation for the decline in morbidity and is a function of the VSL and the QALY (for the 
selected illnesses and eras). The table below provides the VSHLY values utilised in the 
thesis, which uses the VSL identified in Table 8.2 combined with the QALY values 
identified in Table 8.1 (average QALY of the era under consideration, e.g. for breast 
cancer 1900-2000, the 1900 QALY = 0.3333 and 2000 QALY = 0.8333 and therefore, the 
average QALY for 1900-2000 = [0.3333 + 0.8333)] / 2 = 0.5833) for the associated illness 
and era (VSL * QALY = VSHLY) in order to yield the VSHLY. The explanation and 
justification for the VSHLY is outlined in Chapter 3. 
 
 
 
 
 
 
 
                                                 
669
 Miller, “Variations between Countries in Values of Statistical Life”, p. 180. See Appendix 12.1.1 for alternative ‘High’ and ‘Low’ VSL estimates used in 
the sensitivity analysis. 
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Table 8.3: Calculation (VSL * QALY) and results of VSHLY values utilised in the thesis: for thesis morbid states (1990 international $)670 
QALY VSHLY (Millions) Period   VSL (Millions) 
Blind Breast 
cancer 
Stomach 
cancer 
Tuberculosis Blind Breast 
cancer 
Stomach 
cancer 
Tuberculosis 
1900-1925 0.64 0.4167 0.3333 0.3333 0.4167 0.27 0.21 0.21 0.27 
1925-1950 0.77 0.5834 0.4167 0.4167 0.5834 0.45 0.32 0.32 0.45 
1950-1975 1.16 0.6667 0.5834 0.5834 0.7485 0.77 0.68 0.68 0.87 
1975-2000 2.05 0.6667 0.7485 0.6667 0.8333 1.36 1.53 1.36 1.71 
1900-2000 0.88 0.5000 0.5833 0.5000 0.5833 0.44 0.51 0.44 0.51 
 
8) WTP Mortality and 9) WTP Morbidity: Once all of the QALE methodology variables (QALY, VSL, VSHLY, death rates and illness data 
[represented by the QALY and the prevalence data]) have been identified and valued it is possible to combine these in the thesis methodology. This 
QALE methodology is outlined in Equation 8.1 below. 
                                                 
670
 See Appendix 12.1.1 (Diseases) and 12.1.2 (Disability) for alternative ‘High’ and ‘Low’ VSHLY estimates used in the sensitivity analysis 
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Equation 8.1: Summary of the thesis methodology: quality adjusted life expectancy 
(QALE) 
Willingness to Pay Morbidity (MB): 
MBWTP  Considers increased quality of life with an illness or disability   
MBWTP = VSHLY * population weighted fall in the burden of disease/disability (or the change in 
the morbidity burden) = morbidity gain 
For 
MBWTP this would have to be calculated for each type of illness and disability and their 
associated QALY ( λ ) 
This will then be combined with the equivalent information for mortality improvements 
 
Willingness to Pay Mortality (MT): 
MTWTP  Considers increased life expectancy   
MTWTP  = VSL * population weighted fall in the death rate (or the change in the mortality 
burden) = mortality gain 
 
Quality Adjusted Life Expectancy (QALE): 
Such that 
MBWTP  +  MTWTP  OR morbidity gain + mortality gain = QALE improvement: 
* ( *)
( [ ])
dc u c
dµ λ ρ µ λ
−
=
+ + +                                                                                    
( *)u c = the goods value of life,  
*c = consumption,  
ρ = the pure rate of individual time preference,  
µ = set of mortality rates,  
( Pr[λ = ∑ Condition D at t + k] * [QALY for D at t + k])  
 
10) Combined overall results = QALE: Hence, the QALE is a function of the following: i) 
Morbidity Gain (QALY * prevalence yields the change in the morbidity burden. The 
change in the morbidity burden * VSHLY = morbidity gain). This is simultaneously valued 
with ii) Mortality Gain (change in the mortality burden [embodied in the death rate]*VSL 
= mortality gain).  
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This will provide results about the (monetary) value of improvements in ‘quality adjusted 
life expectancy’ (QALE), which is the combined measure of the mortality and morbidity 
gains and forms the basis of the thesis’ extended willingness to pay methodology. These 
results will be presented in absolute (monetary form) and also as an additional proportion 
(percentage) to GDP growth for the era under consideration. 
 
11) Sensitivity analysis: This QALE result will be applied to a series of sensitivity analyses 
in order to provide a range of results and escape from accusations of bias. This analysis has 
been designed to consider the most contentious variables in the thesis’ QALE 
methodology, namely: 
11a) VSL range, 11b) QALY range and 11c) VSHLY range: The sources of 
contention for these variables are outlined in Chapter 3. The thesis will overcome 
these as far as possible through considering a ‘High’ and ‘Low’ value estimates as 
well as the existing ‘Mid’ estimate for these three variables (VSL, QALY and 
VSHLY). 
These calculations will require the QALE methodology to be reformulated (with 
alternative QALY, VSL and VSHLY values) and this will entail recalculating the QALE in 
the same process as was explained above (from stage 5 to stage 10). 
11d) Considerations about age weighting: The appeal and approach of this 
sensitivity analysis are outlined in Chapter 3. Essentially, Murray’s weights for 
different ages will be applied to the QALE results in order to provide estimates that 
adhere to claims of different QALE gain values for different ages. 
 
12) Aggregate QALE results (presented as a range): Due to the subjective and often 
controversial nature of illness and welfare measurement, the estimates of the burden of 
disease will be provided as a range of possible values and will be presented in a tentative 
fashion, whereby the reader will be invited to consider the results as a function of what 
they are willing to believe, rather than stating the results as a definitive estimate. I.e. this 
approach will provide results that are dependent upon whether or not the reader will accept 
a given scenario. Chapter 8.3 will provide a range of estimates, based on the sensitivity 
analysis for the results in Chapters 8.1 and 8.2, for the entire twentieth century (1900-
2000).  
 
The quantitative analysis (which has been explained above: through the flow chart worked 
example) will be applied to ‘Disability’ (i.e. blindness in Chapter 8.2) and ‘Disease’ (i.e. 
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cancer and tuberculosis in Chapter 8.1) separately (i.e. in separate chapters) due to the 
subtle but profound differences in the aetiology, prognosis, burden and ultimate 
measurement of illness linked with disease and disability.  
 
The most noteworthy difference between disease and disability is their relationship with 
death, whereby disease is more closely linked with death. Even though cases of disease are 
not necessarily resolved in death, as increasingly in the twentieth century they increasingly 
resulted in a cure, disability is not usually a direct cause of death. Following on from this 
observation is the generally more confined nature of disease relative to the more 
ambiguous prognosis for disabilities. For example, tuberculosis and cancer are associated 
with a survival rate throughout the twentieth century, usually five years from the date of 
diagnosis in the context of the thesis, which essentially provides a time period for the 
burden of illness, which is either resolved in survival/cure or death. There is no equivalent 
notion for disability, where the average duration of disability, in the context of the thesis, 
varied from 26 to 4 years671.  
 
Because of the different nature of disease and disability, the key quality of life 
considerations are also different. Hence, EuroQol (the thesis’ foundational measuring tool) 
is considering slightly different facets. For example, disability is much more concerned 
with rights and status experienced by sufferers whereas quality of life associated with 
infectious disease is more affected by antibiotic therapy. These distinctions and the key 
variables for measurement associated with disease and disability are explained in Table 
3.5, 3.6 and 3.7 in Chapter 3: Methodology. The result of this is that there is a slight 
variation in the QALY for disability and disease because the base measure (EuroQol) is 
measuring slightly different features. 
 
Although the burden of illness for disability and disease are very similar and both equally 
crucial for the thesis’ consideration of twentieth century quality of life it is necessary to 
consider them separately at a first approximation. Once this has been achieved it will be 
possible to combine these results, in Chapter 8.3 and Chapter 9. This is possible because 
Chapter 8.3 is a summary and Chapter 9 makes more broad and generalised considerations, 
which are based on conservative estimates from the major sources of illness burden 
(analysed in detail in the thesis) in order to extrapolate forward from the thesis illness 
                                                 
671
 See Appendix 12.13.1 for an elaboration 
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results and provide a lower bound estimate about the value of improved quality of life 
associated with illness for all morbidity and mortality in twentieth century England.  
 
Chapter 8.1 will contain the more detailed quantitative disease (tuberculosis and cancer) 
analysis. Chapter 8.2 will make the same quantitative considerations for the thesis’ sample 
disability, blindness. Chapter 8.3 will provide an aggregate (disease and disability) 
quantitative summary and range or results about the twentieth century value of QALE 
gains for the diseases and disability considered in the thesis. This will enable the reader to 
identify their most preferred QALE gain result from the extensive range (i.e. this 
represents stage 12 in the flow chart example). These results from Chapter 8 will then be 
used as the foundation for the Extended Results calculations in Chapter 9. 
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8.1 Disease (Cancer and Tuberculosis) 
8.1.1 Primary Valuation of Improvements in Morbidity     265 
8.1.2 Primary Valuation of Improvements in Mortality      279 
8.1.3 QALE Gain Valuation          281 
8.1.4 Sensitivity Analyses         288 
8.1.4.1 QALY Weights         288 
8.1.4.2 VSL and VSHLY Weights        292 
8.1.4.3 VSL and VSHLY and QALY Weights      297 
8.1.4.4 Age Weights        298 
8.1.5 Value of QALE Gains Relative to GDP       303 
 
The previous chapters of the thesis have highlighted the considerable and extensive 
improvement in health experienced by the population in twentieth century England. These 
developments have provided important contributions to the quality of life of the population 
and to wider, more Fisherian notions of economic development672. This chapter will 
provide the quantitative estimates of the value of these health improvements, through 
applying the QALE methodology to the thesis diseases: breast and stomach cancer and 
tuberculosis.  
 
Through applying the QALE methodology to the mortality and morbidity data and 
providing a value for the mortality and morbidity gain this chapter will provide a first 
approximation about the (monetary) value of increased life expectancy and improved 
quality of life associated with health. After the methodology has been applied to the data 
and the QALE gain identified, it will be possible to consider a broader range of QALE gain 
results through recalculating the QALE with a range of different weights for the most 
tenuous variables within the QALE methodology: the VSL, VSHLY and QALY. This 
sensitivity analysis represents an important part of the thesis’ quantitative results as this 
exercise will generate 27 estimates (instead of one) for each disease and era and in 
aggregate, 405 estimates (instead of 15)673.  
 
These sensitivity analyses will be further complemented through applying all of the above 
ranges of results to an age-weighting function. This will yield results about the range of 
possible (monetary) values of improved health, from an un-weighted and age-weighted 
perspective. The appeal of such considerations has been outlined in Chapter 3. 
 
                                                 
672
 Fisherian growth is a notion that was coined by Nordhaus (1999) and is defined as the maximum amount that a nation can consume while ensuring that 
members of all future generations can have life time utility that is at least as high as that of current generations. When this yardstick is utilised, life expectancy 
and in the context of the thesis, quality adjusted life expectancy, are included in the production function and the value of improvements in mortality can be 
accounted, in terms of consumption.” 
673
 Calculation: 27 results for three illnesses and five eras = (27*3)*5 = 405 versus one result for three illnesses for five years = (1*3)*5 = 15. 
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It will then be possible to add further significance to these results through considering them 
in conjunction with the growth of national income (represented as Gross Domestic Product 
[GDP hereafter] or most frequently, GDP per capita [GDP pc] in the thesis) for different 
eras during the twentieth century. This will add significance to the previously identified 
QALE gain for disease through standardising the value of improved health. This exercise 
will authenticate Fisherian type claims about the desirability of including health in some 
form of extended national income measure, because the contribution of improved health to 
economic growth, identified here for twentieth century England, has been considerable 
compared to GDP per capita only (as shown by Table 8.1.15). 
 
8.1.1 Primary Valuation of Improvements in Morbidity 
The first stage in valuing morbidity improvements is the calculations of the QALY. 
Chapter 7 of the thesis provides the qualitative summary (of Part II) and also the first stage 
in evolving these qualitative interpretations into quantitative indices, through using 
EuroQol to summarise these developments. Once the EuroQol rank had been identified, it 
was converted into a QALY (this represents stage 5 in the previous flow chart example). 
The results of this conversion for the thesis diseases are shown above, in Table 8.1, where 
the QALY is reported for the thesis diseases for different eras of the twentieth century. 
 
The bounds of the QALY are 0.1 and 1, whereby 1 is a full healthy life year and zero 
approximates death. Therefore the closer the QALY is to 1, the better the quality of life 
illness sufferers were experiencing. In Table 8.1 tuberculosis reached a level very close to 
1 or 100 percent of a healthy life year (0.8333 or 83 percent by 1975) and stomach cancer 
remained at a much less favourable standard, closer to 50 percent of a healthy life year 
(0.6667 or 67 percent in 2000). Breast cancer, like tuberculosis, also experienced important 
improvements in quality of life (0.8333 or 83 percent by 2000). These improvements have 
occurred for numerous reasons, which have been analysed in previous qualitative chapters 
of the thesis674. 
 
When this QALY is utilised in the wider thesis QALE methodology (i.e. stages 8, 9 and 10 
in the flow chart example above) it will be computed inversely. For example, breast cancer 
in 1900 achieved a QALY of 0.3333 (which has been evolved from a EuroQol rank of 5 = 
‘poor quality of life’ (see Tables 7.3.1 and 8.1 above) in the QALE methodology the 
QALY will be computed as 1 - QALY = 1 - 0.3333 = 0.6667. This is because of the 
                                                 
674
 See Part II and Chapter 7 of the thesis 
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difference in approach of measurement between the EuroQol QALY and the subsequent 
QALY in the QALE methodology. Although these are measuring the same features, they 
are considering these features from different angles: in the thesis EuroQol (and the 
subsequent thesis QALY) is measuring the fraction of a healthy life year that is achieved 
and the QALE methodology is considering the QALY as an adjustment for the fraction of 
a healthy life year that is lost. Therefore, to standardise the thesis QALY in the QALE 
calculation it is necessary to calculate 1-(EuroQol) QALY.  
 
In the next stage of the thesis QALE methodology these QALY results can be combined 
with prevalence for the associated disease and era, in order to calculate the morbidity 
burden, which comprises the number of disease sufferers (prevalence) multiplied by the 
burden (i.e. 1-QALY in the context of the QALE methodology considering the amount of 
life year lost [rather than the initial EuroQol QALY considering how much of a life year 
gained]) of this disease (QALY).  
 
In an attempt to generate the most precise estimates of the morbidity burden (= 
prevalence*QALY) there are two additional specification for the morbidity burden 
calculation: i) the burden and prevalence are calculated by age group in order to provide 
more detailed estimates675, and ii) these age specific morbidity burden estimates are 
standardised for the age distribution across the population structure at the start and end 
point of the era under consideration. This process yields two sets of results for any era (the 
change in the morbidity rate [or morbidity burden by age relative to the population by age] 
fixed to either the start [T1] point or end [T2] point population), which are then averaged 
in order to present the most indicative estimate about the change in the burden of disease, 
while accounting for the changing age structure of the population between the start and end 
point in any era. This represents a standard weighing/index number process and using the 
mid-point or average represents an orthodox approach. 
 
The morbidity burden results differ for the start and end point populations because of the 
distribution of morbidity across ages. E.g. in the thesis breast and stomach cancer represent 
diseases that are most prevalent at the oldest ages: if there is a significant increase in the 
old age population (as there was over the twentieth century), then the rate of this morbidity 
burden will be less at the end point (2000) than at the start (1900) because the rate 
represents the number of morbidity incidents per population size. Therefore, to try and 
                                                 
675
 The data is divided into the following age groups: 0-4, 5-9, 10-14, 15-19, 20-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75+ 
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standardise these external influences the thesis will consider the rate for the both the start 
and end point population structures and use the average of these values as the final 
morbidity burden estimate. This process is desirable as it provides additional necessary 
detail about the morbidity environment, standardised to the era being considered. 
 
This process of calculation will be applied to the thesis diseases, but not the disability as 
there is not (age-specific prevalence) data of enough detail to perform such calculations.  
 
After the morbidity burden has been identified for different eras it will be possible to 
identify the change in the morbidity burden between these eras. This change in the 
morbidity burden will then be valued (using the VSHLY) in order to estimate the 
morbidity gain, which is essentially the value of a decrease in the morbidity burden over 
time. With reference to the flow chart example at the start of Chapter 8, identifying the 
value of the morbidity gain (change in the morbidity burden * VSHLY) represents stage 9.  
 
Hence, in order to estimate the morbidity gain, the change in the morbidity burden needs to 
be valued. This is achieved through establishing the VSHLY and applying it to the change 
in the morbidity burden. The VSHLY is equated through combining the VSL and the 
QALY for the illness and period being considered (VSL * QALY = VSHLY). Calculating 
the VSHLY represents stage 7 in the above flow chart (Figure 8.1) explanation and Table 
8.3 provides the calculations and result of the VSHLY.  
 
Because of the level of detail in the base morbidity burden calculations (as a result of the 
age standardised population considerations explained above) only the final results (about 
the change in the morbidity burden) will be presented here. However, this will be 
supplemented by a detailed worked example of this meticulous methodological process 
utilised in the thesis in order to estimate the most accurate morbidity gain (see Table 8.1.2.i 
and 8.1.2.ii). The detailed calculations are shown in Appendix 12.3. (In reference to the 
flow chart analysis above, this worked example provides a more detailed explanation of 
stage 9). Once the morbidity burden changes have been identified they will be applied with 
the VSHLY to determine the morbidity gain. This stage of the calculation will be shown 
below (in Tables 8.1.3, 8.1.4 and 8.1.5), after the worked example indicating the 
calculation of the morbidity burden change. This worked example will consider breast 
cancer for 1900-2000. 
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The morbidity burden change for breast cancer between 1900 and 2000 is established 
through considering the prevalence of breast cancer multiplied by the QALY for breast 
cancer at the start and end point of the period: 1900 and 2000. In an effort to yield the most 
accurate results, this calculation will be done on an age standardised population basis. 
Table 8.1.1 shows the non-age standardised, or aggregate prevalence and QALY 
information. For example, the aggregate morbidity burden for breast cancer in 1900 and 
2000: 15,980 cases of breast cancer in 1900 with a (1-QALY) of 0.6667 (in simplistic 
aggregate terms, this translates into a morbidity burden of 10,654 cases {15,980 * [1 - 
0.3333=] 0.6667} – the inverse of the QALY for calculation purposes676 = 10,654) versus 
the 2000 burden: 87,915 cases of breast cancer with a (1-QALY) of 0.1667 which 
translates into a morbidity burden of 14,655 cases (87,915 * [1-0.8333 =] 0.1667 = 
14,655). These aggregate key components for the thesis disease morbidity burdens 
(aggregate prevalence and QALY) are shown in the table below.  
Table 8.1.1: Calculation of morbidity burden of thesis diseases: breast cancer, stomach 
cancer and tuberculosis677 
Year Breast Cancer Stomach Cancer Tuberculosis 
 Prevalence (1-QALY) Prevalence (1-QALY) Prevalence (1-QALY) 
1900 15980 0.6667 7989 0.6667 71959 0.6667 
1925 27055 0.6667 10512 0.6667 57605 0.5000 
1950 61477 0.5000 17300 0.5000 42024 0.3333 
1975 68935 0.3333 14097 0.3333 7119 0.1667 
2000 87915 0.1667 7704 0.3333 6031 0.1667 
 
Table 8.1.1 highlights a subtle and important trend. For modern type illnesses, i.e. breast 
and stomach cancer, a major improvement in the morbidity burden (shown below in Tables 
8.1.3 and 8.1.4) is facilitated by an improved QALY as the prevalence generally increases. 
This trend is most pronounced for breast cancer (and not consistently evident for stomach 
cancer), due to both a significant increase in prevalence and an improvement in the QALY 
(especially after 1950). This trend is crucial because it illustrates one of the key claims of 
the thesis: even though the prevalence of disease and disability increased as the twentieth 
                                                 
676
 Considering the inverse QALY is necessary when calculating prevalence, because EuroQol in the thesis (and the subsequent thesis QALY) is measuring 
the fraction of a healthy life year that is achieved and the QALE methodology is considering the QALY as an adjustment for the fraction of a healthy life year 
that is lost. Therefore, to standardise the thesis QALY in the QALE calculation it is necessary to calculate 1-(EuroQol) QALY. I.e. EuroQol and the 
subsequent thesis QALY consider how much of a life year, the QALY in the QALE methodology considers the burden or how much of an unhealthy life year 
 1-(EuroQol) QALY = QALY in QALE methodology.  
677
 Table 8.1.1 considers the burden of morbidity for different eras of the twentieth century, which is calculated by considering the prevalence multiplied by 
the inverse QALY. The more detailed and age-specific calculations of the morbidity burden see Appendix 12.2. 
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century unfolded the quality of life associated with these diseases and disabilities 
improved. Although many have speculated whether this phenomenon is genuine, the 
results contained in this thesis provide a more substantiated indication about the accuracy 
of such speculation.  
 
Table 8.1.1 also shows a series of trends which all indicate an improvement in the burden 
of disease as the twentieth century unfolded. Tuberculosis displays the most 
straightforward example of this claim, where the prevalence fell consistently and markedly 
during the twentieth century and the QALY experienced equally impressive improvements, 
such that the morbidity burden of tuberculosis was minor by 2000 (see Table 8.1.5). Breast 
and stomach cancer show more mixed and seemingly contradictory (stomach cancer) 
results. For stomach cancer there was an improvement in the morbidity burden, which was 
largely a result of a fall in prevalence as the QALY associated with stomach cancer did not 
improve substantially over time. Conversely, breast cancer shows a large increase in 
prevalence which was compensated by far reaching improvements in the QALY, to the 
extent that the morbidity burden began to decline from 1950 onwards, to such a degree that 
the year 2000 morbidity burden (prevalence*QALY) had returned to a level similar to the 
year 1900 morbidity burden.   
 
The next stage of the thesis methodology is to consider this burden as a rate of the 
population for which it relates. Table 8.1.2.i considers the morbidity rate or age specific 
morbidity index (shown as MBR/1000) which is calculated through dividing the morbidity 
burden number by the population number for the corresponding age group. Also shown in 
Table 8.1.2.i is the percentage of population by age group for 1900 (T1) and 2000 (T2). 
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8.1.2.i: Morbidity burden rate (morbidity/population) by age: breast cancer: 1900 and 
2000678 
1900: Breast Cancer 2000: Breast Cancer 
Age  
% 
Population MBR/1000 Age  
% 
Population MBR/1000 
0-4 0.114068 0 0-4 0.0606449 0 
5-9 0.107086 0 5-9 0.0647742 0 
10-14 0.102585 0 10-14 0.0654486 0 
15-19 0.099601 0.0009236 15-19 0.061065 0 
20-24 0.095741 0.0032028 20-24 0.0587045 0.001969409 
25-34 0.161673 0.036605 25-34 0.1456456 0.024475432 
35-44 0.123151 0.3884269 35-44 0.1471602 0.105797936 
45-54 0.089448 0.9862535 45-54 0.1322942 0.290137932 
55-64 0.059846 1.4674386 55-64 0.1048284 0.470378472 
65-74 0.033199 2.2693267 65-74 0.0559221 0.682198245 
75+ 0.013602 1.5554554 75+ 0.0753201 1.57410013 
 
Once the calculations in Table 8.1.2.i have been made, the morbidity burden – standardised 
to the age structure of the population – has been identified for the start (TI) and end (T2) 
point of the period. Also the distribution of the population has been identified for T1 and 
T2. 
 
The next stage in the QALE calculation (for morbidity) is to calculate the difference (or 
change) in the morbidity burden (MBR/1000) between T1 and T2. This is derived by 
identifying the weighted morbidity rates (WTD MBR) for T1 and T2, which is achieved by 
multiplying the relevant MBR/1000 and % population. The process and result of this 
calculation is shown below in Table 8.1.2.ii, where the difference in MBR/1000 (fixed to 
the population at the start and end point) is calculated to estimate the change in the 
morbidity burden (standardised for the population). The final stage of this calculation is to 
convert the result from a rate into a number, shown in Table 8.1.2.ii as ‘Morbidity Burden’. 
This conversion was achieved through multiplying the ‘Decrease/1000’ (of the WTD 
MBR) by the relevant population number. The T1 and T2 ‘Morbidity Burden’ numbers are 
averaged in the next stage of the thesis methodology (see Table 8.1.3, 8.1.4, 8.1.5). The 
Table below makes the 1900-2000 breast cancer morbidity burden change calculations 
fixed to the start point (T1) population and then the end point (T2) population.  
                                                 
678
 Extract from Appendix 12.3 and 13.1 
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Table 8.1.2.ii: Morbidity burden rate (morbidity/population) and morbidity burden change calculation by age: breast cancer: 1900-2000679 
1900-2000: Fixed to [T1] 
Age  % Pop MBR/1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease/1000 Morbidity Burden 
 1900 1900 1900&1900 1900 2000 1900&2000   
0-4 0.114068 0 0 0.114068 0 0 0 0 
5-9 0.107086 0 0 0.107086 0 0 0 0 
10-14 0.102585 0 0 0.102585 0 0 0 0 
15-19 0.099601 0.0009236 9.199E-05 0.099601 0 0 9.19904E-05 3.887021995 
20-24 0.095741 0.0032028 0.00030663 0.095741 0.00196941 0.0001886 0.000118082 4.989531439 
25-34 0.161673 0.036605 0.00591805 0.161673 0.02447543 0.003957 0.001961029 82.86260848 
35-44 0.123151 0.3884269 0.04783501 0.123151 0.10579794 0.0130291 0.034805926 1470.712206 
45-54 0.089448 0.9862535 0.08821879 0.089448 0.29013793 0.0259524 0.062266418 2631.045684 
55-64 0.059846 1.4674386 0.08782016 0.059846 0.47037847 0.0281502 0.059669949 2521.332801 
65-74 0.033199 2.2693267 0.07534013 0.033199 0.68219825 0.0226485 0.052691607 2226.465416 
75+ 0.013602 1.5554554 0.02115779 0.013602 1.57410013 0.0214114 -0.000253612 -10.71628367 
       0.211351389 8931 
1900-2000: Fixed to [T2] 
Age  % Pop MBR/1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease/1000 Morbidity Burden 
 2000 1900 2000&1900 2000 2000 2000&2000   
0-4 0.060645 0 0 0.060645 0 0 0 0 
5-9 0.064774 0 0 0.064774 0 0 0 0 
10-14 0.065449 0 0 0.065449 0 0 0 0 
15-19 0.061065 0.0009236 5.6399E-05 0.061065 0 0 5.63989E-05 2.383115096 
20-24 0.058705 0.0032028 0.00018802 0.058705 0.00196941 0.0001156 7.24037E-05 3.059393999 
25-34 0.145646 0.036605 0.00533136 0.145646 0.02447543 0.0035647 0.001766622 74.64800639 
35-44 0.14716 0.3884269 0.05716096 0.14716 0.10579794 0.0155692 0.041591718 1757.443481 
45-54 0.132294 0.9862535 0.13047564 0.132294 0.29013793 0.0383836 0.092092068 3891.318088 
55-64 0.104828 1.4674386 0.15382923 0.104828 0.47037847 0.049309 0.104520214 4416.465061 
65-74 0.055922 2.2693267 0.1269055 0.055922 0.68219825 0.03815 0.088755543 3750.334394 
75+ 0.07532 1.5554554 0.11715698 0.07532 1.57410013 0.1185613 -0.001404325 -59.33925127 
       0.327450642 13836 
                                                 
679
 Extract from Appendix 12.3 and 13.1 
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Hence, between 1900 and 2000 the morbidity burden of breast cancer decreased by 8931 
(fixed to start point [T1]) – 13,836 (fixed to end point [T2]). This represents the change in 
the morbidity burden. Hence, it is this change in the morbidity burden (prevalence*QALY, 
for the age standardised population) of breast cancer shown in Tables 8.1.2.i and 8.1.2.ii 
(and all other morbid states in the thesis) that is then valued between different eras (this 
can be done between any two eras) to yield the morbidity gain.  
 
As has been explained above, the next stage in the thesis QALE methodology is to value 
the change in the morbidity burden in order to estimate the morbidity gain. In order to 
identify the morbidity gain (which is the value of the change in the morbidity burden), it is 
necessary to identify the value of a statistically healthy life year (VSHLY) and apply this 
to the morbidity burden change. The calculation of the VSHLY has been outlined above, as 
stage 7 in the flow chart example, and in Table 8.3. 
  
Continuing with the 1900-2000 breast cancer example, the VSHLY is identified by 
determining the VSL multiplied by the average QALY for the period. The VSL is 
determined through identifying the most reasonable approximate of a VSL multiple value 
and the GDP per capita at the mid-point of the period being considered680. These two 
numbers are then multiplied together to provide the VSL. Therefore (as in Table 8.2), the 
VSL multiple = 128 and GDP per capita in 1950 (mid-point between 1900 and 2000) = 
6,907 (1990 international $) and multiplied together to yield the VSL = 0.88 (millions of 
1990 international $). The VSHLY is the sum of the VSL (0.88 million) multiplied by the 
QALY for 1900-2000, which is 0.5833 (shown in Table 8.3). Hence, the VSHLY for 1900-
2000 breast cancer is 0.88*0.5833 = 0.51 (millions of 1990 international $).   
 
The morbidity gain can now be calculated through combining the change in morbidity 
burdens (shown above in bold in Table 8.1.2.ii) with the VSHLY ([8931 * 0.51 + 13,836 * 
0.51]/2), which yields an average morbidity gain of 5,806 (millions of 1990 international 
$). This represents the value of an improved breast cancer burden between 1900 and 2000. 
This process and result is shown in the final row of Table 8.1.4, for breast cancer. 
Calculation of the morbidity gain is shown for all illnesses and eras in the thesis in Tables 
8.1.3, 8.1.4, and 8.1.5, below. 
 
                                                 
680
 See Chapter 3 for a more detailed explanation about the VSL utilised in the thesis. 
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Once the morbidity gain has been identified it can be combined with the mortality gain in 
order to calculate the QALE gain. This process and the evaluation of the mortality gain 
will be explained below.  
 
First, the above example (for breast cancer 1900-2000) will be animated through providing 
the results about the morbidity gain for the thesis illnesses. As has been outlined above, 
this is shown in a summarised format (from the base results in appendices 12.3, 12.4, and 
13.1) because of the intricacy of the base calculations: the thesis diseases have been 
considered by age, i.e. the morbidity burden rate has been considered for each age group 
(0-4, 5-9, 10-14, 15-19, 20-24, 25-34, 35-44, 45-54, 65-74, 75-84, 85+) and the subsequent 
percentage of the population that this age group represented. It was necessary to weight 
these calculations to age profiles at the start and end point (T1 and T2, respectively) of the 
populations being considered. This process yields two sets of results (T1 and T2) for the 
change in the morbidity burden and the subsequent morbidity gain. The reason for the 
difference in these results is the different distribution of the population across age groups 
coupled with the different decline in the morbidity burden for different age groups over 
time. E.g. in 1900 there was a greater proportion of the population in the youngest age 
groups compared to 2000: if these youngest age groups experienced significant declines in 
morbidity then results that are fixed to the population distribution in 1900 will yield a 
greater value. In order to avoid any bias caused by this feature the thesis will utilise the 
mid point between these two sets of results. The detailed calculations for this process are 
contained in appendices 12.3 and 13.1. The summarised results of this analysis are shown 
in the series of tables below (and Appendix 12.4). 
 
Table 8.1.3, 8.1.4 and 8.1.5 consider the value of declines in the burden of morbidity 
through: first, applying the above exercise of identifying the change in the morbidity 
burden (prevalence * QALY) weighted to the start (T1) and end (T2) point populations, 
which is then applied to the VSHLY estimate to generate the monetary value of 
improvements in morbidity, the morbidity gain. These are then averaged through 
identifying the mid point between the T1 and T2 morbidity gain, in order to provide a 
single morbidity gain estimate (morbidity burden change 1 * VSHLY = morbidity gain 1 
and morbidity change 2 * VSHLY= morbidity gain 2  [morbidity gain 1 + morbidity 
gain 2] / 2 = morbidity gain).  
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It is noteworthy that in all of the tables in Chapter 8 and 9, that the result for 1900-2000 
does not equal the sum of the previous five entries in these tables. This is because all of 
these entries are considering averages that relate to the specific numbers of each period. 
For example, the VSL and VSHLY and QALY and prevalence all differ for each era (i.e. 
1900-2000 is not simply summing the results of all the other eras) and the subsequent 
interaction in the methodology yields different average estimates. Furthermore, when 
considering growth (which is achieved in Table 8.1.14, 8.1.15, 8.2.8, 8.3.4, and 9.3) the 
methodology is considering a compound average rate of growth, which again considers an 
average (rate) that is different for each computation of the twentieth century681.  
Table 8.1.3: Morbidity gain (morbidity burden change*VSHLY): monetary value of 
improvements in the burden of morbidity: stomach cancer (millions of 1990 international 
$)682 
Period Morbidity 
Burden 
Change 1 
Morbidity 
Burden 
Change 2 
VSHLY Morbidity 
Gain T1 
Morbidity 
Gain T2 
Morbidity 
Gain 
Average 
1900-1925 1116 1510 0.21 234 317 278 
1925-1950 121 -164 0.32 39 -52 -7 
1950-1975 5598 6611 0.68 3807 4495 4151 
1975-2000 2678 2714 1.36 3642 3691 3677 
1900-2000 6235 12779 0.44 2743 5623 4183 
 
Table 8.1.3 calculates the morbidity gain. Morbidity burden 1 and 2 are calculated in 
appendices 12.3 and 13.1 (which consider the morbidity burden rate change for the age 
distribution of the population, in the same format as Table 8.1.2.i and ii). The morbidity 
burden changes 1 and 2 are calculated as the difference in the morbidity burden in T1 
versus T2, fixed to the corresponding age distribution of the population in T1 (morbidity 
change 1) and T2 (morbidity change 2). The morbidity gain T1 and T2 are the result of: 
morbidity burden change 1 and 2 multiplied by the VSHLY. The morbidity gain average is 
the median of morbidity gain T1 and morbidity gain T2.   
 
The most far reaching morbidity gains related to stomach cancer (in Table 8.1.3 above) 
were evident for 1900-2000. This was closely followed by the morbidity gains in the 
                                                 
681
 This note applies to all of the tables in this results section, which consider the morbidity, mortality and QALE gain consider the following 
eras: 1900-1925, 1925-1950, 1950-1975, 1975-2000 and 1900-2000. 
682
 For detailed calculations underlying the results in Table 8.13 see Appendix 12.3 and 13.1. For summary results shown in Table 8.1.3 see Appendix 12.4.  
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second half of the twentieth century: 1950-1975 and 1975-2000. The reasons for the 
chronology of this trend are largely related to quality of life and prevalence improvements. 
Hence, Table 8.1.1 implies that between 1950 and 1975 there was the greatest decline in 
the morbidity burden as a result of reductions in prevalence (17,300 in 1950 declined to 
14,098 in 1975) and, more importantly, the improving QALY (the burden, represented by 
1-QALY improved from [in QALE terms, a loss of] 0.5000 to only 0.3333 of a healthy life 
year). The morbidity gain in the following period, 1975-2000, was a function of only 
reductions in prevalence as there was no QALY improvement. The morbidity gain for 
1900-2000, which was the most far reaching, was a result of both improved prevalence and 
QALY (Table 8.1.1 shows a decline in prevalence from 7,989 to 7,705 enhanced by a 
decline in the burden of a healthy life year [=1-QALY] from 0.6667 to 0.3333).  
 
Also noteworthy is that relative to the other thesis diseases, the values of the stomach 
cancer morbidity gains were not substantial. This is largely a result of the failure to 
significantly increase the quality of life (as reflected by the QALY in Table 8.1 or 1-QALY 
in Table 8.1.1) for stomach cancer sufferers, especially when this is compared to the other 
illnesses in the thesis. This is also because of a more limited prevalence relative to breast 
cancer and especially tuberculosis. 
 
Breast cancer (see Table 8.1.4) experienced a similar phenomenon to stomach cancer, in 
that the most valuable morbidity gains were evident during the second half of the twentieth 
century. This result is not surprising, as Part II has outlined, there were few advances in 
(the key quality of life variable) medical technology associated with cancer before 1950. 
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Table 8.1.4: Morbidity gain (morbidity burden change*VSHLY): monetary value of 
improvements in the burden of morbidity: breast cancer (millions of 1990 international 
$)683 
Period Morbidity 
Burden 
Change 1 
Morbidity 
Burden 
Change 2 
VSHLY Morbidity 
Gain T1 
Morbidity 
Gain T2 
Morbidity 
Gain 
Average 
1900-1925 -868 -1000 0.21 -182 -210 -196 
1925-1950 -2062 -2586 0.32 -660 -828 -741 
1950-1975 13287 14952 0.68 9035 10167 9601 
1975-2000 11092 11102 1.53 16971 16986 16979 
1900-2000 8931 13836 0.51 4555 7056 5806 
 
Table 8.1.4 shows that the most substantial morbidity gains for breast cancer were in the 
period 1975 to 2000. This is not surprising because as the twentieth century unfolded the 
morbidity gain for breast cancer became increasingly valuable. Compared to stomach 
cancer, breast cancer experienced many more far reaching improvements in quality of life 
(as reflected by the QALY in Table 8.1 or 1-QALY in Table 8.1.1), which explains the 
greater morbidity gain experienced by breast cancer in the second half of the twentieth 
century. However, during the period 1900-1950 breast cancer achieved worsening 
morbidity gains (versus stomach cancer), which was largely as a result of substantially 
increasing prevalence of breast cancer (from 15,980 in 1900 to 61,477 in 1950) and the 
failure of the QALY to improve until 1950. This trend also explains why when the 
twentieth century is considered as a whole, the morbidity gain is of similar magnitude for 
breast and stomach cancer.  
 
This post 1950 breast cancer morbidity gain is particularly important because, as has been 
outlined above, this occurred during an era when the prevalence of breast cancer was 
always increasing (as shown in Table 8.1.1) and therefore the constantly improving QALY 
burden is the factor which drives the morbidity gain, especially between 1975 and 2000, 
which experienced considerable increases in prevalence (from 68,953 in 1975 to 87,915 in 
2000, shown in Table 8.1.1) that were entirely offset by improvements in the quality of life 
associated with breast cancer (in Table 8.1.1, the burden, represented by 1-QALY 
improved from 0.3333 in 1975 to only 0.1667 of a healthy life year in 2000).   
                                                 
683
 For detailed calculations underlying the results in Table 8.14 see Appendix 12.3 and 13.1. For summary results shown in Table 8.1.4 see Appendix 12.4. 
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Tuberculosis sufferers also experienced considerable morbidity gains (see Table 8.1.5), 
some of which can be ascribed to the significant improvements in quality of life related to 
tuberculosis, particularly during the second half of the twentieth century. The substantial 
decline in the prevalence of tuberculosis also contributed to the morbidity gains outlined in 
Table 8.1.5.  
Table 8.1.5: Morbidity gain (morbidity burden change*VSHLY): monetary value of 
improvements in the burden of morbidity: tuberculosis (millions of 1990 international $)684 
Period Morbidity 
Burden 
Change 1 
Morbidity 
Burden 
Change 2 
VSHLY Morbidity 
Gain T1 
Morbidity 
Gain T2 
Morbidity 
Gain 
Average 
1900-1925 28168 22021 0.27 7605 5946 6776 
1925-1950 18728 17215 0.45 8428 7748 8088 
1950-1975 13977 13556 0.87 12160 11794 11977 
1975-2000 377 330 1.71 645 565 605 
1900-2000 61865 41322 0.51 31551 21074 26313 
 
Table 8.1.5 highlights the tremendous tuberculosis morbidity gains as a result of 
improvements in both the prevalence and the QALY. This was most pronounced for the 
period 1900-2000, as would be expected, because the prevalence of tuberculosis declined 
consistently throughout the twentieth century. Also of relatively very high magnitude was 
the morbidity gain between 1950 and 1975, which is a likely result of significant 
improvements in the QALY (in Table 8.1.1, the burden, represented by 1-QALY improved 
from 0.3333 in 1950 to 0.1667 in 1975) and a significant decline in the prevalence during 
this period (from 42,024 in 1950 to 7,119 in 1975, shown in Table 8.1.1), both of which 
were a result of medical developments (see Part II: Chapter 5 and Part III: Chapter 7.2 for 
an elaboration). Along a less positive vein is the relatively minimal morbidity gain between 
1975 and 2000. This is largely a result of minor scope for further improvements, as the 
QALY nearly reached the ideal level (when considering 1-QALY, the ideal level would be 
0 and the tuberculosis 1-QALY had reached 0.1667 by 1975, which can be considered as 
nearly ideal) and the prevalence declined so that a very marginal proportion of the 
population were infected with tuberculosis.  
 
                                                 
684
 For detailed calculations underlying the results in Table 8.1.5 see Appendix 12.3 and 13.1. For summary results shown in Table 8.1.5 see Appendix 12.4. 
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When the morbidity gains for the three diseases are compared, the most striking feature is 
the greater magnitude of the tuberculosis morbidity gain. E.g. if the morbidity gain for 
these diseases are considered for the twentieth century as a whole (1900-2000), the 
tuberculosis morbidity gain was about five times greater than the breast cancer morbidity 
gain and about six times greater than the stomach cancer morbidity gain (26,313 versus 
5,806 and 4,183, respectively [all in 1990 international $]). A key reason for the greater 
magnitude of the tuberculosis morbidity gain relative to the other illnesses in the thesis is 
the dramatic decline in the prevalence of this disease. For example, in 1900, tuberculosis 
represented nearly 10 percent of all deaths in the English population. This is a greater 
proportion than breast cancer and stomach cancer combined, at any point during the 
twentieth century, and any improvements are going to be more far reaching because of the 
greater number of healthy life years that are achieved out of reducing the prevalence and 
morbidity burden associated with tuberculosis. This trend also explains part of the reason 
for breast cancer experiencing higher morbidity gains versus stomach cancer. Hence, the 
greater the prevalence of a disease, the greater is the scope for the morbidity gain, as there 
are more life years that will be effected by any QALY improvements.  
 
Therefore, Tables 8.1.3 to 8.1.5 highlight the value of improvements in morbidity. This is 
particularly pronounced for tuberculosis, which would be expected as this disease had 
transformed from being one of the major health threats in 1900 to being virtually 
eliminated by 2000 (due to the availability of safe and effective antibacterial agents). 
Breast cancer also experienced important gains associated with improved quality of life 
(QALY), which were especially far reaching as they were capable of counteracting 
increases in prevalence. Lastly, although compared to these two diseases stomach cancer 
was less significant, the associated morbidity gains were still noteworthy and also 
contribute to the overall conclusions of the thesis in a similar way to breast cancer and 
tuberculosis, although to a lesser extent. 
 
Now that the morbidity gain for the thesis diseases has been established, the final aspect of 
the methodology is to combine this with the mortality gain as this provides the overall 
health gain or in the context of the thesis’ methodology and terminology, the QALE gain. 
In order to form the overall QALE methodology, the morbidity gain (above) will be 
combined with the mortality gain (below). The methodology and result of the mortality 
gain calculation will be explained below. With reference to the flow chart example at the 
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beginning of Chapter 8, this next stage of valuing the morbidity gain relates to stage 8 in 
the flow chart and WTP mortality in Equation 8.1. 
 
8.1.2 Primary Valuation of Improvements in Mortality 
The results below highlight twentieth century improvements in mortality through a very 
similar process to that which was utilised for morbidity, but instead of considering the 
burden of illness, the death rate burden is utilised and the change in the death rate burden is 
valued with the VSL (rather than the VSHLY which was used to value the change in the 
morbidity burden). Selecting the VSL represents stage 6 in the above flow chart example 
and included in this outline is Table 8.2, which provides the calculation and result of the 
VSL values for different eras of the twentieth century.  
 
The first step in identifying the mortality gain is to identify the change in the mortality 
burden. This is established through considering the change in the death rate. This is a much 
more simplistic and straightforward process compared to disease as the change in the death 
rate has been recorded for the entire twentieth century and it is a straightforward statistic 
(i.e. there is no ambiguity about whether someone is registered as ‘dead’ or remains alive). 
Hence, once the change in the death rate has been identified, it is possible to value this 
through applying the VSL to the change (always a decline in the twentieth century) in the 
death rate. The result of this calculation (decline in death rate*VSL) will yield the 
mortality gain. This process is highlighted below in Table 8.1.6. 
 
Also in common with the above calculation of the change in the morbidity burden, the 
change in the death rate burden was considered relative to the age distribution of the 
population. Therefore, it was necessary to weight these calculations to age profiles at the 
start and end point (T1 and T2, respectively) of the populations being considered and then 
identify the mid point between these two sets of results and utilise this as the mortality 
gain. The summary of this process is shown below in Table 8.1.6 and the detailed 
calculations for this process are contained in appendices 12.3 and 13.1.  
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Table 8.1.6: Mortality gain (mortality burden change*VSL): monetary value of 
improvements in the burden of mortality (millions of 1990 international $)685 
Period Mortality 
burden 
change T1 
Mortality 
burden 
change T2 
VSL 
(millions) 
Mortality 
gain T1 
(MG1) 
Mortality 
gain T2 
(MG2) 
Average 
mortality 
gain 
1900-1925 6201 5968 0.64 3969 3820 3895 
1925-1950 4494 4974 0.76 3415 3780 3598 
1950-1975 1906 2386 1.16 2211 2767 2489 
1975-2000 3781 4034 2.05 7751 8270 8011 
1900-2000 13805 17487 0.88 12149 15389 13769 
 
Table 8.1.6 highlights the methodological process and result of valuing the decline in the 
death rate. I.e. the mortality burden change columns multiplied by the ‘VSL’ column yields 
the mortality gain columns. The mid point between these two mortality gain columns can 
then be identified to yield the ‘average mortality gain’ result, which will be utilised. 
 
The most substantial mortality gains in the above table are those that exist for the entire 
twentieth century. This is essentially a result of the fact that this era includes the largest 
scope for death rate reductions and subsequent mortality gains. Also noteworthy is the 
value of the mortality gain in 1975-2000, which is larger than any of the preceding eras. 
This is a result of continued improvements in the life expectancy and also because of an 
increased value of these improvements. I.e. the VSL for 1975-2000 is nearly double the 
VSL for the preceding era, 1950-1975, which is also higher than all other VSL values 
(1975-2000 VSL = 2.05 and 1950-1975 VSL = 1.16 [1990 international $])686. The reasons 
for this difference are explained in Chapter 3, where the rationale and construction of the 
VSL are detailed.   
 
Lastly, it is important to note that all eras considered in the table experienced important 
mortality gains, which is essentially a result of twentieth century improvements in 
mortality that were unprecedented, such that the entire twentieth century mortality gain 
was worth 13,769,000,000 or approximately fourteen billion (1990 international $).   
 
                                                 
685
 For detailed calculations underlying the results in Table 8.1.6 see Appendix 12.3. For summary results shown in Table 8.1.6 see Appendix 12.4. 
686
 For details of the calculation of the VSL see Appendix 12.1.1. 
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An improvement in the death rate and a subsequent valuable mortality gain has been 
recognised in the literature and is therefore not one of the original contributions of the 
thesis. However, calculating these quantitative gains for morbidity has not, to date, been 
attempted. Moreover, combining these quantitative morbidity gain evaluations with the 
mortality gain in a universal health measure, namely, the QALE, is also one of the original 
key contributions to knowledge. This final aspect of the methodology (combining the 
mortality and morbidity gain) is achieved below with the QALE gain valuation, where the 
novelty of the thesis’ original QALE methodology is highlighted. This QALE 
methodology, which combines the WTP morbidity and WTP mortality gain represents 
stage 10 in the flow chart example provided at the beginning of Chapter 8 and is also the 
final stage in Equation 8.1. 
 
8.1.3 QALE Gain Valuation 
This subsection of results combines the morbidity gain and mortality gain that have been 
calculated above, in order to estimate the QALE gain (i.e. morbidity gain + mortality gain 
= QALE gain).  
 
In Table 8.1.7 the QALE gain is considered for the three thesis diseases independently. 
Hence, ‘QALE Gain stomach cancer’ comprises the morbidity gain for stomach cancer 
(calculated above in Table 8.1.3) summed with the mortality gain (calculated in Table 
8.1.6), and so forth for each disease. In theory all three disease morbidity gains and the 
mortality gain could be summed together (along with the thesis QALE gain for blindness, 
which will be achieved in Chapter 8.3), as well as all disease and disability morbidity in 
the economy (which will be achieved in Chapter 9). However, for analysis purposes the 
three diseases and disability will be kept separate and each will be independently summed 
with the mortality gain. This calculation is shown below in Table 8.1.7. 
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Table 8.1.7: QALE gain (morbidity gain + mortality gain): monetary value of improvements in the burden of morbidity and mortality for thesis 
diseases: breast cancer, stomach cancer, tuberculosis (millions of 1990 international $)687 
Period Mortality Gain Morbidity Gain: 
Stomach cancer 
QALE Gain 
Stomach cancer 
Morbidity 
Gain: Breast 
cancer 
QALE Gain 
Breast cancer 
Morbidity 
Gain: 
Tuberculosis 
QALE Gain 
Tuberculosis 
1900-1925 3895 278 4173 -196 3699 6776 10671 
1925-1950 3598 -7 3591 -741 2857 8088 11686 
1950-1975 2489 4151 6640 9601 12090 11977 14466 
1975-2000 8011 3677 11688 16979 24990 605 8616 
1900-2000 13769 4183 17952 5806 19575 26313 40082 
 
In Table 8.1.7 the mortality gain is derived from Table 8.1.6, where it was calculated. The morbidity gain for stomach cancer is derived from Table 
8.1.3, for breast cancer from Table 8.1.4 and for tuberculosis from Table 8.1.5, where these diseases morbidity gains have been calculated. The 
QALE gain columns in the above table are the sum of the mortality gain column and the associated disease morbidity gain column. For example, 
continuing with breast cancer between 1900 and 2000: the morbidity gain has been calculated (in Table 8.1.4) as 5806 (1990 international $) for 
1900-2000 and the mortality gain for 1900-2000 is 13769 (1990 international $), the QALE gain is the sum of these two facets = 19575 (5806 + 
13769), which is shown in the above table for the QALE gain for breast cancer between 1900 and 2000. 
                                                 
687
 For detailed calculations of the QALE gain in Table 8.1.7 (which  is considering the QALE gain as the sum of the morbidity gain [Table 8.1.3, 8.1.4, 8.1.5] and the mortality gain [Table 8.1.6]) see Appendix 12.5. 
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Hence, Table 8.1.7 considers the value of the morbidity gain (for the specific illness) 
summed with the mortality gain, which represents the QALE gain. This table illustrates a 
trend which is expected: for all eras where the morbidity gain was positive, the QALE is 
higher than the mortality gain and for all eras where there was a worsening in the 
morbidity gain (i.e. a morbidity loss) the QALE gain is lower than the mortality gain. The 
direction and magnitude of these combinations can be deduced from the above table and 
this will be considered in Figure 8.1.1 overleaf, in order to try and indicate the contribution 
of the morbidity gain and mortality gain towards the overall QALE gain.  
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Figure 8.1.1: QALE gain: value and composition of the morbidity gain and mortality gain towards QALE gain for thesis diseases: stomach cancer 
(SC), breast cancer (BC) and tuberculosis (TB), 1900-2000 (millions of 1990 international $)688 
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 See Appendix 12.5 for QALE gain and the composition of the morbidity and mortality gain towards the QALE gain. 
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Figure 8.1.1 illustrates the contribution of the mortality gain (blue bar connected to the x 
axis) and the morbidity gain (orange [stomach cancer], pink [breast cancer], red 
[tuberculosis] bars on top of the blue, mortality bars) to the overall QALE gain (height of 
both bars for each disease and era). Hence, the height of these bars (composed of blue and 
orange or pink or red segments) represents the value of the QALE gain. Furthermore, the 
placement of the morbidity bars also represents the direction (positive or negative) of the 
morbidity contribution to the overall QALE gain. If the morbidity bar is on top of the 
mortality gain bar then the morbidity gain has provided a positive contribution to the 
QALE gain and if the morbidity bar is below the mortality bar the morbidity gain is 
negative and has caused a reduction in the QALE gain. This latter phenomenon only 
occurred twice: for breast cancer in 1900-1925 and 1925-1950. 
 
For example, if we continue with twentieth century breast cancer: Table 8.1.7 has 
calculated the QALE gain by summing the mortality gain (calculated in Table 8.1.6) and 
the morbidity gain for breast cancer (calculated in Table 8.1.4). The relationship of these 
three variables is illustrated in Figure 8.1.1 through, first presenting the mortality gain 
(represented by the blue bar, at a value of 13,769 [shown in Table 8.1.7 and Figure 8.1.1 
where it is represented by the height of the blue bar = 0 to 13,769]), second is the 
morbidity gain which is represented by the pink bar (which sits directly on top of the blue 
bar and represents a value of 5,806 [shown in Table 8.1.7 and Figure 8.1.1 where it is 
represented by the height of the pink bar = 13,769 to 19,575, so 19,575 – 13,769 = 5,806]), 
lastly, the QALE gain is represented by the combined height of the blue and pink bar 
which indicates a QALE gain value of 19,575 (millions of international $) for breast cancer 
between 1900 and 2000. This is calculated by summing the mortality gain and the 
morbidity gain in accordance with the QALE methodology (see Figure 8.1 for a reminder 
of this methodology). Finally, because the pink bar is on-top-of the blue bar, this highlights 
that the morbidity gain has provided a positive contribution to the overall QALE gain. 
 
Hence, for ease of review Figure 8.1.1 illustrates the QALE gain segmented for the 
contribution of the mortality gain and morbidity gain. This illustrates the direction of the 
morbidity gain (or loss) and the magnitude of the morbidity gain in order to highlight how 
mortality and morbidity are driving the change in the overall QALE gains.  
 
Through considering the magnitude and direction of the morbidity gain relative to the 
mortality gain, in order to determine the contribution of improved morbidity to the QALE, 
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Figure 8.1.1 illustrates two key points. First, that there were only two instances where there 
were negative contributions from morbidity (breast cancer in 1900-1925 and 1925-1950, 
shown by the pink bar being below the blue bar in Figure 8.1.1) and there was only one 
zero contribution (from stomach cancer in 1925-1950, shown by only a blue bar for the 
mortality gain as there was no morbidity gain, which is represented by a zero contribution). 
Hence, in 12 out of 15 instances, morbidity provided a positive contribution to mortality. 
This finding provides a strong justification about the value of twentieth century 
improvements in morbidity and the need to measure this in conjunction with mortality. 
  
The other striking feature of Figure 8.1.1 is the magnitude of morbidity gains relative to 
mortality gains in many instances. The reason for this is very important and is essentially 
because of the difference in the inherent nature of morbidity and mortality, with regards to 
their influence upon the population. Mortality is a one time only event whereas morbidity 
has, in theory, an infinite number of possible events (which can even occur concurrently, 
i.e. co-morbidity), confined only by the one time occurrence of mortality. I.e. while an 
individual is alive, there is scope for an infinite number of morbidity events but once one 
mortality event has occurred there is scope for no more as the individual is dead. 
Furthermore, as the twentieth century unfolded the disease environment evolved such that 
the most prevalent illness burdens switched to chronic and not infectious diseases, which 
augmented the persistence of morbidity. This reality provides a subtle but very powerful 
message about the importance of considering more than just mortality when trying to 
gauge the health of the nation, as there are many (more) improvements evident for 
morbidity. This finding helps to bolster one of the foundational claims of the thesis: the 
need to measure health (morbidity) in some form of model that can calculate mortality and 
morbidity improvements in tandem. 
 
Furthermore the momentous improvement in tuberculosis also fills a significant historical 
void. To date, the contribution of improvements in this infectious disease is likely to have 
been underestimated as it was not possible to make the above quantifications, which yield 
important results about morbidity. Furthermore, this trend is likely to be consistent with the 
vast majority of infectious diseases and therefore provides an even greater boost to existing 
credit for the medical revolution which eliminated this category of morbidity and 
mortality.  
 
Results: Quantitative: Disease 
                                                                                                                                                                                                                 - 287 - 
Along a similar vein, the results for breast and stomach cancer are also momentous, largely 
for the evidence against pessimistic commentaries of the epidemiological transition that 
they provide. Hence, even though the prevalence of these diseases has increased (to replace 
infectious diseases) during the twentieth century, the improvements in quality of life 
associated with these diseases (fostered by advanced medical technology and welfare 
initiatives) has been significant enough (in the majority of instances) to have created a 
more favourable morbidity situation over the twentieth century, illustrated by the increase 
in the morbidity gain (pink and orange bars) in Figure 8.1.1. 
 
Finally, when considering breast and stomach cancer, the magnitude of the QALE gain for 
these diseases in the period 1900-2000 is noteworthy. This similarity was identified below 
Table 8.1.4 but deserves an additional consideration. This statistic seems misleading at an 
initial approximation, especially if it is viewed in conjunction with Table 8.1.1, which 
highlights the differing prevalence and burden of stomach and breast cancer. However, it is 
necessary to maintain that the QALE gain is actually considering the compound average 
change in the morbidity burden [and an identical mortality gain for breast and stomach 
cancer] which yields relatively similar results that are accurate when the entire twentieth 
century is considered. A key reason is that the value of the change in the morbidity burden 
between 1900 and 2000, which, by coincidence are relatively similar for breast cancer and 
stomach cancer, and also because of the QALY for 1900-2000, although this is higher for 
breast cancer. These illnesses share the same 1900 QALY and the higher breast cancer 
QALY by 2000 actually serves to contribute to the coincidental (but not wrong or 
anomalistic) similarity in the breast cancer and stomach cancer morbidity gains for 1900-
2000. 
 
The key feature to note from the above analysis (illustrated in Figure 8.1.1) is the largely 
positive contribution provided by the morbidity gain (which embodies improvements in the 
prevalence and/or the burden of morbidity) and the mandate this provides for adopting a 
fuller notion of health and the indication it provides about the inaccuracy of pessimist 
claims about the worsening morbidity associated with improving mortality, which is not 
true when a more rounded view of morbidity is adopted, which has been achieved here for 
the first time in the literature (for example, if the pessimists were correct then every 
morbidity bar in Figure 8.1.1 would be below the corresponding mortality bar, as this 
represents morbidity detracting mortality gains, which is simplistically what the pessimist 
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school are claiming). The above findings and conclusions will be verified below through a 
series of sensitivity analyses. 
 
8.1.4 Sensitivity Analyses 
In order to highlight the veracity of the above findings and the more general claims of the 
thesis which are based upon this analysis, it is desirable to test the results through 
considering different values (Low and High as well as the existing Mid value, utilised 
above) for the most tenuous variables in the thesis, namely, QALY, VSL and VSHLY689. 
This will generate a broad spectrum of possible results (precisely 378) about the QALE 
gain.  
 
A final aspect of the sensitivity analysis is age-weighting. Murray’s age weighting function  
will be applied to the range of QALE gain results in order to provide estimate that account 
for claims in the literature that these gains have been more and less valuable for certain 
ages. For an elaboration of the appeal and process of age weighting see Chapter 3. This 
will provide an additional series (containing 378 results) of QALE gain estimates. 
 
Essentially this section will repeat the above methodological procedures (of identifying the 
morbidity gain then mortality gain and the subsequent QALE gain) but using different 
QALY, VSL and VSHLY variables. These alternative QALE gain results (as well as those 
identified in Table 8.1.7) will also be applied to Murray’s age-weighting function. This 
part of the methodology is represented by stage 11 in the flow chart example at the 
beginning of Chapter 8 (and also draws on stages 5 to 10 as it is repeating the above 
methodological process).  
 
8.1.4.1 QALY Weights 
The QALY was established through an intricate and objective qualitative analysis of the 
health and welfare related quality of life for different illnesses and eras of the twentieth 
century (conducted in Part II of the thesis). Developing a QALY for different illnesses and 
eras is one of the thesis’ core contributions to knowledge. The QALYs used here are totally 
unique and wide reaching as they have been derived from a detailed review of the literature 
and data relevant to the key aspects of health and welfare related quality of life for the 
thesis illnesses during the twentieth century. Because of the potential scope for subjectivity 
                                                 
689
 The author of the thesis believes the ‘Mid’ age-weighted estimates to be the most accurate and plausible, but has provided a series of 
coherent alternatives in an effort to validate the estimates and overall conclusions of the thesis. 
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and/or opinion variance in the thesis’ analysis and also associated with QALYs in general, 
a range of QALY estimates will be considered. With reference to the flow chart example at 
the beginning of Chapter 8, this represents stage 11b of the methodology and will also 
heavily utilise stage 5 as the QALY is reconsidered. Stages 5 to 10 will also be 
implemented as the QALE methodology is recalculated using an alternative QALY for the 
morbidity burden (=prevalence*QALY). 
 
The range of QALY estimates used in this analysis considers the mid QALY estimate, 
which is depicted by ‘Mid’ in conjunction with a ‘Low’ and ‘High’ estimate. These two 
estimates were derived through identifying the QALY level below and above the ‘Mid’ 
estimate (which has been presented above in Table 8.1). This is likely to be an 
exaggeration of the variance that a critic would want, but is intended to provide an extreme 
range in order to highlight the veracity of the thesis claims. The range of QALY estimates, 
for the diseases considered in the thesis are shown below. For a more detailed explanation 
about the QALY and QALY value eliciting in the thesis, see Chapter 3 and the flow chart 
example at the beginning of Chapter 8. 
Table 8.1.8: Alternative QALY values (Low, Mid, High) for thesis diseases: breast cancer, 
stomach cancer, tuberculosis690 
Year Breast Cancer Stomach Cancer Tuberculosis 
 Low Mid  High Low Mid  High Low Mid  High 
1900 0.1667 0.3333 0.5000 0.1667 0.3333 0.5000 0.1667 0.3333 0.5000 
1925 0.1667 0.3333 0.5000 0.1667 0.3333 0.5000 0.3333 0.5000 0.6667 
1950 0.3333 0.5000 0.6667 0.3333 0.5000 0.6667 0.5000 0.6667 0.8333 
1975 0.5000 0.6667 0.8333 0.5000 0.6667 0.8333 0.6667 0.8333 1 
2000 0.6667 0.8333 1 0.5000 0.6667 0.8333 0.6667 0.8333 1 
 
Table 8.1.8 illustrates the mid QALY, which has been derived through the thesis’ analysis 
in the ‘Mid’ column, shown in bold, and this is sandwiched between a lower (‘Low’) and 
upper (‘High’) estimate. This part of the sensitivity analysis is designed to address 
concerns about the accuracy of the valuation of unhealthy life year estimates, and therefore 
an exaggerated margin of error has been considered for the value of the QALYs. The 
alternative positive margin is presented in the ‘High’ column. I.e. this provides a more 
generous QALY estimate for the reader who is concerned that the thesis (mid) QALY 
                                                 
690
 See Part II and Chapter 7 and Chapter 3 and see Appendix 12.6.1 for alternative QALY weights. 
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estimates are too pessimistic, and the negative margin is presented in the ‘Low’ column 
and addresses observer concerns about the thesis (mid) QALYs being too generous.  
 
Once the values of the QALYs have been estimated it is possible to apply them to the 
methodology in the same way that has been achieved above for the ‘Mid’ QALY. Hence, 
the first stage is to estimate the morbidity burden, through the same process outlined 
previously in this chapter: the morbidity burden is estimated through identifying and 
combining (multiplying) the prevalence and the QALY (as above, when doing the 
calculation 1-QALY is utilised) associated with the disease and era, for the age 
standardised population structure in T1 and T2 (which is later average through identifying 
the mid-point between T1 and T2). Once this has been achieved it is possible to measure 
the change in the morbidity burden between the start [T1] and end [T2] point of the period. 
This change in the morbidity burden can then be valued through combining it with the 
VSHLY, which will yield the morbidity gain, in this instance for higher and lower QALY 
variable.  
 
These alternative (higher and lower) QALYs will be utilised in two places in the 
methodology: i) when estimating the morbidity burden (prevalence * QALY) and ii) when 
estimating the VSHLY (VSL * QALY).  
 
As in the above methodological process, this morbidity gain (for higher and lower QALYs) 
can then be combined with the mortality gain (which will remain the same as it was in the 
previous section because the QALY change only affects the morbidity features of the 
QALE methodology) in order to estimate the QALE gain. This is achieved below for 
alternative QALY weights for the QALE gain, where the mortality gain utilised is the same 
as that presented in Tables 8.1.6 and 8.1.7 and the morbidity gain is considered for the 
‘Mid’ QALYs (which are the same as the existing estimate in Tables 8.1.3, 8.1.4, 8.1.5 and 
8.1.7) and the ‘Low’ and ‘High’ alternative sensitivity analysis QALYs. 
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Table 8.1.9: QALE gains for thesis diseases: breast cancer (BC), stomach cancer (SC), 
tuberculosis (TB) with alternative (Low, Mid, High) QALY values (millions of 1990 
international $)691 
Period LOW QALY MID QALY HIGH QALY 
 QALE 
Gain 
SC 
QALE 
Gain 
BC 
QALE 
Gain 
TB 
QALE 
Gain 
SC 
QALE 
Gain 
BC 
QALE 
Gain 
TB 
QALE 
Gain 
SC 
QALE 
Gain 
BC 
QALE 
Gain 
TB 
1900-1925 4035 3794 7935 4173 3699 10671 4317 3593 13318 
1925-1950 3594 3153 9337 3591 2857 11686 3588 2560 13920 
1950-1975 5445 9319 11807 6640 12090 14466 7805 14784 17145 
1975-2000 10770 21260 8493 11688 24990 8616 12610 28835 8734 
1900-2000 16546 17929 32624 17952 19575 40082 19324 21251 47682 
 
Table 8.1.9 is making the same considerations that were made earlier in Table 8.1.7, but in 
less detail. Hence, the above table presents the final QALE gain result (for different QALY 
values), whereas Table 8.1.7 made the same calculation (using the mid QALY) but 
included the mortality gain and the diseases specific ‘morbidity gains’ as well as 
presenting the final result, the QALE gain. These detailed calculations for alternative 
QALY weights are conducted in appendices 12.7.1 and 13.2.1.  
 
The QALE gain results in the above table are generally what would be expected. Hence, 
the higher the QALY weight (i.e. increasing from ‘Low’ to ‘Mid’ to ‘High’), the greater 
the magnitude of the QALE gain. This is for two key reasons; as the QALY approaches 
one, the burden of the disease declines and provides a greater morbidity (and subsequent) 
QALE gain and also, the higher the QALY (closer to one), the higher the VSHLY 
becomes, which also contributes to increasing the value of the morbidity (and subsequent) 
QALE gain. With reference to the flow chart example and specifically the EuroQol to 
QALY conversion table (Table 7.1), the higher the QALY, the closer the quality of life for 
illnesses sufferers was to ‘complete quality of life’, which would represent a lower 
morbidity burden. 
 
However, there are exceptions to this trend: breast cancer in 1900-1925 and 1925-1950, 
and stomach cancer in 1925-1950. These are a result of the morbidity gain being negative 
                                                 
691
 Table 8.1.9 is based on the same type of calculations as Table 8.1.7. See Appendix 12.6.1 for alternative QALY weights. See Appendix 13.2.1 for 
calculation of QALE gain using alternative QALY weights (see mid VSL, mid VSHLY with low, mid, high QALY).  
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or zero (in the case of stomach cancer). Hence, under these circumstances, increasing the 
QALY increases the amount of value lost and the subsequent detraction for the QALE 
gain. This phenomenon (of a negative or zero morbidity gain) is the same as that which 
was identified for the mid QALY QALE gain shown in Table 8.1.7. 
 
Also noteworthy is the similarity of the values yielded, regardless of the QALY weight. 
This adds credibility to the estimates of the thesis as it indicates that, regardless of the 
QALY value chosen (within a very generous margin) the aggregate conclusion is the same. 
 
Hence, the general results of this QALY sensitivity analysis highlight that when the QALY 
is higher the contribution to overall health and the relationship with mortality is higher and 
vice versa when the QALY is lower. In some cases the contribution is negative as a result 
of a worsening morbidity profile. When the QALE contribution is negative, the higher the 
QALY the more negative the QALE gain (or loss) becomes.  
 
8.1.4.2 VSL and VSHLY Weights 
The thesis has already presented the disputes associated with the identification of the 
correct VSL and subsequent VSHLY (see Chapter 3). This will be abated as much as 
possible through considering the QALE gain with a series of additional (‘Low’ and ‘High’) 
weights for the VSL and VSHLY components of the methodology. This aspect of the 
sensitivity analysis makes the same methodological calculations as above (i.e. morbidity 
gain + mortality gain = QALE gain), but will do this with alternative VSL (for valuing the 
mortality gain) and VSHLY (for valuing the morbidity gain) weights, namely, a lower and 
a higher weight series to enhance the mid weights that have been utilised above. 
 
With reference to the stages in the above flow chart example, this represents stage 6: 
selecting the VSL and stage 7: calculating the VSHLY, and also an integral aspect of 
stages 8 and 9: the valuation of the mortality burden change (VSL) and the valuation of the 
morbidity burden change (VSHLY), respectively. After which stage 10 will be conducted, 
where the new morbidity gain and mortality gain are summed to estimate the QALE gain 
(for alternative VSL and VSHLY weights). More specifically, this process relates to stage 
11a and 11c, as this represents the sensitivity analysis of the VSL and VSHLY.  
 
Alternative VSL and VSHLY values are derived through considering the low and high 
estimates of Miller’s VSL multiple, provided in Chapter 3: Table 3.3. With reference to the 
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worked example above in Chapter 8, Table 8.2 illustrates the calculation of the VSL (VSL 
mid multiple [128] * GDP per capita at mid point). In the VSL sensitivity analysis here, the 
thesis will be changing the VSL multiple (from 128 to 101 and 154) in order to estimate a 
lower and higher VSL. The GDP per capita component remains the same. 
 
The VSHLY is a function of the VSL and the QALY (VSL*QALY=VSHLY). With 
reference to the above worked example in Chapter 8, Table 8.3 shows the construction of 
the mid VSHLY. The VSHLY calculation involves: i) a new VSL (higher or lower, 
explained above) and ii) the same, mid QALY for the VSL*QALY=VSHLY calculation.  
 
The results presented in this VSL and VSHLY sensitivity analysis (presented in Table 
8.1.10) are derived from an intricate consideration of all the possible combinations of VSL 
and VSHLY within the QALE methodology (shown in Appendix 13.2.1). Table 8.1.10 
(below) presents the QALE gain results for VSL and VSHLY mid values (which are equal 
to the pre sensitivity analysis results, shown in Table 8.1.7) and the most extreme values 
(i.e. ‘Low’ VSL, ‘Low’ VSHLY and ‘High’ VSL, ‘High’ VSHLY). 
Table 8.1.10: QALE gains for thesis diseases: breast cancer (BC), stomach cancer (SC), 
tuberculosis (TB) with alternative VSL and VSHLY values (millions of 1990 international $)692 
Period Low VSL Low VSHLY Mid VSL Mid VSHLY High VSL High VSHLY 
 QALE 
Gain 
SC 
QALE 
Gain 
BC 
QALE 
Gain 
TB 
QALE 
Gain 
SC 
QALE 
Gain 
BC 
QALE 
Gain 
TB 
QALE 
Gain 
SC 
QALE 
Gain 
BC 
QALE 
Gain 
TB 
1900-1925 3314 2935 8404 4173 3699 10671 5053 4475 12815 
1925-1950 2855 2276 9180 3591 2857 11686 4353 3470 13997 
1950-1975 5220 8678 11405 6640 12090 14466 7959 13231 17390 
1975-2000 9211 19722 6785 11688 24990 8616 14045 30071 10346 
1900-2000 14201 15505 31720 17952 19575 40082 21653 23642 48364 
 
The table above considers the QALE gain with a series of different weights for the 
valuation of the change in the mortality burden (VSL) and for the change in the morbidity 
burden (VSHLY). Table 8.1.10 presents QALE gain results which utilise the mid and most 
extreme (lowest and highest) VSL and VSHLY values. The overall trend is the positive 
correlation between the value of the VSL and VSHLY and the value of the QALE gain. 
                                                 
692
 Table 8.1.10 is based on the same type of calculations as Table 8.1.7, but with alternative VSL and VSHLY values. See Appendix 12.1.1 for VSL and 
VSHLY range of values to be included in sensitivity analyses and Appendix 13.2.1 for calculations (see mid QALY with low, mid, high VSL and VSHLY). 
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This is expected because the higher the value of improvements in these health valuation 
variables (embodied in the VSL being applied to the change in the mortality burden and 
VSHLY to the change in the morbidity burden), the higher the QALE gain.  
 
The results in Table 8.1.10 provide a substantial indication about the consistency of the 
value of improvements in mortality and morbidity, regardless of which VSL and VSHLY 
variables are utilised. This finding is important as it provides a justification for earlier 
claims in the thesis that the precise value of the VSL was not paramount because of the 
nature of the VSL and also the magnitude of improvements in health. This is highlighted 
by Table 8.1.10, where there is variance in the value of the QALE gain depending on the 
VSL and VSHLY, but this variance is not great enough to contradict any of the other 
QALE gain results in the thesis (based on different VSL and VSHLY values). 
 
In order to fully justify the above claims that the values of the VSL and VSHLY will not 
affect the overall findings of the QALE methodology, it is desirable to briefly consider the 
QALE gain value that would be yielded according to the VSL elasticities argued by Costa 
versus Viscusi. Chapter 3: Table 3.4 has highlighted the divergence in opinion about the 
elasticity of the VSL and subsequent change in the VSL over the twentieth century. The 
table below summarises the estimate of an alternative VSL and subsequent QALE gain for 
Costa (who claims a VSL income elasticity of approximately 1.6) versus Viscusi (who 
claims that the VSL is income inelastic over time in the region of 0.6) versus the mid 
(unitary elasticity) VSL that has been used in the thesis (derived from Miller’s estimates). 
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Table 8.1.11: VSL value and subsequent mortality and QALE gain for thesis diseases when assuming different levels of VSL income elasticity: 
Costa versus Viscusi, 1900-2000 (millions of 1990 international $)693 
Study VSL income 
elasticity 
1900-2000 VSL 
value (millions) 
Mortality Gain QALE Gain 
Breast cancer 
QALE Gain 
Stomach cancer 
QALE Gain 
Tuberculosis 
Costa & Kahn694 1.6 0.64 10014 14226 13056 29104 
Viscusi & Aldy695 0.6 1.18 18675 26530 24285 54275 
Thesis (Miller)696 1 0.88 13769 19575 17952 40082 
 
Table 8.1.11 is considering the QALE gain that is yielded through including alternative VSL and VSHLY weights. This process is the same as what 
has been achieved above in Table 8.1.10 for ‘Low’ and ‘High’ VSL and VSHLY weights (relative to the thesis ‘Mid’ estimate, derived from Miller, 
which is shown in Tables 8.1.7, 8.1.10 and here in Table 8.1.11). Hence, the QALE gain yielded here includes a mortality gain and morbidity gain 
that have been calculated in the same way as above. The difference is the weight of the mortality and morbidity change valuation variables (VSL 
and VSHLY). In Table 8.1.11 the VSL and VSHLY have been chosen in accordance with Costa and Viscusi (whereas in Table 8.1.10 the 
alternative valuation weights [VSL and VSHLY] were selected in accordance with Miller’s estimates of a ‘Low’ and ‘High’ VSLs).  
 
The results in Table 8.1.11 are not surprising when the mortality and QALE gains are considered as a function of the VSL (and corresponding 
VSHLY, shown in Appendix 12.7.3). Viscusi’s results are consistently higher than the thesis (Miller) and Costa results, respectively. This is 
because the Viscusi VSL (and subsequent VSHLY [= VSL * QALY]) is higher than the thesis and Costa VSLs. Moreover, the magnitude of 
difference between these QALE gains is also not surprising, as they reflect the difference in magnitude between the VSLs. 
                                                 
693
 See Appendix 12.7.3 for more detailed calculations  
694
 Costa & Kahn, “Changes in the Value of a Statistical Life, 1940-1980”, p. 1 
695
 Viscusi & Aldy, “The Value of a Statistical Life: A Critical Review of Market Estimates Throughout The World”, p. 44 
696
 The thesis estimates are based on Miller, where unitary elasticity is implied 
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The most noteworthy and important observations, for the thesis, are identified when Table 
8.1.11 is compared to Table 8.1.10. Both of these tables provide VSL and VSHLY 
sensitivity analyses (although the rationale is different). The VSL and VSHLY weight 
variance is more pronounced for the VSL weights in Table 8.1.11 (this can be highlighted 
by comparing the VSL weights in Table 8.1.11 with those in Table 8.1.10 and 
subsequently the QALE gain result range is greater in Table 8.1.11. For example, once 
again, considering breast cancer for 1900-2000, the (underlying) VSL range in Table 
8.1.10 is 0.70 – 1.06 and VSHLY is 0.41 – 0.62 compared to the  (underlying) VSL range 
in Table 8.1.11 is 0.64 – 1.18 and VSHLY is 0.37 – 0.69 in Table 8.1.11. The result is that 
the range of the QALE gain estimates (for different VSL and VSHLY weights) is broader 
in Table 8.1.11. In Table 8.1.10 the QALE gain for breast cancer 1900-2000 ranges from 
15,505 (‘Low’ VSL and ‘Low’ VSHLY) to 23,642 (‘High’ VSL and ‘High’ VSHLY) 
compared to the greater range in Table 8.1.11 of 14,226 (Costa) to 26,530 (Viscusi) in 
Table 8.1.11. 
 
The most remarkable feature about the above observation is that, although the results in 
Table 8.1.11 provide a broader range of QALE gain estimates, they still accord with the 
results in Table 8.1.10 and the general QALE gain conclusions throughout the thesis. 
Moreover, because of the evident variance in the literature (highlighted by Costa versus 
Viscusi estimates in Table 8.1.11), it is possible to argue that the thesis VSL selection 
provides a respectable mid-point between the variance in the literature and a representative 
estimate.  
 
Therefore, the consistent trend of the above results is that the higher the value of the VSL 
and subsequent VSHLY, the greater the mortality gain and morbidity gain and ultimate 
QALE gain (as this is the sum of the mortality and morbidity gain).  
 
Finally, in Table 8.1.10 (and Table 8.1.11) there is a fundamental, clear and consistent 
trend which is valuable in the context of the thesis because it confirms that, whatever 
weight (within the thesis’ broad range) is adopted for the VSL (and subsequent VSHLY), 
the QALE gain is still substantial. Hence, the overall conclusions of the thesis remain 
unchanged and the only alteration is the magnitude of the QALE gain, which always 
contributes to the same conclusion about the value of twentieth century improvements in 
health.  
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8.1.4.3 VSL and VSHLY and QALY Weights 
To complete the thesis sensitivity analyses it is desirable to combine the above two 
versions of sensitivity analysis and consider one aggregate series of different results for 
considering the full range of values (‘Low’, ‘Mid, ‘High’) for all methodological variables 
(QALY, VSL, VSHLY). Once this has been achieved all variables of the methodology will 
have been considered for all their possible ranges and combinations of ranges and 
subsequently the QALE will yield the broadest series of estimates possible (within the 
thesis sensitivity analysis), in order to provide the broadest indication about the value of 
improvements in health.  
 
With reference to the flow chart example at the beginning of Chapter 8, this represents the 
combination of stages 11a, 11b and 11c. Also, as was the case in the QALY sensitivity 
analysis and the VSL and VSHLY sensitivity analysis, stages 8, 9 and 10 will also be 
utilised as the QALE will be recalculated for alternative QALY, VSL and VSHLY 
weights. In an effort to simplify the mass of possible results (provided in appendices 12.7.1 
and 13.2.1) the table below will provide a summary about the ‘Mid’ and most extreme 
results: ‘Low’ QALY, VSL, VSHLY and ‘High’ QALY, VSL, VSHLY.  
Table 8.1.12: QALE gains for thesis diseases: breast cancer (BC), stomach cancer (SC), 
tuberculosis (TB) with alternative QALY, VSL and VSHLY values (millions of 1990 
international $)697 
Period Low VSL, Low VSHLY, 
Low QALY 
Mid VSL, Mid VSHLY, 
Mid QALY 
High VSL, High VSHLY, 
High QALY 
 QALE 
Gain 
SC 
QALE 
Gain 
BC 
QALE 
Gain 
TB 
QALE 
Gain 
SC 
QALE 
Gain 
BC 
QALE 
Gain 
TB 
QALE 
Gain 
SC 
QALE 
Gain 
BC 
QALE 
Gain 
TB 
1900-1925 3204 3013 6281 4173 3699 10671 5224 4353 16053 
1925-1950 2857 2510 7389 3591 2857 11686 4350 3113 16781 
1950-1975 4298 7355 9318 6640 12090 14466 9392 17789 20630 
1975-2000 8487 16765 6690 11688 24990 8616 15154 34675 10492 
1900-2000 13107 14198 25793 17952 19575 40082 23327 25645 57444 
 
                                                 
697
 Table 8.1.12 is based on the same type of calculations as Table 8.1.7 and 8.1.9 and 8.1.10. See Appendix 12.1.1 for VSL and VSHLY range of values to be 
included in sensitivity analyses and Appendix 12.6.1 for range of QALY values and Appendix 12.7.1 and 13.2.1 for calculations. 
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Table 8.1.12, consider the most extreme (highest and lowest) and mid point combinations 
of the VSL, VSHLY and QALY (for the thesis’) sensitivity analysis weights, which was 
achieved through recalculating the change in the morbidity burden using a lower and 
higher QALYs (than the mid that was used in the initial part of Chapter 8.1), and then 
valued, to calculate the morbidity gain, through using a lower and higher VSHLY 
(comprised of all combinations of a lower and higher VSLs and QALYs, as VSL * QALY 
= VSHLY). The same considerations were applied to mortality, through recalculating the 
value of the change in the mortality burden with alternative lower and higher VSL values. 
This exercise has created a range of QALE gain values, which are a function of the 
variable weights (i.e. low or high QALY, VSL and VSHLY). 
 
The results from this exercise (in Table 8.1.12) show a general trend, which is expected: as 
the value of the VSL, VSHLY or QALY weight increases the value of the QALE gain also 
increases. This result is logical as the more value is attributed to the change in the mortality 
and morbidity burden, the higher the QALE gain will be.  
 
The level of variance between the results in Table 8.1.12 is greater than for previous 
QALE gain calculations in the thesis (shown in Table 8.1.6 for the ‘Mid’ QALE gain and 
in Table 8.1.8 for the QALE gain with alternative QALYs and in Table 8.1.10 for the 
QALE gain with alternative VSL and VSHLY weights). This result is what would be 
expected, because the thesis is considering different weights for a greater number of 
variables in Table 8.1.12, than in any previous table that is using the alternative thesis 
variable weights (i.e. Table 8.1.11, which considers alternative author weights is not 
included in this observation). 
 
The most noteworthy observations, particularly from the perspective of the thesis, is that, 
regardless of whatever QALYs, VSLs and VSHLYs are utilised, when the twentieth 
century is considered in its entirety all illnesses provide a valuable contribution to 
mortality gains, and the overall QALE estimate, which reinforces the value of improved 
health and substantiates the robustness of the thesis conclusions. 
 
8.1.4.4 Age Weights 
A final process of sensitivity analyses is to consider claims that the value of mortality and 
morbidity improvements are not constant across all age groups. The rationale and theories 
surrounding this have been covered in detail in Chapter 3. Figure 8.1.2 (below) illustrates 
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the weights that will be applied to the QALE gain established above. This calculation 
represents stage 11d in the flow chart example at the beginning of Chapter 8.  
 
The age weighting function (shown in Figure 8.1.2) will only be applied to the central or 
mid QALE gain results. This is desirable because it provides an indication of the effect of 
considering age weighting for the QALE gain without an excess of data that would confuse 
the conclusions of this exercise. For the more comprehensive reader these calculations 
have been made for every combination of the QALE gain (i.e. the age weighting function 
has been applied to all of the sensitivity analyses, above) in appendices 12.8 to 12.10 and 
13.3 to 13.5. Furthermore, the summary twentieth century QALE gain results (presented in 
Chapter 8.3) provides an age weighted equivalent for all QALE gain variable weight 
combinations for 1900-2000. 
 
The procedure here is to recalculate the (central) QALE gain results of the thesis (shown in 
Table 8.1.7) with the age weighting function shown in Figure 8.1.2. I.e. so far the QALE 
gain results have valued mortality and morbidity gains as equal across all age groups of the 
population, whereas the age weighting function is accounting for differences in the value 
of morbidity and mortality gains at different ages. E.g. in Figure 8.1.2 a life year at ages 0-
4 are only worth 30 percent of a life year versus ages 15-34, which are worth 1.5 times a 
life years. Therefore, in simplistic terms, the QALE gain would need to be reduced by 70 
percent for ages 0-4 and inflated by 50 percent for ages 15-34, and so on.  
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Figure 8.1.2: Murray’s age weight function of DALYs: relative value of a year of life lived 
at different ages698 
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The application of such a weighting is very straightforward because the weights provided 
by Murray (1996) are clear and versatile. Moreover, because the thesis has consistently 
considered the morbidity and mortality gain for the age distribution of the population, 
Murray’s age weighting can be directly  applied to the existing data and this will document 
a reduction or increase in the (mortality gain, morbidity gain and subsequent) QALE gain 
of the different age groups, by the magnitude outlined in Figure 8.1.2. 
 
 
                                                 
698
 Murray, “Rethinking DALYs”, in Murray & Lopez, “The Global Burden of Disease”, p. 60 
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Table 8.1.13:  Age weighted QALE gains (using mid value QALY, VSL, VSHLY variables) for thesis diseases: breast cancer, stomach cancer, 
tuberculosis (millions of 1990 international $)699. 
Period Mortality Gain Morbidity Gain: 
Stomach cancer 
QALE Gain 
Stomach cancer 
Morbidity Gain: 
Breast cancer 
QALE Gain 
Breast cancer 
Morbidity Gain: 
Tuberculosis 
QALE Gain 
Tuberculosis 
1900-1925 2710 244 2954 -52 2658 1687 4397 
1925-1950 2943 84 3027 -738 2205 9633 12576 
1950-1975 1415 3145 4560 7854 9269 13540 14955 
1975-2000 4862 2554 7416 14298 19160 596 5458 
1900-2000 9402 3368 12770 5627 15029 19538 28940 
 
This table provides a summary of the age-weighted QALE gain for the mid QALY, VSL and VSHLY sensitivity analysis variables. I.e. this is 
essentially the same calculation as in Table 8.1.7 but it is then applied to the age-weighting function illustrated in Figure 8.1.2 to generate the results 
shown in Table 8.1.13.  
 
Table 8.1.13 relays generally consistent result about the effect of applying an age weighting function to the mortality gain, morbidity gain and 
QALE gain. All of these observations are derived from comparing Table 8.1.7 with Table 8.1.13. The change in the mortality gain when applied to 
the age weighting function is an effect which consistently (and relatively significantly) reduced the value of the mortality gain.  
 
 
                                                 
699
 Table 8.1.13 is considering the QALE gain, which is the sum of the morbidity gain (Table 8.1.3, 8.1.4, 8.1.5) and the mortality gain (Table 8.1.6), which has been conducted for individual illnesses here. Table 8.1.13 is making the same 
considerations as Table 8.1.7 but applied to Murray’s age weighting function (shown in Figure 8.1.2). See Appendix 12.8, 12.9, 12.10.1, 13.3, 13.4, 13.5 for detailed calculations. 
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The change in the morbidity gain when applied to the age weighting function is similar to 
mortality but there are some important exceptions. First is that in five instances in Table 
8.1.13 applying the age weighting function created an increase in the value of the 
morbidity gain compared to the un-weighted equivalent in Table 8.1.7: breast cancer in 
1900-1925 and 1925-1950, stomach cancer in 1925-1950, tuberculosis in 1925-1950 and 
1950-1975. The episodes related to breast and stomach cancer are quite clearly a result of 
the morbidity gain being negative (i.e. a change in the morbidity burden that was negative) 
and therefore when the age weighting function is applied the negative change in the 
morbidity burden is reduced (as the age weighting function generally reduces the 
magnitude, as has been outlined above) which creates a more valuable (albeit still negative 
in most instances morbidity gain). This seemingly perverse effect for tuberculosis between 
1925 and 1975 is more ambiguous. It seems most likely that this could be a result of a 
significant decline in tuberculosis in the 1920s that was much more pronounced for 
middle/working ages (i.e. approximately ages 20-44, this is illustrated in Chapter 5: Figure 
5.6 and 5.8) which receive a greater age weight than all other ages in Murray’s age 
weighting function. This trend was also evident, although to a much lesser extent around 
the 1960s (illustrated in Chapter 5: Figure 5.8).  
 
Finally, the change in the QALE gain when applying to the age weighting function is also 
similar to mortality, with only one important exception, which was the continuation of the 
tuberculosis phenomenon between 1925 and 1975.  
 
A final important observation of the effect of applying an age-weighting function to the 
thesis QALE gain is the difference in the magnitude this effect has upon the mortality and 
morbidity gain. Precisely, the change in the morbidity gain for breast and stomach cancer 
is smaller than for mortality. This result implies that there have been greater improvements 
in middle aged morbidity associated with cancer than for tuberculosis and mortality, where 
the most improvements have been at the youngest and oldest ages, which receive a lower 
value when the age weighting function is applied. 
 
This observation is very important for the thesis as it adds additional weight to the 
arguments of the thesis concerning the need to include morbidity in health measures. 
Hence, a comparison of the mortality and morbidity gains in Table 8.1.7 (un-weighted) and 
Table 8.1.13 (age-weighted) indicates clear improvements in health that are not evident for 
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mortality (namely an improvements in the age burden of disease) and therefore these subtle 
morbidity gains need to be represented. 
 
These findings complete the sensitivity analyses of the thesis through reiterating that 
regardless what values are chosen (within the generous range of thesis variable weights) 
the QALE gain consistently generates results that confirm the conclusions of the thesis. I.e. 
the value of health improvements and the subsequent need to measure health is highlighted 
by all of the above results, regardless of the variable weights. This finding will be 
reinforced throughout the remainder of Part III of the thesis, when these results are 
considered in an extended measure of economic development, i.e. for their contribution to 
economic development (as an appendage to GDP per capita growth, below) and also (in 
Chapter 9) when the limited number of illnesses analysed in Chapter 8 will be extrapolated 
forward in order to provide a lowest bound estimate about the value of all twentieth 
century morbidity (and existing aggregate mortality) improvements.  
 
8.1.5 Value of QALE Gains Relative to GDP 
To bring greater significance to the above findings it is possible to consider the QALE gain 
in conjunction with GDP growth. This exercise is also important because it will highlight 
the authenticity of the thesis claims to consider wider notions of economic development 
that include health, e.g. through appending some form of health statistic to national income 
measures to account for improvements in health and standards of living. Hence, as well as 
standardising the above QALE gains with economic growth the information below will 
provide a more accurate account of aggregate twentieth century economic welfare growth.  
 
This analysis will utilise the age-weighted ‘Mid’ or central QALE gain results that have 
been derived above, in Table 8.1.13, because these are deemed to be the most accurate. 
Therefore, the mortality, morbidity and QALE gain results presented in Table 8.1.13 will 
be used here to calculate the compound average rate of growth for each of these variables 
(see Table 8.1.14) so that the difference in value of growth can be identified between: 
mortality, morbidity, QALE and GDP. This will enable the two key benefits of this section 
to first to highlight the extensiveness of health developments relative to GDP, and second, 
emphasise the demands of the thesis about the need to include health measures in some 
form of extended national income. 
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After this has been achieve the QALE growth will be considered in conjunction with GDP 
growth in order to present a single, rounded growth estimate, where the value of the QALE 
gains will be added to the value of GDP for the era under consideration and the combined 
compound average growth rate will be calculated (see Table 8.1.15) in order to provide a 
first approximation about what the extended national income would have been for 
twentieth century England.  
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Table 8.1.14: Compound average growth rates of: GDP per capita, mortality gain, morbidity gain and QALE gain (using mid value QALY, VSL, 
VSHLY variables and age weighting) for thesis diseases: breast cancer, stomach cancer, tuberculosis (percentage per annum)700 
Period GDP pc 
Growth  
Mortality 
Gain Growth 
Morbidity Gain Growth QALE Gain Growth 
 
 
 Stomach 
cancer 
Breast 
cancer 
Tuberculosis         
 
Stomach 
cancer 
Breast 
cancer 
Tuberculosis 
 
1900-1925 0.3 2.2 0.2 0 1.4 2.4 2.1 3.5 
1925-1950 1.4 2.0 0.1 -0.4 6.5 2.0 1.4 8.4 
1950-1975 2.2 0.7 1.4 3.5 6.0 2.0 4.1 6.4 
1975-2000 1.8 1.3 0.7 3.6 0.2 1.8 4.7 1.4 
1900-2000 1.4 1.4 0.5 0.8 2.8 1.9 2.2 4.2 
 
Table 8.1.14 considers the compound average growth rate of GDP per capita, mortality, morbidity (by disease) and QALE (by disease). This is 
achieved through applying the most credible mortality gain, morbidity gain and QALE gain estimates (which are deemed by the author to be the 
age-weighted mid values presented in Table 8.1.13)  to the compounding formula, in order to generate an estimate about average growth per annum 
for the twentieth century.  
 
Once this has been achieved it is possible to consider the relative value of mortality, morbidity and QALE gains versus GDP gains. This 
consideration reiterates the need to consider both mortality and morbidity: given the magnitude of average annual growth of mortality gains and 
morbidity gains. For example, in Table 8.1.14, mortality gain growth was approximately as much as GDP growth during the entire twentieth 
century, and in the earlier years (1900-1950) mortality growth gains were greater than GDP growth gains.  
                                                 
700
 See Appendix 12.11 for GDP per capita compound average growth rate calculations and see Appendix 12.12.1 and 13.6.1 for mortality and morbidity gain growth calculations. 
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Table 8.1.14 also highlights the value of morbidity gains relative to mortality and GDP 
gains, although the relationship is not as consistent as the contribution of mortality to GDP. 
Tuberculosis experienced the greatest morbidity gain growth for the twentieth century in 
general, which was exceptionally pronounced between 1925 and 1975, when tuberculosis 
morbidity gains were contributing more to welfare growth than mortality or GDP. Between 
1950 and 1975 breast cancer also experienced important gains which were more 
pronounced than mortality and GDP growth. 
 
A final crucial point that is reflected in Table 8.1.14 is the magnitude of mortality and 
morbidity gains (and especially the combination of these facets embodied in the QALE 
gain) in nearly every single era of the twentieth century relative to GDP growth. This 
reinforces the need to consider health in some form of extended GDP measure (which will 
be reiterated below) and also the need to ensure that morbidity (as well as mortality) is 
included in health measures.  
 
Table 8.1.15 (below) aggregates the results of Table 8.1.4 in order to provide an indication 
of what a more rounded welfare national income would represent. This is achieved through 
imputing GDP per capita growth with QALE growth (both shown independently in Table 
8.1.14), in order to create a series of ‘Adjusted Growth’ estimates, which essentially 
represent national income growth adjusted for twentieth century gains in QALE. 
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Table 8.1.15: Compound average growth rates of GDP per capita growth adjusted for 
QALE gain (using mid value QALY, VSL, VSHLY variables and age weighting) for thesis 
diseases: breast cancer, stomach cancer, tuberculosis (percentage per annum)701 
Period GDP pc  
Growth  
QALE Gain Growth ‘Adjusted Growth’  
 (QALE + GDP pc) 
 
 
Stomach 
cancer 
Breast 
cancer 
Tuberculosis 
 
Stomach 
cancer 
Breast 
cancer 
Tuberculosis 
 
1900-1925 0.3 2.4 2.1 3.5 2.7 2.4 3.8 
1925-1950 1.4 2.0 1.4 8.4 3.4 2.8 9.8 
1950-1975 2.2 2.0 4.1 6.4 4.2 6.3 8.6 
1975-2000 1.8 1.8 4.7 1.4 3.6 6.5 3.2 
1900-2000 1.4 1.9 2.2 4.2 3.3 3.6 5.6 
 
Table 8.1.15 considers GDP per capita growth per annum and QALE gain growth per 
annum and (these two indices are summed in order to estimate) ‘Adjusted Growth’, which 
represents what GDP per capita per annum growth would be if it was extended to include 
gains in health or QALE. This exercise provides ‘Adjusted Growth’ levels that are very 
noteworthy, as they highlight the significance of overall health improvements to the value 
of historical economic development. Hence, the findings in Table 8.1.15 justify the need to 
consider health or QALE gains in an extended form of GDP.  
 
Therefore, the above tables suggest that taking account of QALE gains creates a much 
more favourable indication of the improvements in economic growth and particularly 
living standards in twentieth century England. The results highlight the need to rethink the 
way in which national income and health are considered and computed and specifically the 
need to provide national income data that incorporates utility and health measures that 
include morbidity.  
 
These findings will be reinforced in the following chapter when similar considerations and 
calculations are made for the thesis’ disability, blindness. This data provides the first 
genuine quantitative indication about the value of improvements in disability (to match 
those made above for disease) for twentieth century England.  
                                                 
701
 See Appendix 12.11 for GDP per capita compound average growth rate calculations and see Appendix 12.12.1 and 13.6.1 for QALE gain growth 
calculations. 
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8.2 Disability (Blindness)  
8.2.1 QALY Values and Prevalence Estimates      308   
8.2.2 Morbidity Gain         311 
8.2.3 Mortality Gain         315 
8.2.4 QALE Gain           315  
8.2.5 Sensitivity Analyses: QALY and VSL and VSHLY Weights    318 
8.2.6 Value of QALE Gain Relative to GDP       321 
 
8.2.1 QALY Values and Prevalence Estimates 
The qualitative account of blindness in twentieth century England has highlighted that 
there were improvements in the overall quality of life associated with being blind, 
particularly during the first half of the twentieth century. The process below will derive a 
quantitative estimate for the value of these improvements. This will be achieved in a very 
similar process to the methodology that has been outlined above (in Chapter 8 and 8.1). All 
stages of the flow chart example apply to the calculation of the QALE gain for blindness 
(in a very similar way as it was calculated for diseases above).  
 
The key benefit of this exercise is to provide an indication of the value of improvements in 
quality of life associated with disability that can be combined with the QALE gain for 
disease. This will also provide results which are necessary so that the findings about 
disability can be represented in the ‘Extended Results’ (Chapter 9) of the thesis. 
 
The first stage of this quantitative analysis for disability is to calculate the prevalence and 
summarise the quality of life (QALY) associated with blindness for the eras considered in 
the thesis. In accordance with the thesis methodology outlined in the flow chart example, 
this represents stage 5 (identifying the QALY from EuroQol) and also part of stage 9 
(compiling illness data). Once both of these data sets have been identified it will be 
possible to calculate the morbidity burden (prevalence * QALY), which provides the 
foundation for stage 9 and eventually identifying the morbidity gain and subsequent (when 
applied to the mortality gain identified in Chapter 8.1) QALE gain. These primary 
calculations are summarised below in Table 8.2.1 (prevalence) and 8.2.2 (QALY). 
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Table 8.2.1: Number of blind persons and average number of blind years and 
corresponding prevalence of blindness in 1900, 1925, 1950, 1975 and 2000702 
Year Number of blind 
persons 
Average number of 
years of blindness  
Total blind years Blind years per 
annum / Prevalence 
10069 23 1900 
8520 8 
299747 11990 
10956 19 1925 
18120 9 
371244 14850 
10572 68 
19517 24 
1950 
17890 10 
1366204 54648 
24900 26 1975 
53783 9 
1131447 45258 
2000 108896 11 1197856 47914 
 
Estimating the prevalence of blindness in the economy is more complicated than 
identifying disease prevalence (which was achieved above in Chapter 8.1). This is largely 
because of the nature of disabilities (more protracted and ambiguous in duration and cure) 
and the subsequent way in which disability data is collected and recorded (without any 
detail or follow-up). Therefore, an alternative approach to estimating the prevalence of 
blindness is adopted here: the prevalence data above is derived from considering the 
number of people who are blind and the average number of years that they spent in 
blindness (which is equivalent to the number of years of life expectancy at the age of onset 
of blindness). This is necessary as there are no official estimates of the prevalence of 
blindness.  
 
In Table 8.2.1 prevalence is estimated with two (three in 1950) entries for the number of 
blind persons and years because there were generally two (three in 1950) most common 
ages of blindness, which were considered in the estimation of the prevalence of blindness. 
A detailed explanation of the calculations and results of this unique disability prevalence 
estimating process is provided in Chapter 4: Table 4.9 and 4.10.  
 
                                                 
702
 In Table 8.2.1 the ‘Number of blind’: those registered as blind, ‘Average number of blind years’: estimated from the age distribution and profile of 
blindness in the relevant era, for an elaboration and base calculations see Chapter 4: Tables 4.9 and 4.10 and Appendix 12.13.1, ‘Total blind years’: 
multiplying the two previous columns and ‘Blind years per annum’: ‘Total blind years’/25 to achiever per annum estimates. Note: these are period estimates, 
which provide a snapshot of prevalence for the year stated in column 1 of Table 8.2.1. 
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A noteworthy feature associated with the prevalence of blindness calculated in Table 8.2.1 
is the improvement in the approximate average number of years of blindness during the 
twentieth century, which declined from nearly 16 years in 1900 and a peak of 34 years in 
1950 to about 11 years of blindness by 2000 (calculated by averaging the ‘average number 
of years of blindness’ entries in Table 8.2.1 for each year). Although this is only an 
estimate, because of the problems associated with identifying blind prevalence by age, the 
results are still important. In contrast to the average number of blind years the ‘prevalence’ 
of blindness (used in the thesis) has increased from approximately 11,990 blind years per 
annum in 1900 to 47,914 in 2000 (shown in Table 8.2.1)703. 
 
The next key variable, which is also considered consistently across the thesis (although 
contains slightly different facets for disability and disease) is the quality of these blind life 
years, QALY704. The QALY is the variable that represents the burden of illness through 
considering its consequence upon a healthy life year, such that the QALY is the fraction 
(greater than 0 which approximates death) of 1, which represents a full healthy life year. 
These results about the QALY for blindness during different eras of the twentieth century 
are shown in Table 8.2.2. In the same way as for diseases, the blind QALY has been 
derived in Chapter 7 (through EuroQol). Table 8.2.2 also reports 1-QALY, which is the 
index needed for calculating the morbidity burden, because of the way in which the QALY 
is considered in the QALE methodology (this has been explained in more detail above in 
Chapter 8.1: Section 8.1.1). 
Table 8.2.2: QALY values for thesis disability: blindness705 
Year QALY (1-QALY) 
1900 0.3333 0.6667 
1925 0.5000 0.5000 
1950 0.6667 0.3333 
1975 0.6667 0.3333 
2000 0.6667 0.3333 
 
Table 8.2.2 highlights that the quality of life associated with blindness improved between 
1900 and 1950, and that despite marginal improvements in the quality of life during the 
                                                 
703
 It should be noted that the prevalence statistic calculated here (Table 8.2.1) differs from the ‘prevalence of blindness in twentieth century England’ statistic 
provided earlier in the thesis (see Figure 4.1 in Chapter 4). The reason for the difference is that the prevalence (here, in Chapter 8.2) considers ‘blind years’ 
and not just the number of blind who returned an authentic BD8 form, in order to register as such. 
704
 See Chapter 3: Subsection 3.5.1: Key Variables for an elaboration 
705
 See Appendix 12.6.2 for blind QALY calculations. 
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second half of the twentieth century (outlined in Chapter 4 and summarised in Chapter 
7.1); none of these were far reaching enough to improve blind persons’ quality of life into 
a more superior (EuroQol [in Chapter 7.1] and subsequent) QALY between 1950 and 
2000.  
 
The impact of the change in the prevalence (outlined above in Table 8.2.1) and the QALY 
(shown in Table 8.2.2) will be combined in order to calculate the morbidity burden 
(prevalence * QALY) and identify the change in the morbidity burden over time, which 
can subsequently be valued (using the VSHLY) in order to estimate the morbidity gain. 
This methodological process is the same as the calculation of the disease morbidity gain in 
Chapter 8.1, except that for disability (blind) the morbidity burden (and subsequent gain) 
will be calculated in aggregate and not by age, for the age distributional profile of the 
population as was achieved for diseases in Chapter 8.1 because the data to make this more 
sophisticated calculation does not exist for blindness. 
  
8.2.2 Morbidity Gain 
As in Chapter 8.1 the morbidity gain highlights the value of improved morbidity facilitated 
by an improvement in the burden of diseases or disability morbidity. An improvement in 
the morbidity burden can be generated by an improvement in the QALY and/or the 
prevalence.  
 
In order to highlight the morbidity gain it is necessary to first document the change in the 
morbidity burden of blindness, which is achieved in Table 8.2.3. (After the change in 
morbidity burden has been estimated it will be possible to combine this with the associated 
VSHLY and calculate the morbidity gain).  
Table 8.2.3: Calculation of morbidity burden of thesis disability: blindness 
Year Prevalence (1-QALY) Morbidity burden 
1900 11990 0.6667 7994 
1925 14850 0.5000 7425 
1950 54648 0.3333 18214 
1975 45258 0.3333 15084 
2000 47914 0.3333 15970 
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Table 8.2.3 considers the number of blind years ‘prevalence’ (derived from Table 8.2.1) 
and the associated quality of these years ‘QALY’ (Table 8.2.2) in order to determine the 
morbidity burden (prevalence * 1-QALY706) of blindness. This calculation is the 
equivalent of the more detailed process outlined in Chapter 8.1 (Tables 8.1.2.i and 8.1.2.ii) 
but different because the blind morbidity burden is calculated aggregately with no 
accounting for the changing age profile structure of the population. Although the results in 
Table 8.2.3 represent a more approximate estimate of the morbidity gain (versus those 
identified for diseases in Chapter 8.1) the results are still valuable and indicative. 
 
Table 8.2.3 highlights that there were improvements in the burden of blindness during the 
twentieth century, although this was not linear, due to the worsening around the middle of 
the twentieth century and an increase in the prevalence of blindness at the end of the 
century (which was a result of an increase in the number of blind as the average duration of 
blindness declined over the twentieth century [shown in column 3 of Table 8.2.1]). This set 
back in the decline in the prevalence of blindness in 1950 was a result of (accidental) 
adverse medical intervention (for the administration of oxygen to premature babies), which 
caused a condition of blindness known as Retrolental Fibroplasia and a subsequent 
increase in the number of blind at birth. The result of this adverse medical intervention was 
a worsening in period estimates about the burden of blindness for 1950 (shown in the table 
above) but was not significant enough (as the effects of such were identified and largely 
rectified by the 1960s) to show up in the next cohorts estimates707. Although, it should be 
noted that part of the morbidity burden decline between 1950 and 1975 is excessively high 
due to this increase in the prevalence of blindness in 1950. This occurrence is also 
noteworthy as it indicates that medical progress has not always been linear during the 
twentieth century, an important historical detail that is not illustrated by the other 
morbidity states in the thesis. 
 
The table below provides the next stage of the disability quantitative analysis which is 
considering the above blind morbidity burden change in conjunction with a value 
(presented as the VSHLY) of this decline in order to estimate the morbidity gain. 
 
 
                                                 
706
 1-QALY is utilised in the morbidity burden calculation in Table 8.2.3 in accordance with the QALE methodology (this is explained briefly above Table 
8.2.3 and in more detail in Chapter 8.1). 
707
 Silverman, “Retrolental Fibroplasias: A Modern Parable”, Chapters 3, 8, 9, 11 
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Table 8.2.4: Morbidity gain (morbidity burden change*VSHLY): monetary value of 
improvements in the burden of morbidity: blindness (millions of 1990 international $)708 
Period Morbidity burden 
change 
VSHLY Blind morbidity 
gain 
1900-1925 569 0.27 154 
1925-1950 -10789 0.45 -4855 
1950-1975 3130 0.77 2410 
1975-2000 -886 1.36 -1205 
1900-2000 -7976 0.44 -3509 
 
Table 8.2.4 illustrates the process of calculating the morbidity gain. The first stage of this 
calculation is to identify the change in the morbidity burden, which is achieved through 
considering the change between T1 and T2 (shown in the final column of Table 8.2.3) For 
example, the 1900-1925 morbidity burden change = morbidity burden in T1 (1900 in this 
example) minus the morbidity burden in T2 (1925 in this example), i.e. 7,994 - 7,425 = 
569.  
 
The next stage of the calculation in Table 8.2.4 is to value the change in the morbidity 
burden, which is yielded by applying the VSHLY to the morbidity burden change 
(morbidity burden change * VSHLY = morbidity gain). The VSHLY is estimated by 
considering the VSL and the QALY (VSL*QALY), in the same way as was outlined in 
detail in Chapter 8.1 (and is also outlined in the flow chart example [stage 7] at the 
beginning of Chapter 8). For example, continuing with the period 1900-1925, where the 
identified morbidity change was 569, this is then applied to the VSHLY for blindness in 
the period 1900-1925 (which is yielded by multiplying the VSL with the QALY for the 
period 1900-1925 [shown to be 0.4167 in Table 8.3]   0.64*0.4167 = 0.27 [millions of 
1990 international $]). Once the VSHLY has been calculated it is then applied to the 
change in the morbidity burden in order to estimate the morbidity gain. In the example of 
blindness between 1900 and 1925, the morbidity gain = the change in the morbidity 
burden*VSHLY (569*0.27=154), which results in a morbidity gain of 154 (million 1990 
international $) for blindness between 1900 and 1925. 
 
                                                 
708
 See Appendix 12.7.2 (mid estimates) for base calculations underlying the results in Table 8.2.4.  
Results: Quantitative: Disability 
                                                                                                                                                                                                                 - 314 - 
The above table highlights both positive and negative trends in the morbidity gain. The 
negative morbidity gains in 1925-50 and 1975-2000 and 1900-2000 are as a potential result 
of a worsening in the burden (prevalence and/or QALY) of blindness. More precisely a 
worsening in the prevalence of blindness and not the QALY as this improved in the period 
1925-1950 and especially in the period 1900-2000 and was maintained between 1950 and 
2000, as Table 8.2.2 highlights.  
 
Therefore, it should be noted that the worsening in the morbidity gain in 1925-1950, 1975-
2000 and 1900-2000 is entirely a result of increased prevalence of blindness and despite 
the extensiveness of this increase it is partially compensated by improvements in the 
QALY (and also, for the periods 1975-2000 and 1900-2000 it is largely a function of an 
increase in life expectancy). I.e. if there were no QALY improvements for blind sufferers 
during the twentieth century and the same substantial increase in blind prevalence then the 
morbidity gain (or loss as is the case) would have been more than twice as unfavourable (-
8780 instead of -3059 (derived through conducting the same calculation in Table 8.2.3 and 
8.2.4 but holding the QALY constant at the 1900 level709). This dramatises the value of 
improvements in the quality of life (QALY).  
 
Additionally, if there were no improvements in life expectancy between 1900 and 2000710 
then the prevalence of blindness would have been only 26,135 in 2000 and the subsequent 
burden of blindness (prevalence [26135] * QALY [0.3333]) would have been 8,711 in 
2000, which is only marginally greater than the 1900 burden of 7,994, which would mean 
that the blind morbidity gain (loss in this case) would be -315 instead of -3509 (the level 
that is largely a result of increased life expectancy).  
 
Following the same methodological process outlined in the flow chart example and also 
adhered to in Chapter 8.1, the next stage in estimating the QALE for blindness is to 
identify the mortality gain (so that this can be summed with the morbidity gain [presented 
above for blindness in Table 8.2.4] in order to estimate the QALE gain).  
 
                                                 
709
 Calculation: 47914*0.6667=31944  4937-31944=-19954  -19954*0.44=-8780 
710
 Considering life expectancy at 75 for 1900 and 2000. Life expectancy by age data: Figures based on the ‘Office of National Statistics/Government 
Actuaries Department’ England and Wales mortality database. This is still subject to revisions.  Extract was provided by Mita Saha (Office of National 
Statistics) on March 17 2006. See Appendix 12.15 for a copy of exert. 
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8.2.3 Mortality Gain 
The mortality gain results utilised here are the same as those that were yielded above in 
Chapter 8.1 (Table 8.1.6). To recap: the first step in identifying the mortality gain is to 
identify the change in the death rate or mortality burden. This is established through 
considering the change in the death rate. Once the change in the mortality burden has been 
identified it is possible to value this, through applying the VSL to the change (always a 
decline in the death rate in the twentieth century) in the mortality burden. The result of this 
calculation (decline in mortality burden * VSL) will yield the mortality gain. These results 
are shown in the second column of Table 8.2.5. For a more detailed review of the mortality 
gain, see Chapter 8.1: Section 8.1.2: Primary Valuation of Improvements in Mortality.  
 
8.2.4 QALE Gain 
Following the same methodological process as in Chapter 8.1, the next stage in estimating 
the QALE gain is to combine the morbidity gain and the mortality gain. This represents 
stage 10 in the flow chart example at the beginning of Chapter 8. The QALE gain for 
blindness is presented below in Table 8.2.5.   
Table 8.2.5: QALE gain (morbidity gain + mortality gain): monetary value of 
improvements in the burden of morbidity and mortality for thesis disability: blindness 
(millions of 1990 international $)711 
Period Average mortality 
gain 
Blind morbidity 
gain 
QALE gain 
Blindness 
1900-1925 3895 154 4049 
1925-1950 3598 -4855 -1257 
1950-1975 2489 2410 4899 
1975-2000 8011 -1205 6806 
1900-2000 13769 -3509 10260 
 
Table 8.2.5 presents the calculation and results of the QALE gain for blindness (mortality 
gain + blind morbidity gain = QALE gain). These blind QALE gain result highlight that in 
1925-1950, to a lesser degree in 1975-2000, and in 1900-2000, the morbidity burden 
associated with blindness worsened and therefore provided a negative contribution to the 
QALE gain. I.e. the blind morbidity gain was negative and therefore unable to provide 
extended QALE gains in addition to the mortality gain. This was particularly pronounced 
                                                 
711
 See Appendix 12.7.2 (mid estimates) for base calculations.  
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for 1925-1950, which was outlined earlier, as the result of Retrolental Fibroplasia. 
Conversely, in 1900-1925 and 1950-1975 the morbidity burden for blindness improved and 
was able to provide a positive contribution to the QALE gain. As has been mentioned 
above, the mortality gain was positive in all the thesis eras of the twentieth century and 
therefore always provided a positive contribution to the QALE gain.   
 
The relationship between the mortality gain and morbidity gain within the overall QALE 
gain can be considered in order to provide a more vivid indication of the key contributor to 
the QALE gain associated with blindness. This comparison is shown below in Figure 8.2.1. 
Figure 8.2.1: QALE gain: value and composition of the morbidity gain and mortality gain 
towards QALE gain for thesis disability: blindness (millions of 1990 international $)712 
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Figure 8.2.1 illustrates the contribution of the mortality gain (blue bar) and the morbidity 
gain (pink bar) to the overall QALE gain (height of blue bar + pink bar). Furthermore, the 
placements of the morbidity bars also represent the direction (positive or negative) of the 
morbidity contribution to the overall QALE gain. If the morbidity gain bar is on top of the 
mortality gain bar then the morbidity gain has provided a positive contribution to the 
QALE gain, and if the morbidity bar is below the mortality bar the morbidity gain is 
negative and has caused a reduction in the QALE gain. This trend was evident in 1925-
1950, 1975-2000 and 1900-2000. 
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 See Appendix 12.7.2 for the QALE gain and the composition of the morbidity and mortality gain towards the QALE gain. 
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Through considering the magnitude and direction of the morbidity gain relative to the 
mortality gain, in order to determine the contribution of improved morbidity to the QALE 
gain, the above figure illustrates a very important finding: in only two instances were there 
positive contributions of blind morbidity to the blind QALE gain (1900-1925 and 1950-
1975 [which was partially a result of the worsening in the blind morbidity gain in the 
previous era, 1925-1950]). This finding marks a stark contrast to the morbidity gains 
achieved by the thesis disease morbidity (see Figure 8.1.1 for a direct comparison), where 
the morbidity gains were usually positive and in certain instances more valuable than the 
mortality gain. This indicates that, in general, morbidity gains for disabilities were often 
negative and generally much less valuable than the morbidity gains associated with 
diseases in twentieth century England. Although, it should be noted that a major driver of 
blind morbidity increases was prevalence (not the QALY as this improved during the 
twentieth century) and more specifically, more individual cases of prevalence as the 
average number of blind years declined per sufferer. These features are not accounted for 
in the above analysis but should be recognised as they abate a small aspect of the poor 
performance of the blind morbidity burden in twentieth century England.  
 
The above results and analyses are powerful in highlighting the nature and extensiveness 
of improvements in blind morbidity. The final exercise below will ensure that the trends 
above are accurate through applying detailed sensitivity analyses. In keeping with Chapter 
8.1 this will contain additional (Low and High) estimates about the VSL, VSHLY and 
QALY. However, this will not include an age-weighting exercise as the data does not exist 
to make these considerations. With reference to the flow chart example at the beginning of 
Chapter 8, the following section will apply the (QALE gain) results from stage 10 
(identified above) to stages 11a, 11b, and 11c. 
 
When the same sensitivity analysis stages were applied to the disease QALE gain (in 
Chapter 8.1 above), each stage (11b then 11a+11b then 11a+11b+11c) was initially 
conducted separately and then all stages of the QALY, VSL, VSHLY sensitivity analysis 
were considered in aggregate (see Table 8.1.12). This chapter benefits from this previous 
gradual and detailed explanation, and will therefore only consider the aggregate sensitivity 
analysis that comprises all variables: QALY, VSL, VSHLY (i.e. stages 11a, 11b and 11c). 
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8.2.5 Sensitivity Analyses: QALY and VSL and VSHLY Weights 
In this section the sensitivity analysis the morbidity and mortality calculations will be 
conducted with the extremes (Low and High) and mid-point (Mid) value weights for the 
methodology variables: QALY, VSL and VSHLY. Once this has been achieved this 
chapter will yield the broadest possible range of estimates about the value of the QALE 
gain for blindness. In reference to the flow chart example this process will repeat stages 5 
to 10 through applying the sensitivity analysis (stages 11a, 11b, and 11c) alternative 
weights. The alternative weights that will be used for the blind morbidity gain (QALY and 
VSHLY) and the mortality gain (VSL) are shown in Table 8.2.6 below. 
Table 8.2.6: Alternative (Low and High) and Mid: QALY, VSL, VSHLY weights for QALE 
gain sensitivity analysis: thesis disability: blindness (millions of 1990 international $)713 
Year QALY VSL VSHLY 
 Low Mid High Low Mid High Low  Mid High 
1900-1925 0.2500 0.4167 0.5834 0.51 0.64 0.77 0.21 0.27 0.32 
1925-1950 0.4167 0.5834 0.7500 0.60 0.77 0.92 0.35 0.45 0.54 
1950-1975 0.5000 0.6667 0.8333 0.92 1.16 1.40 0.61 0.77 0.93 
1975-2000 0.5000 0.6667 0.8333 1.61 2.05 2.46 1.08 1.36 1.64 
1900-2000 0.3334 0.5000 0.6667 0.70 0.88 1.06 0.35 0.44 0.53 
 
Table 8.2.6 presents the values for the different variable weights used in the thesis’ 
sensitivity analysis for the blind QALE gain, where ‘Mid’ represents the central values that 
have already been utilised above (in Table 8.2.5) as the mainstream values for the blind 
QALE gain. ‘Low’ represents an exaggerated weight for the reader who believes that the 
thesis has over emphasised the extensiveness and value of the morbidity gain (QALY and 
VSHLY) and over valued the mortality gain (VSL). For the reader that believes the 
opposite, i.e. that the thesis’ central weights (represented in ‘Mid’) have underestimated 
the value of the morbidity and mortality and subsequent QALE gain, the ‘High’ weights 
are provided. 
 
As has already been explained, the QALY for blindness during different eras of the 
twentieth century was established through an intricate review of all relevant information 
sources and forms the nucleus of the blind analysis in the thesis. Despite this wide survey it 
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 See Appendix 12.1.2 for alternative VSL and VSHLY values and Appendix 12.6.2 for alternative QALY values for thesis disability: blindness and 
Appendix 13.2.2 for QALE gain calculations. 
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is impossible to identify a definitive and undisputed QALY value. In recognition of this 
and to highlight that the thesis results still hold without an identical QALY to the ones 
utilised above, the analysis below will consider the QALE gains with alternative (Low and 
High) QALYs. The method for calculating these alternatives (lower and upper bound 
estimates for the blind QALY) utilises the same process as Chapter 8.1, where a lower and 
upper bound QALYs are used to represent ‘Low’ and ‘High’ in addition to ‘Mid’, which 
was identified by the thesis’ detailed analysis.  
 
In common with the QALY, the VSL has endured much criticism and a lack of consensus 
about a definitively correct value. Therefore, in an attempt to recognise this and overcome 
any claims of bias the thesis will consider the blind morbidity and QALE gain for a range 
(Low and High) of VSL and subsequent VSHLY values. This consideration is in alignment 
with the analyses conducted for diseases in Chapter 8.1.  
 
Hence, the rationale for considering the QALE gain for all combinations of sensitivity 
analysis is the same for the blind QALE gain as it was for the diseases QALE gains 
outlined (in more detail) above, in Section 8.1. To this end, Table 8.2.7 will provide the 
results of calculating these alternative QALY, VSL and VSHLY weights in the QALE gain 
methodology (for blindness). Also in common with Chapter 8.1, in an effort to simplify the 
mass of possible results (the full range of which are provided in appendices 12.7.2 and 
13.2.2) the tables below will provide a summary about the ‘Mid’ and most extreme results, 
in order to provide the broadest possible array of estimates. This will be achieved through 
considering the highest possible QALE gain estimate (High VSL, High VSHLY, High 
QALY) and the lowest possible (Low VSL, Low VSHLY, Low QALY), in conjunction 
with the mid estimates (Mid VSL, Mid VSHLY, Mid QALY). 
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Table 8.2.7: QALE gains for thesis disability: blindness with alternative QALY, VSL and 
VSHLY values (millions of 1990 international $)714 
Period Low QALY, Low 
VSL, Low VSHLY 
Mid QALY, Mid 
VSL, Mid VSHLY 
High QALY, High 
VSL, High VSHLY 
1900-1925 3212 4049 4897 
1925-1950 -915 -1257 -1464 
1950-1975 3875 4899 5908 
1975-2000 5353 6806 8168 
1900-2000 8028 10260 12271 
 
Table 8.2.7 highlights and summarises a general trend for the blind QALE gain: as the 
value of the QALY, VSL and VSHLY increase so does the value of the QALE gain, with 
the exception of 1925-1950, which displays the opposite trend, whereby increasing the 
weight of the variables (i.e. moving from ‘Low’ to ‘High’) increases the magnitude of the 
loss or increasingly reduces the QALE gain. This can be considered as a result of an 
increasingly valuable opportunity cost of the negative morbidity gain. The general trend in 
Table 8.2.7 (shown for all other years) is sensible as the QALY, VSL and VSHLY are the 
valuation aspects of health improvements (QALY and VSHLY for the morbidity gain + 
VSL for the mortality gain, which all contribute to the QALE gain) and therefore, when the 
magnitude of these variables increases so do the morbidity and mortality gain, which 
subsequently increases the QALE gain. 
 
A final noteworthy trend in Table 8.2.7 is the considerable variance between the lowest 
and highest estimates, i.e. the values in ‘Low QALY, Low VSL, Low VSHLY’ versus 
‘High QALY, High VSL, High VSHLY’. This variance in the QALE gain can be 
interpreted to be a result of the very broad sensitivity analysis (utilised in the thesis), which 
encompasses a range of twenty seven estimates (instead of one estimate) as a result of 
considering QALY: Low, Mid, High; VSL: Low, Mid, High; VSHLY: Low, Mid, High, 
and all possible combinations of these estimates in the QALE methodology.  
 
Despite the wide range of estimates and the considerably lower value of the disability 
QALE gain (compared to the diseases QALE gains identified in Chapter 8.1) these blind 
QALE gain results are still important as they provide a broader indication of twentieth 
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 Table 8.2.7 is based on the same type of calculations as Table 8.1.7 and 8.1.11 and 8.1.10. See Appendix 12.1.2 for VSL and VSHLY range of values to be 
included in sensitivity analyses and Appendix 12.6.2 for range of QALY values and Appendix 12.7.2 and 13.2.2 for calculations. 
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century health (encompassing disability as well as disease) and, although relatively 
minimal (and negative in 1925-1950), these blind QALE gains still contribute to the claims 
and conclusions that have been made throughout the thesis about the importance of 
twentieth century trends in health and the need to measure this in some form of extended 
national income. 
 
8.2.6 Value of QALE Gain Relative to GDP 
It is desirable to consider these results relative to twentieth century GDP per capita. 
Chapter 3 and Chapter 8.1 have explained and justified (in more detail) the appeal of 
considering the QALE results in conjunction with GDP growth. The process conducted in 
Chapter 8.1 will be applied here in order to highlight the contribution of the QALE gain for 
disability relative to GDP, and subsequently estimate a more accurate national income 
index that accounts for disability (in addition to disease which has already been calculated 
in Chapter 8.1). 
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Table 8.2.8: Compound average growth rates of GDP per capita, mortality gain, morbidity gain and QALE gain and GDP per capita growth adjusted 
for QALE gain (using mid value QALY, VSL, VSHLY variables and age weighting mortality) for thesis disability: blindness (percentage per 
annum)715 
Period GDP pc Growth Mortality Gain 
Growth 
Blind Morbidity 
Gain Growth 
Blind QALE Gain 
Growth 
‘Adjusted Growth’  
 (QALE + GDP pc) 
1900-1925 0.3 2.2 0.1 2.3 2.6 
1925-1950 1.4 2.0 -3.2 -1.3 0.1 
1950-1975 2.2 0.7 1.1 1.7 3.9 
1975-2000 1.8 1.3 -0.3 0.9 2.7 
1900-2000 1.4 1.4 -0.5 0.9 2.3 
 
Table 8.2.8 considers the compound average growth rate of GDP per capita, and mortality, morbidity and QALE gain growth (for blindness). This is 
achieved through applying the most credible mortality gain, morbidity gain and QALE gain estimates for blindness (which are deemed by the author 
to be the mid morbidity gain values, presented in Table 8.2.5 and the age-weighted mid mortality gain values presented in Table 8.1.14) to the 
compounding formula, in order to generate an estimate about average growth per annum of these variables for the twentieth century.  
 
Once this has been achieved it is possible to consider the relative value of mortality gains, morbidity gains and QALE gains versus GDP gains. This 
consideration reiterates the limited magnitude of the blind morbidity and QALE gain relative to the morbidity and subsequent QALE gains for the 
diseases considered in the thesis. For example, in Table 8.2.8, the blind morbidity gain growth was less than the mortality gain in 1900-1925, 1925-
1950, 1975-2000 and 1900-2000 (i.e. in every period other than 1950-1975). Furthermore, this detraction was so extensive that the blind QALE gain 
was less valuable than the mortality gain in 1925-1950, 1975-2000 and 1900-2000.  
                                                 
715
 See Appendix 12.11 for GDP per capita compound average growth rate calculations and see Appendix 12.2 and 12.12.2 and 13.6.2 for QALE gain growth calculations. 
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Table 8.2.8 also considers ‘Adjusted Growth’ (shown in the final column), which 
represents what GDP per capita per annum growth would be if it was extended to include 
gains in health or QALE (i.e. ‘Adjusted Growth’ = GDP per capita growth + QALE gain 
growth). The above trend of a generally negative blind QALE gain growth is reflected here 
as the contribution of the blind QALE gain to ‘Adjusted Growth’ is nearly entirely a result 
of the morbidity gain (as the blind morbidity gain tended to be minimal or negative).  
 
Therefore, the above analysis has highlighted the value of twentieth century improvements 
in the quality of life associated with blind morbidity. Although when the blind morbidity 
gain is compared to GDP per capita and the mortality gain (and the disease morbidity 
gains) the results are less impressive, this should not detract from the previous findings in 
this chapter, which highlight important improvements in the quality of life for the blind 
(embodied in the improved QALY [shown in Table 8.2.2] and a decline in the average 
number of blind years per episode [shown in Table 8.2.1]). Finally, the contrast in the 
twentieth century history of disability and disease is highlighted by the analysis here, 
which provides an additional (and not necessarily predictable) important historical detail 
for the story about the health and welfare related quality of life of the population in 
twentieth century England. 
Results: Quantitative: Summary: Disability and Disease 
                                                                                                                                                                                                                 - 324 - 
8.3 Summary Quantitative Results 
8.3.1 Summary Presentation of QALE Gains       324 
 
8.3.1 Summary Presentation of QALE Gains 
This final segment of Chapter 8 will provide a summary of the previous analyses (for 
diseases and disability) and enable the reader to identify and evaluate what they deem to be 
the most feasible estimates about the value of the QALE gain. With reference to the flow 
chart example at the beginning of Chapter 8, this represents stage 12, where the reader is 
able to identify the value of the QALE gain (for tuberculosis, breast and stomach cancer 
and blindness) associated with what they believe about the value of the QALY, VSL and 
VSHLY used in the thesis and also whether they agree that Murray’s age weighting 
function should be applied to the results. 
 
Figure 8.3.1 (below) provides a summary flow chart of the QALE methodology sensitivity 
analyses, which contains different variable weights (‘Low’, ‘Mid’, ‘High’ values for the 
QALY, VSL and VSHLY), which are utilised to calculate the morbidity (QALY and 
VSHLY) and mortality (VSL) gains and then combined to form the QALE gain. Figure 
8.3.1 has been provided to illuminate the methodological process of the QALE gain 
sensitivity analysis and help the reader decipher what they believe to be an accurate QALE 
gain value. 
 
Following on from this flow chart, Table 8.3.1 provides a translation of the flow chart 
decisions. I.e. if the reader decides that: i) they are not willing to accept the thesis QALY 
and ii) that this is because they deem the QALY values outlined in the qualitative illness 
chapters as too high, Table 8.3.1 will translate what QALY value this reader favours (this 
is shown as the ‘Low value’ for the QALY [in the second row of Table 8.3.1]). Once the 
reader has made these considerations for all of the thesis QALE methodology variables 
(i.e. answered all stages of the flow chart) they will have created their profile of QALY, 
VSL and VSHLY values for use in the QALE gain methodology.  
 
Table 8.3.2 presents all of the possible combinations for the QALE methodology variables 
that the reader could have chosen from the flow chart in Figure 8.3.1. Hence, once the 
reader has chosen their preferred variable weights (from answering the flow chart 
questions) these are translated into the QALE gain methodology terminology (i.e. from 
‘flow chart term’ to ‘methodological term’) in Table 8.3.1. Then, Table 8.3.2 presents all 
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possible QALY, VSL and VSHLY and age weighting combinations, which are numbered 
to accord with the final two tables (8.3.3 and 8.3.4) in Chapter 8.3.  
 
Once the reader has identified the number that their profile QALE methodological variable 
weights have been given (shown in Table 8.3.2) they can identify their preferred QALE 
gain result (in Table 8.3.3 and 8.3.4), through finding the same number on these two tables.  
 
Table 8.3.3 and 8.3.4 provide the series of all possible QALE gains for the thesis 
sensitivity analysis variable weights. Table 8.3.3 shows all combinations of the QALE gain 
(i.e. this is the consideration made in Table 8.1.12 and 8.2.7). Table 8.3.4 shows this 
QALE gain in terms of QALE gain growth per annum for the twentieth century, which can 
the be appended to GDP per capita growth (referred to as ‘Adjusted Growth’ in Chapter 
8.1 and 8.2) to represent an extended national income growth that accounts for 
improvements in health (or ‘QALE gain growth’ in Tables 8.1.14, 8.1.15 and 8.2.8). To 
calculate ‘Adjusted Growth’ the QALE gain growth presented in Table 8.3.4 needs to be 
summed with GDP growth of 1.4 percent for 1900-2000. 
 
This process is presented below, starting with Figure 8.1.3, the flow chart for the QALE 
gain methodology choice of variables, and then continues in the sequence outlined above.  
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Figure 8.3.1: QALE gain methodology variable weight options 
1) 
 
 
 
 
 
 
 
2) 
 
 
 
 
 
 
 
3) 
 
 
 
 
 
 
 
4) 
 
 
 
 
 
 
 
 
 
Are you willing to accept the QALY values outlined in the qualitative illness chapters? 
 
YES 
 
NO 
Too High Too Low 
Are you willing to accept the VSL value outlined in the Methodology chapter? 
Are you willing to accept the notion and value of Murray’s Age-Weights? 
 
YES 
 
YES 
 
NO 
 
NO 
Too High Too Low 
QALE Gain 
Are you willing to accept the VSHLY value outlined in the Methodology chapter? 
 
YES 
 
NO 
Too High Too Low 
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Table 8.3.1: Translation of QALE methodological flow chart outlined in Figure 8.3.1 into 
QALE methodology variable weights (used in Tables 8.3.2, 8.3.3 and 8.3.4) 
Flow Chart Term: ‘Yes’ ‘No’ – ‘Too High’ ‘No – Too Low’ 
Methodological Term: Mid Value Low Value High Value 
 
These terms apply to the first three options in the chart, i.e. the QALY, VSL and VSHLY 
(which is a combination of the QALY and VSL). The final option in Figure 8.3.1, which is 
age-weighting, can be deciphered by a simple ‘Yes’ or ‘No’ decision. I.e. either the reader 
agrees with age-weighting (‘b’ in the tables below) or does not (‘a’ in the tables below). The 
blind QALE gain age-weighting only applied to the mortality gain component of the QALE 
gain (as the data does not exist to perform the age weighting calculations to the blind 
morbidity gain) and therefore answer ‘b’ for blind represents the blind QALE gain that 
comprises: un weighted blind morbidity gain + age weighted mortality gain.  
 
The table below provides the QALE methodology variable weight results of all the potential 
combinations of answers from the methodological flow chart. Once these have been 
outlined (in Table 8.3.2) the reader will be able to identify the corresponding QALE gain 
result (for their selected answers to the flow chart, in Table 8.3.3 and 8.3.4. 
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Table 8.3.2: All possible QALE methodology (QALY, VSL, VSHLY) variable weights 
combinations from flow chart in Figure 8.3.1 
Combination  
Number 
QALY VSL VSHLY Age Weights 
1 Low Low Low No (a) Yes (b) 
2 Low Low Mid No (a) Yes (b) 
3 Low Low High No (a) Yes (b) 
4 Low Mid Low No (a) Yes (b) 
5 Low Mid Mid No (a) Yes (b) 
6 Low Mid High No (a) Yes (b) 
7 Low High Low No (a) Yes (b) 
8 Low High Mid No (a) Yes (b) 
9 Low High High No (a) Yes (b) 
10 Mid Low Low No (a) Yes (b) 
11 Mid Low Mid No (a) Yes (b) 
12 Mid Low High No (a) Yes (b) 
13 Mid Mid Low No (a) Yes (b) 
14 Mid Mid Mid No (a) Yes (b) 
15 Mid Mid High No (a) Yes (b) 
16 Mid High Low No (a) Yes (b) 
17 Mid High Mid No (a) Yes (b) 
18 Mid High High No (a) Yes (b) 
19 High Low Low No (a) Yes (b) 
20 High Low Mid No (a) Yes (b) 
21 High Low High No (a) Yes (b) 
22 High Mid Low No (a) Yes (b) 
23 High Mid Mid No (a) Yes (b) 
24 High Mid High No (a) Yes (b) 
25 High High Low No (a) Yes (b) 
26 High High Mid No (a) Yes (b) 
27 High High High No (a) Yes (b) 
 
Therefore, in the following two tables, the QALE gain and the QALE gain growth (as an 
appendage to GDP per annum growth) will be presented for all illnesses and combinations 
of QALE methodology variable weights for the period 1900-2000. The connectivity 
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between the above table and those below, which provides the results, is the number (1 to 
27) in the first column of all the tables. Additionally, in an attempt to make the referencing 
easier, the tables below will also contain a column that summarises the combinations. 
Hence, the column ‘Code’ will provide the first letter (L for Low, M for Mid and H for 
High) of the level of the QALY, VSL, VSHLY, respectively. For example, No. 1 (in the 
two tables below) relates to combination 1 in the table above, which represents the result 
for Low QALY, Low VSL and Low VSHLY, which is summarised in the ‘Code’ column 
(in the two tables below) as LLL (i.e. Low, Low, Low).  
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Table 8.3.3: QALE gain results for all combinations of variable weights in methodological 
flow chart for thesis diseases and disability 1900-2000 (millions of 1990 international $)716 
No. Code Breast cancer Stomach cancer Tuberculosis Blindness 
  a b a b a b a b717 
1 LLL 14198 10553 13107 9136 25793 18419 8028 4580 
2 LLM 17052 11821 15961 10017 28647 22819 8062 4614 
3 LLH 19925 13094 18834 10902 31521 27241 7143 3694 
4 LML 15075 11404 13693 9608 29771 21372 8490 5041 
5 LMM 17929 12998 16546 10740 32624 26909 7325 3876 
6 LMH 20803 14624 19420 11845 35498 32552 6160 2711 
7 LHL 15920 12223 14257 10063 33601 24216 8016 4568 
8 LHM 18774 14155 17111 11406 36454 30925 6615 3166 
9 LHH 21648 16097 19985 12754 39328 37667 5213 1764 
10 MLL 15505 12583 14201 11166 31720 20448 11874 7563 
11 MLM 18359 13850 17054 12047 34573 24849 10955 6644 
12 MLH 21233 15124 19928 12931 37447 29270 10035 5724 
13 MML 16733 13434 12123 11638 37281 23402 11382 7071 
14 MMM 19575 15029 17952 12770 40082 28940 10260 5893 
15 MMH 22460 16654 20807 13875 43009 34582 9052 4741 
16 MHL 17914 14253 15925 12093 42637 26246 10909 6598 
17 MHM 20768 16185 18779 13436 45491 32955 9507 5196 
18 MHH 23642 18127 21653 14784 48364 39697 8105 3794 
19 HLL 16819 14399 15299 12982 37657 22265 14659 9379 
20 HLM 19673 15667 18152 13864 40528 26665 13740 8460 
21 HLH 22547 16940 21026 14748 43402 31087 12821 7540 
22 HML 18398 15250 16471 13454 44828 25218 14167 8887 
23 HMM 21251 16845 19324 14586 47682 30755 13003 7722 
24 HMH 24125 18470 22198 15691 50556 36398 11838 6557 
25 HHL 19918 16069 17599 13909 51717 28062 13694 8414 
26 HHM 22771 18001 20453 15252 54570 34771 12293 7012 
27 HHH 25645 19943 23327 16600 57444 41513 12271 6991 
 
                                                 
716
 See Appendix 12.7, 12.10, 13.2 and 13.5 for base calculations. 
717
 This combines the un-weighted blind morbidity gain with the age-weighted mortality gain. See Appendix 12.10.2 and 13.5.2 for calculations. 
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Table 8.3.4: QALE gain contribution to compound average GDP per capita growth per 
annum: results for all combinations of variable weights in methodological flow chart for 
thesis diseases and disability 1900-2000 (percent pa)718 
No. Code Breast cancer Stomach cancer Tuberculosis Blindness 
  a b a b a b a b719 
1 LLL 2.1 1.5 1.9 1.3 3.7 2.7 1.3 0.8 
2 LLM 2.5 1.7 2.1 1.5 4.1 3.3 1.2 0.7 
3 LLH 2.4 1.9 2.2 1.6 5.5 3.9 1.0 0.5 
4 LML 2.6 1.9 2.0 1.6 4.3 3.9 1.2 0.7 
5 LMM 2.3 1.9 1.8 1.6 4.7 3.9 1.1 0.6 
6 LMH 2.7 2.1 2.4 1.7 6.5 4.7 0.9 0.4 
7 LHL 2.3 1.8 2.1 1.5 4.9 3.5 1.2 0.7 
8 LHM 2.7 2.0 2.3 1.7 5.3 4.5 1.0 0.5 
9 LHH 3.1 2.3 2.5 1.8 5.7 5.5 0.8 0.3 
10 MLL 3.1 1.8 2.5 1.7 5.4 3.0 1.7 1.1 
11 MLM 2.7 2.0 2.5 1.8 5.0 3.6 1.6 1.0 
12 MLH 2.8 2.2 2.6 2.0 5.9 4.2 1.5 0.8 
13 MML 2.2 1.9 2.3 1.7 4.6 3.4 1.6 1.0 
14 MMM 3.3 2.2 2.6 1.9 5.8 4.2 1.5 0.9 
15 MMH 3.1 2.4 2.8 1.6 6.9 5.0 1.3 0.7 
16 MHL 2.4 2.1 2.5 1.8 5.4 3.8 1.6 1.0 
17 MHM 3.0 2.3 2.7 1.9 6.6 4.8 1.4 0.8 
18 MHH 3.4 2.6 3.0 2.1 7.0 5.7 1.2 0.5 
19 HLL 2.3 2.1 2.7 1.9 4.6 3.2 2.1 1.4 
20 HLM 2.7 2.3 2.9 2.0 5.0 3.9 2.0 1.2 
21 HLH 3.3 2.5 3.0 2.1 6.3 4.5 1.9 1.1 
22 HML 2.4 2.2 2.8 1.9 5.4 3.7 2.1 1.3 
23 HMM 2.8 2.4 3.0 2.1 5.8 4.5 1.9 1.1 
24 HMH 3.5 2.7 3.2 2.3 7.3 5.3 2.0 0.9 
25 HHL 2.9 2.3 2.9 2.0 7.5 4.1 2.0 1.2 
26 HHM 3.3 2.6 3.1 2.2 7.9 5.0 1.8 1.0 
27 HHH  3.7 2.9 3.4 2.4 8.3 6.0 1.6 0.8 
                                                 
718
 See Appendix 12.12 and 13.6.1 for base calculations. 
719
 This combines the un-weighted blind morbidity gain with the age-weighted mortality gain. See Appendix 12.12.2 and 13.6.2 for calculations. 
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The above two tables contain the broad set of results for the same calculations that were 
made for the diseases QALE gain in Tables 8.1.12 and 8.1.13 and disease QALE gain 
growth in Tables 8.1.14 and 8.1.15  and the disability QALE gain in Table 8.2.7 and 
disability QALE gain growth in Table and 8.2.8. These estimates exist for all the time 
periods (in addition to 1900-2000, presented here) considered in the thesis (in Appendix 
12.7, 12.10, 12.2 and 13.2, 13.5, 13.6) but for simplicity in answering the key questions of 
the thesis, about twentieth century improvements in health, only the twentieth century as a 
whole will be considered here.  
 
In both tables the QALE gain (Table 8.3.3) and QALE gain growth contribution to GDP 
growth per annum (Table 8.3.4) there are two columns for all illnesses. As has been 
explained above, these represent the un-weighted (a) and age-weighted (b) estimates. It is 
important to explain why column b is consistently lower in value and contribution than 
column a. As was identified in Chapter 8.1, when the age-weighting is applied the QALE 
gain results become more circumscribed than their un-weighted counterparts, because 
certain ages receive lower weighting than others: and the QALE gain (improved morbidity 
+ mortality) was often skewed towards the youngest and oldest age groups (which receive 
a lower weighting than middle ages) in twentieth century England. However, it should be 
noted that, although the age weighting function does noticeably reduce the QALE gain 
(both in absolute terms [Table 8.3.3] and in percentage growth per annum [Table 8.3.4]), 
this reduction does not change the overall conclusions of the thesis. 
  
Another remarkable feature in Table 8.3.3 and 8.3.4 is that, in the ‘blind’ columns, the 
lowest overall estimate is not yielded by LLL and the highest overall estimate is not 
yielded by HHH. At a first approximation this result seems counter intuitive and perhaps 
incorrect. However, this is not the case. The reason for this relationship is the negative 
morbidity gain for blindness between 1900 and 2000, which means that the interaction 
between the QALY, VSL and VSHLY variables in the thesis QALE methodology is not 
consistent or reinforcing. Hence, when the QALE gain is negative: making the QALY and 
the VSHLY positive increases the magnitude of the loss, as the QALE gain becomes 
increasingly negative and increasing the VSL would help (as this would make the mortality 
gain component of the QALE gain methodology more valuable) but this in turn will cause 
detractions from the morbidity gain (as the morbidity gain = the morbidity burden change * 
VSHLY and the VSHLY = VSL * QALY).  
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Table 8.3.3 and 8.3.4 (and the previous analysis) highlight that: however low the values of 
the QALE methodology variables (within the realms of those provided in the thesis’ 
analysis) the QALE gain still yields significant results which provide an important 
contribution to economic development and standards of living. This is even true for 
blindness, which in the above analysis did not experience marked QALE gains. 
Conversely, this optimistic conclusion about the QALE gain is most applicable to 
tuberculosis, which is to be expected as this disease experienced a considerable 
improvement during the twentieth century, along with the general class of infectious 
diseases which were largely eliminated or much more easily managed during the twentieth 
century.  
 
The veracity of these claims concerning the contribution of improved health, and morbidity 
in particular will be reinforced in the following chapter when these results are extended to 
estimate the significance of twentieth century improvements in the aggregate QALE.  
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9. Extended Results (Disability and Disease) 
9.1 Introduction          334 
9.2 Aggregate QALE Gain         337  
9.3 Value of Aggregate QALE Gain Relative to GDP      342 
9.4 Value of Aggregate Health (QALY) Gains       345 
9.5 Summary          347 
 
9.1 Introduction 
In an attempt to add greater significance to the findings of the thesis it is desirable to 
consider the wider implications of the results from the three diseases and one disability 
analysed previously (in Chapter 8.1 and 8.2). The objective of this exercise is to highlight 
the extensiveness of improvements in health through providing a lower bound estimate 
about the value of aggregate QALE improvements in twentieth century England.   
 
The aggregate QALE gain will be estimated using the following structure. The entire 
twentieth century profile of diseases will be differentiated into four states: i) infectious 
(proxied by tuberculosis), ii) non-infectious (proxied by stomach cancer), iii) disabilities 
(proxied by blindness) and iv) the residual. In order to adhere to the objective of producing 
lowest bound estimates, these states will be considered with the following constraints. 
 
Infectious diseases will be represented by only tuberculosis and will assume:  
(1) ‘The only improvements in twentieth century health and welfare related quality of life 
for infectious diseases  were for tuberculosis’ 
This is conservative because of the breadth (prevalence) and depth (quality of life) of 
twentieth century QALE adjustments associated with infectious diseases, such that at no 
time did tuberculosis represent more than 12 percent of this category. The extensiveness of 
the twentieth century decline of infectious mortality is illustrated by Figure 2.3.2 (which 
outlines the burden of disease [infectious and other key categories of mortality] at the start 
and end of the twentieth century). 
 
Non-infectious diseases will be conservatively estimated through applying the twentieth 
century stomach cancer quality of life profile to all non-infectious diseases. The non-
infectious series of calculations will assume: 
(2) ‘All non-infectious diseases had the unfavourable quality of life experienced by 
stomach cancer’ 
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This is conservative because it is almost certain that the average burden of non-infectious 
diseases was not as detrimental to quality of life as stomach cancer. The severity of the 
stomach cancer burden is highlighted in Table 7.3.1 in Chapter 7.3 and Table 8.1.1 in 
Chapter 8.1. Hence, breast cancer is also classified as a non-infectious disease and 
therefore comparing the margin in the QALY between these two diseases highlights the 
conservativeness of the assumptions in this chapter. Moreover, although the QALY 
improvements associated with breast cancer are impressive (e.g. Table 7.3.1 shows that the 
breast cancer QALY improved from 0.3 of a healthy life year in 1900 to 0.8 in 2000), these 
are not necessarily representative of the most far reaching improvement in non-infectious 
diseases. For example, circulatory diseases affected more of the population (more fractions 
of healthy life years) and experienced a more sustained decline in prevalence and (likely) 
improvement in quality of life. Therefore, this provides further justification for the 
stringency with which the non-infectious component is being estimated in this chapter.  
 
The twentieth century burden of all disabilities will be most conservatively approximated 
through utilising only blind quality of life to represent all twentieth century quality of life 
improvements for disabilities: 
(3) ‘The only disability to experience quality of life improvements in the twentieth century 
was blindness and therefore this represents all twentieth century quality of life 
improvements in disabilities’   
This is conservative because of the likelihood that blindness experienced more limited 
developments in quality of life than an ‘average’ disability and subsequently, because there 
is no accounting for a positive, aggregate disability improvement. Moreover, in a similar 
way to the role of stomach cancer in the non-infectious category, blindness was a greater 
burden to quality of life than the ‘average’ disability during the twentieth century. 
 
The final category is the residual, which includes all illnesses that cannot be classified into 
infectious, non-infectious and disability. The twentieth century fall in the morbidity burden 
of this category is likely to be sizeable, because of general quality of life improvements 
and more substantially, because of the decline in the size of this category. The residual has 
shrunk over the twentieth century as disease classification became more precise: from 192 
categories in ICD1 used in 1900 to 5,292 in ICD9 used in 2000. I.e. as illnesses have 
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become more precisely categorised the residual has declined: the extent of this precision is 
highlighted by the substantial growth of the number of ICD categories720. 
 
Because of the ambiguity involved in estimating the residual and the associated negative 
influence on the justifiability of the extended results, the residual will be eliminated 
altogether and none of the residual QALE gains will be included, as:   
(4) ‘No residual illness will be evaluated’ 
 
After the results have been presented for the above assumptions the thesis will highlight 
that even with these lowest bound estimate assumption constraints, the contribution of 
improved health was substantial. This will be vividly highlighted in Table 9.4 which 
calculates the value of twentieth century improvements in health.  
 
The above assumptions (1) to (4), which will be applied throughout this chapter in order to 
yield the most conservative estimate for the aggregate twentieth century QALE gain are 
summarised in Table 9.1. 
 
 
 
 
 
 
 
 
 
 
 
                                                 
720
 Calculated from: Office of Population, Censuses and Surveys, “Twentieth Century Mortality” 
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Table 9.1: Definition of aggregate QALE morbidity categories used in extended results 
Illness Definition / Context 
Infectious 
 
Tuberculosis is used to represent an excessively conservative situation in which 
tuberculosis was the only infectious disease to improve. The magnitude of improvement 
would be significantly greater if all infectious diseases were included and profiled with 
the tuberculosis QALY improvements. 
Non-Infectious 
 
Non-infectious diseases have been conservatively estimated through the application of the 
stomach cancer profile (which is excessively pessimistic compared to the majority of non-
infectious diseases) to all twentieth century non-infectious diseases. 
Disability 
 
The improved quality of life associated with blindness has been used to represent all 
disabilities and subsequently, provides a conservative proxy for the value of twentieth 
century disability gains, especially as blindness can be considered as a particularly 
adverse disability. 
Residual The residual represents all other causes of death that are not contained in the above three 
categories. Because of the varied and hybrid nature of this category it is impossible to 
generate a reliable summary measure and therefore, the residual gains will not be 
estimated.  
TOTAL This contains the sum of the above categories and therefore represents the entire twentieth 
century morbidity burden (based on a most conservative forward extrapolation of the 
thesis illnesses). 
 
In addition to making these stringent assumptions (summarised in Table 9.1) this chapter 
will utilise the lowest bound estimates possible. In Chapter 8.1 and 8.2 the sensitivity 
analysis included the estimation of the QALE gain using all ‘Low’ variables (i.e. ‘Low’ 
QALY, ‘Low’ VSL and ‘Low’ VSHLY) which represent the variables that will be used 
here721.  
 
9.2 Aggregate QALE Gain 
Chapters 8.1 and 8.2 have highlighted the importance of considering the QALE gain 
(mortality gain + morbidity gain) in order to gauge a more accurate account of twentieth 
century economic development. In the previous chapters the morbidity (and QALE) gain 
was a direct function of the illness to which it was related. I.e. the morbidity (or QALE) 
gain for breast cancer between 1900 and 2000 depends on the morbidity burden 
                                                 
721
 See Appendix 12.7.and 13.2 for detailed calculation of the ‘Low’ combination of all variables in the tuberculosis and blind morbidity gain, 
respectively. These lowest bound QALE variable weights will be utilised here. Non-infectious disease calculations will also utilise ‘Low’ 
QALY, VSL and VSHLY variable weights. It should be noted that because of the interaction between the numbers and variables (which are 
features not strictly related to the QALE considerations of the thesis) it is possible to find values which are lower than the ‘Low’ QALY, VSL 
and VSHLY estimates ( for example, see Table 8.3.3 and the subsequent explanation about this phenomenon). Hence, it should be noted that 
what needs to be evaluated here in order to provide original estimates about the lowest bound approximation of the value of QALE in twentieth 
century England is the QALE gain that encompasses the lowest variable weights as these are based on the most stringent assumptions about 
the value of improvements in QALE.  
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(prevalence * QALY) of breast cancer and the morbidity gain (change in the morbidity 
burden * VSHLY [= VSL * QALY]) of breast cancer, and (when combined with the 
mortality gain), the QALE gain for breast cancer between 1900 and 2000. The exercise 
below makes slightly more ambiguous calculations, where the QALE gain represents more 
than only one underlying illness. The assumptions that will be used in this chapter, to yield 
a more aggregate QALE gain estimate are outlined in Table 9.1. For example, in Chapter 
8.1, the QALE gain for stomach cancer was (directly and only) related to the morbidity 
gain for stomach cancer (+ the mortality gain). In the Chapter 9 analysis (below), the 
stomach cancer morbidity gain profile will be used to proxy all non-infectious diseases, 
through utilising the stomach cancer variables (QALY, VSHLY) and applying these to the 
non-infectious prevalence. The results of this process will be a (lower bound) estimate of 
the QALE gain (stomach cancer morbidity gain variables + non-infectious morbidity gain 
prevalence = non-infectious morbidity gain  non-infectious morbidity gain + mortality 
gain = non-infectious QALE gain) for all non-infectious diseases.  
 
This process (of using the QALY and VSHLY profile [for the specific disease, presented 
in Chapter 8] combined with the more broad disease class prevalence [presented here]) is 
(the aggregate QALE gain methodology) utilised only for non-infectious diseases. This is 
because the QALE gain for infectious diseases and disability requires a different approach 
(due to the nature of these broad morbidity classes).  
 
Chapter 8.1 has highlighted the substantial QALE gains associated with tuberculosis (see 
Table 8.1.7 and 8.3.3722), which can be considered as a typical twentieth century trend for 
infectious diseases (e.g. Part I of the thesis has indicated the nature of twentieth century 
morbidity through the epidemiological transition, which represents a decline in infectious 
morbidity that was replaced by non-infectious). Therefore, Chapter 9 will present the 
lowest bound (‘Low’ QALY, ‘Low’ VSL, ‘Low’ VSHLY and age-weighted) morbidity 
and QALE gain for tuberculosis (see Table 8.3.3) as the infectious disease QALE gain. 
This represents the lowest bound infectious QALE gain for two reasons: because it is the 
lowest bound tuberculosis QALE gain and also because it is utilising the assumption that:  
‘The only improvements in twentieth century health and welfare related quality of 
life for infectious diseases were for tuberculosis’ 
                                                 
722
 The values utilised in Chapter 9 are derived from Table 8.3.3 ‘b’ columns (and not Table 8.1.7 or 8.2.7) because Table 8.3.3 considers the age weighted, 
‘Low’ QALY, VSL, VSHLY morbidity and QALE gain, which represents the lowest bound estimate. 
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This creates a significant underestimate of the potential QALE gain for all types of 
infectious morbidity (additional to tuberculosis).  
 
The QALE gain for disability, presented here will utilise the QALE gain for blindness 
from Chapter 8.2. In a similar way to the abovementioned QALE gain for infectious 
diseases (where only tuberculosis was valued for the entire infectious gain) only the blind 
QALE gain will be used as the representative of all disability improvements. This is 
conservative because of the likelihood that blindness experienced more limited 
developments in quality of life than an ‘average’ disability and subsequently, because there 
is no accounting for a positive, aggregate disability improvement (as the 1900-2000 blind 
morbidity gain is negative). Hence, in a similar way to the role of stomach cancer in the 
non-infectious category, blindness was a greater burden to quality of life than the ‘average’ 
disability during the twentieth century. Therefore, Chapter 9 will present the lowest bound 
(‘Low’ QALY, ‘Low’ VSL, ‘Low’ VSHLY) morbidity and QALE gain for blindness (see 
Table 8.3.3723) as the disability QALE gain. 
 
Table 9.2 (below) applies the above methodological assumptions to produce estimate about 
the morbidity, mortality and QALE gain for the hypothetical disease environment that 
Chapter 9 has generated (summarised in Table 9.1) in order to provide a lower bound 
estimate about the aggregate QALE gain in twentieth century England.  
Table 9.2: Aggregate QALE gain (morbidity gain + mortality gain): monetary value of 
improvements in the burden of morbidity and mortality for aggregate disease environment, 
1900-2000 (millions of 1990 international $)724 
Illness Morbidity Gain Mortality Gain QALE Gain 
Infectious 11047 7372 18419 
Non-Infectious -7467 7372 -813 
Disability -2792 7372 4580 
   8160 
 
Table 9.2 is following the thesis QALE gain methodology, where the morbidity and 
mortality gain are calculated (through valuing [using the VSHLY and VSL] the change in 
the morbidity and mortality burden) and summed to estimate the QALE gain. The data 
                                                 
723
 Ibid 
724
 See Appendix 13.3 (age weighted, Low VSL) for mortality gain calculation. See Appendix 13.4 (age-weighted, Low VSL, VSHLY and QALY estimate) 
for morbidity gain calculations. See Appendix 12.10 and 13.5 (age-weighted, Low VSL, VSHLY and QALY estimate) for QALE gain calculations. 
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about the prevalence, QALY, VSL and VSHLY for the disease categories in Table 9.2 are 
outlined in detail in Appendix 12.14.1. This represents stages 8, 9 and 10 in the flow chart 
example at the beginning of Chapter 8. Also, the sensitivity analysis stages 11a, 11b, 11c 
and 11d are utilised as these values represent the QALE gain for the ‘Low’ thesis variables 
that have also been age weighted. I.e. the results here, for infectious (which equals 
tuberculosis) and disability (which equals blindness) are the same as the age weighted, 
‘Low’ QALY, VSL, VSHLY QALE gain results in Table 8.3.3. 
 
Hence, the table above presents the morbidity gain, mortality gain and subsequent QALE 
gain for the aggregate diseases environment. For infectious diseases this is the same 
calculation that was made in the first row (column 8 [Tuberculosis: b]) of Table 8.3.3, 
which represents the tuberculosis QALE gain that utilises the ‘Low’ QALY, ‘Low’ VSL 
and ‘Low’ VSHLY variables which is then subjected to Murray’s age weighting function. 
Tuberculosis represents all infectious diseases (QALE gains) here because of the 
conservative assumptions of this chapter (outlined in Table 9.1).  
 
For disability the result in Table 9.2 is also derived from the same calculation that was 
made in the first row of Table 8.3.3 (column 10 [Blind: b]), which represents the blind 
QALE gain that utilises the ‘Low QALY’, ‘Low’ VSL and ‘Low’ VSHLY variables. 
Murray’s age weighting function is also applied to the mortality gain (but not to the 
morbidity gain is not because the data does not exist to make this calculation). 
 
The second row of Table 9.2 represents the non-infectious morbidity, mortality and QALE 
gain. The mortality gain is derived from the same calculation as for disability and 
infectious diseases (i.e. through using a ‘Low’ VSL in the mortality gain methodology and 
using Murray’s age weighting function). The morbidity gain is derived through a slightly 
different process: this calculation is constructed through combining the prevalence of non-
infectious diseases (as the total number of reported diseases that are non-infectious and not 
in the residual, shown in Appendix 12.14.1) with the stomach cancer variable (QALY and 
VSHLY) profile, which is thought to be worse than the average variable profile for non-
infectious diseases. Hence, the non-infectious morbidity burden is calculated as: non-
infectious disease prevalence * stomach cancer [‘Low’] QALY) and the subsequent 
morbidity gain is calculated: change in the morbidity burden (between 1900 and 2000) * 
[‘Low’] VSHLY (‘Low’ VSL * ‘Low’ [stomach cancer] QALY). 
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The mortality gain shown in column three of Table 9.2 represents the lowest possible 
estimate of the mortality gain throughout all of the thesis’ analysis. This was derived 
through valuing the change in the mortality burden with a ‘Low’ VSL, and also through 
subjecting this mortality gain to Murray’s age weighting function (Chapter 8.1 has 
explained why this reduced the mortality gain). 
 
Finally, the QALE gain column is established by summing the morbidity gain and the 
mortality gain, for each disease category (this accords with the thesis QALE methodology 
and is explained in detail in Chapter 8.1). The final row of the QALE gain column (Total 
QALE gain) represents the aggregate QALE gain. This is calculated by summing all the 
morbidity gains with the mortality gain (i.e. 11047 + -7467 + -2792 + 7372 = 8160), which 
yields an aggregate QALE gain of 8,160 (thousand 1990 international $) or in excess of 8 
billion (1990 international $) for twentieth century England. 
 
Hence, Table 9.2 highlights the extensiveness of improvements in health, which were most 
significant for infectious causes, as a result of a substantial decline in the prevalence and an 
improvement in the QALY. Table 9.2 illustrates that the infectious QALE gain was so 
extensive that it was able to entirely offset the losses for non-infectious and disability. 
Similarly although not to the same extent, the mortality gain was positive and significant as 
a result of a substantial decline in the death rate and secondarily, the value (even at a 
lowest approximation) of this improvement. The other two broad categories of morbidity 
(non-infectious and disability) reflect a less positive trend: where the QALY has improved 
but the prevalence has increased (see Table 8.1.1 for tuberculosis and Table 8.2.3 for blind) 
to such an extent that there is a negative morbidity gain and a subsequently lower QALE 
gain. This was most noteworthy for non-infectious diseases between 1900 and 2000. 
  
However, even in this lowest bound exercise, from a quality of life perspective, the actual 
situation was more optimistic than what is implied in the table, because the pessimism is 
more associated with prevalence than the QALY. It should also be noted that in actuality 
these improvements would be much more substantial than they are here, as the thesis 
extended results aggregate QALE gain is trying to calculate the lowest bound value (in 
order to escape from accusations of bias).  
 
As well as generating an approximate lowest bound value of the aggregate QALE gain 
(which was substantial, at about 8 billion [1990 international $]), Table 9.2 is also valuable 
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for reiterating the thesis message about the value of morbidity gains and the need to 
measure these in tandem with mortality gains. This is most crucial for the morbidity gain 
associated with infectious diseases, which was more valuable than the mortality gain for 
the twentieth century, which highlights that only considering mortality would create a 
serious underestimate of twentieth century health gains.   
 
9.3 Value of Aggregate QALE Gain Relative to GDP 
In common with Chapter 8.1, 8.2 and 8.3, the value of the aggregate QALE gain results in 
Table 9.2 can be further emphasised by comparing them with national income growth in 
twentieth century England. Also in common with Chapter 8.1, 8.2 and 8.3 this exercise 
will highlight the authenticity of the thesis claims to consider wider notions of economic 
development that include health, e.g. through appending some form of health statistic to 
national income measures to account for improvements in health and standards of living. 
Hence, as well as standardising the aggregate QALE gains with economic growth the 
information below will provide a more accurate account of twentieth century economic 
development.  
 
This analysis will use the mortality, morbidity and subsequent QALE gain values 
presented in Table 9.2, which will be utilised here to calculate the compound average rate 
of growth for each of these variables so that the difference in value of growth can be 
identified for mortality, morbidity, QALE and GDP. After this has been achieved the 
QALE growth will be considered in conjunction with GDP growth in order to present a 
single, rounded growth estimate (presented here as ‘Adjusted Growth’), where the growth 
of the aggregate QALE will be added to the growth of GDP. This will provide a first 
approximation about what the extended ‘Fisherian’ national income would have been for 
twentieth century England. 
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Table 9.3: Compound average growth rates of GDP per capita, mortality gain, morbidity gain and QALE gain and GDP per capita growth adjusted 
for aggregate QALE gain, 1900-2000 (percentage per annum)725 
Illness GDP pc Growth  Mortality Gain Growth Morbidity Gain Growth QALE Gain Growth ‘Adjusted Growth’ 
(QALE + GDPpc) 
Infectious   1.6 2.7 4.1 
Non-Infectious   -1.1 -0.01 1.4 
Disability   -0.4 0.8 2.2 
TOTAL 1.4 1.1 0.1 1.2 2.6 
 
Table 8.2.8 considers the compound average growth rate of GDP per capita and the mortality, morbidity and QALE gain growth (for infectious and 
non-infectious diseases and for disability) for the aggregate twentieth century QALE. This is achieved through applying the mortality, morbidity and 
QALE gain for the morbid states used in Chapter 9 to the compounding formula, in order to generate an estimate about average growth per annum 
for the twentieth century.  
 
The reason that the mortality gain growth in this table is different to that which was present in Chapter 8 in Tables 8.1.14 and 8.2.8 is because these 
tables utilised the age-weighted ‘Mid’ mortality gain and Table 9.3 utilises the age-weighted ‘Low’ mortality gain. This is also the reason that the 
infectious morbidity gain does not equal the tuberculosis morbidity gain in Table 8.1.14 and the disability morbidity gain does not equal the blind 
morbidity gain in Table 8.2.8. The infectious and disability QALE gains presented in Table 9.3 do correspond with the same indices in Table 8.3.4 
(tuberculosis in row 1 column 8 [b] and blindness in row 1 column 10 [b]) as these are the same (age weighted ‘Low’ QALY, VSL, VSHLY) 
measures. 
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 See Appendix 12.11 for GDP per capita compound average growth rate calculations and see Appendix 12.14.2  and 13.6 for calculations in Table 9.3. 
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It is possible to consider the relative value of mortality gains and morbidity gains and 
QALE gains versus GDP gains. This consideration reiterates the negative nature of the 
non-infectious and to a lesser extent the disability morbidity gain. On a more positive note 
the substantial infectious morbidity gains are evident in Table 9.3, and are calculated to be 
grater than GDP growth and the mortality gain, which provided a valuable addition to 
economic development. These results are also reflected in the QALE gain column for each 
morbid state, i.e. the QALE gain for infectious was substantial at a twentieth century per 
annum growth of 2.6 percent (nearly double GDP growth for the same era, which was 1.4 
percent). The QALE gain for non-infectious diseases was negative as a result of the 
magnitude of the negative non-infectious morbidity burden and the disability QALE gain 
was positive but small, also as a result of the negative morbidity gain (which was not as 
severe as for non-infectious diseases and this is why the disability QALE gain is positive). 
 
Possibly the most important QALE gain in Table 9.3 is the total QALE gain, because this 
presents the aggregate QALE gain growth contribution to twentieth century GDP growth. 
This is also noteworthy because of the magnitude of the aggregate QALE gain growth, 
which was nearly as significant as the compound average rate of GDP growth per annum 
in twentieth century England (1.2 percent versus 1.4 percent per annum, respectively). 
 
Table 9.3 also considers ‘Adjusted Growth’ (shown in the final column), which represents 
what GDP per capita per annum growth would be if it was extended to include gains in 
health or QALE (i.e. ‘Adjusted Growth’ = GDP per capita growth + QALE gain growth). 
This shows that for infectious diseases and disability there would be an increase in 
‘Adjusted Growth’ and for non-infectious a marginal decrease (of 0.01 percent). Moreover, 
when GDP growth is combined with aggregate QALE gain growth this shows the 
magnitude of ‘Adjusted Growth’, where accounting for the aggregate QALE gain nearly 
doubles existing levels of economic growth. This is significant for two key reasons: the 
relative value of QALE gains compared to GDP gains (where GDP is 1.4 percent and the 
QALE gain is 1.2 percent) and also, if this per annum growth gain is considered for the 
entire twentieth century then this represents a lot of growth (e.g. approximately an 
additional 120 percent of twentieth century economic growth).  
 
Hence, if improved twentieth century health was included in some form of extended 
national income measure, then growth would have been more like 2.6 percent per annum 
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rather than the GDP only measure of 1.4 percent per annum, where the difference between 
these two represents the value of improvements in health in twentieth century England. 
 
9.4 Value of Aggregate Health (QALY) Gains 
Finally, an alternative method for illuminating the extensiveness of the twentieth century 
aggregate QALE gains is to consider the value of the QALE gain with and without the 
documented QALY improvements in the morbidity part of this methodology. To recap, the 
QALY is multiplied with the prevalence to estimate the morbidity burden (prevalence * 
QALY). The change in the morbidity burden is then valued (by applying the VSHLY, 
which equals the VSL * QALY), to estimate the morbidity gain, which can then be 
combined with the mortality gain to calculate the QALE gain (see the QALE methodology 
flow chart worked example at the beginning of Chapter 8 for a more detailed outline of the 
thesis QALE gain methodology, especially stages 5 to 10). 
 
As has been outlined above, the QALY is utilised to calculate the morbidity burden 
(prevalence * QALY) and the morbidity gain (change in the morbidity burden * VSHLY 
[= QALY * VSL]). Also outlined above, is that the QALY (for all thesis illnesses) 
improved over the twentieth century. It was these improvements (embodied in the QALY) 
that were very valuable and provided one of the major contributors to the QALE gain. In 
order to highlight this point, which will also reaffirm the thesis claims (about the 
extensiveness of health improvements, the value of these QALE gains and the subsequent 
need to measure them in some form of extended national income), it is necessary to 
recalculate the morbidity burden change, morbidity gain and subsequent QALE gain, with 
a constant QALY value (i.e. one that has not improved beyond the 1900 level). This can 
then be compared to the genuine morbidity burden change, morbidity gain and QALE gain 
(using the actual dynamic and improving QALY between 1900 and 2000) in order to 
identify the margin of difference (i.e. how much more valuable the latter QALE gain is 
than the former), which represents the value of the changing QALY or the value of health 
improvements in twentieth century England. 
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Table 9.4: Value of twentieth century health improvements for aggregate disease 
environment, 1990-2000 (millions of 1990 international $)726 
Illness Mortality 
Gain 
Morbidity Gain  
(with no health 
improvements) 
Morbidity Gain  
(with health 
improvements) 
QALE Gain Value of health 
improvements 
Infectious 
 
 506 11047 
Non-Infectious 
 
 -8811 -7467 
Disability 
 
 -23950 -2792 
N
o
 
he
al
th
 
im
pr
o
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em
en
ts
 
 
H
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lth
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o
v
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ts
 
 
TOTAL 7372 -32760 788 -25388 8160 33548 
  
In Table 9.4 the mortality gain estimate is the same as what has been calculated above (see 
Table 9.2). The morbidity gain estimate (with health improvements) is also the same as the 
morbidity gain that was calculated in Table 9.2. The subsequent QALE gain for health 
improvements (which is the sum of all health improvement morbidity gains and the 
mortality gain [11047 - 7467 - 2792 {=788} + 7372=8160]) is also the same calculations 
as in Table 9.2.  
 
The morbidity gain (with no health improvements) has been calculated by conducting the 
same QALE gain methodological process (morbidity burden [prevalence * QALY]  
morbidity burden change between 1900 and 2000  value of the change in the morbidity 
burden [change in the morbidity burden * VSHLY = VSL * QALY] = morbidity gain  
morbidity gain + mortality gain = QALE gain) but instead of allowing the QALY to 
improve between 1900 and 2000 (as it did), this version of the QALE gain holds the 
QALY constant. The results shown as the morbidity and QALE gain (with no health 
improvements) represent the results of this calculation.  
 
The appeal of calculating the aggregate QALE gain (with no health improvements), 
achieved through holding the QALY constant (at 1900 levels) is so that the difference 
between this calculation and the aggregate QALE gain (with health improvements) 
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 In Tale 9.4 the mortality gain and morbidity gain (with health improvements) and subsequent QALE gain (health improvements) are derived from earlier 
analysis in Table 9.2 and Appendix 12.14.1. See Appendix 12.14.3 for morbidity gain (with no heal improvements) QALE gain (no health improvements) 
calculations. 
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calculation can be estimated in an effort to identify the value of twentieth century health 
gains: the difference between these two results equals the value of twentieth century health 
improvements. In Table 9.4 the final result, ‘value of health improvements’ is the 
difference between the result in the previous two columns (i.e. 33,548 is the magnitude of 
the difference between -25,388 and 8,160). 
 
Therefore, through holding the QALY aspects of the thesis methodology constant, Table 
9.4 highlights the significance of the twentieth century gains in morbidity that has been 
solely a result of improvements in the health and welfare related quality of life. The result 
of this exercise provides significant results, where these health and welfare quality of life 
(or QALY) improvements were worth approximately 33,548 million (1990 international $) 
or 33.5 billion (1990 international $). This finding in Table 9.4 provides the single biggest 
evidence for the claims of the thesis: about the value of twentieth century improvements in 
health and the subsequent need to measure these far reaching developments.  
 
9.5 Summary 
The key objective of this extended results chapter was to calculate a lowest bound estimate 
that is (as far as possible) verified, in order to highlight the authenticity of the thesis 
claims. Hence, the author recognises that the figures derived here are not precise or even a 
close approximation about the actual twentieth century aggregate QALE gain (as this 
would be considerably higher, albeit unjustified). However, what is undeniable is the 
illustration that improvements in health in twentieth century England were substantial.  
 
Therefore, the previous results reiterate the claims of the thesis about the value of 
improved health (mortality and morbidity) and the need to include this index in some form 
of economic development measure. Chapter 9 has substantiated these claims through 
extending the (thesis morbidity and QALE gain) results in order to indicate a lower bound 
estimate about the value of the twentieth century aggregate QALE gain. Hence, in this 
chapter the calculations made stringent assumptions which were applied to the existing 
thorough findings of the thesis evaluations about health, in order to justify the claims of the 
thesis. This process has also generated more universal and therefore meaningful findings, 
which fill an important void in the literature to date. 
 
The key feature to note from the above analysis is the largely positive nature of the 
aggregate QALE gain (which embodies improvements in the prevalence and/or the burden 
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of morbidity and improvements in the burden of mortality) and the mandate this provides 
for adopting a fuller notion of health (rather than only gauging mortality improvements): 
both because of the need to more accurately propagate improvements in health (namely, 
infectious diseases) and also because of the need to better specify and understand the 
dynamics of twentieth century health improvements (i.e. the nature and magnitude of 
changes in health across all disease classes). This adds weight to the literature that has 
made similar claims (but with less evidence) about the need to measure health in some 
form of extended national income. For example, Usher claims that measures of economic 
development are seriously misleading without accounting for health improvements, wich 
have been empirically justified here: in simple terms, not accounting for health 
developments reduces economic development by nearly half (e.g. 1.4 percent versus 2.6 
percent). The full implications of such extensive and valuable developments in the QALE 
will be highlighted in the following chapter: Conclusion.  
 
Moreover, identifying and measuring more detailed aspects of health provide important 
contributions to the existing literature and debates about the twentieth century health 
transition in England. The trends in health identified here (i.e. the aggregate QALE gain 
which has been evaluated in Chapter 9) confirm the accuracy of the epidemiological 
transition and also provide evidence against the more pessimistic theories associated with 
the next stage of the epidemiological transition. For example, the ‘failure of success’ 
hypothesis (which is explained in detail in Chapter 2: Section 2.1.2.3, and essentially 
insinuates that the products of twentieth century medical developments have served more 
to prolong diseases and increase the proportion of morbidity in the economy, instead of 
diminishing disease and enriching life727) marks a contrast with the thesis findings about 
the existence and value associated with twentieth century health and welfare related quality 
of life (embodied in the QALY), which is shown in Table 9.4. The thesis has also provided 
evidence in support of the more optimistic theories (e.g. ‘compression of morbidity’, 
‘dynamic equilibrium’ and to a lesser extent ‘the fourth stage’ of the epidemiological 
transition hypothesis728), which will be outlined in detail in the following chapter. 
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 Gruenberg, “The Failure of Success”, p. 5 
728
 For a detailed explanation of these theories see Part I: Chapter 2.1: Section 2.2.2.3: Implications of the Epidemiological Transition in General. 
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10. Conclusion 
The thesis has highlighted both qualitatively and quantitatively that during the twentieth 
century the English population experienced far reaching improvements in health and that the 
quality of life implications of these improvements were substantial. In addition to creating a 
methodology capable of yielding a detailed spectrum of results about the value of improved 
health, the thesis has also filled a historical void, about the nature of health improvements and 
their contribution to twentieth century improvements in standards of living and more utility 
based economic development.  
 
Throughout the thesis, health has been considered as a dual entity, comprising mortality and 
morbidity. The mortality component accounted for improvements in the death rate or 
increased life expectancy and the morbidity component accounted for improvements in the 
prevalence of disease and/or the burden (i.e. the health and welfare related QALY). These two 
health indices have been combined and simultaneously measured in the thesis QALE 
methodology in order to provide an accurate and comprehensive health measure which is 
capable of providing credible answers to the central questions of the thesis: what was the 
extent and value of improvements in health? And, what has been the impact of these health 
improvements upon standards of living and economic development in twentieth century 
England?  
 
One of the thesis’ most important contributions to knowledge is the developments of a 
representational health measurement methodology that can account for historical health 
improvements, from a health and welfare related quality of life perspective. Blindness, 
tuberculosis and cancer (breast and stomach) were evaluated in intricate qualitative detail and 
all aspects that were important for the health and welfare related quality of life were 
considered and gauged on the thesis’ universal measurement spectrum (EuroQol). Once this 
had been achieved it was possible to derive QALY weights for different eras of the twentieth 
century for each of these illnesses, which were then utilised as the core morbidity component 
in the quantitative model. As well as providing a detailed justification for the QALY values, 
this enabled considerations about the extent to which health (mortality and morbidity, proxied 
by these three broad illnesses) had improved and the monetary value of these improvements 
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and the implications of such valuable contributions upon the entire burden of mortality and 
morbidity in twentieth century England.  
 
Hence, the thesis has transformed the qualitative morbidity analyses into indices which were 
utilised for the foundation of the quantitative morbidity measurement. This was partnered with 
mortality in order to provide an original quantitative (monetary) measure of the contribution of 
improved health (mortality and morbidity) for the thesis illnesses (Chapter 8). These findings 
then formed the basis of calculations about the entire burden of health (aggregate QALE) in 
twentieth century England in order to provide conservative estimates about the value of 
improved health, which has been estimated as extremely valuable and significant in the thesis 
(Chapter 9). Moreover, the findings of the thesis highlight that even for disabilities and 
diseases that have experienced a sizeable increased prevalence rate during the twentieth 
century, there have been improvements related their prognosis, for example, although the 
calculations are very approximate, there seems to be improvements in the average length of 
duration of morbidity between 1900 and 2000. E.g. the blind prevalence rate increased 
substantially but when the approximate average years of blindness are estimated (16 years in 
1900 versus 11 in 2000), the implications become much more positive729. Furthermore, the 
burden of all morbidity experienced an improvement in the health and welfare related quality 
of life for all illnesses in the thesis (highlighted by the 2000 QALY always being more 
favourable than its 1900 counterpart). This scenario is greatly exaggerated through considering 
diseases that have experienced an improved burden (QALY) and a decline in the prevalence 
rate, as the morbidity contribution of a declined prevalence rate and a reduced burden of 
illness provides very far-reaching contributions. For example, this has been highlighted with 
the tuberculosis considerations made throughout the thesis.  
 
The findings of the thesis seem sensible, since mortality and morbidity improvements in 
twentieth century England have been substantial and health gains are valuable to individuals 
(which is highlighted by the magnitude of the VSL and VSHLY). The calculations of such 
valuable developments even at the lowest bound, provides considerable weight to claims for 
measuring health. Hence, the findings that, at a lower bound estimate, the value of twentieth 
century health improvements of 33,548 million (1990 international $) adds to a new view of 
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 See Chapter 8.2: Table 8.2.1. 
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the economics of health730. This new view is that improvements in health have been a major 
contributor to economic welfare in twentieth century England and have provided considerable 
additions to the growth of national income defined on a utility basis. 
 
The above types of claim, which, towards the end of the twentieth century became 
increasingly more commonplace in the health and developmental literature, are reiterated by 
the findings of the thesis. The most notorious proponents of these claims and the associated 
contribution of the thesis to these claims are outlined below.  
 
Usher (1980) propagated the need to measure health in some form of extended national 
income through claims that the growth of GNP alone significantly understates the extent to 
which current generations are better off than earlier generations731.  The thesis has empirically 
justified Usher’s claims through considering the contribution of the aggregate QALE gain to 
GDP per annum for the twentieth century, to highlight that, in simple terms, not accounting for 
twentieth century health (mortality and morbidity) developments reduces economic 
development by nearly half: GDP average growth for the twentieth century was 1.4 percent 
per annum versus 1.2 percent per annum for QALE (or health) gains, and a subsequent 
‘Adjusted Growth’, which combines GDP growth with the aggregate QALE gains of 2.6 
percent per annum732.  
 
Nordhaus (1999) has claimed that twentieth century improvements in health have provided a 
substantial contribution to standards of living, which was justified by his study about the WTP 
for mortality improvements733. The thesis has complimented Nordhaus’ findings through 
considering the WTP for morbidity as well as mortality, which has facilitated a more 
comprehensive bolster for his claims (that were based solely on mortality gains). The most 
substantial justification that the thesis provides for these claims is the identified value of 
twentieth century improvements in health improvements, which is shown in Table 9.4, as 
being in excess of 33 billion 1990 international dollars. 
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Crafts (2005) also conducted a WTP mortality study which allowed him to illustrate that since 
1870 increases in life expectancy in the UK have contributed a great deal to the growth of real 
national income per head defined on a utility basis734. The thesis has added weight to these 
findings through reiterating the WTP mortality gains that Crafts originally identified and also 
through extending these with original WTP morbidity gains. When these components are 
combined (WTP mortality + WTP morbidity) the QALE gain is calculated in order to provide 
a more rounded approximation of the contribution of increased life expectancy and improved 
health. The thesis has shown that the QALE gain has contributed even more (than mortality 
only) to the growth of real income per head defined on a utility basis. For example, Table 9.3 
highlights that GDP or national income per annum compound average growth was 1.4 percent, 
the mortality gain contributed an additional 1.1 percent and the morbidity gain 0.1 percent, or 
the QALE gain (mortality gain + morbidity gain) contributed an additional 1.2 percent to 
national income (1.4 percent) when defined on a utility basis, which contributes to Crafts’ 
original findings about the contribution of WTP mortality in twentieth century England. 
 
Bradford DeLong (2000) has highlighted the astronomical income that would be necessary to 
compensate an individual enjoying their health in the year 2000 to return to the health 
conditions that were evident in 1900, and the chance that no amount of income could 
compensate for improved health735. The thesis has made provisional estimates about the value 
of improved health, which, given their magnitude –in excess of 33 billion 1990 international 
dollars – accord with the claims of Bradford DeLong736. 
 
Hence, the above types of claims, which, towards the end of the twentieth century became 
increasingly more commonplace in the health and developmental literature, are in tandem with 
the findings of the thesis and in places the findings of the thesis provide a valuable 
contribution for confirming the veracity of these theories. This is for two fundamental reasons: 
first, the thesis provides results about mortality which accord with the implications of the 
above claims, second, the thesis has gone a step further to provide an initial and, to date, the 
only existing estimates about the value of morbidity improvements, which provides an 
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important contribution to existing measures and claims, which are generally based upon only 
mortality improvements. 
 
The findings of the thesis also provide a more involved contribution to one of the most 
pertinent twentieth century health debates (which is more applicable to the later years of the 
century), which relates to the collection of theories that have evolved out of the 
epidemiological transition, which has generated a range of opinions and theories about: the 
meaning of current trends in health, the outlook for future scenarios, and the general nature of 
the link between mortality and morbidity (i.e. the ‘optimists’ versus the ‘pessimists’).  
 
The (qualitative and quantitative) findings of the thesis provide evidence against the more 
pessimistic theories associated with the next stage of the epidemiological transition. Hence, 
‘the failure of success’ hypothesis, which represents the pessimist school of thought, 
essentially contends that: the twentieth century products of medical developments have served 
more to prolong disease and increase the proportion of the population suffering from disabling 
and chronic illnesses instead of diminishing disease and enriching life737. I.e. for the 
pessimists, most noteworthy, Kramer (1980)738 and Gruenberg (1977)739, medical 
improvements have merely postponed death and not necessarily improved health and 
subsequently have prolonged disease and increase the portion of the population suffering from 
disabling and chronic illness740. The thesis highlights the shortcomings of such a theory, 
through the detailed qualitative analysis which has charted the evolution of improved 
prognosis and therapy regimes associated with illnesses and most importantly, a significantly 
improved quality of life (QALY) profile as a result of improved medical technology. The 
quantitative analysis of the thesis provides a vivid indication about the value of the improving 
QALY and the subsequent aggregate QALE, which has generated substantial results. Hence, 
although the pessimist claims about increased prevalence are sometimes correct (e.g. for 
disability and non-infectious illnesses), their theories and reasoning about the mechanisms that 
are perpetuating this trend and the result of this trend seem erroneously pessimistic.  
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A preferable set of theories for according with the findings of the thesis are the more 
optimistic schools of thought from this epidemiological debate, for example, the theory of 
‘dynamic equilibrium’, which claims that in the long term chronic illness will be confined to 
the last few years of life so that the proportion of a healthy life will increase. The thesis 
analysis provides justification of this trend through estimates about the decreasing average 
number of years spent in blindness (shown quantitatively in Chapter 8.2: Table 8.2.1) and also 
the later average age of onset of breast cancer and stomach cancer as the twentieth century 
unfolded (shown qualitatively in Chapter 6: Table 6.4 to 6.7).  
 
Along a similar vein, the theory of the ‘compression of morbidity’, which envisages the 
reduction in the national illness burden by postponing the age of onset of chronic infirmity 
relative to the average life duration, such that the period of morbidity is compressed between 
an increasing age of onset and a relatively fixed life expectancy also receives some agreement 
from the thesis741. Although this is better considered as a possible next stage, the thesis does 
show some evidence that this is possible (and perhaps still more viable than the pessimistic 
theories). This accordance is best highlighted by the compliance of the thesis results with the 
‘dynamic equilibrium’ theory, which can be considered as a first stage of the more 
exaggerated ‘compression of morbidity’. Hence, the thesis has shown a postponement in the 
average age of onset but this has not been as large as the postponement in the average age of 
mortality.  
 
Therefore, the findings of the thesis provide additional support for the ‘dynamic equilibrium’ 
type hypothesis, which mark a stark contrast with the pessimistic literature and also, but to a 
much lesser extent the overly optimistic theories (‘compression of morbidity and especially 
the ‘fourth stage’ hypothesis, which is an even more optimistic theory, outlined in Chapter 2.1: 
Section 2.1.2.3). 
 
A final contribution of the thesis to contemporary debates and literature is the implications that 
the thesis’ analysis and results have for the possible contribution of the NHS during the second 
half of the twentieth century. A consistent theme in the qualitative analysis has been the 
inefficiency of the NHS, most notoriously confirmed by the social class inequality in mortality 
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and (although in a more ad hoc fashion) morbidity, and that in many instances this has 
worsened to the disadvantage of the poorer social classes during the second half of the 
twentieth century. Given that one of the objectives of the NHS was to reduce this gradient and 
provide universal health care to the British population, this marks a serious shortcoming. This 
failure of the NHS is exacerbated by its under funding and comparative mediocrity compared 
to other developed economies. All of these problems contribute to creating an impression of 
an inefficient health service. 
 
When the output of the NHS is evaluated a very different impression is generated. Current 
measures of national income or GDP only account for the inputs of the NHS, i.e. as a cost, and 
do not appraise any of the benefits, returns, or outputs of this spending. The quantitative 
analysis of the thesis and most precisely, the aggregate QALE gain ‘Adjusted Growth’ 
considerations (made in Table 9.3, where GDP growth is summed with aggregate QALE 
growth or health output growth) provide an estimate of the returns on this spending. When the 
magnitude of these QALE gains or health benefits are considered relative to GDP and the cost 
of achieving these gains, it would suggest that the image of an unproductive healthcare system 
is far off the mark.  
 
It should be noted that not all QALE gains are attributable to the NHS. A suitable approximate 
would be that fifty percent of the documented QALE gain is attributable to the NHS742. 
Moreover, until a detailed comparative study of health services has been conducted, it is 
difficult to provide a substantiated appraisal of the NHS. 
 
Nonetheless, the results of this thesis highlight a need to reconsider the healthcare system in an 
effort to quell the disquiet, which seems rather unfounded if the value and contribution of 
healthcare spending identified in the thesis is considered. Furthermore, the thesis has provided 
much detail that indicates the major contribution of technological medical improvements in 
the reduced mortality and particularly morbidity burden. For example, out of all the (EuroQol) 
variables considered in the thesis for their effect upon health related quality of life of sufferers, 
medical developments have provided the largest overall contribution to quality of life 
improvements. And for all the morbidity and mortality states considered in detail in the thesis, 
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the most significant health gains have tended to be during the second half of the twentieth 
century, after the introduction of the NHS (although this is less consistent for tuberculosis and 
especially blindness). This reinforces the value of the NHS output and the possible need to 
reconsider the value of the NHS. 
 
In addition to the benefit of a more detailed historical account about twentieth century 
standards of living in England the contribution of the thesis is also important because of the 
initial developments it has made towards a more rounded and accurate health measure, which 
provides results that have not necessarily been predicted and would have been unidentifiable 
without the thesis QALE gain methodology. Most noteworthy is the point that: although the 
prevalence of certain disease groups has increase (namely, chronic, degenerative diseases) 
and, as a result of the nature of these illnesses and advancements in medical technology, there 
are more unhealthy life years associated with these later twentieth century illnesses, the quality 
of life gains associated with these illnesses have often outweighed the increase in their 
prevalence. Hence, the findings of the thesis not only provide a mandate for including 
improvements in mortality (previous measures of health) in some form of extended GDP 
measure, but they also illuminate an endorsement for including a morbidity index in 
conjunction with mortality. 
 
Therefore, the thesis has provided an important contribution to knowledge regarding the 
history and value of health improvements. However, there are still numerous facets that could 
benefit from a more detailed and thorough analysis in order to provide an increasingly 
indicative estimate towards the actual value of improved health in twentieth century England. 
Many of these problems are generally insurmountable (and not just in the confines of the 
thesis), but still ought to be recognised.  
 
The most obvious features for improvement are the methodological variables (QALY, VSL 
and VSHLY) that were subject to detailed sensitivity analyses. Although the thesis has 
highlighted that regardless of where in the range the value is selected, the contributions have 
still been noteworthy, it would be ideal to identify universally accepted values as this would 
lead to a more agreeable result about improved health. 
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Although verging on the impossible, it would be ideal to consider a much greater number of 
illnesses in the same detail as has been conducted as a major component of the thesis. The 
amount of detail is necessary and desirable in order to yield the most potentially accurate 
(QALY) results. Failing this, and more realistically, it should be possible to proxy and 
manipulate the results identified here, in order to provide an estimate of the effect for all 
illnesses in the epidemiological environment during the twentieth century, which is more 
accurate than the findings presented in the thesis’ Extended Results. Both of these objectives 
are highly desirable because they would enable a full picture to be provided about morbidity. 
Additionally, it would be desirable to approximate the influence of co-morbidity for any set of 
QALE gain results. The thesis has provided a valuable first attempt and most conservative 
estimate, but it would be ideal to have a much more varied and far-reaching pool of morbidity 
indices.  
 
Finally, in answering the two nucleus questions of the thesis: what has been the value of health 
improvements and what is the impact of these health improvements upon standards of living 
and economic development, the thesis has provided a valuable contribution to knowledge 
through the following key mechanisms. First, it has provided qualitative and quantitative 
historical detail. This detail has been utilised to provide a thorough and pragmatic indication 
about the contribution of improved health to standards of living and economic development in 
twentieth century England. Second, this has highlighted how valuable and far-reaching health 
improvements have been and subsequently added weight to existing claims about the need to 
include health (output) in the national accounts. Third, this thesis has added more optimistic 
and accurate detail to many of the debates associated with health. Fourth, the findings of the 
thesis add to the overall scholarship concerning the contribution of reduced illness and 
increase longevity towards economic gains. This reinforces the work of Nordhaus, Crafts and 
Hickson743. Lastly, the thesis also enhances these works, through making the same 
considerations, but for morbidity as well as mortality. This has served to reinforce these claims 
and, if anything strengthens existing arguments about the value of improved health and its far-
reaching impact on standards of living and economic development. The findings of the thesis 
also add weight to claims about the need to consider national income measures that account 
for health utility. 
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12.1: VSL and VSHLY Values 
This Appendix relates to Tables 8.1 and 8.2 in the main thesis. 
 
The VSL represents the value of a statistical life, a term that is fundamental in the 
methodology for estimating the willingness to pay or value of improved life expectancy. In 
order to estimate societies willingness to pay it is necessary to establish the amount that a 
group of people would be willing to pay for a reduction in the current period probability of 
death. VSL studies estimate the value of fatal risk reduction in the expectation of saving 
one life (of an unidentified person) in the current period, and therefore estimate the VSL 
and societies willingness to pay for improved mortality. For example, if people are on 
average willingness £10 for a safety improvement that will reduce their individual risk of 
death during the coming year by 1 in 100,000, this risk reduction would mean that on 
average, in group of 100,000 people there would be 1 fewer premature deaths. These 
100,000 people would between them, be willing to pay £10 * 100,000 = £1,000,000 for the 
prevention of 1 statistical fatality. Hence in this example the VSL is £1,000,000.  
 
The main body of the thesis (Chapter 3) has highlighted the mass of VSL studies and 
subsequent wide range of estimates of the value of death averted. The thesis has adopted 
one of the most plausible VSL results that was generated by Miller’s detailed statistical 
analysis and endeavour to identify a best estimate VSL, based on applying this detailed 
statistical analysis to a range of most credible UK VSL studies.  
 
As well as providing a single VSL estimate the Miller study has also generated associated 
VSL multiples: a VSL index number (101, 128 and 154, representing a low, mid and high 
VSL multiple estimate) that is then multiplied with the corresponding GDP per capita 
value (which is GDP per capita for the mid-point of the period under consideration). This 
is the approach used here. 
 
After the VSL has been identified, which will be achieved in the thesis through applying 
the low, mid, and high VSL multiple, this multiple (101, 128, and 154) will multiplied with 
mid-point GDP per capita for the periods: 1900-1925 (1913 GDP per capita), 1925-1950 
(1938 GDP per capita), 1950-1975 (1963 GDP per capita), 1975-2000 (1988 GDP per 
capita) and 1900-2000 (1950 GDP per capita). Once this process has been conducted the 
(low, mid, and high) VSL will have been identified for the above eras that the thesis is 
considering. 
 
This VSL has two primary uses in the thesis methodology: i) to provide a valuation for the 
decline in mortality (i.e. the change in the mortality burden * VSL = the value of improved 
mortality or the mortality gain) and, ii) to provide part of the VSHLY.  
 
The VSHLY provides the morbidity equivalent of the VSL, where the VSHLY values the 
improvement in the burden of illness or the morbidity burden. The VSHLY represents a 
more tenuous index than the VSL, as the thesis has approximated the VSHLY through 
combining the VSL and the QALY (VSL*QALY=VSHLY). The QALY was derived from 
the detailed analysis of the thesis and is illness and era specific. The results for the range of 
QALYs derived for the thesis illnesses and eras are outlined below in Appendix 12.6.   
 
The result for this VSHLY (as well as the VSL) is shown below, where the range of low, 
mid and high VSHLY is considered for the thesis morbidity states and eras.  
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Hence, Appendix 12.1.1 considers the mortality gain (the change in the mortality 
burden*VSL) that is yielded from different VSL (multiple and era) values. The VSL is 
derived by multiplying the VSL multiple (identified by Miller) with GDP per capita for the 
mid point of the period under consideration.  
 
The thesis utilises three VSL multiples: 128*mid point GDP which is used as the central or 
‘Mid’ estimate of the VSL. In the sensitivity analysis the thesis considers a VSL multiple 
that is lower: 101*mid point GDP, which is referred to as ‘Low’ and a VSL multiple that is 
higher: 154*mid point GDP, which is referred to as ‘High’. 
 
The VSHLY values have been derived through considering the VSL value in conjunction 
with the QALY in order to account for the health adjustment for the according illness and 
era. This has been conducted for the thesis diseases (Appendix 12.1.1) and disability 
(Appendix 12.1.2). The VSHLY will also be considered with a ‘Low’ and ‘High’ VSL 
estimate, as well as ‘Mid’. 
 
 
Sources 
GDP data  
• 1900 and 1925: Maddison, “Monitoring the World Economy 1820-1992”.  
• 1950 and 1975 and 2000: Maddison, “The World Economy: A Millennial Perspective”  
Maddison presents these historical GDP estimates in 1990 international $ (and therefore 
the subsequent VSL in the thesis is represented in this currency). 
VSL 
• The VSL (multiples) data comes from Miller, “Variations between Countries in Values 
of Statistical Life”. 
QALY (for use in the VSHLY) 
• The QALY data comes from the thesis, the underlying rational is presented in Part II 
and the summary results are presented in Chapter 7 and summarised at the beginning of 
Chapter 8. This data is also summarised in Appendix 12.6. 
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12.1.1: VSL and VSHLY Values: Disease: Mortality  
 
 
VSL Values   
   
      
Low VSL = 101 * Midpoint GDP pc   
 
Period VSL multiple Midpoint GDP pc at Midpoint VSL VSL (Millions) 
1900-1925 101 1913 5032 508232 0.51 
1925-1950 101 1938 5983 604283 0.60 
1950-1975 101 1963 9070 916070 0.92 
1975-2000 101 1988 15988 1614788 1.61 
1900-2000 101 1950 6907 697607 0.70 
      
Mid VSL = 128 * Midpoint GDP pc 
   
Period VSL multiple Midpoint GDP pc at Midpoint VSL VSL (Millions) 
1900-1925 128 1913 5032 644096 0.64 
1925-1950 128 1938 5983 765824 0.77 
1950-1975 128 1963 9070 1160960 1.16 
1975-2000 128 1988 15988 2046464 2.05 
1900-2000 128 1950 6907 884096 0.88 
      
High VSL = 154 * Midpoint GDP pc 
   
Period VSL multiple Midpoint GDP pc at Midpoint VSL VSL (Millions) 
1900-1925 154 1913 5032 774928 0.77 
1925-1950 154 1938 5983 921382 0.92 
1950-1975 154 1963 9070 1396780 1.40 
1975-2000 154 1988 15988 2462152 2.46 
1900-2000 154 1950 6907 1063678 1.06 
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VSHLY (VSL*QALY) Values  
 
Breast Cancer  
 
   
 
QALY   
 
Year Value Period Value 
1900 0.3333 1900-1925 0.3333 
1925 0.3333 1925-1950 0.4167 
1950 0.5000 1950-1975 0.5834 
1975 0.6667 1975-2000 0.7485 
2000 0.8333 1900-2000 0.5833 
    
    
    
Low VSHLY = (101 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (Millions) QALY VSHLY (Millions) 
1900-1925 0.51 0.3333 0.17 
1925-1950 0.60 0.4167 0.25 
1950-1975 0.92 0.5834 0.53 
1975-2000 1.61 0.7485 1.21 
1900-2000 0.70 0.5833 0.41 
    
Mid VSHLY = (128 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (Millions) QALY VSHLY (Millions) 
1900-1925 0.64 0.3333 0.21 
1925-1950 0.77 0.4167 0.32 
1950-1975 1.16 0.5834 0.68 
1975-2000 2.05 0.7485 1.53 
1900-2000 0.88 0.5833 0.51 
   
 
High VSHLY = (154 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (Millions) QALY VSHLY (Millions) 
1900-1925 0.77 0.3333 0.26 
1925-1950 0.92 0.4167 0.38 
1950-1975 1.40 0.5834 0.81 
1975-2000 2.46 0.7485 1.84 
1900-2000 1.06 0.5833 0.62 
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VSHLY (VSL*QALY) Values  
 
Stomach Cancer  
 
   
 
QALY:   
 
Year Value Period Value 
1900 0.3333 1900-1925 0.3333 
1925 0.3333 1925-1950 0.4167 
1950 0.5000 1950-1975 0.5834 
1975 0.6667 1975-2000 0.6667 
2000 0.6667 1900-2000 0.5000 
    
    
    
Low VSHLY = (101 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (Millions) QALY VSHLY (Millions) 
1900-1925 0.51 0.3333 0.17 
1925-1950 0.60 0.4167 0.25 
1950-1975 0.92 0.5834 0.53 
1975-2000 1.61 0.6667 1.08 
1900-2000 0.70 0.5000 0.35 
    
Mid VSHLY = (128 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (Millions) QALY VSHLY (Millions) 
1900-1925 0.64 0.3333 0.21 
1925-1950 0.77 0.4167 0.32 
1950-1975 1.16 0.5834 0.68 
1975-2000 2.05 0.6667 1.36 
1900-2000 0.88 0.5000 0.44 
    
High VSHLY = (154 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (Millions) QALY VSHLY (Millions) 
1900-1925 0.77 0.3333 0.26 
1925-1950 0.92 0.4167 0.38 
1950-1975 1.40 0.5834 0.81 
1975-2000 2.46 0.6667 1.64 
1900-2000 1.06 0.5000 0.53 
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VSHLY (VSL*QALY) Values  
 
Tuberculosis   
 
   
 
QALY:   
 
Year Value Period Value 
1900 0.3333 1900-1925 0.4167 
1925 0.5000 1925-1950 0.5834 
1950 0.6667 1950-1975 0.7485 
1975 0.8333 1975-2000 0.8333 
2000 0.8333 1900-2000 0.5833 
    
    
    
Low VSHLY = (101 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (Millions) QALY VSHLY (Millions) 
1900-1925 0.51 0.4167 0.21 
1925-1950 0.60 0.5834 0.35 
1950-1975 0.92 0.7485 0.69 
1975-2000 1.61 0.8333 1.35 
1900-2000 0.70 0.5833 0.41 
    
Mid VSHLY = (128 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (Millions) QALY VSHLY (Millions) 
1900-1925 0.64 0.4167 0.27 
1925-1950 0.77 0.5834 0.45 
1950-1975 1.16 0.7485 0.87 
1975-2000 2.05 0.8333 1.71 
1900-2000 0.88 0.5833 0.51 
    
High VSHLY = (154 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (Millions) QALY VSHLY (Millions) 
1900-1925 0.77 0.4167 0.32 
1925-1950 0.92 0.5834 0.54 
1950-1975 1.40 0.7485 1.05 
1975-2000 2.46 0.8333 2.05 
1900-2000 1.06 0.5833 0.62 
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12.1.2: VSL and VSHLY Values: Disability 
 
 
VSHLY (VSL*QALY) Values 
  
BLIND 
   
 
 
  
QALY:  
  
Year Value Period QALY 
1900 0.3333 1900-1925 0.4167 
1925 0.5000 1925-1950 0.5834 
1950 0.6667 1950-1975 0.6667 
1975 0.6667 1975-2000 0.6667 
2000 0.6667 1900-2000 0.5000 
 
Low VSHLY = (101 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2)VSL  Low VSHLY 
Period VSL (millions) QALY VSHLY (millions) 
 
LOW 
 
LOW 
1900-1925 0.51 0.4167 0.21 
1925-1950 0.60 0.5834 0.35 
1950-1975 0.92 0.6667 0.61 
1975-2000 1.61 0.6667 1.08 
1900-2000 0.70 0.5000 0.35 
 
 
 
 
Mid VSHLY = (128 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (millions) QALY VSHLY (millions) 
 
MID 
 
MID 
1900-1925 0.64 0.4167 0.27 
1925-1950 0.77 0.5834 0.45 
1950-1975 1.16 0.6667 0.77 
1975-2000 2.05 0.6667 1.36 
1900-2000 0.88 0.5000 0.44 
 
 
 
 
High VSHLY = (154 * Midpoint GDP pc)* ((T1QALY+T2QALY)/2) 
Period VSL (millions) QALY VSHLY (millions) 
 
HIGH 
 
HIGH 
1900-1925 0.77 0.4167 0.32 
1925-1950 0.92 0.5834 0.54 
1950-1975 1.40 0.6667 0.93 
1975-2000 2.46 0.6667 1.64 
1900-2000 1.06 0.5000 0.53 
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12.2: Prevalence, QALY and Morbidity Burden: Disease 
This Appendix relates to Table 8.1.1 in the main thesis. 
 
It was necessary to estimate the prevalence of all thesis illnesses for the purpose of the thesis 
QALE methodology. This is because the burden of illness or the morbidity burden is a function 
of both how many life years were affected by illness (= prevalence) and also how severely these 
life years were affected by illness (= QALY). Hence the morbidity burden = prevalence * QALY. 
 
The prevalence of morbidity is approximated through estimating the number of people in the 
economy with the referenced diseases for any one year. This is a measure that is not readily 
available in the data for any of the thesis morbidity states.  
 
Therefore it was necessary to estimate the prevalence of morbidity for the key eras considered by 
the thesis: 1900, 1925, 1950, 1975, and 2000. The data needed to make these morbidity 
prevalence approximations is: i) a survival rate and, ii) the death rate. This data has been derived 
and in some case approximated (see below) from the illness specific information in Part II of the 
thesis. Due to unique idiosyncrasies and illness specific limitations in the data, these calculations 
were achieved in a slightly different way for each illness in the thesis. 
 
Breast Cancer: Prevalence data only exists for the 1970s onwards and therefore it was necessary 
to estimate a prevalence figure for the period 1900 to 1970. This process: 
1. Assumes 1945 1 year survival rate (1 YSR) for all years preceding 1945. 
2. For years after and including 1945, the actual 1YSR for the according year has been used. 
 
The prevalence is calculated through utilising the 1 YSR to identify the percentage of breast 
cancer deaths (which is the inverse of survival). The mortality data is then utilised to identify the 
number of deaths that the I YSR percentage of deaths relates to. Once this has been achieved it is 
possible to calculate the number of survivors (through establishing the number of deaths that the 
inverse of the survival rate relates to it is possible to subsequently identify the number of 
survivors represented by the I YSR. Both of these numbers are then summed (due to the inherent 
assumption that breast cancer mortality for any one year represents prevalence for that year [as an 
individual needed to first suffer from breast cancer to die of it] and likewise for those who 
survived from breast cancer.  
 
This was estimated for the age groups utilised in later sections of the thesis quantitative analysis 
(see Appendix 12.3), which was necessary to facilitate a more detailed analysis and ultimate 
QALE gain result in the thesis, which is estimated by using age specific prevalence. 
 
Stomach Cancer: The prevalence for stomach cancer was calculated in exactly the same way as 
for breast cancer. The nature of cancer data is the same for all cancers, especially from the 1970s 
onward when the national cancer registry was implemented, which is responsible for collating 
and compiling national cancer data in the UK.  
 
Tuberculosis: Prevalence data exists but only as an aggregate for all ages. Because of the age 
specific analysis in the thesis it was necessary to identify the age specific prevalence of 
tuberculosis. This was estimated through identifying the age specific mortality data and 
combining this with the aggregate prevalence data in order to identify a survival rate for each age 
group, which could then be applied to the mortality data (in a similar way as for breast and 
stomach cancer) in order to estimate the age specific prevalence of tuberculosis. Hence, this 
process:  
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1. Identify the relationship between notification/prevalence and total deaths which provided an 
estimate for the survival rate. 
2. This rate was then applied to the existing death data for each age group. 
3. The 1900 approximate for tuberculosis is based on the 1900 mortality data and the 1915 
tuberculosis notification (as the 1900 data does not exist in this format). 
 
When estimating the prevalence for all of the thesis diseases an equal survival rate across all age 
groups has been assumed. It should be noted that this is not likely to be the case in actuality but 
there is no alternative due to data limitations. I.e. aggregate prevalence did not exist for cancer 
before 1970 and for tuberculosis there is no official data about the age specific prevalence or 
survival rate. However, it is also important to note that this data problem does not affect the 
aggregate results. 
 
It was also necessary to estimate a prevalence rate for the disability: blindness. This has been 
conducted through a different methodology (due to the differences in the data and is explained in 
Chapter 8.2 and Appendix 12.13.1). 
 
Once the prevalence has been identified it is possible to combine this data with the QALY in 
order to estimate the morbidity burden. Hence, prevalence * QALY = morbidity burden. This is 
calculated here. 
 
Sources 
Survival rate data for cancer:  
• 1945: Parliamentary Papers, “Cancer Registration in England and Wales” 
• 1966-1971: Office of National Statistics, “Cancer Trends in England and Wales 1971” 
• 1971-1990: Coleman, “Cancer Survival Trends in England and Wales, 1971-1995: 
Deprivation and NHS Region” 
• 1998-2000: National Statistics Online, “Cancer Survival: Rates Improved during 1996-2001”. 
Retrieved 24 November 2005, from:http://www.statistics.gov.uk/cci/nugget_print.asp?ID=861 
Prevalence data for tuberculosis: 
• 1920 to 1980: Citron & Raynes & Berrie, “Tuberculosis Today” 
• 1990: Watson & Fern & Whitmore, “Notifications of Tuberculosis in England and Wales, 1982-
1989” 
• 1992 and 2000: Joint Tuberculosis Committee of the British Thoracic Society, “Control and 
Prevention of Tuberculosis in the UK: Code of Practice 2000” 
Mortality data for cancer and tuberculosis: 
• Office of National Statistics, “Twentieth Century Mortality: 100 Years of Mortality Data in 
England and Wales by Age, Sex, Year and Underlying Cause” 
QALY 
• The QALY data comes from the thesis, the underlying rational is presented in Part II and the 
summary results are presented in Chapter 7 and summarised at the beginning of Chapter 8. 
This data is also summarised in Appendix 12.6. 
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BREAST CANCER 
  
1901 (1911) 
   
1925 
  
 
 
    Age Prevalence (1-QALY) BURDEN  Age Prevalence (1-QALY) BURDEN  
Year Survival Deaths            
 PERCENT PRECENT  0-4 0 0.6667 0  0-4 0 0.6667 0  
1900 80 20  5-9 0 0.6667 0  5-9 0 0.6667 0  
1925 80 20  10-14 0 0.6667 0  10-14 0 0.6667 0  
1950 87 13  15-19 5 0.6667 3  15-19 0 0.6667 0  
1975 83 17  20-24 15 0.6667 10  20-24 10 0.6667 7  
2000 87 13  25-34 290 0.6667 193  25-34 465 0.6667 310  
    35-44 2340 0.6667 1560  35-44 2955 0.6667 1970  
    45-54 4315 0.6667 2877  45-54 6820 0.6667 4548  
    55-64 4295 0.6667 2864  55-64 6835 0.6667 4558  
    65-74 3685 0.6667 2457  65-74 5725 0.6667 3817  
    75+ 1035 0.6667 690  75+ 4245 0.6667 2831  
   
 
 
15980 
  
 
 
27055 
   
   
 
    
 
     
1950 
  
 
 
1975 
    
2000 
  
 
Age Prevalence (1-QALY) BURDEN  Age Prevalence (1-QALY) BURDEN  Age Prevalence (1-QALY) BURDEN 
   
 
    
 
    
 
0-4 0 0.5000 0  0-4 0 0.3333 0  0-4 0 0.1667 0 
5-9 0 0.5000 0  5-9 0 0.3333 0  5-9 0 0.1667 0 
10-14 0 0.5000 0  10-14 0 0.3333 0  10-14 0 0.1667 0 
15-19 0 0.5000 0  15-19 0 0.3333 0  15-19 0 0.1667 0 
20-24 38 0.5000 19  20-24 41 0.3333 14  20-24 38 0.1667 6 
25-34 785 0.5000 392  25-34 735 0.3333 245  25-34 1108 0.1667 185 
35-44 5677 0.5000 2840  35-44 4188 0.3333 1397  35-44 4838 0.1667 808 
45-54 12485 0.5000 6245  45-54 12006 0.3333 4005  45-54 11931 0.1667 1992 
55-64 14969 0.5000 7488  55-64 16153 0.3333 5389  55-64 15323 0.1667 2559 
65-74 15046 0.5000 7526  65-74 18159 0.3333 6058  65-74 17831 0.1667 2978 
75+ 12477 0.5000 6241  75+ 17653 0.3333 5889  75+ 36846 0.1667 6153 
 
61477 
 
 
  
68935 
 
 
  
87915 
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STOMACH CANCER 
 
1901 (1911) 
   
1925 
  
 
    Age Prevalence (1-QALY) BURDEN  Age Prevalence (1-QALY) BURDEN 
Year Survival Deaths           
 PERCENT PRECENT  0-4 0 0.6667 0  0-4 0 0.6667 0 
1900 15 85  5-9 0 0.6667 0  5-9 0 0.6667 0 
1925 15 85  10-14 0 0.6667 0  10-14 0 0.6667 0 
1950 15 85  15-19 4 0.6667 3  15-19 4 0.6667 3 
1975 15 85  20-24 9 0.6667 6  20-24 9 0.6667 6 
2000 25 75  25-34 108 0.6667 72  25-34 110 0.6667 73 
    35-44 517 0.6667 345  35-44 575 0.6667 383 
    45-54 1385 0.6667 924  45-54 1758 0.6667 1172 
    55-64 2378 0.6667 1586  55-64 3128 0.6667 2086 
    65-74 2552 0.6667 1702  65-74 3395 0.6667 2264 
    75+ 1036 0.6667 691  75+ 1533 0.6667 1022 
   
 
 
7989 
  
 
 
10512 
  
   
 
    
 
    
1950 
  
 1975 
    
2000 
  
 
Age Prevalence (1-QALY) BURDEN Age Prevalence (1-QALY) BURDEN  Age Prevalence (1-QALY) BURDEN 
   
 
   
 
    
 
0-4 0 0.5000 0 0-4 0 0.3333 0  0-4 0 0.3333 0 
5-9 0 0.5000 0 5-9 0 0.3333 0  5-9 0 0.3333 0 
10-14 0 0.5000 0 10-14 0 0.3333 0  10-14 0 0.3333 0 
15-19 3 0.5000 2 15-19 1 0.3333 0.4  15-19 1 0.3333 0.4 
20-24 11 0.5000 6 20-24 7 0.3333 2  20-24 3 0.3333 1 
25-34 112 0.5000 56 25-34 41 0.3333 14  25-34 25 0.3333 8 
35-44 700 0.5000 350 35-44 162 0.3333 54  35-44 105 0.3333 35 
45-54 1808 0.5000 904 45-54 865 0.3333 288  45-54 317 0.3333 106 
55-64 3891 0.5000 1946 55-64 2533 0.3333 845  55-64 868 0.3333 290 
65-74 5796 0.5000 2899 65-74 5201 0.3333 1735  65-74 2244 0.3333 749 
75+ 4979 0.5000 2490 75+ 5287 0.3333 1764  75+ 4141 0.3333 1382 
 
17300   
 
14097   
  
7704   
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TUBERCULOSIS 
   
1901 (1911) 
    
1925 
  
 
     Age Prevalence (1-QALY) BURDEN  Age Prevalence (1-QALY) BURDEN 
Year Survival Deaths            
 PERCENT PRECENT   0-4 38160 0.6667 25445  0-4 5026 0.5000 2513 
1900 85 15   5-9 9933 0.6667 6624  5-9 1664 0.5000 832 
1925 30 70   10-14 6220 0.6667 4147  10-14 2130 0.5000 1065 
1950 62 38   15-19 4547 0.6667 3032  15-19 5821 0.5000 2911 
1975 82 18   20-24 2680 0.6667 1787  20-24 7268 0.5000 3634 
2000 94 6   25-34 3633 0.6667 2423  25-34 12102 0.5000 6051 
     35-44 2853 0.6667 1903  35-44 9985 0.5000 4993 
     45-54 1693 0.6667 1129  45-54 8762 0.5000 4381 
     55-64 1420 0.6667 947  55-64 2545 0.5000 1273 
     65-74 573 0.6667 382  65-74 1932 0.5000 966 
     75+ 247 0.6667 164  75+ 370 0.5000 185 
      
71959 
 
 
  
57605 
 
 
              
1950 
  
 
 
1975 
    
2000 
  
 
Age Prevalence (1-QALY) BURDEN  Age Prevalence (1-QALY) BURDEN  Age Prevalence (1-QALY) BURDEN 
   
 
    
 
    
 
0-4 1618 0.3333 544  0-4 41 0.1667 7  0-4 17 0.1667 3 
5-9 453 0.3333 152  5-9 17 0.1667 3  5-9 17 0.1667 3 
10-14 321 0.3333 108  10-14 0 0.1667 0  10-14 17 0.1667 3 
15-19 1424 0.3333 478  15-19 39 0.1667 6  15-19 0 0.1667 0 
20-24 2924 0.3333 982  20-24 67 0.1667 11  20-24 33 0.1667 6 
25-34 7576 0.3333 2546  25-34 100 0.1667 17  25-34 80 0.1667 13 
35-44 6747 0.3333 2267  35-44 256 0.1667 43  35-44 300 0.1667 50 
45-54 7924 0.3333 2662  45-54 1028 0.1667 172  45-54 283 0.1667 47 
55-64 7289 0.3333 2449  55-64 1544 0.1667 258  55-64 750 0.1667 125 
65-74 4582 0.3333 1539  65-74 2194 0.1667 366  65-74 1517 0.1667 253 
75+ 1166 0.3333 392  75+ 1833 0.1667 306  75+ 3017 0.1667 504 
 
42024 
 
 
  
7119 
 
 
  
6031 
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12.3: Changes in Mortality and Morbidity Burden 
This Appendix relates to Tables 8.1.2.i, 8.1.2.ii, 8.1.3, 8.1.4, 8.1.5, and 8.1.6 in the main 
thesis. 
 
The change in the mortality and morbidity burden is identified for the age specific burden 
of mortality and morbidity, i.e. the mortality and morbidity burdens are considered relative 
to the size of the age group in the era that they relate to. This provides a mortality or 
morbidity burden rate. The appeal of identifying and utilising such an index is that the 
mortality or morbidity considerations are standardised to a population and are therefore 
more meaningful and accurate, which provides a more indicative measure of the change in 
the burden of mortality or morbidity. This rate will be reversed for the morbidity gain once 
the calculations have been completed, i.e. the final stage of the morbidity burden change 
calculation below, ‘Actual Morbidity Gain’, which converts the morbidity burden back 
into an actual number. This is desirable as it i) facilitates a more detailed considerations of 
the change in the morbidity rate and, ii) converts the change in the morbidity burden into 
the same format as the other (disability and Chapter 9) morbidity burden used in the thesis 
that lack the data which is necessary to make the type of morbidity rate calculations that 
are contained here. 
 
The first stage in identifying the change in the mortality or morbidity burden is to identify 
the rate of mortality or morbidity within the population. This is achieved by dividing the 
mortality or morbidity burden by the number of population for each age group. This 
provides an age specific mortality or morbidity burden index. Presented here as the 
mortality or morbidity burden per 1000. 
 
After this has been achieved the mortality or morbidity burden change will be compared 
across different eras (and the correspondingly different populations and mortality / 
morbidity profiles and mortality / morbidity rates). This is achieved through weighting the 
change in the burden of morbidity to either the start [T1] or end point [T2] population 
between two eras, which is referred to as the weighted mortality / morbidity rate (WTD 
MR / WTD MBR). The calculation for the change in the mortality and morbidity rate is 
conducted for a WTS MR or WTD MBR to T1 and T2: once this has been achieved the 
average of these two results represents the change in the mortality or morbidity burden. 
 
After this has been achieved the results for the morbidity gain are transformed into actual 
numbers, i.e. this is shown as ‘morbidity burden change’ for morbidity. This is achieved by 
achieved through transforming the morbidity burden from an age rate back into the actual 
morbidity burden. The ‘mortality burden change’ considers the mortality rate per million. 
This represents the mortality indices that are utilised in the main body of the thesis. 
 
These considerations are made for mortality and all diseases morbidity (tuberculosis, breast 
cancer and stomach cancer) in the thesis for all of the thesis eras: 1900-1925, 1925-1950, 
1950-1975, 1975-2000, and 1900-2000. Because of the density of these calculations, they 
are provided on the attached CD Rom. See Appendix 13.1 for all of these calculations. The 
thesis will provide an indication of these calculations here: mortality, breast and stomach 
cancer and tuberculosis for the period 1900 to 2000 are presented below. The reason that 
1900-2000 have been selected to provide an example of the methodology contained in 
Appendix 13.1 is because 1900-2000 is the most referenced era throughout the thesis and 
especially in the case of breast cancer as this was used to represent a detailed worked 
example throughout Chapter 8.1. 
 
12.3: Changes in Mortality and Morbidity Burden: Disease 
  - 394 -  
It is noteworthy that these calculations are not made for the thesis disability because the 
necessary data (prevalence by age) does not exist and it is not possible to generate an 
accurate estimated about the disability prevalence by age trend. Therefore, blindness will 
be considered in aggregate which is achieved below in Appendix 12.13.1. 
 
Sources: 
See Appendix 13.1 for the full range of these calculations 
 
Death and population data 
• Office of National Statistics, “Twentieth Century Mortality: 100 Years of Mortality 
Data in England and Wales by Age, Sex, Year and Underlying Cause” 
Morbidity data 
• See Appendix 12.2. 
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Mortality Burden Change     
   
1900-2000     
   
1901     2000 
   
Age  % Pop DR/1000 WTD DR  Age  % Pop DR/1000 WTD DR 
0-1 0.02412 178.8 4.31263488  0-1 0.0116673 5.58 0.065103512 
1-4 0.089948 20.83 1.8736212  1-4 0.04897759 0.23 0.011264847 
5-9 0.107086 4.06 0.43476924  5-9 0.06477421 0.11 0.007125163 
10-14 0.102585 2.34 0.24004802  10-14 0.06544862 0.14 0.009162806 
15-19 0.099601 3.34 0.33266757  15-19 0.06106495 0.4 0.024425981 
20-24 0.095741 4.24 0.40593988  20-24 0.05870452 0.55 0.032287484 
25-34 0.161673 5.75 0.92962045  25-34 0.14564562 0.72 0.104864848 
35-44 0.123151 9.62 1.18470887  35-44 0.14716016 1.3 0.191308202 
45-54 0.089448 15.85 1.41775706  45-54 0.13229423 3.27 0.432602125 
55-64 0.059846 29.79 1.78280893  55-64 0.10482839 8.4 0.880558489 
65-74 0.033199 61.52 2.04242303  65-74 0.05592209 23.54 1.316406049 
75-84 0.012103 129.8 1.5709525  75-84 0.05592209 60.79 3.399503981 
85+ 0.001499 257.81 0.38657152  85+ 0.01939796 164.27 3.186503492 
         
1900-2000 (T1)         
Age  % Pop DR/1000 WTD DR % Pop DR/1000 WTD DR Decrease/1000 Mortality Burden Change 
 1901 1901 1901&1901 1901 2000 1901&2000   
0-1 0.02412 178.8 4.31263488 0.02412 5.58 0.13458894 4.17804594 4178.04594 
1-4 0.089948 20.83 1.8736212 0.089948 0.23 0.02068809 1.852933114 1852.933114 
5-9 0.107086 4.06 0.43476924 0.107086 0.11 0.01177946 0.42298978 422.9897799 
10-14 0.102585 2.34 0.24004802 0.102585 0.14 0.01436185 0.225686172 225.6861717 
15-19 0.099601 3.34 0.33266757 0.099601 0.4 0.03984043 0.292827141 292.8271408 
20-24 0.095741 4.24 0.40593988 0.095741 0.55 0.0526573 0.353282585 353.2825853 
25-34 0.161673 5.75 0.92962045 0.161673 0.72 0.11640465 0.8132158 813.2158003 
35-44 0.123151 9.62 1.18470887 0.123151 1.3 0.16009579 1.024613073 1024.613073 
45-54 0.089448 15.85 1.41775706 0.089448 3.27 0.29249625 1.125260808 1125.260808 
55-64 0.059846 29.79 1.78280893 0.059846 8.4 0.50270544 1.280103489 1280.103489 
65-74 0.033199 61.52 2.04242303 0.033199 23.54 0.78151232 1.260910705 1260.910705 
75-84 0.012103 129.8 1.5709525 0.012103 60.79 0.73573345 0.835219044 835.2190445 
85+ 0.001499 257.81 0.38657152 0.001499 164.27 0.24631358 0.140257941 140.2579411 
       
13.80534559 13805.34559 
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1900-2000 (T2)         
Age  % Pop DR/1000 WTD DR % Pop DR/1000 WTD DR Decrease/1000 Mortality Burden Change 
 2000 1901 2000&1901 2000 2000 2000&2000   
0-1 0.011667 178.8 2.08611255 0.011667 5.58 0.06510351 2.021009033 2021.009033 
1-4 0.048978 20.83 1.02020329 0.048978 0.23 0.01126485 1.00893844 1008.93844 
5-9 0.064774 4.06 0.26298328 0.064774 0.11 0.00712516 0.25585812 255.8581195 
10-14 0.065449 2.34 0.15314977 0.065449 0.14 0.00916281 0.143986959 143.9869588 
15-19 0.061065 3.34 0.20395694 0.061065 0.4 0.02442598 0.179530957 179.5309574 
20-24 0.058705 4.24 0.24890715 0.058705 0.55 0.03228748 0.216619663 216.6196635 
25-34 0.145646 5.75 0.83746233 0.145646 0.72 0.10486485 0.732597481 732.5974812 
35-44 0.14716 9.62 1.41568069 0.14716 1.3 0.1913082 1.22437249 1224.37249 
45-54 0.132294 15.85 2.09686351 0.132294 3.27 0.43260212 1.664261386 1664.261386 
55-64 0.104828 29.79 3.12283778 0.104828 8.4 0.88055849 2.242279294 2242.279294 
65-74 0.055922 61.52 3.44032711 0.055922 23.54 1.31640605 2.123921059 2123.921059 
75-84 0.055922 129.8 7.25868756 0.055922 60.79 3.39950398 3.859183578 3859.183578 
85+ 0.019398 257.81 5.00098901 0.019398 164.27 3.18650349 1.814485521 1814.485521 
       
17.48704398 17487.04398 
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Morbidity Burden Change 
      
Breast Cancer 
       
1900-2000 
       
         
1900 
    
2000 
   
         
Age  % Pop MBR per 1000   Age  % Pop MBR per 1000  
0-4 0.114068 0   0-4 0.0606449 0  
5-9 0.107086 0   5-9 0.0647742 0  
10-14 0.102585 0   10-14 0.0654486 0  
15-19 0.099601 0.0009236   15-19 0.061065 0  
20-24 0.095741 0.0032028   20-24 0.0587045 0.001969409  
25-34 0.161673 0.036605   25-34 0.1456456 0.024475432  
35-44 0.123151 0.3884269   35-44 0.1471602 0.105797936  
45-54 0.089448 0.9862535   45-54 0.1322942 0.290137932  
55-64 0.059846 1.4674386   55-64 0.1048284 0.470378472  
65-74 0.033199 2.2693267   65-74 0.0559221 0.682198245  
75+ 0.013602 1.5554554   75+ 0.0753201 1.57410013  
         
1900-2000 (T1)         
Age  % Pop MBR per 1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease per 1000 Morbidity Burden Change 
 1900 1900 1900&1900 1900 2000 1900&2000   
0-4 0.114068 0 0 0.114068 0 0 0 0 
5-9 0.107086 0 0 0.107086 0 0 0 0 
10-14 0.102585 0 0 0.102585 0 0 0 0 
15-19 0.099601 0.0009236 9.199E-05 0.099601 0 0 9.19904E-05 3.887021995 
20-24 0.095741 0.0032028 0.00030663 0.095741 0.00196941 0.0001886 0.000118082 4.989531439 
25-34 0.161673 0.036605 0.00591805 0.161673 0.02447543 0.003957 0.001961029 82.86260848 
35-44 0.123151 0.3884269 0.04783501 0.123151 0.10579794 0.0130291 0.034805926 1470.712206 
45-54 0.089448 0.9862535 0.08821879 0.089448 0.29013793 0.0259524 0.062266418 2631.045684 
55-64 0.059846 1.4674386 0.08782016 0.059846 0.47037847 0.0281502 0.059669949 2521.332801 
65-74 0.033199 2.2693267 0.07534013 0.033199 0.68219825 0.0226485 0.052691607 2226.465416 
75+ 0.013602 1.5554554 0.02115779 0.013602 1.57410013 0.0214114 -0.000253612 -10.71628367 
       
0.211351389 8931 
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1900-2000 (T2) 
Age  % Pop MBR/1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease/1000 Morbidity Burden Change 
 2000 1900 2000&1900 2000 2000 2000&2000   
0-4 0.060645 0 0 0.060645 0 0 0 0 
5-9 0.064774 0 0 0.064774 0 0 0 0 
10-14 0.065449 0 0 0.065449 0 0 0 0 
15-19 0.061065 0.0009236 5.6399E-05 0.061065 0 0 5.63989E-05 2.383115096 
20-24 0.058705 0.0032028 0.00018802 0.058705 0.00196941 0.0001156 7.24037E-05 3.059393999 
25-34 0.145646 0.036605 0.00533136 0.145646 0.02447543 0.0035647 0.001766622 74.64800639 
35-44 0.14716 0.3884269 0.05716096 0.14716 0.10579794 0.0155692 0.041591718 1757.443481 
45-54 0.132294 0.9862535 0.13047564 0.132294 0.29013793 0.0383836 0.092092068 3891.318088 
55-64 0.104828 1.4674386 0.15382923 0.104828 0.47037847 0.049309 0.104520214 4416.465061 
65-74 0.055922 2.2693267 0.1269055 0.055922 0.68219825 0.03815 0.088755543 3750.334394 
75+ 0.07532 1.5554554 0.11715698 0.07532 1.57410013 0.1185613 -0.001404325 -59.33925127 
       
0.327450642 13836 
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Morbidity Burden Change 
      
Stomach Cancer 
       
1900-2000 
       
         
1900 
    
2000 
   
         
Age  % Pop MBR/1000   Age  % Pop MBR/1000  
0-4 0.114068091 0   0-4 0.06064489 0  
5-9 0.10708602 0   5-9 0.06477421 0  
10-14 0.102584623 0   10-14 0.06544862 0  
15-19 0.099601068 0.000923588   15-19 0.06106495 0.000126219  
20-24 0.095740538 0.00192166   20-24 0.05870452 0.000295411  
25-34 0.161673121 0.013655761   25-34 0.14564562 0.001058397  
35-44 0.12315061 0.085902097   35-44 0.14716016 0.004582831  
45-54 0.089448395 0.31675294   45-54 0.13229423 0.015439067  
55-64 0.059845885 0.812624891   55-64 0.10482839 0.053305884  
65-74 0.033199334 1.571995936   65-74 0.05592209 0.171580418  
75+ 0.013602313 1.557709648   75+ 0.07532006 0.35355215  
         
1900-2000 (T1)         
Age  % Pop MBR/1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease/1000 Morbidity Burden Change 
 1900 1900 1900&1900 1900 2000 1900&2000   
         
0-4 0.114068091 0 0 0.1140681 0 0 0 0 
5-9 0.10708602 0 0 0.107086 0 0 0 0 
10-14 0.102584623 0 0 0.1025846 0 0 0 0 
15-19 0.099601068 0.000923588 9.19904E-05 0.0996011 0.0001262 1.2572E-05 7.94189E-05 3 
20-24 0.095740538 0.00192166 0.000183981 0.0957405 0.0002954 2.8283E-05 0.000155698 7 
25-34 0.161673121 0.013655761 0.00220777 0.1616731 0.0010584 0.00017111 0.002036655 86 
35-44 0.12315061 0.085902097 0.010578896 0.1231506 0.0045828 0.00056438 0.010014517 423 
45-54 0.089448395 0.31675294 0.028333042 0.0894484 0.0154391 0.001381 0.026952042 1139 
55-64 0.059845885 0.812624891 0.048632256 0.0598459 0.0533059 0.00319014 0.045442118 1920 
65-74 0.033199334 1.571995936 0.052189218 0.0331993 0.1715804 0.00569636 0.046492862 1965 
75+ 0.013602313 1.557709648 0.021188455 0.0136023 0.3535522 0.00480913 0.016379327 692 
       
0.14755264 6235 
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1900-2000 (T2)         
Age  % Pop MBR/1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease/1000 Morbidity Burden Change 
 2000 1900 2000&1900 2000 2000 2000&2000   
        
 
0-4 0.06064489 0 0 0.0606449 0 0 0 0 
5-9 0.064774207 0 0 0.0647742 0 0 0 0 
10-14 0.065448618 0 0 0.0654486 0 0 0 0 
15-19 0.061064951 0.000923588 5.63989E-05 0.061065 0.0001262 7.7075E-06 4.86913E-05 2 
20-24 0.058704516 0.00192166 0.00011281 0.0587045 0.0002954 1.7342E-05 9.54682E-05 4 
25-34 0.145645622 0.013655761 0.001988902 0.1456456 0.0010584 0.00015415 0.001834751 78 
35-44 0.147160155 0.085902097 0.012641366 0.1471602 0.0045828 0.00067441 0.011966956 506 
45-54 0.132294228 0.31675294 0.041904586 0.1322942 0.0154391 0.0020425 0.039862086 1684 
55-64 0.104828392 0.812624891 0.08518616 0.1048284 0.0533059 0.00558797 0.07959819 3363 
65-74 0.055922092 1.571995936 0.087909302 0.0559221 0.1715804 0.00959514 0.078314166 3309 
75+ 0.075320056 1.557709648 0.117326778 0.0753201 0.3535522 0.02662957 0.09069721 3832 
       
0.302417518 12779 
 
 
 
12.3: Changes in Mortality and Morbidity Burden: Disease: Tuberculosis 
         - 401 -  
Morbidity Burden Change 
      
Tuberculosis 
       
1900-2000 
       
         
1900 
    
2000 
   
         
Age  % Pop MBR/1000 WTD MBR  Age  % Pop MBR/1000  
0-4 0.114068 6.8400538 0.78023188  0-4 0.0606449 0.000953198  
5-9 0.107086 1.8967443 0.20311479  5-9 0.0647742 0.000892432  
10-14 0.102585 1.2395755 0.12716139  10-14 0.0654486 0.000883236  
15-19 0.099601 0.9334401 0.09297163  15-19 0.061065 0  
20-24 0.095741 0.5723345 0.05479561  20-24 0.0587045 0.001969409  
25-34 0.161673 0.4595543 0.07429758  25-34 0.1456456 0.001719895  
35-44 0.123151 0.473831 0.05835257  35-44 0.1471602 0.006546902  
45-54 0.089448 0.3870282 0.03461905  45-54 0.1322942 0.006845624  
55-64 0.059846 0.485218 0.0290383  55-64 0.1048284 0.022976674  
65-74 0.033199 0.3528216 0.01171344  65-74 0.0559221 0.057957071  
75+ 0.013602 0.3697024 0.00502881  75+ 0.0753201 0.128936529  
         
1900-2000 (T1)         
Age  % Pop MBR/1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease/1000 Morbidity Burden Change 
 1900 1900 1900&1900 1900 2000 1900&2000   
0-4 0.114068 6.8400538 0.78023188 0.114068 0.0009532 0.0001087 0.780123148 32964 
5-9 0.107086 1.8967443 0.20311479 0.107086 0.00089243 9.557E-05 0.203019228 8579 
10-14 0.102585 1.2395755 0.12716139 0.102585 0.00088324 9.061E-05 0.127070785 5369 
15-19 0.099601 0.9334401 0.09297163 0.099601 0 0 0.092971627 3928 
20-24 0.095741 0.5723345 0.05479561 0.095741 0.00196941 0.0001886 0.05460706 2307 
25-34 0.161673 0.4595543 0.07429758 0.161673 0.0017199 0.0002781 0.074019516 3128 
35-44 0.123151 0.473831 0.05835257 0.123151 0.0065469 0.0008063 0.05754632 2432 
45-54 0.089448 0.3870282 0.03461905 0.089448 0.00684562 0.0006123 0.034006722 1437 
55-64 0.059846 0.485218 0.0290383 0.059846 0.02297667 0.0013751 0.027663242 1169 
65-74 0.033199 0.3528216 0.01171344 0.033199 0.05795707 0.0019241 0.009789308 414 
75+ 0.013602 0.3697024 0.00502881 0.013602 0.12893653 0.0017538 0.003274973 138 
       
1.464091929 61865 
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1900-2000 (T2) 
Age  % Pop MBR/1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease/1000 Morbidity Burden Change 
 2000 1900 2000&1900 2000 2000 2000&2000   
0-4 0.060645 6.8400538 0.41481431 0.060645 0.0009532 5.781E-05 0.414756503 17525 
5-9 0.064774 1.8967443 0.12286011 0.064774 0.00089243 5.781E-05 0.1228023 5189 
10-14 0.065449 1.2395755 0.08112851 0.065449 0.00088324 5.781E-05 0.0810707 3426 
15-19 0.061065 0.9334401 0.05700047 0.061065 0 0 0.057000472 2409 
20-24 0.058705 0.5723345 0.03359862 0.058705 0.00196941 0.0001156 0.033483006 1415 
25-34 0.145646 0.4595543 0.06693207 0.145646 0.0017199 0.0002505 0.066681576 2818 
35-44 0.14716 0.473831 0.06972904 0.14716 0.0065469 0.0009634 0.068765598 2906 
45-54 0.132294 0.3870282 0.0512016 0.132294 0.00684562 0.0009056 0.050295962 2125 
55-64 0.104828 0.485218 0.05086462 0.104828 0.02297667 0.0024086 0.048456016 2047 
65-74 0.055922 0.3528216 0.01973052 0.055922 0.05795707 0.0032411 0.016489444 697 
75+ 0.07532 0.3697024 0.02784601 0.07532 0.12893653 0.0097115 0.018134501 766 
       
0.977936079 41322 
 
 
 
 
 
 
 
 
12.4: Valuation of Changes in Mortality and Morbidity Burden: Disease 
   
   
   
  - 403 -  
12.4: Valuation of Changes in Mortality and Morbidity Burden: Disease 
This Appendix relates to Tables 8.1.3, 8.1.4, 8.1.5, and 8.1.6 in the main thesis. 
 
The next stage in the thesis QALE methodology is to value the change in the mortality and 
morbidity burdens that have been identified in Appendix 12.3 (and in more detail in 
Appendix 13.1). This is achieved through identifying the average change in the morbidity 
burden (between the change weighted to T1 and T2) and then valuing this change. For the 
change in the mortality burden the VSL is used to value the change and estimate the 
mortality gain. The change in the burden of morbidity is valued by applying the VSHLY to 
the change, which yields the morbidity gain (the VSL and VSHLY values that are 
multiplied by the morbidity and mortality change are contained in Appendix 12.1). 
 
Hence: the mortality gain = change in the burden of mortality * VSL. In the case below, 
the precise calculation = (change in morbidity burden 1 * VSL = mortality gain 1 and 
change in morbidity burden 2 * VSL = mortality gain 2)  (mortality gain 1 + mortality 
gain 2) / 2 = Average mortality gain. This process is the same for the morbidity gain (but 
using morbidity and the VSHLY instead of mortality and the VSL).  
 
This process is necessary because of the weighting of the change in the burden of 
morbidity to either the start [T1] or end point [T2] population. Mortality and morbidity 
change 1 represents the change in mortality and morbidity fixed to T1 and the mortality 
and morbidity change 2 represents the result fixed to T2. Once these have both been 
applied to the VSL or VSHLY the corresponding mortality / morbidity gain is derived. 
This is then average to provide a single estimate, which is the mid-point between the 
results for the two populations.  
 
The mortality and morbidity gains here utilised the mid VSL and VSHLY values. 
 
 
Sources: 
Mortality and morbidity burden change 
• Appendix 12.3 (and in more detail in Appendix 13.1) 
VSL and VSHLY values 
• Appendix 12.1.1 and 12.1.2. 
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Summary Mortality Gain 
     
 
      
 
Period Mortality Burden Change 1 Mortality Burden Change 2 VSL Mortality Gain 1 Mortality Gain 2 Average Mortality Gain 
   millions millions millions millions 
1900-1925 6201 5968 0.64 3969 3820 3895 
1925-1950 4494 4974 0.76 3415 3780 3598 
1950-1975 1906 2386 1.16 2211 2767 2489 
1975-2000 3781 4034 2.05 7751 8270 8011 
1900-2000 13805 17487 0.88 12149 15389 13769 
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Summary Morbidity Gain  
     
BREAST CANCER  
     
       
Period Morbidity Burden Rate Change1 Morbidity Burden Rate Change2 VSHLY Morbidity Gain 1 Morbidity Gain 2 Average Morbidity Gain 
   millions millions millions millions 
1900-1925 -868 -1000 0.21 -182 -210 -196 
1925-1950 -2062 -2586 0.32 -660 -828 -741 
1950-1975 13287 14952 0.68 9035 10167 9601 
1975-2000 11092 11102 1.53 16971 16986 16979 
1900-2000 8931 13836 0.51 4555 7056 5806 
 
Summary Morbidity Gain  
    
 
STOMACH CANCER  
    
 
      
 
Period Morbidity Burden Rate Change1 Morbidity Burden Rate Change2 VSHLY Morbidity Gain 1 Morbidity Gain 2 Average Morbidity Gain 
   millions millions millions millions 
1900-1925 1116 1510 0.21 234 317 278 
1925-1950 121 -164 0.32 39 -52 -7 
1950-1975 5598 6611 0.68 3807 4495 4151 
1975-2000 2678 2714 1.36 3642 3691 3677 
1900-2000 6235 12779 0.44 2743 5623 4183 
 
Summary Morbidity Gain  
    
 
TUBERCULOSIS  
    
 
      
 
Period Morbidity Burden Rate Change1 Morbidity Burden Rate Change2 VSHLY Morbidity Gain 1 Morbidity Gain 2 Average Morbidity Gain 
   millions millions millions millions 
1900-1925 28168 22021 0.27 7605 5946 6776 
1925-1950 18728 17215 0.45 8428 7748 8088 
1950-1975 13977 13556 0.87 12160 11794 19977 
1975-2000 377 330 1.71 645 565 605 
1900-2000 61865 41322 0.51 31551 21074 26313 
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12.5: Value of QALE Gain: Disease 
This Appendix relates to Tables 8.1.7 in the main thesis. 
 
The next stage in the thesis methodology is to combine the mortality gain and the 
morbidity gain in order to identify the QALE gain. This is achieved in two stages below. 
Stage one, which is the top series of data summarises the results generated above, where 
the mortality and morbidity gains here are the same as those presented as the average 
mortality and morbidity gain above in Appendix 12.4. The second stage provides the 
QALE gain, which is achieved by summing the mortality gain and the morbidity gain. This 
consideration is made for independent diseases below. Hence, it is possible to sum all 
diseases and mortality (which will be considered later in the Appendices) but for initial 
analysis purposes the mortality gain will be summed with each individual morbidity gain. 
 
 
Sources: 
Mortality and morbidity gains 
• Calculated in Appendix 12.4 
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QALE Considerations 
   
     
 Deaths Stomach Cancer Breast Cancer Tuberculosis 
Period Average Mortality Gain  Average Morbidity Gain  Average Morbidity Gain  Average Morbidity Gain  
 millions millions millions millions 
     
1900-1925 3895 278 -196 6776 
1925-1950 3598 -7 -741 8088 
1950-1975 2489 4151 9601 19977 
1975-2000 8011 3677 16979 605 
1900-2000 13769 4183 5806 26313 
 
 
QALE Gain 
   
    
Period QALE Gain QALE Gain QALE Gain 
 Stomach Cancer Breast Cancer Tuberculosis 
    
1900-1925 4173 3699 10670 
1925-1950 3591 2857 11686 
1950-1975 6640 12090 14466 
1975-2000 11688 24990 8616 
1900-2000 17952 19575 40082 
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12.6: Alternative QALY Weights 
This Appendix relates to Tables 8.1 and 8.1.8 in the main thesis. 
 
The QALY represents the index for the burden of morbidity. This QALY provides a 
standardised index, across all thesis illnesses and all thesis eras. The series of QALYs used 
in the thesis have been constructed by the detailed qualitative analysis in Part II of the 
thesis. This was achieved through considering the twentieth century health and welfare 
history of the thesis morbidity states and summarising this evolution on a standardised 
spectrum, which considers all illnesses and their level of development, namely, EuroQol. 
Once all thesis illnesses and eras had received a EuroQol rank (summarised in Chapter 7) 
these ranks were then converted into QALYs.  
 
Although the QALY values utilised in the thesis and presented below are unique to the 
thesis, the general concept of a quality adjusted life year is not new. Economists have 
designed a series of econometric scaling techniques in an attempt to assign a numerical 
value to health status. These are known as utility ratings, of which the most famous is the 
QALY. QALYs have become increasingly used in the estimation of cost-effectiveness of 
different forms of medical intervention.  
 
As well as making similar QALY considerations to the existing literature, the thesis QALY 
is also subject to a variety of contentions associated with trying to identify the burden of 
morbidity and summarise this in the QALY.  A pertinent problem with the QALY is their 
potential to misrepresent consumer preferences. Many have highlighted that QALYs fail to 
accurately represent an individuals’ preferences, and the high potential for bias due to the 
problems of framing effects influencing the results. Although these problems cannot be 
avoided, they will be recognised and accommodated by the methods of the thesis. 
 
The QALY in this thesis is based upon a comprehensive analysis of the changing health 
and welfare conditions faced by illness sufferers as the twentieth century unfolded. 
Moreover, due to the subjective and often controversial nature of illness and welfare 
measurement, the estimates of the burden of disease in the thesis are presented as a range 
of possible values, these are shown below.  
 
The key advantages of this approach are that is recognises and therefore to an extent 
overcomes many of the contentions associates with trying to determine QALY weights. 
Furthermore, because the results will be presented in a range (shown below for each illness 
and era considered in the thesis) they will provide a broader consideration about the 
contributions of improved health. Finally, the analysis that forms the basis of the QALY 
weights represents a significant proportion of the volume of the thesis, and therefore will 
be available for the reader to identify the evidence from which the conclusions (QALYs) 
have been drawn.  
 
Hence, the QALYs presented below, for the illnesses (blindness, breast and stomach 
cancer and tuberculosis) and eras (1900, 1925, 1950, 1975, and 2000) considered in the 
thesis have been derived through a detailed qualitative account of the twentieth century 
health and welfare associated quality of life faced by sufferers of the illness in question. 
Furthermore, the thesis has created a foundational standardised measurement spectrum 
(EuroQol), which has generated a consistent account of the effects of the thesis morbidity 
states upon quality of life at different historical points during the twentieth century. After 
EuroQol was utilised to summarise all states of thesis morbidity for all eras considered in 
the thesis, these EuroQol ranks were converted into a QALY indices, which will represent 
12.6: Alternative QALY Weights 
  - 409 - 
the changing (diminishing) burden of different illnesses upon quality of life. This will 
essentially provide the morbidity measure component of the thesis. The results of this 
process, the QALY indices, are shown below. These are represented by ‘Mid’. The other 
QALY values shown below, ‘Low’ and ‘High’ represent the provision of a range of QALY 
estimate, the appeal of which has been outlined above. 
 
This QALY has two primary uses in the thesis methodology: i) to provide a morbidity 
burden index (which is combined with the prevalence in order to estimate the morbidity 
burden) and, ii) to provide part of the VSHLY, which is used to value the change in the 
morbidity burden and estimate the morbidity gain (VSHLY = VSL * QALY) and 
(morbidity burden change * VSHLY = morbidity gain).  
 
In the tables below the QALYs are presented in two formats: i) as a QALY for the years or 
periods the thesis has identified the quality of life through EuroQol (1900, 1925, 1950, 
1975, and 2000) and, ii) as a QALY for the eras that the thesis applied the QALE 
methodology (1900-1925, 1925-1950, 1950-1975, 1975-2000, and 1900-2000). The 
detailed analysis in the main body of the thesis that has generated EuroQol ranks and 
subsequent QALY weights has conducted this for specific years. The QALE methodology 
used throughout Chapter 8 and 9 considers periods. These QALY values are converted into 
era estimates through identifying the mid value of the QALY between the start and end 
point of the era under consideration. This is shown below. 
 
Appendix 12.6.1 presents the range of QALY weights for the thesis diseases: breast cancer, 
stomach cancer, tuberculosis. Appendix 12.6.2 presents the range of QALY weights for the 
thesis disability: blindness. 
 
 
Sources: 
QALY  
• The QALY data comes from the thesis, the underlying rational is presented in Part II 
and the summary results are presented in Chapter 7 and summarised at the beginning of 
Chapter 8. This data is also summarised in Appendix 12.6. 
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12.6.1: Alternative QALY Weights: Disease 
 
Breast Cancer 
  
    
Low QALY 
  
Period QALY Value Era QALY Value 
1900 0.1667 1900-1925 0.1667 
1925 0.1667 1925-1950 0.2500 
1950 0.3333 1950-1975 0.4167 
1975 0.5000 1975-2000 0.5834 
2000 0.6667 1900-2000 0.4167 
    
Mid QALY 
  
Period QALY Value Era QALY Value 
1900 0.3333 1900-1925 0.3333 
1925 0.3333 1925-1950 0.4167 
1950 0.5000 1950-1975 0.5834 
1975 0.6667 1975-2000 0.7485 
2000 0.8333 1900-2000 0.5833 
    
High QALY 
  
Period QALY Value Era QALY Value 
1900 0.5000 1900-1925 0.5000 
1925 0.5000 1925-1950 0.5834 
1950 0.6667 1950-1975 0.7500 
1975 0.8333 1975-2000 0.9167 
2000 1 1900-2000 0.7500 
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QALY Weights 
 
Stomach Cancer 
  
    
Low QALY 
  
Period QALY Value Era QALY Value 
1900 0.1667 1900-1925 0.1667 
1925 0.1667 1925-1950 0.2500 
1950 0.3333 1950-1975 0.4167 
1975 0.5000 1975-2000 0.5000 
2000 0.5000 1900-2000 0.3333 
    
Mid QALY 
   
Period QALY Value Era QALY Value 
1900 0.3333 1900-1925 0.3333 
1925 0.3333 1925-1950 0.4167 
1950 0.5000 1950-1975 0.5834 
1975 0.6667 1975-2000 0.6667 
2000 0.6667 1900-2000 0.5000 
    
High QALY 
   
Period QALY Value Era QALY Value 
1900 0.5000 1900-1925 0.5000 
1925 0.5000 1925-1950 0.5834 
1950 0.6667 1950-1975 0.7500 
1975 0.8333 1975-2000 0.8333 
2000 0.8333 1900-2000 0.6667 
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QALY Weights 
 
Tuberculosis 
  
  
  
Low QALY 
  
Era QALY Value Era QALY Value 
1900 0.1667 1900-1925 0.2500 
1925 0.3333 1925-1950 0.4167 
1950 0.5000 1950-1975 0.5834 
1975 0.6667 1975-2000 0.6667 
2000 0.6667 1900-2000 0.4167 
    
Mid QALY 
   
Era QALY Value Era QALY Value 
1900 0.3333 1900-1925 0.4167 
1925 0.5000 1925-1950 0.5834 
1950 0.6667 1950-1975 0.7485 
1975 0.8333 1975-2000 0.8333 
2000 0.8333 1900-2000 0.5833 
    
High QALY 
   
Era QALY Value Era QALY Value 
1900 0.5000 1900-1925 0.5834 
1925 0.6667 1925-1950 0.7500 
1950 0.8333 1950-1975 0.9167 
1975 1 1975-2000 1 
2000 1 1900-2000 0.7500 
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12.6.2: Alternative QALY Weights: Disability 
 
QALY Weights  
  
Blind  
  
    
Low QALY 
   
Period  Era QALY Value 
1900 0.1667 1900-1925 0.2500 
1925 0.3333 1925-1950 0.4167 
1950 0.5000 1950-1975 0.5000 
1975 0.5000 1975-2000 0.5000 
2000 0.5000 1900-2000 0.3334 
    
Mid QALY 
   
Period  Era QALY Value 
1900 0.3333 1900-1925 0.4167 
1925 0.5000 1925-1950 0.5834 
1950 0.6667 1950-1975 0.6667 
1975 0.6667 1975-2000 0.6667 
2000 0.6667 1900-2000 0.5000 
    
High QALY 
   
Period  Era QALY Value 
1900 0.5000 1900-1925 0.5834 
1925 0.6667 1925-1950 0.7500 
1950 0.8333 1950-1975 0.8333 
1975 0.8333 1975-2000 0.8333 
2000 0.8333 1900-2000 0.6667 
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12.7: Value of QALE Gain for Alternative VSL and VSHLY and QALY Weights 
This Appendix relates to Tables 8.1.9 and 8.1.10 in the main thesis. 
 
This appendix combines the analysis of the previous Appendices in order to provide a 
range of QALE gain estimates. Appendix 12.1 considered the range (low, mid, high) of 
VSL and VSHLY values and Appendix 12.6 considered the range (low, mid, high) of 
QALY values for all of the thesis illnesses (diseases and disability) and eras. The analysis 
below will repeat the QALE gain calculation (shown in Appendix 12.4 and 12.5) but for all 
ranges and subsequent combinations of QALY, VSL and VSHLY weight, for all illnesses 
and eras.  
 
Hence, the methodological process here is essentially the same as Appendix 12.5, but it 
applies the series (Low, Mid or actual, High) of variable weights in order to consider the 
full array of sensitivity analysis QALE gain results, instead of only considering the ‘Mid’ 
QALY, VSL and VSHLY estimates, which is the case in Appendix 12.5. 
 
These results represent the foundation of the thesis sensitivity analysis. The desire of 
making this series of considerations is to provide the reader with the broadest (within the 
bounds of the thesis analysis) range of results from an exaggeratedly large margin of error. 
Hence, one of the ways in which the thesis aims to overcome issues of bias and variable 
selection is to provide the reader with the broadest possible range of estimates. This allows 
the reader to identify a QALE gain with an alternative (lower or higher) variable value, for 
the QALY, VSL, VSHLY, or all of these variables, in whichever combination (lower or 
higher or mid) the reader prefers.  
 
The starting point of the QALE methodological variables has been outlined in detail in the 
main body of the thesis: the VSL and VSHLY were considered in Chapter 3 and the 
QALY is substantiated by the qualitative analysis in Part II of the thesis, which is 
summarised in Chapter7. For the reader who is still unsure of what they believe to be the 
most accurate weight, these sections should be reconsidered. 
 
Hence, instead of only providing one estimate of the QALE gain for each illness and era, 
this analysis enables the thesis to provide twenty seven different estimates for each illness 
and era. 
 
Additionally, this section also considers alternative VSL values that are selected from 
sources not within the thesis. Appendix 12.7.3 considers the VSL and VSHLY and 
subsequent QALE gain that is generated by utilising the VSL suggested by Costa and 
Viscusi. Costa suggests that the VSL over time has an income elasticity of 1.6, which 
basically means that as income rises, the value of life is increasing at 0.6 times the rate (1) 
of the income rise. An alternative view is that represented by Viscusi who contends that 
over time the VSL is income inelastic, such that the VSL is only increasing 0.6 times as 
much as income over time.  
 
A final appeal of this exercise is to highlight that whichever weights for the QALY, VSL, 
and VSHLY are preferred by the reader, the overall QALE gain is still significant and still 
contributes to the same overall conclusions of the thesis. The full veracity of this claim is 
highlighted best in Appendix 13.2, which provides the full range of twenty seven estimates 
for each of the four morbidity states and five eras considered in the thesis. Because of the 
density of this analysis the majority of the results are contained in the CD-Rom 
Appendices. This Appendix will present the most extreme and mid point estimates, i.e. the 
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QALE gain results using a low, mid, and high QALY, VSL and VSHLY. For all other 
variable weight combinations, see Appendix 13.2. Appendix 12.7 will also contain the 
alternative QALE gain for the Viscusi and Costa weights. 
 
 
Sources: 
QALY  
• The QALY data comes from the thesis, the underlying rational is presented in Part II 
and the summary results are presented in Chapter 7 and summarised at the beginning of 
Chapter 8. This data is also summarised in Appendix 12.6. 
VSL 
The VSL (multiples) data for the thesis sensitivity analysis, which considers a low, mid, 
high VSL multiple values, comes from: 
• Miller, “Variations between Countries in Values of Statistical Life”  
The alternative VSL for different income elasticity comes from: 
• Costa & Kahn, “Changes in the Value of a Statistical Life, 1940-1980” 
• Viscusi & Aldy, “The Value of a Statistical Life: A Critical Review of Market 
Estimates Throughout The World” 
QALE methodology 
• Uses the same as the more detailed methodological outline in Appendix 12.5. 
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12.7.1: QALE Gain for Alternative VSL and VSHLY and QALY Weights: Disease 
 
LOW QALY 
     
Low VSHLY 
    
Low VSL 
     
 
    
BREAST CANCER 
    
Period Morbidity Burden Change VSHLY Morbidity Gain Mortality Gain QALE Gain 
  millions millions Millions millions 
1900-1925 -934 0.08 -79 3092 3013 
1925-1950 -2324 0.15 -351 2861 2510 
1950-1975 14120 0.38 5389 1966 7355 
1975-2000 11097 0.94 10455 6310 16765 
1900-2000 11384 0.29 3283 10915 14198 
      
STOMACH CANCER 
    
Period Morbidity Burden Change VSHLY Morbidity Gain Mortality Gain QALE Gain 
  millions millions Millions millions 
1900-1925 1313 0.08 111 3092 3204 
1925-1950 -22 0.15 -3 2861 2857 
1950-1975 6104 0.38 2332 1966 4298 
1975-2000 2696 0.81 2178 6310 8487 
1900-2000 9507 0.23 2192 10915 13107 
      
TUBERCULOSIS 
    
Period Morbidity Burden Change VSHLY Morbidity Gain Mortality Gain QALE Gain 
  millions millions Millions millions 
1900-1925 25095 0.13 3189 3092 6281 
1925-1950 17972 0.25 4529 2861 7389 
1950-1975 13766 0.53 7352 1966 9318 
1975-2000 354 1.08 381 6310 6690 
1900-2000 51594 0.29 14878 10915 25793 
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MID QALY 
     
Mid VSHLY 
     
Mid VSL 
     
      
BREAST CANCER  
    
Period Morbidity Burden Change VSHLY Morbidity Gain Mortality Gain QALE Gain 
  millions Millions millions millions 
1900-1925 -934 0.21 -196 3895 3699 
1925-1950 -2324 0.32 -741 3598 2857 
1950-1975 14120 0.60 9601 2489 12090 
1975-2000 11097 1.53 16979 8011 24990 
1900-2000 11384 0.51 5806 13769 19575 
      
STOMACH CANCER  
    
Period Morbidity Burden Change VSHLY Morbidity Gain Mortality Gain QALE Gain 
  millions Millions millions millions 
1900-1925 1313 0.21 278 3895 4173 
1925-1950 -22 0.32 -7 3598 3591 
1950-1975 6104 0.68 4151 2489 6640 
1975-2000 2696 1.36 3677 8011 11688 
1900-2000 9507 0.44 4183 13769 17952 
      
TUBERCULOSIS  
    
Period Morbidity Burden Change VSHLY Morbidity Gain Mortality Gain QALE Gain 
  millions Millions millions millions 
1900-1925 25095 0.27 6776 3895 10671 
1925-1950 17972 0.45 8088 3598 11686 
1950-1975 13766 0.87 1977 2489 14466 
1975-2000 354 1.70 605 8011 8616 
1900-2000 51594 0.51 26313 13769 40082 
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HIGH QALY 
     
High VSHLY 
     
High VSL 
     
      
BREAST CANCER  
    
Period Morbidity Burden Change VSHLY Morbidity Gain Mortality Gain QALE Gain 
  millions Millions millions millions 
1900-1925 -934 0.39 -362 4715 4353 
1925-1950 -2324 0.54 -1248 4362 3113 
1950-1975 14120 1.05 14792 2997 17789 
1975-2000 11097 2.26 25055 9621 34675 
1900-2000 11384 0.79 9003 16643 25645 
      
STOMACH CANCER  
    
Period Morbidity Burden Change VSHLY Morbidity Gain Mortality Gain QALE Gain 
  millions Millions millions millions 
1900-1925 1313 0.39 509 4715 5224 
1925-1950 -22 0.54 -12 4362 4350 
1950-1975 6104 1.05 6395 2997 9392 
1975-2000 2696 2.05 5534 9621 15154 
1900-2000 9507 0.70 6684 16643 23327 
      
TUBERCULOSIS  
    
Period Morbidity Burden Change VSHLY Morbidity Gain Mortality Gain QALE Gain 
  millions Millions millions millions 
1900-1925 25095 0.45 11337 4715 16053 
1925-1950 17972 0.69 12419 4362 16781 
1950-1975 13766 1.28 17633 2997 20630 
1975-2000 354 2.46 871 9621 10492 
1900-2000 51594 0.79 40802 16643 57444 
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12.7.2: QALE Gain for Alternative VSL and VSHLY and QALY Weights: Disability 
 
BLIND 
Low VSL Low VSHLY Low QALY 
      
Period Morbidity Burden Change VSHLY Morbidity Gain  Mortality Burden Change VSL  Mortality Gain QALE Gain 
  millions millions  millions millions millions 
1900-1925 569 0.21 120 6085 0.51 3092 3212 
1925-1950 -10789 0.35 -3776 4734 0.60 2861 -915 
1950-1975 3130 0.61 1909 2146 0.92 1966 3875 
1975-2000 -886 1.08 -957 3907 1.61 6310 5353 
1900-2000 -7976 0.35 -2792 15646 0.69 10820 8028 
 
 
 
BLIND 
Mid VSL Mid VSHLY Mid QALY 
      
Period Morbidity Burden Change VSHLY Morbidity Gain  Mortality Burden Change VSL  Mortality Gain QALE Gain 
  millions millions  millions millions millions 
1900-1925 569 0.27 154 6085 0.64 3895 4049 
1925-1950 -10789 0.45 -4855 4734 0.77 3598 -1257 
1950-1975 3130 0.77 2410 2146 1.16 2489 4899 
1975-2000 -886 1.36 -1205 3907 2.05 8011 6806 
1900-2000 -7976 0.44 -3509 15646 0.88 13769 10260 
 
 
 
BLIND 
High VSL High VSHLY High QALY 
      
Period Morbidity Burden Change VSHLY Morbidity Gain  Mortality Burden Change VSL  Mortality Gain QALE Gain 
  millions millions  millions millions millions 
1900-1925 569 0.32 182 6085 0.77 4715 4897 
1925-1950 -10789 0.54 -5826 4734 0.92 4362 -1464 
1950-1975 3130 0.93 2911 2146 1.40 2997 5908 
1975-2000 -886 1.64 -1453 3907 2.46 9621 8168 
1900-2000 -7976 0.53 -4227 15646 1.05 16498 12271 
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12.7.3: QALE Gain for Alternative VSL and VSHLY: Costa versus Viscusi 
 
 
VSL Values: 1900-2000  
   
     
 
1900-2000 Costa 0.64    
 Viscusi 1.18    
 Thesis 0.88    
      
 
 
 
Summary Mortality Gain: Cost Vs Aldy VSLs 
   
 
    
 
  
Period Death Rate Change 1 Death Rate Change 2 VSL Mortality Gain 1 Mortality Gain 2 Mortality Gain 
Viscusi 
1900-2000 13805.35 17487.04 1.18 16290 21060 18675 
Costa 
1900-2000 13805.35 17487.04 0.64 8835 11192 10014 
Thesis 
1900-2000 13805.35 17487.04 0.88 12149 15389 13769 
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VSHLY Values  
 
Breast Cancer  
 
   
 
Period VSL (Millions) QALY VSHLY (Millions) 
Viscusi 1900-2000 1.18 0.5833 0.69 
Costa 1900-2000 0.64 0.5833 0.37 
Thesis 1900-2000 0.88 0.5833 0.51 
 
 
 
VSHLY Values  
 
Stomach Cancer  
 
   
 
Period VSL (Millions) QALY VSHLY (Millions) 
Viscusi 1900-2000 1.18 0.5000 0.59 
Costa 1900-2000 0.64 0.5000 0.32 
Thesis 1900-2000 0.88 0.5000 0.44 
  
 
 
VSHLY Values  
 
Tuberculosis  
 
   
 
Period VSL (Millions) QALY VSHLY (Millions) 
Viscusi 1900-2000 1.18 0.5833 0.69 
Costa 1900-2000 0.64 0.5833 0.37 
Thesis 1900-2000 0.88 0.5833 0.51 
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Author 
Period / Illness 
Morbidity Burden 
Change1 
Morbidity Burden 
Change2 VSHLY Morbidity Gain 1 Morbidity Gain 2 Average Morbidity Gain 
 
Average Mortality Gain 
 
QALE Gain 
 
   millions millions millions millions millions millions 
Viscusi 
 
Breast Cancer 
1900-2000 
 
8931 
 
13836 0.69 6162 9547 7855 18675 
 
26530 
Costa 
Breast Cancer 
1900-2000 
 
8931 
 
13836 0.37 3304 5119 4212 10014 
 
14226 
Thesis 
Breast Cancer 
1900-2000 
 
8931 
 
13836 0.51 4555 7056 5806 
 
13769 
 
19575 
 
 
 
Author 
Period / Illness 
Morbidity Burden 
Change1 
Morbidity Burden 
Change2 VSHLY Morbidity Gain 1 Morbidity Gain 2 Average Morbidity Gain 
 
Average Mortality Gain 
 
QALE Gain 
 
   millions millions millions millions millions millions 
Viscusi 
 
Stomach Cancer 
1900-2000 
 
6235 
 
12779 0.59 3679 7540 5610 18675 
 
24285 
Costa 
Stomach Cancer 
1900-2000 
 
6235 
 
12779 0.32 1995 4089 3042 10014 
 
13056 
Thesis 
Stomach Cancer 
1900-2000 
 
6235 
 
12779 0.44 2743 5623 4183 
 
13769 
 
17952 
 
 
 
Author 
Period / Illness 
Morbidity Burden 
Change1 
Morbidity Burden 
Change2 VSHLY Morbidity Gain 1 Morbidity Gain 2 Average Morbidity Gain 
 
Average Mortality Gain 
 
QALE Gain 
 
   millions millions millions millions millions millions 
Viscusi 
 
Tuberculosis 
1900-2000 
 
61865 
 
41322 0.69 42687 28512 35600 18675 
 
54275 
Costa 
Tuberculosis 
1900-2000 
 
61865 
 
41322 0.37 22890 15289 19090 10014 
 
29104 
Thesis 
Tuberculosis 
1900-2000 
 
61865 
 
41322 0.51 31551 21074 26312 
 
13769 
 
40082 
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12.8 and 12.9: Age-Weighting: Mortality and Morbidity 
 
This Appendix relates to Figure 3.3 and 8.1.2 and Tables 8.1.13 and 8.3.3 in the main 
thesis. 
 
Chapter 3 of the thesis has highlighted that there is evidence about the VSL not being 
constant across all age groups. I.e. the value of saving one life year of an unidentified 
person varies with the age of the person. Therefore a more valuable approach for 
estimating society’s willingness to pay would be to include a methodology that considers 
the potential for different ages to have varying VSL values.  
 
There are disputes in the literature about the standpoint from which age weighting should 
be conducted. Some theorist have called for equity to be the key function in age weighting: 
where age weights reflect the feeling that everyone is entitled to some normal span of life 
and anyone failing to achieve this has been cheated, while anyone living longer is getting 
more than their fair share. In this type of theory, younger ages receive a higher age weight. 
At the other end of the spectrum, some theorist claim weights should be related to the 
value of human capital or income. 
 
The main body of the thesis has emphasised an alternative and more commonly utilised 
method of age weighting, which considers the relationship between age and efficiency, 
through reflecting an individuals social role, where: the population is supported by others 
during infancy and old age but support others during adulthood and therefore greater 
importance needs to be attached to these years. This form of age weighting is best 
represented by Murray. This is the age weighting approach that is used in the thesis. 
Murray’s age weight function also provides a desirable mid-point between age-weighting 
theories. 
 
Murray’s age weighting function is not flawless but it does still represent the most 
attractive model for the purposes of the thesis. The main flaws of Murray’s model is the 
static nature of the age weights for the thesis which considers a historical period of one 
hundred years, which almost certainly would have experienced some movement in the 
most valuable ages. 
 
Murray’s age weights can be applied to the mortality and the morbidity (except blindness 
were the data is not age specific) QALE gain calculations in the thesis. This is achieved 
through adjusting the VSL for Murray’s age weight. For example, for mortality in 1900-
1925 using a Low VSL, when there is no age weighting the VSL = 0.64 for all age groups 
(shown in Appendix 12.1.1) when there is an age weight the VSL = 0.64 * 0.3 (age weight 
for 0-4 age group) = 0.192 (shown in the first row of Appendix 12.8). 
 
These age weighting considerations are made for all the previous QALE gain sensitivity 
analysis calculations. Appendix 12.8 considers the low, mid, high VSL mortality gain 
calculations and Appendix 12.9 considers the low, mid, high VSL, VSHLY, QALY 
morbidity gain calculations. Because of the density of these calculations, the bulk of the 
age weighted QALE gain calculations and results are provided in Appendix 13.3 (age 
weighted mortality) and 13.4 (age weighted morbidity). The mid VSL estimates will be 
shown for the age weighted mortality gain below. In Appendix 12.9 the mid VSL, QALY 
and subsequent VSHLY will be shown. All other calculations are contained in the CD-
Rom Appendices.  
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Sources: 
Mortality and morbidity gain data that is applied to the age weights  
• See Appendix 12.7 
Age weights 
• Murray & Lopez, “The Global Burden of Disease”  
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12.8: Age-weighting: Mortality 
 
 
Age-weighting Mortality 
     
VSL MID   
     
   
     
1900-1925 
      
Age Weight VSL (Mid) Weighted VSL (Mid) Fall in DR 1 Fall in DR 2 Mortality Gain 1 Mortality Gain 2 
      million million 
0-4 0.3 0.64 0.192 3435.94 2594.55 659.70 498.15 
5-14 1.0 0.64 0.640 318.72 374.67 203.98 239.79 
15-24 1.5 0.64 0.960 175.04 159.48 168.04 153.10 
25-34 1.5 0.64 0.960 347.18 328.50 333.29 315.36 
35-44 1.3 0.64 0.832 507.87 569.53 422.55 473.85 
45-64 1.0 0.64 0.640 1025.55 1398.45 656.35 895.01 
65-74 0.7 0.64 0.448 340.82 477.24 152.69 213.80 
75+ 0.45 0.64 0.288 49.71 66.09 14.32 19.03 
    
6201 5968 2611 2808 
        
1925-1950 
      
Age Weight VSL (Mid) Weighted VSL (Mid) Fall in DR 1 Fall in DR 2 Mortality Gain 1 Mortality Gain 2 
      million million 
0-4 0.3 0.76 0.228 1459.97 1340.78 332.87 305.70 
5-14 1.0 0.76 0.760 215.95 154.90 164.12 117.73 
15-24 1.5 0.76 1.140 324.12 238.91 369.50 272.36 
25-34 1.5 0.76 1.140 310.93 297.17 354.46 338.77 
35-44 1.3 0.76 0.988 723.10 813.77 714.42 804.01 
45-64 1.0 0.76 0.760 755.27 893.66 574.01 679.18 
65-74 0.7 0.76 0.532 398.59 630.10 212.05 335.21 
75+ 0.45 0.76 0.342 305.81 604.66 104.59 206.79 
    
4494 4974 2826 3060 
 
      
1950-1975 
      
Age Weight VSL (Mid) Weighted VSL (Mid) Fall in DR 1 Fall in DR 2 Mortality Gain 1 Mortality Gain 2 
      million million 
0-4 0.3 1.16 0.348 279.60 219.64 97.30 76.44 
5-14 1.0 1.16 1.160 38.87 46.00 45.09 53.36 
15-24 1.5 1.16 1.740 53.66 56.50 93.37 98.32 
25-34 1.5 1.16 1.740 119.56 113.17 208.03 196.92 
35-44 1.3 1.16 1.508 -237.26 -174.71 -357.78 -263.47 
45-64 1.0 1.16 1.160 397.25 403.31 460.81 467.84 
65-74 0.7 1.16 0.812 484.39 600.90 393.33 487.93 
75+ 0.45 1.16 0.522 632.47 846.51 330.15 441.88 
    
1769 2111 1270 1559 
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1975-2000 
Age Weight VSL (Mid) Weighted VSL (Mid) Fall in DR 1 Fall in DR 2 Mortality Gain 1 Mortality Gain 2 
      million million 
0-4 0.3 2.05 0.615 144.01 134.03 88.56 82.43 
5-14 1.0 2.05 2.050 23.99 19.40 49.19 39.76 
15-24 1.5 2.05 3.075 26.89 22.86 82.69 70.28 
25-34 1.5 2.05 3.075 4.46 4.69 13.72 14.44 
35-44 1.3 2.05 2.665 55.69 71.60 148.40 190.82 
45-64 1.0 2.05 2.050 981.72 965.03 2012.52 1978.31 
65-74 0.7 2.05 1.435 1143.99 701.74 1641.63 1007.00 
75+ 0.45 2.05 0.923 1062.04 1436.44 979.74 1325.12 
    
3443 3356 5016 4708 
        
1900-2000 
      
Age Weight VSL (Mid) Weighted VSL (Mid) Fall in DR 1 Fall in DR 2 Mortality Gain 1 Mortality Gain 2 
      million million 
0-4 0.3 0.88 0.264 6030.98 3029.95 1592.18 799.91 
5-14 1.0 0.88 0.880 648.68 399.85 570.83 351.86 
15-24 1.5 0.88 1.320 646.11 396.15 852.86 522.92 
25-34 1.5 0.88 1.320 813.22 732.60 1073.44 967.03 
35-44 1.3 0.88 1.144 1024.61 1224.37 1172.16 1400.68 
45-64 1.0 0.88 0.880 2405.36 3906.54 2116.72 3437.76 
65-74 0.7 0.88 0.616 1260.91 2123.92 776.72 1308.34 
75+ 0.45 0.88 0.396 835.22 3859.18 330.75 1528.24 
    
13665 15673 8486 10317 
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12.9: Age-Weighting: Morbidity 
 
Age-weighting Morbidity 
     
BREAST CANCER  
     
Mid QALY and Mid VSHLY 
    
        
1900-1925 
       
Age Weight VSHLY (Mid) Weighted VSHLY  Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.21 0.063 0 0 0.00 0.00 
5-14 1.0 0.21 0.210 0 0 0.00 0.00 
15-24 1.5 0.21 0.315 7.400679194 6.750870817 2.33 2.13 
25-34 1.5 0.21 0.315 -93.1946039 -88.17946381 -29.36 -27.78 
35-44 1.3 0.21 0.273 101.3650163 113.6714463 27.67 31.03 
45-64 1.0 0.21 0.210 169.1754082 230.9940786 35.53 48.51 
65-74 0.7 0.21 0.147 198.8753719 278.4774472 29.23 40.94 
75+ 0.45 0.21 0.095 -1251.96364 -1541.310123 -118.31 -145.65 
      
-53 -51 
1925-1950 
       
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.32 0.096 0 0 0.00 0.00 
5-14 1.0 0.32 0.320 0 0 0.00 0.00 
15-24 1.5 0.32 0.480 -15.6813014 -12.47244262 -7.53 -5.99 
25-34 1.5 0.32 0.480 -59.9331832 -57.28011318 -28.77 -27.49 
35-44 1.3 0.32 0.416 -299.648738 -337.2218944 -124.65 -140.28 
45-64 1.0 0.32 0.320 -1259.9512 -1519.940858 -403.18 -486.38 
65-74 0.7 0.32 0.224 -454.481359 -718.4506349 -101.80 -160.93 
75+ 0.45 0.32 0.144 27.70783873 59.15467739 3.99 8.52 
      
-662 -813 
        
1950-1975 
       
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Falling MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.68 0.204 0 0 0.00 0.00 
5-14 1.0 0.68 0.680 0 0 0.00 0.00 
15-24 1.5 0.68 1.020 7.051689492 7.068419936 7.19 7.21 
25-34 1.5 0.68 1.020 173.1515881 163.9046285 176.61 167.18 
35-44 1.3 0.68 0.884 1233.746114 908.5091965 1090.63 803.12 
45-64 1.0 0.68 0.680 5717.188384 5724.110671 3887.69 3892.40 
65-74 0.7 0.68 0.476 3405.173296 4224.221886 1620.86 2010.73 
75+ 0.45 0.68 0.306 2750.560381 3924.677915 841.67 1200.95 
      
7625 8082 
1975-2000 
       
Age Weight VSHLY (Mid) Weighted VSL (Mid) Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 1.53 0.459 0 0 0.00 0.00 
5-14 1.0 1.53 1.530 0 0 0.00 0.00 
15-24 1.5 1.53 2.295 7.506614431 6.433704377 17.23 14.77 
25-34 1.5 1.53 2.295 79.33362467 83.49086531 182.07 191.61 
35-44 1.3 1.53 1.989 817.5821771 1051.271652 1626.17 2090.98 
45-64 1.0 1.53 1.530 5169.091839 5188.104845 7908.71 7937.80 
65-74 0.7 1.53 1.071 3054.499154 1873.685355 3271.37 2006.72 
75+ 0.45 1.53 0.689 1963.623105 2899.268269 1351.95 1996.15 
      
14358 14238 
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1900-2000 
       
Age Weight VSHLY (Mid) Weighted VSLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.51 0.153 0 0 0.00 0.00 
5-14 1.0 0.51 0.510 0 0 0.00 0.00 
15-24 1.5 0.51 0.765 8.876553434 5.442509095 6.79 4.16 
25-34 1.5 0.51 0.765 82.86260848 74.64800639 63.39 57.11 
35-44 1.3 0.51 0.663 1470.712206 1757.443481 975.08 1165.19 
45-64 1.0 0.51 0.510 5152.378485 8307.783149 2627.71 4236.97 
65-74 0.7 0.51 0.357 2226.465416 3750.334394 794.85 1338.87 
75+ 0.45 0.51 0.230 -10.7162837 -59.33925127 -2.46 -13.62 
      
4465 6789 
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Age-weighting Morbidity 
     
STOMACH CANCER  
     
Mid QALY and Mid VSHLY 
    
   
     
1900-1925 
       
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.21 0.063 0 0 0 0 
5-14 1.0 0.21 0.210 0 0 0 0 
15-24 1.5 0.21 0.315 0.796183774 0.725302166 0.250797889 0.228470182 
25-34 1.5 0.21 0.315 8.443717402 7.989330305 2.659770982 2.516639046 
35-44 1.3 0.21 0.273 67.44677644 75.63529215 18.41296997 20.64843476 
45-64 1.0 0.21 0.210 587.2936471 802.2982129 123.3316659 168.4826247 
65-74 0.7 0.21 0.147 397.9904028 557.2904797 58.50458921 81.92170052 
75+ 0.45 0.21 0.095 53.82097704 66.25976514 5.08608233 6.261547806 
    
1116 1510 208 280 
1925-1950 
       
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.32 0.096 0 0 0 0 
5-14 1.0 0.32 0.320 0 0 0 0 
15-24 1.5 0.32 0.480 -2.57562752 -1.963917159 -1.23630121 -0.942680236 
25-34 1.5 0.32 0.480 3.253138053 3.109130965 1.561506265 1.492382863 
35-44 1.3 0.32 0.416 11.8325508 13.3162423 4.922341134 5.539556798 
45-64 1.0 0.32 0.320 391.3878549 468.0769038 125.2441136 149.7846092 
65-74 0.7 0.32 0.224 76.02677083 120.1842072 17.02999667 26.92126241 
75+ 0.45 0.32 0.144 -359.160407 -766.7872703 -51.71909866 -110.4173669 
    
121 -164 96 72 
1950-1975 
       
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.68 0.204 0 0 0 0 
5-14 1.0 0.68 0.680 0 0 0 0 
15-24 1.5 0.68 1.020 6.307354573 6.602388563 6.433501665 6.734436334 
25-34 1.5 0.68 1.020 45.65610678 43.2178954 46.56922892 44.0822533 
35-44 1.3 0.68 0.884 303.3666536 223.3939314 268.1761218 197.4802354 
45-64 1.0 0.68 0.680 1991.702777 2027.860592 1354.357888 1378.945202 
65-74 0.7 0.68 0.476 1766.641911 2191.573461 840.9215498 1043.188968 
75+ 0.45 0.68 0.306 1484.393607 2118.029056 454.2244438 648.1168912 
    
5598 6611 2971 3319 
1975-2000 
       
Age Weight VSHLY (Mid) Weighted VSL (Mid) Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 1.37 0.411 0 0 0 0 
5-14 1.0 1.37 1.370 0 0 0 0 
15-24 1.5 1.37 2.055 0.971036667 0.832882807 1.99548035 1.711574169 
25-34 1.5 1.37 2.055 6.919597396 7.282198142 14.21977265 14.96491718 
35-44 1.3 1.37 1.781 28.74164964 36.95687398 51.18887801 65.82019256 
45-64 1.0 1.37 1.370 763.9095819 746.5698186 1046.556127 1022.800651 
65-74 0.7 1.37 0.959 984.771448 604.0767232 944.3958187 579.3095776 
75+ 0.45 1.37 0.617 893.1640807 1318.747102 550.6356558 813.0075883 
    
2678 2714 2609 2498 
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1900-2000 
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.44 0.132 0 0 0 0 
5-14 1.0 0.44 0.440 0 0 0 0 
15-24 1.5 0.44 0.660 9.934779215 6.091409269 6.556954282 4.020330118 
25-34 1.5 0.44 0.660 86.05815066 77.52675782 56.79837943 51.16766016 
35-44 1.3 0.44 0.572 423.1599142 505.6595231 242.0474709 289.2372472 
45-64 1.0 0.44 0.440 3058.989918 5047.752165 1345.955564 2221.010953 
65-74 0.7 0.44 0.308 1964.539632 3309.137658 605.0782068 1019.214399 
75+ 0.45 0.44 0.198 692.1027505 3832.378863 137.0363446 758.8110148 
    
6235 12779 2393 4343 
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Age-weighting Morbidity 
     
TUBERCULOSIS  
     
Mid QALY and Mid VSHLY 
    
   
     
1900-1925 
       
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.27 0.081 26125.87925 19449.66491 2116.19622 1575.422858 
5-14 1.0 0.27 0.270 10644.00358 11734.69911 2873.880966 3168.368759 
15-24 1.5 0.27 0.405 -1369.13356 -1213.610125 -554.4990905 -491.5121006 
25-34 1.5 0.27 0.405 -3357.63795 -3176.951255 -1359.843368 -1286.665258 
35-44 1.3 0.27 0.351 -2089.95076 -2343.685564 -733.5727165 -822.6336328 
45-64 1.0 0.27 0.270 -1615.2181 -2181.72411 -436.1088871 -589.0655097 
65-74 0.7 0.27 0.189 -224.146506 -313.8636331 -42.36368961 -59.32022666 
75+ 0.45 0.27 0.122 54.28464825 66.83059732 6.595584762 8.119917574 
    28168 22021 1870 1503 
1925-1950 
       
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.44 0.132 2034.03609 2035.673289 268.4927639 268.7088741 
5-14 1.0 0.44 0.440 1642.834566 995.6207823 722.8472092 438.0731442 
15-24 1.5 0.44 0.660 5313.084531 3921.539499 3506.635791 2588.216069 
25-34 1.5 0.44 0.660 4063.123997 3883.261156 2681.661838 2562.952363 
35-44 1.3 0.44 0.572 3532.128437 3975.024396 2020.377466 2273.713954 
45-64 1.0 0.44 0.440 1993.287763 2146.536845 877.0466159 944.4762119 
65-74 0.7 0.44 0.308 111.573124 176.376391 34.3645222 54.32392841 
75+ 0.45 0.44 0.198 37.98332589 81.09226457 7.520698526 16.05626838 
    18728 17215 10119 9147 
1950-1975 
       
Age Weight VSHLY (Mid) Weighted VSL (Mid) Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.87 0.261 570.8908145 464.7444803 149.0025026 121.2983094 
5-14 1.0 0.87 0.870 274.2410447 326.3057436 238.5897089 283.8859969 
15-24 1.5 0.87 1.305 1538.696728 1620.621496 2007.99923 2114.911053 
25-34 1.5 0.87 1.305 2692.867169 2549.057724 3514.191656 3326.52033 
35-44 1.3 0.87 1.131 2357.787479 1736.233723 2666.657639 1963.680341 
45-64 1.0 0.87 0.870 5034.308945 4961.43806 4379.848782 4316.451112 
65-74 0.7 0.87 0.609 1359.797661 1686.870694 828.1167755 1027.304252 
75+ 0.45 0.87 0.392 147.9352809 211.0836518 57.91666247 82.63924969 
    
13977 13556 13842 13237 
1975-2000 
       
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 1.71 0.513 3.829283096 3.356569916 1.964422228 1.721920367 
5-14 1.0 1.71 1.710 -4.185318867 -3.361278263 -7.156895262 -5.74778583 
15-24 1.5 1.71 2.565 10.58021691 8.993643574 27.13825638 23.06869577 
25-34 1.5 1.71 2.565 5.353274348 5.633796633 13.7311487 14.45068836 
35-44 1.3 1.71 2.223 6.07897602 7.816529444 13.51356369 17.37614495 
45-64 1.0 1.71 1.710 268.2953826 271.2939947 458.7851043 463.9127309 
65-74 0.7 1.71 1.197 107.1861569 65.7499388 128.3018298 78.70267675 
75+ 0.45 1.71 0.770 -19.85980144 -29.32278196 -15.28211721 -22.56388072 
    
377 330 621 571 
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1900-2000 
Age Weight VSHLY (Mid) Weighted VSHLY Fall in MBR 1 Fall in MBR 2 Morbidity Gain 1 Morbidity Gain 2 
0-4 0.3 0.51 0.153 32963.83056 17525.39089 5043.466076 2681.384806 
5-14 1.0 0.51 0.510 13947.83794 8614.582243 7113.39735 4393.436944 
15-24 1.5 0.51 0.765 6235.885789 3823.347706 4770.452629 2924.860995 
25-34 1.5 0.51 0.765 3127.668735 2817.606638 2392.666582 2155.469078 
35-44 1.3 0.51 0.663 2431.599597 2905.666277 1612.150533 1926.456742 
45-64 1.0 0.51 0.510 2605.842774 4172.730281 1328.979815 2128.092443 
65-74 0.7 0.51 0.357 413.6437681 696.7556916 147.6708252 248.7417819 
75+ 0.45 0.51 0.230 138.382849 766.2670101 31.75886384 175.8582788 
 
   
61865 41322 22441 16634 
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12.10: Age-Weighted Value of QALE Gain 
 
This Appendix relates to Tables 8.1.13 in the main thesis. 
 
After the mortality gain and morbidity gain have been applied to Murray’s age weighting 
function (as has been achieved in Appendix 12.8 and 12.9) they can be combined in order 
to identify the age-weighted QALE gain. This is achieved here. 
 
The analysis below will repeat the QALE gain calculation for all ranges and subsequent 
combinations of QALY, VSL and VSHLY weight (shown in Appendix 12.7), for all 
illnesses and eras, applied to Murray’s age weighting function.  
 
Appendix 12.10.1 will present the age weighted QALE gain for the thesis diseases, which 
combined the age weighted mortality gain and individual age weighted morbidity gains. 
Appendix 12.10.2 considers the age weighted disability gain, this comprises the age 
weighted mortality gain and a un-weighted morbidity gain (as the data does not exist to 
make age weighted morbidity gain calculations for blindness). 
 
Because of the density of this analysis the majority of the results are contained in the CD-
Rom Appendices. This Appendix will present the most extreme and mid point estimates, 
i.e. the age weighted QALE gain results using a low, mid, and high QALY, VSL and 
VSHLY. For all other variable weight combinations, see Appendix 13.5.  
 
 
Sources: 
• QALE methodology outlined in Appendix 12.7 is used here, but applied to Murray’s 
age weighting function. 
Age weights 
• Murray & Lopez, “The Global Burden of Disease”  
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12.10.1: Age-Weighted Value of QALE Gain: Disease  
 
Low VSL and Low VSHLY and Low QALY 
      
 
Deaths 
 
Stomach Cancer 
 
Breast Cancer 
 
Tuberculosis 
 
Period Mortality Gain 1 Mortality Gain 2 Morbidity Gain 1 Morbidity Gain 2 Morbidity Gain 1 Morbidity Gain 2 Morbidity Gain 1 Morbidity Gain 2 
 millions millions millions millions millions millions millions millions 
1900-1925 2081 2238 84 113 -21 -21 880 707 
1925-1950 2231 2416 45 34 -312 -384 5795 5238 
1950-1975 1007 1237 1669 1864 4280 4536 8497 8126 
1975-2000 3940 3698 1538 1472 8841 8768 391 359 
1900-2000 6654 8089 1254 2276 2525 3839 12689 9406 
         
Period QALE Gain QALE Gain QALE Gain      
 Stomach Cancer Breast Cancer Tuberculosis      
         
1900-1925 2258 2138 2953      
1925-1950 2363 1975 7840      
1950-1975 2889 5530 9434      
1975-2000 5324 12623 4194      
1900-2000 9136 10553 18419      
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Mid VSL and Mid VSHLY and Mid QALY 
      
 
Deaths 
 
Stomach Cancer 
 
Breast Cancer 
 
Tuberculosis 
 
Period Mortality Gain 1 Mortality Gain 2 Morbidity Gain 1 Morbidity Gain 2 Morbidity Gain 1 Morbidity Gain 2 Morbidity Gain 1 Morbidity Gain 2 
 millions millions Millions millions millions millions millions millions 
1900-1925 2611 2808 208 280 -53 -51 1870 1503 
1925-1950 2826 3060 96 72 -662 -813 10119 9147 
1950-1975 1270 1559 2971 3319 7625 8082 13842 13237 
1975-2000 5016 4708 2609 2498 14358 14238 621 571 
1900-2000 8486 10317 2393 4343 4465 6789 22441 16634 
         
Period QALE Gain QALE Gain QALE Gain      
 Stomach Cancer Breast Cancer Tuberculosis      
         
1900-1925 2954 2658 4397      
1925-1950 3027 2205 12576      
1950-1975 4560 9269 14955      
1975-2000 7416 19160 5458      
1900-2000 12770 15029 28940      
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High VSL and High VSHLY and High QALY 
    
 
 
 
Deaths 
 
Stomach Cancer 
 
Breast Cancer 
 
Tuberculosis 
 
Period Mortality Gain 1 Mortality Gain 2 Morbidity Gain 1 Morbidity Gain 2 Morbidity Gain 1 Morbidity Gain 2 Morbidity Gain 1 Morbidity Gain 2 
 millions millions millions millions millions millions millions millions 
1900-1925 3141 3378 384 517 -98 -94 3129 2514 
1925-1950 3421 3704 161 121 -1111 -1364 15892 14365 
1950-1975 1533 1882 4577 5112 11746 12450 20379 19488 
1975-2000 6020 5650 3908 3741 21187 21011 894 822 
1900-2000 10125 12310 3825 6941 6924 10527 34797 25794 
         
Period QALE Gain QALE Gain QALE Gain      
 Stomach Cancer Breast Cancer Tuberculosis      
         
1900-1925 3710 3164 6081      
1925-1950 3704 2325 18691      
1950-1975 6552 13806 21641      
1975-2000 9660 26934 6693      
1900-2000 16600 19943 41513      
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12.10.2: Age weighted Value of QALE Gain: Disability 
 
Low VSL Low VSHLY Low QALY 
  
Period Morbidity Gain  Mortality Gain QALE Gain 
 millions millions millions 
    
    
1900-1925 120 2160 2280 
1925-1950 -3776 2324 -1452 
1950-1975 1909 1122 3031 
1975-2000 -957 3819 2862 
1900-2000 -2792 7372 4580 
 
 
Mid VSL Mid VSHLY Mid QALY 
  
Period Morbidity Gain  Mortality Gain QALE Gain 
 millions millions millions 
    
    
1900-1925 154 2710 2864 
1925-1950 -4855 2943 -1912 
1950-1975 2410 1415 3825 
1975-2000 -1205 4862 3657 
1900-2000 -3509 9402 5893 
 
 
High VSL High VSHLY High QALY 
  
Period Morbidity Gain  Mortality Gain QALE Gain 
 millions millions millions 
    
    
1900-1925 182 3260 3442 
1925-1950 -5826 3563 -2263 
1950-1975 2911 1708 4619 
1975-2000 -1453 5835 4382 
1900-2000 -4227 11218 6991 
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12.11: GDP per capita Compound Average Growth Rates 
This Appendix relates to Tables 8.1.14, 8.1.15, 8.2.8, 8.3.4, and 9.3 in the main thesis. 
 
This Appendix identifies the growth rate of national income for the eras of the thesis. This 
is necessary to address one of the main questions of the thesis, about the value of improved 
QALE and what this contributes to twentieth century welfare economic development.   
 
Hence, the main body of the thesis has consistently emphasised the need to consider more 
comprehensive or utility inclusive measures of national income. This exercise is conducted 
in the following Appendix (12.12). However, in order to illuminate the veracity of this 
thesis claim it is desirable to compare GDP growth and GDP+QALE gain growth. GDP 
growth is calculated here (and QALE gain growth is calculated in Appendix 12.12).  
 
The compound average growth rates of GDP pc (which is the average rate of annual 
growth within a defined period) was calculated using the natural exponential function S = 
Pert, for all five eras considered in the thesis: 1900-1925, 1925-1950, 1950-1975, 1975-
2000 and 1900-2000.  
 
 
Sources:  
GDP per capita data 
• Maddison, “Monitoring the World Economy 1820-1992”  
• Maddison, “The World Economy: A Millennial Perspective” 
Compound average growth rate methodology 
• Dowling, “Mathematical Methods for Business and Economics” 
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GDP per capita Compound Average Rate of Growth per annum 
    
        
Period GDPpc at Start (t1) GDPpc at End (t2) t t2 / t1 Ln Ln / t Growth 
        
1900-1925 4593 4912 25 1.069454 0.067148 0.002686 0.3 
1925-1950 4912 6907 25 1.406148 0.340854 0.013634 1.4 
1950-1975 6907 11845 25 1.714927 0.53937 0.021575 2.2 
1975-2000 11845 18714 25 1.579907 0.457366 0.018295 1.8 
1900-2000 4593 18714 100 4.074461 1.404739 0.014047 1.4 
        
        
        
Period Midpoint GDPpc at Midpoint      
        
1900-1925 1913 5032      
1925-1950 1938 5983      
1950-1975 1963 9070      
1975-2000 1988 15988      
1900-2000 1950 6907      
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12.12: Value of QALE Gain relative to GDP per capita Growth 
This Appendix relates to Tables 8.1.15, 8.2.8, and 9.3 in the main thesis. 
 
The main body of the thesis has consistently emphasised the need to value and standardise 
health improvements in twentieth century England. As a result of this objective the QALE 
gain methodology was developed in such a way that the QALE gain results generated by 
this methodology could be compared to the national income measures. Following on from 
this, another consistent objective of the thesis has been to provide a more thorough and 
accurate account of economic developments from a standards of living or welfare 
economics perspective, i.e. a Fisharian measure of economic development, which 
essentially represents a more rounded utility national income. Hence, the thesis will 
ultimately generate an alternative estimate for national income growth that includes the 
value of the QALE gain. 
 
This extended GDP or utility national income is estimated by calculating the compound 
average rate of GDP per capita growth and the compound average rate of QALE gain 
growth. These are then summed to provide ‘Adjusted Growth’, which represents utility 
national income or Fisharian growth, or extended GDP growth.  
 
In addition the mortality and morbidity gain growth are also considered here (as this 
provides the foundation level and a more detailed indication of the QALE gain growth 
construction). Finally, another layer of detail is that these considerations are made for the 
un-weighted and age-weighted QALE gain results shown above in Appendix 12.7 and 
12.9, respectively. 
 
Appendix 12.12 provides the mortality gain and morbidity gains. Appendix 12.12.1 
presents the QALE gain growth for the thesis diseases and Appendix 12.12.2 makes the 
same consideration but for the thesis disability. Because of the density of the calculations 
in Appendix 12.12.1 and 12.12.2, the bulk of these results will be presented in Appendix 
13.6.1 and 13.6.2 in the CD-Rom Appendices. The most extreme (low and high) and mid 
calculations for the un-weighted and age-weighted calculations will be shown here and the 
complete set of calculations are contained in the CD-Rom appendices.  
 
Sources: 
GDP per capita data 
• Maddison, “Monitoring the World Economy 1820-1992”  
• Maddison, “The World Economy: A Millennial Perspective” 
Compound average growth rate methodology 
• Dowling, “Mathematical Methods for Business and Economics” 
QALE Gain numbers  
• Appendix 12.7 (un-weighted) 
• Appendix 12.10 (age-weighted) 
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Mortality Gains - UN-WEIGHTED as a proportion of GDP Growth   
     
           
Period Death Rate Change 1 Death Rate Change 2 VSL Mortality Gain 1 Mortality Gain 2      
   millions millions millions      
1900-1925 6200.828 5968.488 0.64 3969 3820      
1925-1950 4493.741 4973.952 0.76 3415 3780      
1950-1975 1906.388 2385.516 1.16 2211 2767      
1975-2000 3780.775 4034.04 2.05 7751 8270      
1900-2000 13805.35 17487.04 0.88 12149 15389      
           
           
Period t Mortality Gain 1 Mortality Gain 2 Midpoint GDPpc at Midpoint      
  millions millions   Mortality Gain 1 Mortality Gain 2   
      
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 25 3969 3820 1913 5032 79 3.2 76 3.0   
1925-1950 25 3415 3780 1938 5983 57 2.3 63 2.5   
1950-1975 25 2211 2767 1963 9070 24 1.0 31 1.2   
1975-2000 25 7751 8270 1988 15988 48 1.9 52 2.1   
1900-2000 100 12149 15389 1950 6907 176 1.8 223 2.2   
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Mortality Gains - AGE-WEIGHTED as a proportion of GDP Growth   
    
           
Period t VSL (LOW)  Midpoint GDPpc at Midpoint      
  Mortality Gain 1 Mortality Gain 2   Mortality Gain 1 Mortality Gain 2   
      
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 25 2081 2238 1913 5032 41 1.7 44 1.8   
1925-1950 25 2231 2416 1938 5983 37 1.5 40 1.6   
1950-1975 25 1007 1237 1963 9070 11 0.4 14 0.5   
1975-2000 25 3940 3698 1988 15988 25 1.0 23 0.9   
1900-2000 100 6654 8089 1950 6907 96 1.0 117 1.2   
           
Period t VSL (MID)  Midpoint GDPpc at Midpoint      
  Mortality Gain 1 Mortality Gain 2   Mortality Gain 1 Mortality Gain 2   
      
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 25 2611 2808 1913 5032 52 2.1 56 2.2   
1925-1950 25 2826 3060 1938 5983 47 1.9 51 2.0   
1950-1975 25 1270 1559 1963 9070 14 0.6 17 0.7   
1975-2000 25 5016 4708 1988 15988 31 1.3 29 1.2   
1900-2000 100 8486 10317 1950 6907 123 1.2 149 1.5   
           
Period t VSL (HIGH)  Midpoint GDPpc at Midpoint      
  Mortality Gain 1 Mortality Gain 2   Mortality Gain 1 Mortality Gain 2   
      
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 25 3141 3378 1913 5032 62 2.5 67 2.7   
1925-1950 25 3421 3704 1938 5983 57 2.3 62 2.5   
1950-1975 25 1533 1882 1963 9070 17 0.7 21 0.8   
1975-2000 25 6020 5650 1988 15988 38 1.5 35 1.4   
1900-2000 100 10125 12310 1950 6907 147 1.5 178 1.8   
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Breast Cancer Morbidity Gain Age-Weighted 
       
           
Period t Morbidity Gain 1 Morbidity Gain 2 Midpoint 
GDPpc at 
Midpoint      
      Morbidity Gain 1 Morbidity Gain 2   
      
AS A PROPORTION OF GDPpc (TOTAL / PER 
ANNUM) 
1900-1925 25 -53 -51 1913 5032 -1 0.0 -1 0.0   
1925-1950 25 -662 -813 1938 5983 -11 -0.4 -14 -0.5   
1950-1975 25 7625 8082 1963 9070 84 3.4 89 3.6   
1975-2000 25 14358 14238 1988 15988 90 3.6 89 3.6   
1900-2000 100 4465 6789 1950 6907 65 0.6 98 1.0   
 
Stomach Cancer Morbidity Gain Age-Weighted 
       
           
Period t Morbidity Gain 1 Morbidity Gain 2 Midpoint 
GDPpc at 
Midpoint      
      Morbidity Gain 1 Morbidity Gain 2   
      
AS A PROPORTION OF GDPpc (TOTAL / PER 
ANNUM) 
1900-1925 25 208 280 1913 5032 4 0.2 6 0.2   
1925-1950 25 96 72 1938 5983 2 0.1 1 0.0   
1950-1975 25 2971 3319 1963 9070 33 1.3 37 1.5   
1975-2000 25 2609 2498 1988 15988 16 0.7 16 0.6   
1900-2000 100 2393 4343 1950 6907 35 0.3 63 0.6   
 
Tuberculosis Morbidity Gain Age-Weighted 
       
           
Period t Morbidity Gain 1 Morbidity Gain 2 Midpoint 
GDPpc at 
Midpoint      
      Morbidity Gain 1 Morbidity Gain 2   
      
AS A PROPORTION OF GDPpc (TOTAL / PER 
ANNUM) 
1900-1925 25 1870 1503 1913 5032 37 1.5 30 1.2   
1925-1950 25 10119 9147 1938 5983 169 6.8 153 6.1   
1950-1975 25 13842 13237 1963 9070 153 6.1 146 5.8   
1975-2000 25 621 571 1988 15988 4 0.2 4 0.1   
1900-2000 100 22441 16634 1950 6907 325 3.2 241 2.4   
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Blind Morbidity Gain Un-Weighted 
       
          
Period t  Midpoint 
GDPpc at 
Midpoint      
     Morbidity Gain     
     
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 25 154 1913 5032 3 0.1     
1925-1950 25 -4855 1938 5983 -81 -3.2     
1950-1975 25 2410 1963 9070 27 1.1     
1975-2000 25 -1205 1988 15988 -7.5 -0.3     
1900-2000 100 -3509 1950 6907 -51 -0.5     
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12.12.1: Value of QALE Gain relative to GDP per capita Growth: Disease 
QALE Gain as a % of GDP pc - Un-Weighted -Low VSLs 
         
             
Low VSL and Low VSHLY with Low QALY 
          
Period QALE Gain QALE Gain QALE Gain t Midpoint GDPpc at Midpoint QALE Gain QALE Gain QALE Gain 
 Stomach Cancer Breast Cancer Tuberculosis    Stomach Cancer Breast Cancer Tuberculosis 
       
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 3204 3013 6281 25 1913 5032 63.7 2.5 59.9 2.4 124.8 6281 
1925-1950 2857 2510 7389 25 1938 5983 47.8 1.9 41.9 1.7 123.5 7389 
1950-1975 4298 7355 9318 25 1963 9070 47.4 1.9 81.1 3.2 102.7 9318 
1975-2000 8487 16765 6690 25 1988 15988 53.1 2.1 104.9 4.2 41.8 6690 
1900-2000 13107 14198 25793 100 1950 6907 189.8 1.9 205.6 2.1 373.4 25793 
 
             
Mid VSL and Mid VSHLY with MID QALY 
         
Period QALE Gain QALE Gain QALE Gain t Midpoint GDPpc at Midpoint QALE Gain QALE Gain QALE Gain 
 Stomach Cancer Breast Cancer Tuberculosis    Stomach Cancer Breast Cancer Tuberculosis 
       
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 4175 3694 10626 25 1913 5032 83.0 3.319 73.4 2.9 211.2 8.4 
1925-1950 3591 2856 11607 25 1938 5983 60.0 2.401 47.7 1.9 194.0 7.8 
1950-1975 6613 10995 14452 25 1963 9070 72.9 2.917 121.2 4.8 159.3 6.4 
1975-2000 11688 25008 8613 25 1988 15988 73.1 2.924 156.4 6.3 53.9 2.2 
1900-2000 17933 22460 40135 100 1950 6907 259.6 2.596 325.2 3.3 581.1 5.8 
 
             
High VSL and High VSHLY with High QALY 
         
Period QALE Gain QALE Gain QALE Gain t Midpoint GDPpc at Midpoint QALE Gain QALE Gain QALE Gain 
 Stomach Cancer Breast Cancer Tuberculosis    Stomach Cancer Breast Cancer Tuberculosis 
       
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 5224 4353 16053 25 1913 5032 103.8 4.2 86.5 3.5 319.0 12.8 
1925-1950 4350 3113 16781 25 1938 5983 72.7 2.9 52.0 2.1 280.5 11.2 
1950-1975 9392 17789 20630 25 1963 9070 103.6 4.1 196.1 7.8 227.5 9.1 
1975-2000 15154 34675 10492 25 1988 15988 94.8 3.8 216.9 8.7 65.6 2.6 
1900-2000 23327 25645 57445 100 1950 6907 337.7 3.4 371.3 3.7 831.7 8.3 
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QALE Gain as a % of GDP pc - Age-Weighted -Low VSLs 
         
             
Low VSL and Low VSHLY with Low QALY 
          
Period QALE Gain QALE Gain QALE Gain t Midpoint GDPpc at Midpoint QALE Gain QALE Gain QALE Gain 
 Stomach Cancer Breast Cancer Tuberculosis    Stomach Cancer Breast Cancer Tuberculosis 
       
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 2258 2138 2953 25 1913 5032 44.9 1.8 42.5 1.7 58.7 2.3 
1925-1950 2363 1975 7840 25 1938 5983 39.5 1.6 33.0 1.3 131.0 5.2 
1950-1975 2889 5530 9434 25 1963 9070 31.8 1.3 61.0 2.4 104.0 4.2 
1975-2000 5324 12623 4194 25 1988 15988 33.3 1.3 79.0 3.2 26.2 1.0 
1900-2000 9136 10553 18419 100 1950 6907 132.3 1.3 152.8 1.5 266.7 2.7 
 
             
Mid VSL and Mid VSHLY with MID QALY 
         
Period QALE Gain QALE Gain QALE Gain t Midpoint GDPpc at Midpoint QALE Gain QALE Gain QALE Gain 
 Stomach Cancer Breast Cancer Tuberculosis    Stomach Cancer Breast Cancer Tuberculosis 
       
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 3005 2647 4396 25 1913 5032 59.7 2.4 52.6 2.1 87.4 3.5 
1925-1950 3035 2131 12576 25 1938 5983 50.7 2.0 35.6 1.4 210.2 8.4 
1950-1975 4592 9349 14954 25 1963 9070 50.6 2.0 103.1 4.1 164.9 6.6 
1975-2000 7371 18700 5458 25 1988 15988 46.1 1.8 117.0 4.7 34.1 1.4 
1900-2000 12931 15028 28939 100 1950 6907 187.2 1.9 217.6 2.2 419.0 4.2 
 
             
High VSL and High VSHLY with High QALY 
          
Period QALE Gain QALE Gain QALE Gain t Midpoint GDPpc at Midpoint QALE Gain QALE Gain QALE Gain 
 Stomach Cancer Breast Cancer Tuberculosis    Stomach Cancer Breast Cancer Tuberculosis 
       
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 3710 3164 6081 25 1913 5032 73.7 2.9 62.9 2.5 120.9 4.8 
1925-1950 3704 2325 18691 25 1938 5983 61.9 2.5 38.9 1.6 312.4 12.5 
1950-1975 6552 13806 21641 25 1963 9070 72.2 2.9 152.2 6.1 238.6 9.5 
1975-2000 9660 26934 6693 25 1988 15988 60.4 2.4 168.5 6.7 41.9 1.7 
1900-2000 16600 19943 41513 100 1950 6907 240.3 2.4 288.7 2.9 601.0 6.0 
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12.12.2: Value of QALE Gain relative to GDP per capita Growth: Disability  
 
Blind QALE Gain: Un-weighted 
       
Low VSL Low VSHLY Low QALY Midpoint GDPpc at Midpoint QALE Gain     
Period  QALE Gain   Blindness      
 t millions   AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 25 3212 1913 5032 63 2.5     
1925-1950 25 -915 1938 5983 2 0.1     
1950-1975 25 3875 1963 9070 37 1.5     
1975-2000 25 5353 1988 15988 35 1.4     
1900-2000 100 8028 1950 6907 130 1.3     
           
Mid VSL Mid VSHLY Mid QALY Midpoint GDPpc at Midpoint QALE Gain     
Period  QALE Gain   Blindness      
 t millions   AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 25 4049 1913 5032 81 3.2     
1925-1950 25 -1257 1938 5983 -20 -0.8     
1950-1975 25 4899 1963 9070 54 2.2     
1975-2000 25 6806 1988 15988 42 1.7     
1900-2000 100 10260 1950 6907 148 1.5     
           
 
High VSL High VSHLY High QALY Midpoint GDPpc at Midpoint QALE Gain     
Period  QALE Gain   Blindness      
 t millions   AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
1900-1925 25 4897 1913 5032 99 4.0     
1925-1950 25 -1464 1938 5983 -52 -2.1     
1950-1975 25 5908 1963 9070 73 2.9     
1975-2000 25 8168 1988 15988 49 2.0     
1900-2000 100 12271 1950 6907 158 1.6     
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Blind QALE Gain using Age-weighted Mortality Gain 
 
     
Low VSL Low VSHLY Low QALY 
       
Period t QALE Gain Midpoint GDP at Midpoint QALE Gain  
  millions   Blindness   
     
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
     total per annum 
1900-1925 25 2280 1913 5032 44 1.8  
1925-1950 25 -1452 1938 5983 -7 -0.3  
1950-1975 25 3031 1963 9070 28 1.1  
1975-2000 25 2862 1988 15988 19 0.8  
1900-2000 100 4580 1950 6907 80 0.8  
        
Mid VSL Mid VSHLY Mid QALY 
       
Period t QALE Gain Midpoint GDP at Midpoint QALE Gain  
  millions   Blindness   
     
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
     total per annum 
1900-1925 25 2864 1913 5032 57 2.3  
1925-1950 25 -1912 1938 5983 -31 -1.3  
1950-1975 25 3825 1963 9070 42 1.7  
1975-2000 25 3657 1988 15988 23 0.9  
1900-2000 100 5893 1950 6907 86 0.9  
        
High VSL High VSHLY High QALY 
      
Period t QALE Gain Midpoint GDP at Midpoint QALE Gain  
  millions   Blindness   
     
AS A PROPORTION OF GDPpc (TOTAL / PER ANNUM) 
     total per annum 
1900-1925 25 3442 1913 5032 70 2.8  
1925-1950 25 -2263 1938 5983 -65 -2.6  
1950-1975 25 4619 1963 9070 59 2.4  
1975-2000 25 4382 1988 15988 25 1.0  
1900-2000 100 6991 1950 6907 81 0.8  
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12.13: Blind Quantitative Estimates 
 
12.13.1: Years in Blindness 
This appendix provides the calculations and base data for the number of years of blindness 
estimates in the thesis. 
 
12.13.2: Cohort Effect Calculations 
This appendix utilises the results of Appendix 12.13.1 in order to calculate the extent of 
cohort effect distortions. 
 
12.13.3: Blind Income Details 
This appendix provides the collection of more detailed tables that were used to construct a 
summary in Table 4.2 in the main thesis. 
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12.13.1: Years in Blindness 
• In order to highlight the trends of an increased age at onset of blindness and the subsequent 
fewer years of blindness it is necessary to estimate the average number of years spent in 
blindness at different times during the twentieth century (namely, 1900, 1925, 1950, 1975 and 
2000). 
 
• This is exceptionally difficult to estimate as a result of the following: 
o The ideal method of estimating the average number of years spent in blindness would 
be to consider the most common age of onset of blindness in conjunction with average 
life expectancy (at the average age of onset) for each period during the twentieth 
century. This is not possible for the following reasons: 
1. The main problem is related to the data for blindness, whereby the data for the 
prevalence of blindness is only provided in 5 to 10 year blocks, so it is 
impossible to determine the exact age within a block. For example, in 1901 the 
greatest numbers of blind persons were aged between 65 and 74.  
2. This problem is exacerbated by the nature of life expectancy data, whereby life 
expectancy is only an average. This problem is evident throughout the twentieth 
century. The calculations will overcome this problem as far as possible through 
using age specific life expectancy, for the average age of onset of blindness. 
o Therefore, the combination of these problems means that it is only possible to provide 
an indication of the likely number of years spent in blindness at different times during 
the twentieth century. This will be achieved below. 
• Along a more positive vein, this exercise still vividly highlights the improved trend in the age of 
onset of blindness (as it is possible to illustrate the increase in the average age of blindness 
and therefore the decline in the number of years spent in this less than optimal state). 
 
• The average age of onset of blindness and the subsequent average number of years spent in 
blindness will be estimates through graphically identifying the most common ages of blindness 
for the eras considered by the thesis (1900, 1925, 1950, 1975 and 2000). This will often 
contain three reference points, where blindness was most common. 
• Once the most common ages of blindness have been identified this information will be 
considered in conjunction with life expectancy in order to identify the number of average years 
spent in blindness.  
• After the profile of estimates about the average number if years in blindness has been 
constructed, consideration will be made about double counting and cohort effects. 
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• The graph above illustrates the percentage of blind in each age group in 1901. Between the 
ages of 35 and approximately 77 were the most cases of blindness. Hence, the most common 
age of onset of blindness is somewhere between these two ages.  
• This implies that during this time, there were two trends for the prevalence of blindness. 
1. The onset of blindness during middle age, where an individual would be blind for 
23 years (using 45 as age of onset of blindness and life expectancy [LE45] in 
1900 of 23). 
2. The second trend was the onset of blindness very late in life, at an age greater than life 
expectancy, which implies that very few years were spent in blindness on average. 
This is particularly apparent in the graph above as there is a decline in blindness after 
age 65 and a substantial decline above the age of 85. This is not likely to be due to 
improvements in the prevalence, but instead as a result of there being much fewer 
people at these ages as a result of a relatively low age of life expectancy. The onset 
of blindness here is averaged at 71 years of age, where an individual would be 
blind for 8 years (using 71 as age of onset of blindness and life expectancy 
[LE71] in 1900 of 9). 
 
1900:  
Row 2: most common ages of onset of blindness and subsequent average number of blind years 
per registered blind person 
Row 3: Percent of blind represented in above age group 
Row 4: Number of blind and subsequent total number of blind years for most common ages of 
onset of blindness (total number of blind years [299747] = {number of blind 1 [10069] * average 
years of blindness 1 [23] = average years of blindness 1 [231587]} + {number of blind 2 [8520] * 
average years of blindness 2 [8] = average years of blindness 2 [68160]}) 
 
 Average most 
common age 
of blindness 1 
(Age) 
Average most 
common age 
of blindness 2 
(Age) 
LEx  
Life Expectancy at age 
of onset of blindness  
(Years) 
1                    2 
Average 
years of 
blindness 
1 
(Years) 
Average 
years of 
blindness 
2 
(Years) 
Total number 
of blind years 
for most 
common ages 
of onset 
 35-55  45 65-77  71 23 8 23 8  
Percent of 
blind  
39 33      
Number of 
blind 
10069 8520   231587 68160 299747 
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1925 
 
Prevalence of Blindness at Different Ages - 1925
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• In 1925 the incidence of blindness above age 16 was a direct function of age; as age increased 
so did the prevalence of blindness. This means that there was an increasing number of old 
aged blind and a proportionate decrease in the number of younger blind. 
• However as a result of increased life expectancy it was still possible that a blind persons spent 
many years in this state. 
1. If this onset of blindness occurred at about age 50. The onset of blindness here is 
averaged at 55 years of age, where an individual would be blind for 19 years 
(using 55 as age of onset of blindness and life expectancy [LE55] in 1925 of 19). 
2. However many more of the blind were increasingly likely to obtain this disability 
towards the end of their life and therefore spend a much smaller fraction of time with 
this burden. For example, the most common ages for contracting blindness were those 
aged 70 and older. The onset of blindness here is estimated to be 70 years of age, 
where an individual would be blind for 9 years (using 70 as age of onset of 
blindness and life expectancy [LE70] in 1925 of 9). 
 
1925:  
Row 2: most common ages of onset of blindness and subsequent average number of blind years 
per registered blind person 
Row 3: Percent of blind represented in above age group 
Row 4: Number of blind and subsequent total number of blind years for most common ages of 
onset of blindness (total number of blind years [371244] = {number of blind 1 [10956] * average 
years of blindness 1 [19] = average years of blindness 1 [208164]} + {number of blind 2 [18120] * 
average years of blindness 2 [9] = average years of blindness 2 [163080]}) 
 
 Average 
most 
common age 
of blindness 
1 
(Age) 
Average 
most 
common age 
of blindness 
2 
(Age) 
LEx  
Life Expectancy 
at age of onset of 
blindness  
(Years) 
1                    2 
Average 
years of 
blindness 
1 
(Years) 
Average 
years of 
blindness 
2 
(Years) 
Total number of 
blind years for 
most common 
ages of onset 
 50 70 19 9 19 9  
Percent of 
blind  
26 43      
Number of 
blind 
10956 18120   208164 68160 371244 
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1950 
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0
5
10
15
20
25
0-4 5-10 11-15 16-20 21-30 31-39 40-49 50-59 60-64 65-69 70+
Age
Pe
rc
en
ta
ge
 
o
f T
o
ta
l B
lin
d
 
 
 
• This is a very unusual and unexpected pattern. This unexpected increase was a result of a 
condition known as Retrolental Fibroplasia and was caused through problems with the 
administration of oxygen to premature babies, which caused blindness. 
• There are three trends of interest here, although only 1 of them seems to be in alignment 
with the situation during the rest of the twentieth century (increase in the old aged blind). 
1. There is a comparatively high number of blind from birth or very young childhood in 
1950. About 12 percent of the 1950 blind cohort spent virtually their entire life in 
blindness. The onset of blindness here is at birth: subsequently an individual 
would be blind for 68 years (using 0 as age of onset of blindness and life 
expectancy [LE0] in 1950 of 68). 
2. A slightly more common trend was the onset of blindness during middle age. From 
the ages of 40 to 60 there were a sizeable number of individuals contracting 
blindness. These individuals represent about 24 percent of the blind population in 
1950. The onset of blindness here is averaged at 50 years of age, where an 
individual would be blind for 24 years (using 50 as age of onset of blindness 
and life expectancy [LE50] in 1950 of 24).  
3. Finally, there was an evident trend of very old aged blind. There were about 22 
percent of the blind contracting this impairment after age 70. The onset of 
blindness here is estimated at 70 years of age, where an individual would be 
blind for 10 years (using 70 as age of onset of blindness and life expectancy 
[LE70] in 1950 of 10). 
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1950:  
Row 2: most common ages of onset of blindness and subsequent average number of blind years 
per registered blind person 
Row 3: Percent of blind represented in above age group 
Row 4: Number of blind and subsequent total number of blind years for most common ages of 
onset of blindness (total number of blind years [1366204] = {number of blind 1 [10572] * average 
years of blindness 1 [68] = average years of blindness 1 [718896]} + {number of blind 2 [19517] * 
average years of blindness 2 [24] = average years of blindness 2 [468408]} + {number of blind 3 
[17890] * average years of blindness 3 [10] = average years of blindness 3 [178900]}) 
 
 
 Average 
most 
common 
age of 
blindness 
1 
(Age) 
Average 
most 
common 
age of 
blindness 2 
(Age) 
Average 
most 
common 
age of 
blindness 
3 
(Age) 
LEx  
Life Expectancy at 
age of onset of 
blindness  
(Years) 
 
1            2          3 
Average 
years of 
blindness 
1 
(Years) 
Average 
years of 
blindness 
2 
(Years) 
Average 
years of 
blindness 
3 
(Years) 
Total 
number of 
blind years 
for most 
common 
ages of 
onset 
 0  0 40-60  50 70  70 68 24 10 68 24 10  
Percent 
of blind  
13 24 22        
Number 
of blind 
10572 19517 17890    718896 468408 178900 1366204 
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• In 1975 there were two main ages of blind onset. 
1. There were a considerable number (which represents about 25 percent of the blind 
population in 1975) of blind persons at working age, somewhere between 16 and 64. 
Due to the format of the data for this period it is not possible to stipulate whether the 
onset of blindness was at the beginning or end of this age group, although from what is 
available (18-49=10% and 50-64 = 8%) it seems best to adopt a conservative estimate 
for the average age (during working age) of onset of blindness, for example 50 years 
old. Hence, the onset of blindness here is estimated at 50 years of age, where an 
individual would be blind for 26 years (using 50 as age of onset of blindness and 
life expectancy [LE50] in 1975 of 26). 
2. The second trend which is very noteworthy, in relation to all the previous years, is the 
substantial increase in the number of blind aged 75 and older. Approximately 54 
percent of the blind population contracted this impairment in the last few years of life. 
The onset of blindness here is estimated at 75 years of age, where an individual 
would be blind for 9 years (using 75 as age of onset of blindness and life 
expectancy [LE75] in 1975 of 9). 
 
1975: 
Row 2: most common ages of onset of blindness and subsequent average number of blind years 
per registered blind person 
Row 3: Percent of blind represented in above age group 
Row 4: Number of blind and subsequent total number of blind years for most common ages of 
onset of blindness (total number of blind years [1131447] = {number of blind 1 [24900] * average 
years of blindness 1 [26] = average years of blindness 1 [647400} + {number of blind 2 [53783] * 
average years of blindness 2 [9] = average years of blindness 2 [484047]}) 
 
 Average most 
common age 
of blindness 1 
(Age) 
Average most 
common age 
of blindness 2 
(Age) 
LEx  
Life Expectancy at 
age of onset of 
blindness  
(Years) 
1                    2 
Average 
years of 
blindness 
1 
(Years) 
Average 
years of 
blindness 
2 
(Years) 
Total number 
of blind years 
for most 
common ages 
of onset 
 50 75+ 26 9 26 9  
Percent of 
blind  
25 54      
Number of 
blind 
24900 53783   647400 484047 1131447 
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2000 
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• The graph above highlights what would appear to be a considerable improvement in the 
conditions surrounding blindness. This is result of a massive increase in the average age of 
onset of blindness.  
1. There is only one situation above, and this represents 69 percent of the blind 
population who were aged 75 and older in 2000. This means that the vast majority of 
the blind population were only in this less than optimal state for the last years of life. 
Hence by 2000 there has been an important reduction in the disabling and adverse 
effects of blindness, as it is now an old age disability rather than a burden that could 
strike at any age during the most productive years of life. The onset of blindness 
here is estimated at 75 years of age, where an individual would be blind for 11 
years (using 75 as age of onset of blindness and life expectancy [LE75] in 2000 of 
11). 
 
 
2000: 
Row 2: most common ages of onset of blindness and subsequent average number of blind years 
per registered blind person 
Row 3: Percent of blind represented in above age group 
Row 4: Number of blind and subsequent total number of blind years for most common ages of 
onset of blindness (total number of blind years [1197856] = {number of blind 1 [108896] * average 
years of blindness 1 [11] = average years of blindness 1 [1197856]}) 
 
 
 Average most common 
age of blindness 1 
(Age) 
LEx  
Life Expectancy at age 
of onset of blindness  
(Years) 
Average years of 
blindness 1 
(Years) 
Total number of blind 
years for most 
common ages of onset 
 75+  75 11 11  
Percent of 
blind  
69    
Number of 
blind 
108896  1197856 1197856 
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• The above situations and the distribution and average years of blindness for 1900, 1925, 1950, 1975 and 2000 are summarised in the tables 
below: summary table for estimates of the average number of years spent in blindness during the twentieth century and the percentage and 
number of blind this represented. 
 
Average number of years spent in blindness during the twentieth century. 
Year Average most 
common age of onset 
of blindness 1 
(Age) 
Average most 
common age of onset 
of blindness 2 
(Age) 
Average most 
common age of onset 
of blindness 3 
(Age) 
LEx 
Life Expectancy at age of onset of 
blindness  
(Years) 
Average number 
of years of 
blindness 1 
(Years) 
Average number 
of years of 
blindness 2 
(Years) 
Average number 
of years of 
blindness 3 
(Years) 
1900 35-55  45 65-77  71  LE45 = 
23 
LE71 = 
8 
23 8  
1925 55  55 70+  70  LE55 = 
19 
LE70 = 
9 
19 9  
1950 0  0 40-60  50 70+  70 LE0 = 
68 
LE50 = 
24 
LE70 = 
10 
68 24 10 
1975 50  50 75+  75  LE50 = 
26 
LE75 = 
9 
26 9  
2000 75+  75   LE75 = 
11 
11   
 
 
Sources: 
Calculated from: 1901 Census and 1925, 1950, 1975, 2000 Local Authority Blind Returns 
Life expectancy by age data: Figures based on the ‘Office of National Statistics/Government Actuaries Department’ England and Wales mortality database. See Appendix 12.15 for a copy of exert. 
 
 
Percent and number of blind population represented and subsequent number of blind years from most common ages of onset of blindness 
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Year Blind at common age of 
blindness onset 1 
Blind at common age of 
blindness onset 2 
Blind at common age of 
blindness onset 3 
Total number of blind years (from life expectancy at most 
common ages of onset) 
 Percent Number Percent Number Percent Number  
1900 39 10069 33 8520   (10069*23=231587) + (8520*8=68160) = 
299,747  
1925 26 10956 43 18120   (10956*19=208164) + (18120*9=163080) =  
371,244 
1950 13 10572 24 19517 22 17890 (10572*68=718896) + (19517*24=468408) + 
(17890*10=178900) = 
1,366,204 
1975 25 24900 54 53783   (24900*26=647400) + (53783*9=484047) =  
1,131,447 
2000 69 108896     (108896*11) = 
 1,197,856 
 
The table highlights the developments that have been made in preventing or delaying the onset of blindness. As a result, by 2000 the most common 
age of onset of blindness (by a significant majority 69 percent) was older than 75. When an individual contracts blindness at this age they are only 
burdened with it for a few years. This has meant there has actually been a reduction in the average number of blind years.  
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12.13.2: Cohort Effect Calculations 
 
• There was a substantial increase in the average age of blindness during the twentieth century.  
• It is crucial to determine whether this is a genuine effect or a result of the ageing of many blind. 
I.e. the increase in the 75+ population with blindness in 2000 could be a result of the 1975, 50+ 
age group getting older. 
• This will be achieved through the following process: 
1. Identifying the age group where blindness was most prevalent in time T. 
2. Determining the age group that this would have been in the previous (-25 years) time 
period = T-1. 
3. Identifying the number of blind people in the most common age group in time T. 
4. Identifying the number of blind people in the most common age group in time T-1. 
5. Calculating what percentage of the number in T-1 as a percentage of T to identify the 
proportion of the blind in T that had also been in T-1. 
• E.g. for T = 1925 where the most common age group was 16-64. Period T-1 = 1900 and T-1 
population age would be -9 to 39, i.e. 0-39 (as in 25 years time this would be the 16-25 age 
group). The number of blind aged between 0 and 39 in 1900 was 8676 and the number aged 
16-64 in 1925 was 24723. Therefore 8676/24723*100 = 35.09  35 percent of the 1925 blind 
are carried over from 1900. Hence, the cohort effect is 35 percent. 
• These calculations have been done for all of the necessary years and are shown in the table 
below. 
 
Year (T) Most 
common 
age group 
Period T-1 Age in period 
T-1 
Number of 
blind in age 
group in T 
Number of blind 
in age group in 
T-1 
Cohort effect (%) % 
in T that are from 
T-1 
1900 16-64 - - - - - 
1925 16-64 1900 0-39 24723 8676 35 
1950 16-64 1925 0-39 39472 12027 30 
1974 65+ 1950 40-60 71117 19800 28 
1975  1950    (25)∗ 
1976 75+ 1950 50-60 54638 11394 21 
 
 
                                                 
∗
 This is a mid point between the 1974 and 1976 estimates that is necessary due to data constraints for 1975 
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12.13.3: Blind Income Details 
This Appendix provides the detailed tables about blind: pensions, benefits and wages, that underlie 
Table 4.2 in Chapter 4 of the thesis. 
 
 
Table 12.13.3.1: The rate of weekly pension payable to the blind aged 50 to 70 years old under 
1920 Blind Persons Act 
Means of claimant or pensioner Weekly pension rate 
Annual means of the claimant:  
Do not exceed £26.25 50p 
Exceed £26.25, but do not exceed £36.50 40p 
“ £36.50 “ £36.75 30p 
“ £36.75 “ £42.00 20p 
“ £42.00 “ £47.25 10p 
“ £47.25 “ £49.88 5p 
Annual means of more than £49.88 No pension 
Sources: 
Parliamentary Bills, “Allowances under the 1920 Blind Persons Act” 
 
 
Table 12.13.3.2: Weekly pensions and other payments to soldiers and sailors blinded in the Great 
War 
Rank Degree of blindness Weekly pension Other payments 
Senior Officer Complete loss of sight  £300 p.a. + 
  25p for retraining  
Officer Complete loss of sight  £175 p.a.  
  25p for retraining  
NCO and Men Complete loss of sight £1.38 - £2.13  
  25p for retraining  
 Loss of vision in 1 eye £0.69 - £1.06  
  25p for retraining  
 Alternative pension based on 
pre-war earnings 
£1.38 - £3.75  
  25p for retraining  
Sources: 
Parliamentary report of the departmental committee on the welfare of the blind 
 
Table 12.13.3.3: 1948 National Assistance Act: weekly rates of allowance (excluding rents) for 
blind persons. 
Type of blind individual Weekly rate of allowance (excluding rent) 
Husband and wife:  
1. Of whom 1 is blind £2.75 
2. Of whom, both are blind £3.25 
Single person:  
1. Aged 21 or over  £1.95 
2. Aged 18 years or over but less than 21 £1.50 
3. Aged 16 years or over but less than 18 £1.25 
Sources: 
Beacon 1948: National Assistance Rates 
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Table 12.13.3.4: Average wages for blind home workers in various industries 1924 and 1933 
Trade 
 
General average earnings per 
week (1924) 
General average earnings per 
week (1933) 
Basket makers 88p 90p 
Boot repairers 13p 79p 
Carpenters £1.02 40p 
Chair caners 50p 58p 
Fancy basket makers 36p 57p 
Hand knitters 36p 31p 
Machine knitters 40p 52p 
Mat makers 43p 89p 
Music teachers £1.00 97p 
Piano tuners £1.20 £1.37 
Straw basket makers 56p - 
Weavers  84p 35p 
Wood choppers 75p 90p 
Sources: 
Beacon 1924: Home Industries for the Blind and Beacon 1933: The Social and Economic Value of Home 
working Schemes 
 
 
Table 12.13.3.5: Comparison of average weekly wages between blind and mainstream industries 
1924, 1933 and 1935. 
Industry Male / Female weekly wage 
average 1924 
Male / Female weekly wage 
average 1933 and 1935 
Blind Home workers average 65p 71p (1933) 
 
Unskilled mainstream industry £1.99 
(33%) 
£2.09 (1935) 
(34%) 
Semi-skilled mainstream 
industry 
£2.25 
(29%) 
£2.35 (1935) 
(30%) 
Sources: 
Blind home worker wage data: Beacon 1924 and 1933 and mainstream industry wage data; Routh, 
“Occupation and Pay in Great Britain 1906-79” 
 
 
Table 12.13.3.6: Comparison of average weekly wages between blind workshops, blind in 
mainstream industries and the able bodied population 1935, 1944 and 1955. 
Industry Male/Female weekly 
wage average 1938 
Male/Female weekly 
wage average 1944 
Male/Female weekly 
wage average 1955 
Blind Workshop  £3.49  
Blind in mainstream 
industry 
 £3.27  
Able bodied in 
mainstream industry 
£2.72  £7.70 
Sources: 
1938: Chapman, “Wages and Salaries in the United Kingdom 1920-1938” and 1944: TNA: MH 55 (1089) and 
1955: Routh, “Occupation and Pay in Great Britain 1906-79” 
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12.14 Extended Results 
This Appendix relates to Tables 9.2, 9.3, and 9.4 in Chapter 9 of the thesis. The 
calculations here represent variations of those that are presented throughout the thesis. The 
QALE gain methodology is consistent here but the data that is used differs from that which 
has been presented above. This is because Chapter 9 (and this corresponding appendix) 
considers the entire burden of morbidity through extrapolating forward the findings about 
the thesis disease and disability morbidity (contained in the previous appendices). 
 
12.14.1: Lowest Bound Estimates for Key Morbidity Categories 
Appendix 12.14.1 presents the lowest morbidity gain estimates for the extended results 
illnesses. This utilises the methodology applied in Appendix 12.3 and 12.4. The values that 
have been utilised here are the Low VSL and VSHLY (presented in Appendix 12.1) and 
the Low QALY (presented in Appendix 12.6). 
 
The infectious morbidity gain is equal to the lowest tuberculosis morbidity gain (as a result 
of the conservative assumption of Chapter 9: that tuberculosis was the only infectious 
disease to experience a morbidity gain), shown in Appendix 13.4. The disability morbidity 
gain is also equal to the lowest blind morbidity gain in the thesis. This is equal to the blind 
morbidity gain shown in Appendix 12.7.2 (for an explanation see Table 9.1). 
 
The non-infectious morbidity gain is an additional calculation to the previous appendix. 
This applied the (‘Low’) stomach cancer VSHLY and QALY profile to the aggregate 
number of non-infectious deaths in twentieth century England. This is because of the 
conservative assumptions in Chapter 9 (see Table 9.1 for details).  
 
 
Sources: 
• Appendix 12.2 for VSL and VSHLY information (utilising Low) 
• Appendix 12.3 for the change in the morbidity burden calculations 
• Appendix 12.4 for the morbidity gain calculation 
• Appendix 12.10 for the age-weighted mortality, morbidity and QALE gain calculations 
Death and population data 
• Office of National Statistics, “Twentieth Century Mortality: 100 Years of Mortality 
Data in England and Wales by Age, Sex, Year and Underlying Cause” 
 
 
12.14.2: Value of QALE Gain relative to GDP per capita growth: Extended Results: 
Disease and Disability 
After the morbidity gain has been identified (in Appendix 12.14.1) this can be combined 
with the mortality gain calculation, which represents the lowest age-weighted estimated 
(presented in Appendix 12.8) to estimate the QALE gain, or given the underlying 
assumptions of this appendix, the aggregate QALE gain.  
 
GDP per capita growth has been calculated in Appendix 12.11. Appendix 12.12 calculated 
the mortality, morbidity and QALE gain relative to GDP growth. This same methodology 
and process is conducted here, but for the different morbidity and QALE gain values that 
were yielded in Appendix 12.14.1. 
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Sources: 
GDP per capita data 
• Maddison, “Monitoring the World Economy 1820-1992”  
• Maddison, “The World Economy: A Millennial Perspective” 
Compound average growth rate methodology 
• Dowling, “Mathematical Methods for Business and Economics” 
QALE Gain numbers  
• Appendix 12.14.1 
  
 
12.14.3: Value of morbidity (QALY) improvements 
This appendix readdresses the considerations made in Appendix 12.14.1, but holds all 
QALY gain (from 1900 onwards) constant in order to identify the value of the twentieth 
century (1900-2000) health improvements. This is then compared to actual QALE gain 
(including 1900-2000 QALY improvements) identified in Appendix 12.14.2, in order to 
identify the value of health improvements for the most conservative twentieth century 
disease environment. 
 
 
Sources: 
• Appendix 12.3 for the change in the morbidity burden calculations 
• Appendix 12.4 for the morbidity gain calculations 
• Appendix 12.10 for the age-weighted mortality, morbidity and QALE gain calculations 
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12.14.1: Lowest Bound Estimates for Key Morbidity Categories 
 
 
Infectious Morbidity Gain 
       
Period 
Morbidity 
Gain        
1900-2000 11047        
         
Tuberculosis Morbidity Gain (Low VSHLY, Low QALY, Age-Weighted)     
1900-2000         
Age Weight VSHLY (Mid) 
Weighted VSL 
(Mid) Fall in MBR 1 Fall in MBR 2 
Morbidity Gain 
1 
Morbidity Gain 
2 Average Mortality Gain 
         
0-4 0.3 0.288375099 0.08651253 32963.83056 17525.39089 2851.78437 1516.1659  
5-14 1 0.288375099 0.288375099 13947.83794 8614.582243 4022.209147 2484.231007  
15-24 1.5 0.288375099 0.432562649 6235.885789 3823.347706 2697.411273 1653.83741  
25-34 1.5 0.288375099 0.432562649 3127.668735 2817.606638 1352.912672 1218.79139  
35-44 1.3 0.288375099 0.374887629 2431.599597 2905.666277 911.5766069 1089.298341  
45-64 1 0.288375099 0.288375099 2605.842774 4172.730281 751.4601679 1203.311508  
65-74 0.7 0.288375099 0.201862569 413.6437681 696.7556916 83.49919381 140.6488941  
75+ 0.45 0.288375099 0.129768795 138.382849 766.2670101 17.9577755 99.43754621  
    61864.69201 41322.34673 12688.81121 9405.721995 11047 
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Non-Infectious Morbidity Gain 
 
 
       
Period Morbidity Gain          
1900-2000 -7467          
  
 
        
Stomach Cancer   Non-Infectious Disease 
Year Deaths (1-QALY) Survival Year Deaths Survival/Prevalence (1-QALY) Burden Morbidity Burden Change  
 percent  percent  Percent percent     
1900 85  15 1900 85 15     
2000 75  25 2000 75 25     
  0.6667  1900 97760 17252 0.6667 11502   
  0.3333  2000 391518 130506 0.3333 43498 -31996  
  
 
        
Summary Morbidity Gain 
 
 
   
 
 
 
 
Summary Morbidity Gain          
Period 
Morbidity Burden 
Change 
 
Low VSL 
Low QALY 
1900-2000 VSHLY Morbidity Gain     
  
 
  Millions millions     
1900-2000 -31996  0.7 0.3334 0.2334 -7467     
  
 
      
 
 
Sources: non-infectious deaths are calculated as all deaths not included in infectious and residual. Death data provided by: Office of National Statistics (2003) “Twentieth Century 
Mortality: 100 Years of Mortality Data in England and Wales by Age, Sex, Year and Underlying Cause” 
 
 
Disabled Morbidity Gain 
  
 
  
Blind Morbidity Gain 
  
Low VSL Low VSHLY Low QALY 
  
Period Morbidity Burden Change VSHLY Morbidity Gain  
  millions millions 
1900-2000 -7976 0.35 -2792 
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12.14.2: Value of QALE Gain relative to GDP per capita growth: Extended Results: Disease and Disability 
 
Mortality 
      
Period t Mortality Gain Midpoint GDPpc at Midpoint Gain as a proportion of GDP (total/per annum) 
1900-2000 100 7372 1950 6907 107 1.1 
       
Infectious 
     
Period t Morbidity Gain: Infectious Midpoint GDPpc at Midpoint Gain as a proportion of GDP (total/per annum) 
1900-2000 100 11047 1950 6907 160 1.6 
       
 t QALE Gain: Infectious Midpoint GDPpc at Midpoint Gain as a proportion of GDP (total/per annum) 
1900-2000 100 18419 1950 6907 267 2.7 
       
Non-Infectious 
     
Period t Morbidity Gain: Infectious Midpoint GDPpc at Midpoint Gain as a proportion of GDP (total/per annum) 
1900-2000 100 -7467 1950 6907 -108 -1.1 
       
 t QALE Gain: Infectious Midpoint GDPpc at Midpoint Gain as a proportion of GDP (total/per annum) 
1900-2000 100 -95 1950 6907 -1.4 -0.01 
       
Disability 
      
Period t Morbidity Gain: Infectious Midpoint GDPpc at Midpoint Gain as a proportion of GDP (total/per annum) 
1900-2000 100 -2792 1950 6907 -40 -0.4 
       
 t QALE Gain: Infectious Midpoint GDPpc at Midpoint Gain as a proportion of GDP (total/per annum) 
1900-2000 100 6353 1950 6907 80 0.8 
       
Total 
      
Period t Morbidity Gain: Total Midpoint GDPpc at Midpoint Gain as a proportion of GDP (total/per annum) 
1900-2000 100 788 1950 6907 11 0.1 
      
 t QALE Gain: Total Midpoint GDPpc at Midpoint Gain as a proportion of GDP (total/per annum) 
1900-2000 100 8160 1950 6907 118 1.2 
  (7372+11047-7467-2792)     
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12.14.3: Value of morbidity (QALY) improvements 
 
Infectious Morbidity Gain  
 
   
 
Morbidity Gain Morbidity Gain Value of Infectious Health Improvements 
Health Improvements No Heath Improvements   
11047 506 10541  
   
 
Infectious Morbidity Gain: (Health Improvements)  
 
Period Morbidity Gain   
1900-2000 11047   
    
Infectious Morbidity Gain: (No Health Improvements)  
 
Period Morbidity Gain   
1900-2000 506   
 
 
Summary Morbidity 
Gain       
Period Morbidity Rate Change 1 Morbidity Rate Change 2 Low VSL Low QALY 1900-2000 VSHLY Morbidity Gain 1 
     millions millions 
1900-2000 5045 3631 0.7 0.1667 0.11669 589 
 
 
Age-Weighted Morbidity Gain      
Tuberculosis 1900-2000      
1900-2000: Constant QALY      
Age Weight VSHLY (Mid) 
Weighted VSL 
(Mid) Fall in MBR 1 Fall in MBR 2 
Morbidity Gain 
1 
Morbidity Gain 
2 
0-4 0.3 0.1167 0.03501 32951.40206 17518.78321 1153.628586 613.3326002 
5-14 1 0.1167 0.1167 13926.55707 8601.366887 1625.229211 1003.779516 
15-24 1.5 0.1167 0.17505 6214.341868 3810.13778 1087.820544 666.9646183 
25-34 1.5 0.1167 0.17505 3091.205943 2784.758592 541.1156002 487.4719916 
35-44 1.3 0.1167 0.15171 2329.368277 2783.503855 353.3884614 422.2853698 
45-64 1 0.1167 0.1167 2353.35804 3751.769479 274.6368832 437.8314982 
65-74 0.7 0.1167 0.08169 169.9526224 286.2740021 13.88342972 23.38572323 
75+ 0.45 0.1167 0.052515 -83.28082287 -461.1506962 -4.373492413 -24.21732881 
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Morbidity Burden Change 
       
Tuberculosis         
1900-2000: Constant QALY        
1900     2000    
Age  % Pop MBR/1000   Age  % Pop MBR/1000 
0-4 0.114068091 6.840053763   0-4 0.06064489 0.003531775  
5-9 0.10708602 1.896744266   5-9 0.064774207 0.003306627  
10-14 0.102584623 1.239575549   10-14 0.065448618 0.003272554  
15-19 0.099601068 0.933440059   15-19 0.061064951 0  
20-24 0.095740538 0.572334497   20-24 0.058704516 0.007294835  
25-34 0.161673121 0.459554291   25-34 0.145645622 0.007057392  
35-44 0.12315061 0.473830985   35-44 0.147160155 0.026192846  
45-54 0.089448395 0.387028213   45-54 0.132294228 0.027517142  
55-64 0.059845885 0.485218015   55-64 0.104828392 0.091925078  
65-74 0.033199334 0.35282165   65-74 0.055922092 0.23167149  
75+ 0.013602313 0.369702435   75+ 0.075320056 0.514598878  
      0.971807728 0.916368616  
         
Age  % Pop MBR/1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease/1000 Morbidity Rate Change 
 1900 1900 1900&1900 1900 2000 1900&2000   
0-4 0.114068091 6.840053763 0.780231877 0.114068091 0.003531775 0.000402863 0.779829014 32951 
5-9 0.10708602 1.896744266 0.203114795 0.10708602 0.003306627 0.000354093 0.202760701 8568 
10-14 0.102584623 1.239575549 0.127161391 0.102584623 0.003272554 0.000335714 0.126825677 5359 
15-19 0.099601068 0.933440059 0.092971627 0.099601068 0 0 0.092971627 3928 
20-24 0.095740538 0.572334497 0.054795613 0.095740538 0.007294835 0.000698411 0.054097201 2286 
25-34 0.161673121 0.459554291 0.074297577 0.161673121 0.007057392 0.001140991 0.073156586 3091 
35-44 0.12315061 0.473830985 0.058352575 0.12315061 0.026192846 0.003225665 0.05512691 2329 
45-54 0.089448395 0.387028213 0.034619052 0.089448395 0.027517142 0.002461364 0.032157688 1359 
55-64 0.059845885 0.485218015 0.029038302 0.059845885 0.091925078 0.005501338 0.023536964 995 
65-74 0.033199334 0.35282165 0.011713444 0.033199334 0.23167149 0.007691339 0.004022105 170 
75+ 0.013602313 0.369702435 0.005028808 0.013602313 0.514598878 0.006999735 -0.001970927 -83 
     0.916368616 0.916368616 1.442513547 60953 
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Age  % Pop MBR/1000 WTD MBR % Pop MBR/1000 WTD MBR Decrease/1000 Morbidity Rate Change 
 2000 1900 2000&1900 2000 2000 2000&2000   
0-4 0.06064489 6.840053763 0.41481431 0.06064489 0.003531775 0.000214184 0.414600126 17519 
5-9 0.064774207 1.896744266 0.122860107 0.064774207 0.003306627 0.000214184 0.122645922 5182 
10-14 0.065448618 1.239575549 0.081128506 0.065448618 0.003272554 0.000214184 0.080914322 3419 
15-19 0.061064951 0.933440059 0.057000472 0.061064951 0 0 0.057000472 2409 
20-24 0.058704516 0.572334497 0.03359862 0.058704516 0.007294835 0.00042824 0.03317038 1402 
25-34 0.145645622 0.459554291 0.066932071 0.145645622 0.007057392 0.001027878 0.065904193 2785 
35-44 0.147160155 0.473830985 0.069729041 0.147160155 0.026192846 0.003854543 0.065874498 2784 
45-54 0.132294228 0.387028213 0.051201599 0.132294228 0.027517142 0.003640359 0.047561239 2010 
55-64 0.104828392 0.485218015 0.050864624 0.104828392 0.091925078 0.009636358 0.041228266 1742 
65-74 0.055922092 0.35282165 0.019730525 0.055922092 0.23167149 0.012955554 0.00677497 286 
75+ 0.075320056 0.369702435 0.027846008 0.075320056 0.514598878 0.038759616 -0.010913608 -461 
      0 0.92476078 39075 
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Non-Infectious 
   
 
   
Morbidity Gain Morbidity Gain Value of Infectious Health Improvements 
Health Improvements No Heath Improvements   
-7467 -8811 1344  
   
 
Infectious Morbidity Gain: (Health Improvements)  
 
Period Morbidity Gain   
1900-2000 -7467   
    
Infectious Morbidity Gain: (No Health Improvements)  
 
Period Morbidity Gain   
1900-2000 -8811   
 
 
Period Morbidity Burden Change Low VSL Low QALY 1900-2000 Low VSHLY Morbidity Gain 
     millions 
1900-2000 -75506 0.7 0.1667 0.11669 -8811 
      
Non-Infectious Disease      
Year Deaths Survival/Prevalence (1-QALY) Burden Morbidity Burden Change 
 percent Percent    
1900 85 15    
2000 75 25    
1900 97760 17252 0.6667 11502  
2000 391518 130506 0.6667 87008 -75506 
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Disability 
    
     
Morbidity Gain Morbidity Gain Value of Disability Health Improvements 
 
Health Improvements No Heath Improvements   
 
-2792 -23950 22111  
 
   
  
 
 
     
     
Blind Morbidity Gain 
    
Low VSL Low VSHLY Low QALY 
   
Period Morbidity Burden Change VSHLY Morbidity Gain   
  millions millions  
1900-2000 -7976 0.35 -2792  
     
Blind     
Year Prevalence (1-QALY) Burden Morbidity Burden Change 
 percent    
1900 11990 0.6667 7994  
2000 47914 0.6667 31944 -23950 
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12.15: Life Expectancy by Age 
 
This Appendix relates to Tables 4.10 and 4.11 and 8.2.1 in the main thesis.  
 
This Appendix contains life expectancy by age estimates for the reference years used in the thesis 
(1900, 1925, 1950, 1975, and 2000). These figures are based on the ONS/GAD England & Wales 
mortality database.  
 
It should be noted that this database is subject to further revision and that this dataset should be used 
for internal research/work purposes only. This dataset represents the best available estimates for life 
expectancy by age. 
 
Sources: 
Life expectancy by age data:  
• Figures based on the ‘Office of National Statistics/Government Actuaries Department’ England 
and Wales mortality database. Extract was provided by Mita Saha (Office of National Statistics) 
on March 17 2006. 
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England and Wales: Period expectation of life (years) 
 Males Females 
Age 1900 1925 1950 1975 2000 1901 1925 1950 1975 2000 
0 43.72 56.38 66.09 69.70 75.68 48.83 60.24 70.61 75.85 80.41 
1 51.49 60.44 67.38 69.93 75.14 55.46 63.39 71.47 75.91 79.81 
2 53.33 60.86 66.65 69.01 74.17 57.17 63.77 70.73 74.98 78.84 
3 53.46 60.49 65.76 68.05 73.19 57.24 63.39 69.84 74.01 77.85 
4 53.18 59.88 64.84 67.09 72.21 56.94 62.79 68.91 73.04 76.86 
5 52.71 59.17 63.90 66.12 71.22 56.46 62.08 67.97 72.07 75.87 
6 52.09 58.40 62.97 65.15 70.22 55.84 61.32 67.03 71.09 74.88 
7 51.36 57.58 62.03 64.17 69.24 55.12 60.51 66.08 70.11 73.89 
8 50.56 56.72 61.08 63.19 68.24 54.33 59.65 65.12 69.13 72.89 
9 49.71 55.84 60.13 62.21 67.25 53.49 58.76 64.15 68.14 71.90 
10 48.82 54.93 59.17 61.23 66.26 52.63 57.85 63.19 67.16 70.91 
11 47.93 54.02 58.20 60.25 65.27 51.75 56.94 62.21 66.17 69.92 
12 47.03 53.11 57.24 59.27 64.28 50.87 56.03 61.24 65.18 68.92 
13 46.15 52.20 56.27 58.29 63.29 49.99 55.12 60.27 64.19 67.93 
14 45.27 51.29 55.31 57.31 62.30 49.12 54.22 59.30 63.20 66.94 
15 44.39 50.39 54.35 56.33 61.31 48.25 53.33 58.34 62.21 65.95 
16 43.52 49.49 53.39 55.35 60.33 47.39 52.45 57.38 61.23 64.95 
17 42.67 48.61 52.44 54.39 59.35 46.54 51.58 56.42 60.25 63.97 
18 41.84 47.74 51.49 53.45 58.38 45.71 50.71 55.47 59.28 62.98 
19 41.02 46.88 50.55 52.51 57.42 44.87 49.85 54.53 58.30 62.01 
20 40.20 46.02 49.61 51.56 56.47 44.03 48.99 53.59 57.32 61.02 
21 39.39 45.17 48.68 50.62 55.51 43.20 48.14 52.65 56.35 60.04 
22 38.58 44.33 47.74 49.68 54.56 42.36 47.29 51.71 55.37 59.06 
23 37.79 43.48 46.81 48.73 53.60 41.53 46.43 50.77 54.39 58.08 
24 37.00 42.63 45.87 47.77 52.64 40.71 45.58 49.84 53.41 57.10 
25 36.21 41.78 44.94 46.81 51.68 39.88 44.73 48.91 52.44 56.11 
26 35.42 40.94 44.01 45.85 50.73 39.07 43.88 47.97 51.46 55.13 
27 34.63 40.09 43.09 44.89 49.77 38.25 43.02 47.04 50.49 54.15 
28 33.85 39.24 42.16 43.92 48.81 37.44 42.17 46.11 49.51 53.17 
29 33.07 38.39 41.23 42.96 47.86 36.64 41.31 45.19 48.54 52.19 
30 32.29 37.54 40.31 41.99 46.91 35.84 40.46 44.26 47.56 51.21 
31 31.51 36.68 39.38 41.03 45.95 35.04 39.60 43.33 46.59 50.23 
32 30.74 35.82 38.45 40.07 45.00 34.25 38.74 42.40 45.62 49.25 
33 29.97 34.97 37.53 39.11 44.05 33.46 37.88 41.47 44.65 48.28 
34 29.22 34.12 36.60 38.16 43.09 32.68 37.02 40.54 43.68 47.30 
35 28.47 33.28 35.68 37.20 42.14 31.90 36.17 39.62 42.71 46.33 
36 27.73 32.45 34.75 36.25 41.19 31.13 35.32 38.69 41.75 45.36 
37 27.00 31.62 33.83 35.30 40.24 30.36 34.47 37.77 40.79 44.40 
38 26.28 30.79 32.92 34.35 39.30 29.61 33.63 36.85 39.83 43.43 
39 25.57 29.97 32.01 33.40 38.35 28.86 32.78 35.93 38.88 42.47 
40 24.86 29.16 31.10 32.46 37.41 28.12 31.94 35.02 37.93 41.50 
41 24.17 28.35 30.19 31.52 36.47 27.38 31.09 34.10 36.98 40.54 
42 23.49 27.55 29.29 30.59 35.53 26.65 30.25 33.19 36.05 39.59 
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England and Wales: Period expectation of life (years)…continued…  
 
 Males Females 
Age 1900 1925 1950 1975 2000 1901 1925 1950 1975 2000 
43 22.81 26.75 28.40 29.67 34.60 25.93 29.41 32.29 35.12 38.64 
44 22.13 25.96 27.52 28.76 33.66 25.21 28.57 31.38 34.19 37.69 
45 21.46 25.17 26.64 27.86 32.73 24.49 27.74 30.49 33.27 36.75 
46 20.80 24.40 25.78 26.96 31.81 23.77 26.92 29.60 32.35 35.81 
47 20.15 23.63 24.94 26.08 30.89 23.06 26.11 28.72 31.44 34.87 
48 19.50 22.86 24.10 25.21 29.99 22.35 25.30 27.85 30.54 33.94 
49 18.87 22.10 23.27 24.34 29.08 21.65 24.50 26.99 29.65 33.01 
50 18.24 21.34 22.46 23.50 28.19 20.95 23.70 26.13 28.77 32.09 
         51 17.63 20.58 21.65 22.67 27.31 20.26 22.91 25.27 27.89 31.18 
52 17.02 19.83 20.85 21.85 26.43 19.58 22.12 24.43 27.03 30.26 
53 16.42 19.09 20.07 21.04 25.54 18.91 21.35 23.59 26.17 29.36 
54 15.83 18.36 19.30 20.24 24.68 18.24 20.58 22.75 25.31 28.46 
55 15.25 17.65 18.55 19.46 23.81 17.59 19.82 21.93 24.46 27.56 
56 14.67 16.95 17.81 18.68 22.95 16.94 19.08 21.11 23.61 26.68 
57 14.11 16.27 17.08 17.92 22.12 16.30 18.35 20.30 22.79 25.80 
58 13.55 15.59 16.37 17.18 21.29 15.67 17.63 19.50 21.96 24.93 
59 13.02 14.93 15.68 16.45 20.46 15.05 16.91 18.71 21.14 24.06 
60 12.49 14.27 15.01 15.74 19.66 14.45 16.20 17.94 20.33 23.20 
61 11.98 13.63 14.36 15.04 18.87 13.87 15.49 17.17 19.53 22.35 
62 11.48 13.00 13.72 14.37 18.10 13.29 14.80 16.42 18.74 21.51 
63 10.99 12.38 13.10 13.71 17.33 12.73 14.12 15.68 17.96 20.67 
64 10.51 11.79 12.50 13.07 16.57 12.18 13.46 14.96 17.19 19.84 
65 10.03 11.21 11.91 12.44 15.83 11.64 12.82 14.25 16.45 19.04 
66 9.57 10.66 11.33 11.84 15.11 11.13 12.20 13.55 15.71 18.23 
67 9.12 10.13 10.77 11.26 14.40 10.62 11.60 12.87 14.98 17.45 
68 8.69 9.62 10.23 10.70 13.71 10.13 11.01 12.20 14.26 16.67 
69 8.27 9.11 9.70 10.15 13.04 9.65 10.43 11.56 13.56 15.91 
70 7.86 8.62 9.19 9.63 12.39 9.19 9.87 10.93 12.87 15.16 
71 7.47 8.13 8.69 9.13 11.76 8.74 9.33 10.33 12.20 14.43 
72 7.10 7.66 8.21 8.64 11.14 8.30 8.80 9.75 11.55 13.72 
73 6.74 7.20 7.75 8.18 10.56 7.89 8.29 9.19 10.91 13.03 
74 6.39 6.77 7.30 7.75 10.00 7.48 7.81 8.65 10.30 12.35 
75 6.06 6.37 6.88 7.35 9.47 7.10 7.36 8.14 9.72 11.70 
76 5.72 6.00 6.47 6.96 8.95 6.73 6.92 7.66 9.15 11.06 
77 5.40 5.66 6.09 6.60 8.44 6.38 6.52 7.20 8.60 10.45 
78 5.08 5.34 5.72 6.23 7.96 6.04 6.13 6.77 8.08 9.85 
79 4.78 5.04 5.37 5.88 7.50 5.72 5.77 6.36 7.58 9.26 
80 4.50 4.75 5.03 5.56 7.06 5.41 5.42 5.97 7.10 8.70 
81 4.23 4.46 4.70 5.23 6.64 5.10 5.10 5.61 6.66 8.17 
82 3.97 4.18 4.39 4.92 6.18 4.80 4.80 5.27 6.23 7.61 
83 3.72 3.91 4.10 4.63 5.79 4.52 4.50 4.94 5.84 7.11 
84 3.50 3.67 3.83 4.38 5.43 4.26 4.22 4.64 5.47 6.64 
85 3.29 3.47 3.59 4.12 5.10 4.03 3.97 4.35 5.13 6.20 
86 3.10 3.29 3.38 3.88 4.79 3.82 3.73 4.08 4.80 5.79 
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England and Wales: Period expectation of life (years)…continued… 
 Males Females 
Age 1900 1925 1950 1975 2000 1901 1925 1950 1975 2000 
87 2.93 3.13 3.18 3.65 4.50 3.62 3.52 3.85 4.50 5.39 
88 2.77 2.98 2.98 3.43 4.22 3.43 3.34 3.63 4.21 5.01 
89 2.62 2.83 2.79 3.22 3.96 3.26 3.17 3.41 3.93 4.67 
90 2.47 2.69 2.62 3.04 3.71 3.09 3.00 3.22 3.67 4.33 
91 2.34 2.54 2.46 2.86 3.48 2.93 2.84 3.03 3.45 4.03 
92 2.21 2.40 2.30 2.67 3.24 2.77 2.66 2.86 3.23 3.74 
93 2.09 2.31 2.15 2.51 3.04 2.63 2.48 2.70 3.03 3.49 
94 1.98 2.26 2.02 2.37 2.84 2.50 2.33 2.56 2.84 3.25 
95 1.87 2.18 1.96 2.24 2.66 2.37 2.19 2.41 2.67 3.03 
96 1.78 2.07 1.93 2.12 2.51 2.25 2.08 2.26 2.51 2.84 
97 1.68 1.94 1.87 2.01 2.38 2.14 1.97 2.14 2.36 2.68 
98 1.60 1.86 1.79 1.96 2.27 2.03 1.83 2.05 2.23 2.53 
99 1.52 1.77 1.74 1.94 2.17 1.93 1.70 1.92 2.12 2.38 
100 1.45 1.66 1.66 1.87 2.00 1.83 1.65 1.78 2.02 2.21 
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12.16: Methodological Algebra 
This appendix provides the algebraic representation of the methodology used in the thesis 
(summarised in Equation 3.2 and 8.1). Hence, this section provides the detailed outline of the 
quantitative willingness to pay: mortality and morbidity methodology. This methodology was 
outlined in Chapter 3 and applied in Chapters 8 and 9 of the thesis.  
 
12.16.1 Contains the methodological algebra for improvements in the death rate, or mortality. 
 
12.16.2 Contains the methodological algebra for considering improvements in the quality of life of 
additional years of life expectancy. 
 
12.16.3 Contains the methodological algebra for the combination of improved mortality and the 
improved morbidity associated with these additional life years. 
 
Sources: 
Mortality gain algebra is derived from: 
• Nordhaus, “The Health of Nations: The Contribution of Improved Health to Living Standards” 
Morbidity gain algebra is derived from: 
• Cutler & Richardson, “The Value of Health: 1970-1990”  
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12.16.1: Methodological Algebra: Mortality 
This approach had been refined by Nordhaus to provide a method of measuring the gain in real 
income from improved life expectancy, in the context of the life-cycle model of consumption. This 
approach represents part of the Hickson QALE methodology. 
 
An individual is assumed to value consumption and health according to a lifetime utility function:  
( )[ ; , , ] ( ) [ ]tt t t tV c u c e S dtρ θ
θ
θ ρ µ µ
∞
− −
= ∫                     (1) 
 
Where [ ; , , ]t tV c θ ρ µ  is the value at time t of the consumption stream, now and in the future, faced be 
an individual of ageθ ; ( )tc is the stream of instantaneous utility or felicity consumption; ρ  is the 
pure rate of individual time preference; [ ]tS µ is the set of survival probabilities; and tµ is the set of 
mortality rates. The key assumption here is that utility is a function of the expected value of 
consumption weighted by the probability of survival. It is also assumed that the survival function is 
exponential, and therefore equation (1) becomes: 
( )( )[ ; , , ] ( ) tt t tV c u c e dtρ µ θ
θ
θ ρ µ
∞
− + −
= ∫          (2) 
 
This equation can be further simplified by assuming that the real interest rate faced by the individual 
is equal to the mortality adjusted rate of time preference ( )ρ µ+ . Given these assumptions, an 
individual will choose a consumption annuity that yields constant consumption during the 
individual’s lifetime, tc = *c . Integrating equation (2) yields a simpler outcome: 
( *)[ ; , , ] ( )t t
u cV c θ ρ µ
ρ µ
=
+
          (3) 
 
Equation (3) shows that the total utility value of consumption, discounted by a discount rate that 
equals the sum of the force of impatience and the force of mortality. 
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An individual will often face a trade-off between health and wealth. At age θ , changes in 
consumption and health yield: 
'( *)
* ( )
dV u c
dc ρ µ
=
+
 
              (4) 
2
( *)
( )
dV u c
dµ ρ µ
=
+
 
 
Hence, the trade=off between consumption and mortality is: 
* ( *)
[ '( *)( )]
dc u c
d u cµ ρ µ
−
=
+
          (5) 
 
It is then possible to further simplify through making two normalisations. First, utility is defined so 
that one unit of utility is one extra unit of the consumption good, by setting '( *)u c = 1. Second, the 
pure rate of time preference is set equal to zero, such that when the utility of consumption is ( )u c = 
0, the individual is indifferent between life and death. This implies that there is zero utility after 
death. Given these assumptions, equation (5) can be reduced to: 
* ( *)
( )
dc u c
dµ ρ µ
−
=
+
           (6) 
 
Or without discounting: 
* ( *)dc Tu c
dµ
=             (7) 
 
Where, T is life expectancy (T=1/ µ ). The interpretation here is that a uniform change in mortality 
rates at every age will produce a welfare change equal to the number of years of life (T) times the 
goods value of life, given by u(c*).  
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12.16.2: Methodological Algebra: Morbidity 
In this methodology health capital is defined as: 
0
[ ]
(1 )
t t k
k
k
E HL
r
∞
+
=
+
∑            (8) 
 
Where tH represents a person’s quality of life in any year (scaled on a 0 to 1 basis, where 0 = death 
and 1 = perfect health) or the QALY. L represents the value of a year in perfect health and r is the 
real discount rate and k is the number of years of life.  
 
After identifying health capital the next stage in the methodology is to consider the quality of life. 
The starting point for this (more difficult) measurement is the probability that a person is alive or 
dead in each year of the future. This can be achieved through considering life expectancy and life 
tables. These survival rates then need to be adjusted for the prevalence of disease. Quality of life 
weights also need to be attached to every condition considered in the methodology and for the 
variance of the QALY over time. Hence, combining estimates of the share of the population who are 
still alive, at t+k, the prevalence of people with particular conditions, where d is the range of 
conditions a person could have, and the quality of life for people with those conditions, quality of life 
can be estimated as: 
Pr[t kH + = alive at t+k] * ( Pr
d
=∑ [condition d at t+k] * [QALY for d at t+k])   (9) 
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12.16.3: Methodological Algebra: Hickson QALE 
The two above methodologies consider measuring the value of mortality and morbidity, the thesis 
QALE methodology considers the value of mortality and morbidity in a single methodology that 
combined the two above approaches to measuring life and health. The result of combining the two 
above approaches is a methodology that considers the value of improvements in life expectancy 
whilst considering the quality and subsequent value of these additional years from a health (or 
QALY) perspective. This QALE (quality adjusted life expectancy) methodology is expressed as: 
* ( *)
( [ ])
dc u cQALE
dµ λ ρ µ λ
−
= =
+ + +
         (10) 
 
Where, ( *)u c = the goods value of life and *c = consumption. µ  represents the set of mortality rates 
and ( Pr
d
λ = ∑ Condition D at t + k] * [QALY for D at t + k]), which is essentially the consideration 
for the health aspect of improved mortality rates, where d represents the range of possible health 
conditions. ρ = the pure rate of individual time preference. Finally, it should be noted that,  
*dc
dµ λ+ > 0  
because individuals are likely to forego some consumption in return for improved healthy life years.  
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